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This section provides a medium through which Canadian
surgeons can declare themselves, briefly and informally, on
the day-to-day affairs of surgery.

Treatment of Colorectal Cancer
Colorectal cancer ranks second to
I lung cancer as a cause of cancer-related
[ deaths in Canada. In 1984, approximately
6000 Canadians will die of this disease.
Although surgical resection is the most
^.effective treatment, recurrent disease
develops in many patients, and the 5-year
* survival for all patients with colorectal
cancer is only 50%.'
*■ What can be done to improve these
results? Surgery has inherent limitations
and, ultimately, a better form of
chemotherapy is needed to treat residual
microscopic disease. Currently, the adju
t a n t measures available, including
chemotherapy and radiotherapy, are not
K effective.2 There is evidence, however,
that improvements can be made in the
^surgical management of colonic cancer.
Variations in surgical technique affect
the survival of patients with colonic
^.cancer. Turnbull and associates,3 using a
method of early venous ligation of the
tumour, reported a 57.8% 5-year survival
compared with 28% in patients treated by
►their colleagues. Recently, a large pro
spective multicentre study of patients

with colorectal cancer found that recur
rence rates varied from 5% to 20%.
Statistical analysis of these data showed
that the individual surgeon was a signifi
cant, independent factor associated with
local recurrrence.4
What are the surgical techniques that
prevent or minimize the recurrence of
cancer? Unfortunately, a review of the
surgical literature reveals that many of the
existing experimental and clinical studies
on this subject are inadequate. Surgical
techniques that may reduce the recurrence
of colonic cancer can be divided into three
areas: early venous ligation to prevent
intravascular dissemination of cancer
cells, radical resection of the lymphatics
that drain colonic cancers and mechani
cal or chemical measures to prevent
implantation of exfoliated cancer cells.
In 1954, Cole and colleagues5 demon
strated venous embolization of colonic
cancer cells and suggested that tumour
manipulation at the time of operation
might predispose to recurrence. Based on
this evidence, Turnbull and associates at
the Cleveland Clinic used a technique of

early venous ligation of the tumour.
Although their results were excellent,3
the data were retrospective and there was
no control group, so it is possible that the
“ no-touch early isolation” method was
only one of the important variables. In
another retrospective study, Bussey and
associates6 found no advantage for early
venous ligation. This technique needs to
be evaluated by a prospective clinical trial.
Ligation of the inferior mesenteric
artery at its origin facilitates extensive
removal of the lymphatics that drain
cancers of the rectum and sigmoid. The
oretically, this should minimize the poten
tial for recurrent disease; however,
Grinnell7 and Busuttil and colleagues8
failed to show any advantage for high
ligation of the inferior mesenteric artery
as opposed to low ligation. Since there are
potential complications with this tech
nique, it cannot be recommended without
further study.
Various mechanical and chemical
measures have been used to prevent
implantation of exfoliated cancer cells.
Tumours that have penetrated the bowel
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wall can be covered and occluding tapes
placed on the proximal and distal sides
of the tumour. Chemical agents used to
prevent tumour implantation in the
peritoneal cavity or in the suture line in
clude nitrogen mustard, cetrimide, dis
tilled water, sodium hypochlorite and
iodinated sutures. Experimental studies of
these substances have produced conflict
ing results and they have not been as
sessed in clinical trials.9
What can be done to improve the sur
gical treatment of colorectal cancer? The
available evidence suggests th a t
meticulous attention to the technical
aspects of surgery will produce the best
results. Treatment is based on a wide
resection of the tumour and an en-bloc
removal of the lymphatic vessels. Sur
geons should also consider ancillary meas
ures to prevent tumour implantation:
occluding tapes, covers for penetrating
tumours and perhaps nontoxic chemical
agents.

The factors influencing tumour recur
rence after surgical resection need to be
studied and controversies such as low
versus high ligation of the inferior mesen
teric artery resolved by clinical trials.
Also, surgical techniques must be stan
dardized in trials of adjuvant therapy for
colorectal cancer, so technical factors do
not obscure important differences.
Colonic cancer is an important cause
of cancer-related deaths in Canadians.
Current surgical practice needs to be care
fully evaluated to ensure that our patients
receive the best treatment.
D.R. G rant , md , frcs[C]
Fellow, Colorectal Surgery,
Toronto General Hospital,
Toronto, Ont.
M5G 1L7
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Excision of Pilonidal Sinus as an Office Procedure
•f

In this issue (pages 604 and 605), Hurst
reports his experience in managing pilo
nidal sinus in an outpatient setting.
Independently, I concluded 3 to 4 years
ago that pilonidal sinus was “ over
operated” upon and also began to
manage these cases in the office. Over the
past 35 months, 26 consecutive cases
managed in this way have produced no
recurrences — at least no one has
returned with problems, although I recog
nize that many are McMaster University
students who may have moved away. My
procedure, slightly different from that of
H urst’s, is also extremely simple.
There are two basic premises: (a) over
bridging must be avoided and (b) recur
rence is caused by hair in the wound,
entrapped by the moisture of the granu
lation tissue. Discouraged by the need for
weekly visits, shaving and the use of
depilatories and by the months of heal
ing time, I followed the suggestion of Dr.
Barton Hexter of Long Island, New York
in the use of a dental Water Pik (Teledyne
Water Pik Ltd., Montreal, PQ) and deve
loped the following routine:
1. For acute infections with abscess,
xylocaine with epinephrine, 0.5 to 1.0
mL, is used. The sinus is incised and
drained, the contents are evacuated and
526

the cavity is wiped out, removing all visi
ble hairs. The patient is encouraged to
take showers twice daily and cleanse the
area vigorously with a washcloth. A dry
4 x 4-inch gauze dressing is applied and
held in place by underwear. Healing
usually occurs in 1 to 2 weeks.
2. For the quiescent sinus with dimples
in a patient with a history of infection,
an ellipse of skin, 4 x 0.5 cm, is excised,
including the dimples, the underlying fat
pad and the sinus. The area is cleansed
by daily Water Pik irrigation, allowing
the wound to heal by secondary intention.
The routine for this is as follows:
• Obtain “ cut down” tray with only
9 to 10 instruments.
• With patient prone on the examin
ing table, tape buttocks apart with 2-inch
tape.
• Apply xylocaine without epineph
rine, 8 to 10 mL, so bleeding vessels will
be immediately visible.
• Excise an ellipse of skin with the
underlying fat pad and sinus. This should
take 3 to 5 minutes.
• Gently blot with gauze sponges,
identify all bleeding points, use silver
nitrate stick for coagulation.
• Observe for 30 to 45 minutes to
ensure that the wound is dry.

• Insert loose gauze pack (one 4 x 4
inch) and instruct patient to remove in the
shower after 36 to 48 hours. Dry dressings are held in place with underwear.
• Institute Water Pik irrigations, three
times a day, 4 or 5 days after excision..* j
• Observe at weekly intervals.
• Expect closure in 3 to 5 weeks.
This procedure is always done on Fri
day afternoon. Two people had bleeding *
(30 to 50 mL) while at home and, returning to the emergency room, they were
admitted for an overnight stay (there is M
always an available bed on Friday). Use
of the dental Water Pik is mandatory. It
costs about $40. and may be used later
for dental hygiene. One boy and one girl •»
who refused to spend this money
experienced delayed healing and required
constant visits to the office to pick out
hairs, shave the buttocks and encourage
perineal hygiene. The shortest healing
time in my experience was 3 weeks. With
a good office nurse who can manage the f
follow-up, this procedure is quick, easy
and simple, the results are good and it *leaves hospital beds free for others.
C. Barber M ueller , md, frcsic]
Coeditor
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Incidence of Funerals and Cancer in Canada
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Despite a steady diet of optimistic survival
reports after sundry treatments for our
common cancers, many practitioners
wonder uncomfortably if in truth we only
succeed in delaying the inevitable. Accept
i n g that many kinds of cancer are fatal
if untreated, the nihilist is tempted to
believe that aggressive intervention may
occasionally improve the unfortunate
patient’s “ quality of life” but rarely succeeds in achieving cure. It is sometimes
difficult to reconcile reports of impressive
,.5-year survivals, free of disease, with the
common observation that funerals for
cancer victims seem as frequent as ever.

A recent report from Statistics Canada
contains welcome news for all profesY
sionals involved in cancer care:1 from
1975 to 1979, inclusive, the mortality
► from several common cancers was con; siderably lower than the incidence of new
►cases. The only reasonable explanation is
that intervention in these particular
cancers has reduced the number of
deaths.
►
This statistical tabulation is worth
V celebrating for other reasons. Most of us
are accustomed glibly to quote survival
♦data for cancer in the United States, Bri
tain and other countries, making the
implicit assumption that these figures also
p . apply to Canada. In fact, both American
and British vital statistics depend heavily
y
on sampling techniques from selected
hospital admissions; but in Canada,
►provincial and federal regulations com
bine to provide central registration not
only of deaths but also of all new cases
of cancer. The data in Cancer Incidence
r and Mortality at Different Ages, Canada
^ 1975-1979' are derived from a national
file started in 1921 and a system of notifi
catio n of cancer from provincial registries
dating from 1969.1 refuse editorial com
ment on a footnote in that publication
(page 5) which ruefully admits that the
4 cancer incidence tables exclude the
province of Ontario “ because recent data
are not available” .
If these dry figures are converted to
histograms, cancer incidence and mortal
ity relative to age can be examined for the
entire Canadian population (assuming of

course that Ontario’s failure to get its
statistical act together did not unduly bias
the results). Since these figures do not
depend on sampling, they may be
superior to similar US and British data.
Fig. 1 shows the leading causes of death
from cancer for both sexes in Canada for
1982, the latest year for which these cal
culations have been made. Similar esti
mates are published regularly for the US
by the American Cancer Society.2
The remaining three figures (Figs. 2 to
4) show age-specific incidence and mor
tality for four common cancers — lung
and colorectal in both sexes, and breast
and cervix uteri in women. These rates are
the annual average per 100 000 of a stan
dard population for 1975 to 1979 inclu-

sive; similar graphs can readily be derived
for other common cancers.
Features of interest include the close
relation between incidence and deaths
from lung cancer in both men and
women, confirming our worst fears about
failure of treatment to modify the death
rate, at least when reviewed in this fashion
(Fig. 2). In fact, this graph is unfair to
those who struggle to treat patients with
lung cancer. In the last decade there was
an increase in the incidence of new cases
of lung cancer in both men and women,
as has been noted elsewhere.3'4 Thus,
any gains in survival may be hidden in a
graph of this kind.
For cancer of the breast and cervix uteri
(Fig. 3), age-specific incidence and mor-

10 20 30 40 50 60 70 80 90
AGE

FIG. 1—Cancer deaths by site and sex,
Canada, 1982, expressed as percentage of total
cancer deaths.

AGE
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FIG. 3—Average annual incidence (solid
line) and mortality (broken line) for cancer o f
breast (left) and cervix uteri (right) in women,
Canada, 1975 to 1979.
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FIG. 2—Average annual incidence (solid
line) and mortality (broken line) for lung cancer
for men (left) and women (right), Canada, 1975
to 1979.
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AGE

FIG. 4—Average annual incidence (solid
line) and mortality (broken line) for cancer o f
colon and rectum for men (left) and women
(right), Canada, 1975 to 1979.
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tality for 1975 to 1979 show a hopeful
separation. Since there is no evidence that
the incidence of either has been increas
ing,34 it appears that intervention is
preventing about half the deaths from
these cancers. For breast cancer, this
result is derived from a period in which
Canadian surgeons moved to abandon
radical mastectomy as the initial treat
ment of choice.5
In contrast, the graph for cancer of the
colon and rectum shows a gloomier pic
ture (Fig. 4). Now ranked second in
importance in both men and women as
a cause of death due to cancer in Canada
(Fig. 1), the difference between the inci
dence of new cases and death rates at all
ages is not impressive, and no sophisti
cated statistical techniques are required to
observe that the number of Canadians
who died of this cancer between 1975 and
1979 were four fifths of the number of
new cases discovered in the same period.
These results are of particular concern to
surgeons since, during this period, the
primary therapy for most colorectal
cancer was excision, the neoplasm
responding poorly if at all to other inter
ventions.6 These disconcerting results
cannot be ascribed to a change in inci
dence of colorectal cancer.3,4

The authors of the Statistics Canada
report1 plan similar future publications.
It is likely that this kind of information
will provide not only food for thought for
practitioners involved in active therapy of
cancer but may also be useful in determin
ing the focus of attempts at prevention
or early detection, and perhaps even indi
cate new directions for research. At the
very least, it may stimulate Ontario to
catch up with the rest of the country.
R.M.
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ISBN 0-7710-1414-7.
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Complications of Fracture Management. ^
Edited by Harry R. Gossling and Stephen ~
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Summary of product information
DEXON * “S”

INDICATIONS: DEXON "S" Sutures and DEXON PLUS Sutures are
indicated whenever absorbable sutures and ligatures are employed.

DEXON* PLUS

POLYGLYCOL1C ACID SUTURE
SYNTHETIC, ABSORBABLE
U SP

POLYGLYCOL1C ACID SUTURE
COATED WITH POLOXAM ER 188
SYNTHETIC, ABSORBABLE
USP

DESCRIPTION: DEXON “S" polyglycolic acid Suture —Synthetic
Absorbable, USP and DEXON PLUS polyglycolic acid Suture —Syn
thetic. Absorbable, USP are homopolymers of glycolic acid, con
structed of filaments finer than in an original DEXON Suture to
provide optimal handling properties. DEXON PLUS Suture, in addi
tion, is coated with poloxamer 188. a surfactant. The coating material
is inert, non-collagenous, non-antigenic and non-pyrogenic.
The sutures are sterile, inert, non-collagenous, non-antigenic, nonpyrogenic, and flexible. The braided and monofilament sutures are
colored green to enhance visibility in tissue. DEXON “S ” and
DEXON PLUS braided sutures are also available undyed with a nat
ural beige color. They are uniform in size and tensile strength, but are
smaller in diameter than other absorbable surgical sutures of equiva
lent tensile strength.
ACTIONS: When DEXON "S" Sutures or DEXON PLUS Sutures are
placed in tissues, a minimal tissue reaction occurs which is followed by
a microscopic layer of fibrous connective tissue which grows into the
suture material.
Absorption studies in animals show DEXON “S” Sutures and
DEXON PLUS Sutures to be equivalent to original DEXON Sutures.
Studies in rabbits revealed minimal absorption at 7 to 15 days, signifi
cant absorption at 30 days and maximum resorption after 60-90 days
With DEXON PLUS Sutures. 80% to 97% of the coating was excreted
in the urine during the first 3 days following implantation in rabbits.
The remainder was excreted within 40 days.
Tensile strength, not being a function of the absorption rate, may vary
from tissue to tissue depending in part on the rate of hydrolysis. The
early tensile strength of DEXON “S" Sutures and DEXON PLUS
Sutures is reported to be greater than that of comparable chromic cat
gut. In animal studies (subcutaneous tissue in rats) it has been shown
that at two weeks post-implantation approximately 55% of the original
tensile strength of a DEXON "S” or DEXON PLUS Suture remains,
while at three weeks approximately 20% of its original strength is
retained.

-*

CONTRAINDICATIONS: DEXON "S" Sutures and DEXON PLUS
Sutures are contraindicated where extended approximation of tissues
under strain must be maintained.
WARNINGS: The safe use of this suture in neural tissue and in car
diovascular surgery has not been established.
Under certain circumstances, notably orthopedic procedures, im
mobilization by external support may be employed at the discretion of
the surgeon.
Do not resterilize. Discard opened, unused sutures.
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PRECAUTIONS: Acceptable surgical practice should be followed
with respect to drainage and closure of infected wounds.
The knot with DEXON “S” polyglycolic acid Suture must be properly
placed to be secure. Therefore, place the first throw in precise position
for the final knot using a double loop; tie the second throw square
using horizontal tension; additional throws may be used as desired.
DEXON PLUS Sutures, which are treated to enhance handling char
acteristics, require the standard surgical technique of flat and square
ties with additional throws if indicated by surgical circumstances and
the experience of the surgeon.
Skin sutures which remain in place for periods of longer than seven
days may cause localized topical irritation and the extended portion of
the suture may be snipped off after five to seven days, as indicated.
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ADVERSE REACTIONS: Those reactions that have been reported
include tissue reaction or inflammation, fibrous or granulation tissue,
bleeding, wound separation in the eye, and accumulation of fluid
around subcuticular stitches
DOSAGE AND ADMINISTRATION: Use as required
HOW SUPPLIED: DEXON ”S" and DEXON PLUS Sutures sizes 8-0
braided through 2 braided (metric size 0.4 —5) dyed green, and 7-0
braided through 2 braided (metric size 0.5 —5) natural beige.
Supplied in cut lengths or ligating reels, non-needled or affixed to the
various Davis + Geek ATRAUMATIC* needles or D-TACH* remova
ble needles USP in one, two and three dozen packages DEXON'S"
Suture, monofilament, dyed green, is available in size 9-0 (metric size
0.3) in a variety of lengths with needles in one dozen packages
1 data on file
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2 data available on request
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Another Use for Temporarily
Placed Atrial Electrodes

To the editors.—The use of temporarily
placed atrial electrodes implanted during
y cardiac surgery has been advocated both
to diagnose and to treat cardiac arrhythV
mias postoperatively.1 We have recently
adapted this technique to allow continu*"ous electrocardiographic (Holter) record
ing of atrial activity in four patients after
coronary artery surgery. The electrodes
y of one of the two leads of an Oxford
I Medilog series 4:24 recorder (Oxford
it Medical Systems Ltd., Abington, Oxon.,
England) were attached as a surface elec►trocardiographic lead while the electrodes
of the other were each attached to one of
the two implanted atrial wires. The Holter
record was then obtained in the usual
way. In all four patients, satisfactory
i y recording of the atrial electrogram and
the simultaneous surface electrocardio► gram were obtained. As a result,
supraventricular and ventricular arrhythV mias could be differentiated more easily
and the P-R interval accurately measured.
As has been found in patients after
myocardial infarction, important arrhyth* mias that were not clinically apparent,
L despite continuous electrocardiographic
monitoring, were demonstrated on Holter
t records.
Ian D. M alcolm ,

m d , frcpicj

D.A. C herry , md
J.E. M orin , m d , fa cs ,
V

Department of Medicine,
y Division of Cardiology,
Department of Surgery,
Division of Cardiovascular
Surgery,
Royal Victoria Hospital,
•- Montreal, PQ H3A 1A1

f
^

'

frcsic ]
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Operative Myocardial Protection
** To the editors.—We appreciate the com
ments and valuable suggestions of Dr.
Tyers (Can J Surg 19S4; 27: 322) in rela
tion to our paper “ Operative myocardial

protection: does an elevated level of crea
tine phosphokinase-M B isoenzyme
always indicate myocardial necrosis?”
(Can J Surg 1984; 27: 80-3). The reason
why the perioperative release of CPK-MB
isoenzyme is greater after valve replace
ment than after coronary bypass may
indeed, as pointed out by Tyers, be due
to the greater mass of myocardium in
many patients with valve disease. Another
possibility is the diminished margin for
error in our technique of perioperative
myocardial protection as a result of the
unique biologic properties of hyper
trophic hearts. For example, Wechsler1
has shown that the baseline content of
high-energy phosphate is lower in hyper
trophic than in normal myocardium, and
the time taken to initiate ischemic con
tracture is substantially shorter in hyper
trophic ventricle during total ischemia,
indicating increased sensitivity of the
hypertrophic myocytes to ischemic injury.
In our article, we suggested that the
CPK-MB isoenzyme released may not
always originate from irreversibly
damaged myocytes. Our clinical study
had one major limitation, as mentioned
in the discussion; we used needle biopsy
to obtain samples of myocardial tissue for
ultrastructural studies, and this does not
assure that there are no “ focal” sites of
myocyte necrosis that could be the source
of CPK-MB isoenzyme leakage. This
issue has been further clarified by the
recent study of Piper and associates2
who showed that in tissue-cultured myo
cytes, early enzyme release can occur in
cells that are not irreversibly damaged;
the leaking enzymes appear to be carried
out by microblebs formed at the cell sur
face. Confirmation of such findings in
relation to CPK-MB isoenzyme release
should offer a definitive answer to this
controversial question.
R ay C-J. C h iu ,

m d , ph d , frcsic ]

Professor of Surgery,
McGill University,
Montreal General Hospital,
1650 Cedar Ave.,
Montreal, PQ
H3G 1A4

2. P iper HM, S c h w a r tz P, S pa h r R, H unter JF,
SPIECKERMANN PG: Early enzyme release from
myocardial cells is not due to irreversible cell damage. J
M ol Cell Cardiol 1984; 16: 385-8

Intragastric Balloons for Obesity
To the editors.—Because we are research
ing into the value of intragastric balloons
in the treatment of obesity, I turned to
the paper by Percival (Can J Surg 1984;
27: 135—6) hoping to discover some valu
able information. I was disappointed to
find that although Dr. Percival has per
formed 108 procedures over 4 years, the
report contained only a single anecdotal
report of weight loss and a few unpub
lished quotes from other sources, which
included no data on weight loss beyond
a few weeks.
There is no justification for publishing
a report recommending a new procedure
without producing data to show it is
effective. The title “ A preliminary report
on 108 patients” is misleading. Surely,
Dr. Percival has performed enough of
these procedures to give us some figures.
R obert M c F a r l a n d ,

m d , frcs

Surgical Research Fellow,
St. George’s Hospital Medical School,
University of London,
Cranmer Terrace,
Tooting,
London SW17 ORE,
England

To the ed ito rs.— In reply to M r.
M cFarland’s letter concerning my paper
on the intragastric balloon for the
management of morbid obesity, I am dis
appointed, of course, that I could not give
a better statistical analysis of my patients
and their progress. Thus the paper was
identified as a preliminary report. I am
in solo practice in a small western Ontario
city with no facilities for research. I am
presently assessing the results of the “ bal
loon diet” and trust that I shall be able
to provide a statistical analysis when the
survey is completed.
W alter L. P e r civ a l ,

m d , frcsic ]
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SURGEONS UPDATE
What s new in surgery is the subject of this column. The short items are designed to let
readers know who s doing what and why. Surgeons are interested in w hat other surgeons
are doing in research, education, practice and administration. Surgery is a vibrant specialty, and,
as its practitioners, you must be the source as well as the readers of this column.

Bone Regrowth:
Stimulating Experience
A Canadian orthopedic surgeon research
ing electrical stimulation to encourage
bone regrowth will be in Japan in Novem
ber to stinulate — he hopes — electric dis
cussion. Dr. Hugh Cameron of the
University of Toronto will be addressing
the annual meeting of the Bioelectric
Repair and Growth Society, Nov. 5-8 in
Kyoto; his subject: findings from a 5-year
cooperative study of bone-growth stimuk- lation with input from colleagues across
the country. He will also be participating
in a panel to review clinical uses of bonegrowth stimulation.
Cameron has been concentrating on the
use of implanted batteries, about the size
of a thumbnail, to improve the outcome
of spinal fusion. His patients have all had
at least one failed attempt at fusion and
f some as many as a half dozen. The bat
tery he used initially — an internal stimu
lator available from 3M — produced an
electric current of 12 piA. However, for
the last 3 years, he has been relying on
one that produces 20 piA around the
cathode. He has had only one failure —
, before he started using the higher current
— even though the failure rate for spinal
fusions is normally 15% and for second
attempts about 30%.
Cameron’s report to the Japanese so
ciety will focus on investigations into an
external apparatus. With Dr. Edward
English, also of the University of
Toronto, Dr. Andre Beaupre of Laval
University and Dr. William DeHaas of
Surrey, BC, he has been documenting a
noninvasive method to stimulate healing
of fractures that have remained ununited
for 9 months to 13 years. The success
rate, says Cameron, is about 80%.
The apparatus is similar to commer
cially available equipment developed in
the United States and marketed there
since 1979. The main component is a
solid-core electromagnet that is attached
to the cast immobilizing an injured limb.
Contributions to this column are welcome.
Please send your material to: Mrs. Amy
Chouinard, Canadian Journal of Surgery, PO
Box 8650, Ottawa, Ont. K1G 0G8.

The major difference is the pulse rate
produced by the electromagnetic field: the
Canadian group has slowed the frequency
considerably (1 to 12 pulses/s). In con
trast, the American equipment produces
thousands of pulses a second. According
to DeHaas, the rapid pulsing may be
responsible for damage to the liver and
other organs in rats subjected to the
American apparatus by Japanese re
searchers. Cameron and colleagues want
the Japanese to test their equipment
thoroughly and are preparing to publish
details of their own findings (a contribu
tion to an American journal that will
devote an upcoming issue to Canadian re
search).
Another experimental method for
inducing new bone growth is showing
promise; it is the use of implants made
of porous material similar to bone
mineral and is geared to providing old
bone with an adjacent medium conducive
to invasion and takeover by nearby
tissues.
An allied problem concerns the bonding
to the host bone of prosthetic implants
for joint replacement. This has tradition
ally been done by the use of plastic
“ cement” . In a new development, the
implants are porous-coated. This allows
host bone to grow into the spaces to pro
vide strong fixation without the use of
foreign material.
Obviously, research is still a long way
from stimulating adult bone to grow more
than about 1 cm, but, says Cameron,
“Don’t forget the salamander’s leg: scien
tists have already stimulated regrowth of
a salamander’s leg. It’s an exciting field.
Magic!”
Oncogene Research:
the Other Side
Ironically, while orthopedic surgeons are
attempting to stimulate cells to reproduce,
doctors involved in cancer research are
searching for a mechanism to “ turnoff”
cell replication. Both groups of research
ers have one thing in common: excitement
and enthusiasm about current progress.
Scientists from the Ontario and Na
tional cancer institutes and from the Uni
versity of British Columbia reported

recent findings about oncogenes at a spe
cial session held during the 53rd annual
meeting of the Royal College of Physi
cians and Surgeons of Canada, held in
Montreal in September. The session was
held in cooperation with the Canadian
Oncology Society and was chaired by
Louis Siminovitch of Mount Sinai Hospi
tal, Toronto.
A. J. Pawson, of the University of Brit
ish Columbia, hypothesized that tumour
development begins during cell differen
tiation, when, normally, human growth
factor is recognized by a receptor and is
carried through the plasma membrane to
the cell nucleus. According to Pawson,
there are several possibilities: the cell
makes its own factor or has an abnormal
receptor, or the receptor takes an abnor
mal route to the nucleus or picks up an
aberrant protein that is similar to the nor
mal factor.
He has opted for the last explanation
— that a mutant protein becomes in
volved in cell differentiation when a
platelet-derived growth factor binds to its
receptor. Pawson believes that the aber
rant protein activates the proliferation of
tissues and the resulting cells phosphorylate tyrosine residues. All human cells
regulate the activity of their proteins by
phosphorylation but not all produce tyro
sine residues. Tyrosine seems to be
characteristic of normal growth factors
that prompt cell division. Aberrant pro
teins are like a broken record, continu
ally instructing the cell to divide.
The theory receives some support from
work at the National Cancer Institute.
Barbacid noted that tumours develop
over 10 years and that researchers are
dealing only with the finished product. He
reported a study in rats injected with
nitrosomethyl urea, carrying a mutant
oncogene, Hras. Cancer developed in rats
that were maturing sexually when they
received the injection, whereas in youn
ger and older rats it did not. These find
ings suggest that the Hras locus plays an
important role in mammary gene differ
entiation.
Hras is part of the ras family of
oncogenes found on human chromo
somes. Other families have been identi-
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The first effective anti-herpes,
therapy is now available in an I.V. j
infusion for treatment of initial and ?
recurrent m ucosal and cutaneous
herpes sim plex infections in im 
munocompromised adults and chil
dren. It is also indicated for severe
initial episodes of herpes simplex*
in fection s in im m u n o co m p eten t t
patients.
(
Highly efficaciou s in con ?
trolled clinical studies, ZOVIRAX I.V
selectively blocks the viral replica-^
tion process and significantly short
ens the period o f viral shedding.
“
ZOVIRAX-treated patients
becom e contagion-free faster.
j
W hat’s m ore, if therapy is
initiated at the earliest possible mo-’1
ment, patients will heal faster and *
experience significantly less pain. ^
To date, efficacy has not
been complicated or compromised
by side effects.
Note: ZOVIRAX I.V Infusion,
is for intravenous infusion only
Th erap y is reco m m en d ed
for at least 5 days for immunocom 
petent p atien ts and for at least 7^
days for im m u n o c o m p ro m ise d
patients.
F i n a l l y . . . ZOVI RAX I.V.
INFUSION.
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REVIEW ARTICLE
Robert Jackson,

m d , f r c p [C]

Epidermotropic Malignant Melanoma: the Distinction
between Metastatic and New Primary Lesions in the Skin

v-

I

Although there are scattered reports in
the literature, little is known of the
difficulties in reconciling the clinical and
histologic findings in patients with malig
nant melanoma in whom more skin
lesions develop in different areas after
removal of the primary lesion. In some
cases, what appears to be metastatic
disease is, in reality, primary. In 33 biop
sies from five patients with clinically
metastatic disease, histologic examina
tion showed metastatic disease in 12
specimens, new primary malignant
lesions in 17 and atypical nevi in 4. The
purpose of this paper is to define and
discuss the difficulties in differentiating
metastatic lesions from new primary
malignant tumours.
Bien qu'on puisse retrouver des rapports
epars dans la litterature, on connait mal
les difficultes qui existent £ concilier les
donnees cliniques et histologiques des
patients atteints de melanome malin,
chez qui on assiste au developpement de
nouvelles lesions cutanges apres resec
tion du cancer primitif. Dans certains
cas, ce qui semble etre une l6sion metastatique est, en fait, un cancer primitif.
Sur 33 pieces de biopsie prises chez cinq
patients souffrant d'un cancer en metastase, I'examen histologique a diagnostiqu6 des mdtastases dans 12 pieces de
biopsie, de nouvelles lesions malignes
primitives dans 17 et des naevi atypiques dans 4. Le but de cet article est de
d£finir et de commenter les difficult^ a
diffdrencier les lesions metastatiques des
nouvelles tumeurs primitives malignes.

I
V

Consultant in Dermatology, The Ontario
Cancer Treatment and Research Founda
tion; Dermatologist, Ottawa Civic Hospital;
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During the last 10 years at the Ottawa
Civic Hospital Clinic of the Ontario
Cancer Treatment and Research Founda
tion, 388 patients with malignant mela
noma have been seen. Of these, 124 had
recorded clinical or histologic evidence of
secondary disease. Of the 124 patients
with secondary disease, 40 had what ap
peared to be metastases in the skin or sub
cutaneous tissue. Table I1 is a synopsis
of generally accepted characteristics of
metastatic melanoma in the skin. Table
II shows the clinical and histologic find
ings in 5 of these 40 patients. Of the 33
biopsies of clinically metastatic disease in
these 5 patients, only 12 biopsies demon
strated metastases, while 17 showed new
primary malignant melanomas and 4
atypical nevi on histologic examination.
In two patients (cases 1 and 3) all the biopsied clinically metastatic lesions were
diagnosed as primary malignant melano
mas. Examples of their histologic appear
ance are shown in Figs. 1 and 2 and com
pared with the appearance of metastases
(Fig. 3).
What would happen to these new
primary lesions if they were not excised
is not known. Would they continue to
grow? Would they eventually metasta
size?
There are two reports2'3 on the histo
logic distinction between primary and
metastatic malignant melanoma in the
skin. Kornberg and associates3 reported
four patients in whom clinically
metastatic disease appeared on histologic

examination in the epidermis and epidermodermal junction with marked inflam
matory infiltration. They used the term
epidermotropic metastatic malignant
melanoma for this phenomenon. They
listed the three microscopic features that
favour the diagnosis of metastatic rather
than primary disease as follows:
1. Thinning of the epidermis by atypical
melanocytes within the dermis, often associated
with widening of the dermal papillae and elon
gation of inward turning rete ridges at the
periphery of the specimen.
2. Atypical melanocytes within intradermal
endothelial-lined spaces and
3. A zone of atypical melanocytes within the
dermis equal to or broader than that within the
epidermis.

A review of our material showed that
the first feature (the elongation and
inward turning of the dermal papillae at
the periphery) was present in only a few
cases. The other two features mentioned
above were not seen in our biopsy
specimens.
It seems as if either our clinical concep
tions of what is metastatic disease or the
histologic criteria for diagnosing meta
static disease are incorrect. How are we
to reconcile these notions?
In a study of 500 patients with malig
nant melanoma, Olsen4 suggested two
possibilities. The first was that the
primary malignant melanoma in some
way activated preexisting benign melanocytic nevi and made them appear histo-

T a b le 1—Fea tu re s of M align an t M e lan o m a M e ta sta tic to the S k in
C lin ic a l
S m a ll- to m edium -sized
p a p u le s or nodules

H is to lo g ic '
b ro w n -b la ck

m acules,

Fre q u e n tly m ultiple
M ore lik e ly in lym p h a tic drainage area o f prim ary
lesion
So m e m ay be deep in derm is or h yp o d e rm is and

C e lls in d eposit sh o u ld be m a lig n a n t
No a typ ica l m elanocytes at th e derm oepiderm al
ju n ctio n , i.e., no " ju n c tio n a l a c t iv it y "
D e p o sit sh o u ld be se p ara te d fro m th e o ve rly in g
ep id e rm is, i.e., there sh o u ld be a gren z zone
L ittle or no in flam m ato ry ce ll in filtra te

m a y prese n t a s sm all rubbery n o d u le s w ith no
c h a n g e in the o ve rlyin g skin
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Table 11-Data on Five Patients with Apparent Metastatic Malignant Melanoma
Interval between
removal of primary
Histologic
No. of
and biopsy of
Site(s) of
Site of
diagnosis
lesions
later lesions, mo
later lesions
primary
Primary
1
20
Chin
Vulva

1

Sex
F

Age,
yr*
67

2

F

39

Neck

Cheek
Cheek
Cheek

3

F

39

Foot

Patient
no.

Primary
Metastasis
Metastasis
Primary

Present
status
Died. MM in lung
and lymph nodes
Alive and
well

75
116
144

1
1
1
1

Calf
Deltoid
Calf
Calf
Chest
Calf

79
79
79
84
84
96

1
1
2
1
1
3
1
1
1
1

Primary
Primary
Metastasis
Metastasis

Died (MM)

Died (MM)

Alive and
well

"I
All new
primaries
-

4

F

61

Leg

Right chest
Nape of neck
Left elbow
Left shoulder

6
6
15
15

5

F

56

Elbow

Neck
Left shoulder
Right shoulder
Scapula
Sites not
identified

40
40
40
40

1
1
1
1

Metastasis
Metastasis
Metastasis
Metastasis

40
40
40
40
42
44
44
44
52

2
1
1
1
1

Primary
Metastasis
Metastasis
Metastasis
Compound nevus
BCN n o ,•
*
BCN J ■ma*,9nant
Primary
Metastasis

Right scalp
Left scalp
Cheek
Forehead
Loin
Back
Neck

2

1
1
1

*A t the time the primary lesion was removed.
MM - malignant melanoma.
BCN = balloon-cell nevus.

FIG. 1—Case 3. Late-appearing new pri
mary tumour in right calf. Nests of malignant
melanoma cells are seen in epidermis, at dermoepidermal junction and in dermis. Mild
inflammatory cell infiltrate is present at base
of lesion. There is no grenz zone (hematoxy
lin and eosin, reduced by 50% from X 100).
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FIG. 2—Case 3. Another new primary lesion appearing 5 months after tumour in Fig. 1 »
Nests and single malignant melanoma cells are seen not only at dermoepidermal junction but
also throughout epidermis. There is no dermal invasion. Moderate inflammatory cell infiltrate ^
is present in upper dermis. There is no grenz zone (hematoxylin and eosin, reduced by 30%
from X 100).
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logically malignant. In the second, she
postulated that whatever originally stimu► lated the melanocytes to undergo malig
nant change existed in an anatomical area
in which other melanocytes could be simi
larly stimulated.
In support of the latter view is the
knowledge that “ activated” melanocytes
nd malignant melanoma can be seen at
he site of a malignant melanoma years
after its total primary removal.5-6 Activa
tion of nevi in patients with malignant
melanoma has been reported by others.7
►Are some dysplastic nevi caused by a
primary cutaneous melanoma? The crux
i f this problem is that the histologic
criteria for differentiation of intraepidermal melanocytic dysplasia from intraepidermal (in situ) melanoma have not yet
been clearly defined.8 Perhaps there is
^some internal factor (perhaps also the
cause of the original tumour) that stirs up
existing melanocytes or moles to produce
new lesions.9
Olsen correlated the location of
primary melanomas with the cutaneous
nerves on the face and neck, the foot and
^ the back.4 She reported that many of the
primary melanomas in her patients
occurred along the course of these nerves.
Could a factor be mediated along these
nerves? Masson10 proposed that cellular
nevi arise in two ways. One is by prolifer
ation of the intraepidermal melanoblasts
similar to that of the junctional nevi fol
lowed by their downward migration into
the dermis. The second is by proliferation
of the Schwann cells of the dermic nerves

and subsequent migration into the dermis.
This problem has not been fully
addressed before because the clinician
assumed that newly appearing mela
nomas, especially in proximity to the
primary lesions, were secondary deposits.
Hence, histologic examination was not
deemed necessary. As I have shown, this
assumption is not necessarily correct.
There are now enough reports to war
rant a reappraisal of our clinical and
histologic criteria for primary and
metastatic malignant melanoma. Perhaps,
even more importantly, we should be
rethinking our biologic conception of
malignant disease of the epidermal
melanocytes. There is sufficient evidence
that in some patients with malignant
melanoma, more than one local malig
nant transformation occurs.
I thank Dr. John Fielding, plastic surgeon
and Dr. Egils Liepa, pathologist at the Ottawa
Civic Hospital, for their assistance.

Addendum
At the 1983 annual meeting of the Ameri
can Society of Dermatopathology, Bergfeld
and associates presented a case in which about
100 new pigmented lesions developed 25 years
after a malignant melanoma was removed
(Arch Dermatol 1984; 120: 1086). Biopsy or
all the lesions demonstrated atypical pleo
morphic melanoma cells within the dermis with
an architectural pattern of junctional, intradermal or compound nevi. Initially it was thought
that the morphologic changes were suggestive
of multiple primary malignant melanomas;

h

Fig. 3a
Fig. 3b
FIG. 3—Dermal metastases. (a) Case 4. Photomicrograph of iate-appearing shoulder lesion
excised 15 months after removal of primary tumour. Note atypical melanocytes in upper der
mis with much melanin pigment. There is clear grenz zone (i.e., area of uninvolved subepidermal
papillary dermis) and epidermis is uninvolved. There is more of round-cell inflammatory response
"than is usually seen in metastatic deposit, (b) Case 5. Neck lesion excised 52 months after remo
val of primary lesion. See three clusters of malignant melanocytes in lower dermis (hematoxy
lin and eosin, reduced by 51% from X 100).

however, the conclusion was that these lesions
represented epidermotropic metastases of
malignant melanoma.
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fied, and every chromosome has at least
one oncogene. The ras family is concen
trated on chromosomes 1, 11 and 12.
Within the ras genes, codon 12 and codon
61 are the hot spots where mutations are
detected. For example, when normal Nras
is detected, its configuration at codon 61
is CAA/GTT; in some leukemias, how
ever, Nras has a codon 61 of GAT/CTA.
To date, only 17 oncogenes have been
detected, and the same oncogenes have
shown up over and over, in different
methods of detection, in about 15% of
tumours.
Oncogenes, or as Pawson refers to
them “ protooncogenes” , are normal
genes that seem to play a key role in cell
differentiation or growth. When they
become mutant or activated by chro
mosomal rearrangements or gene amplifi
cation, they are “ switched on” and so far
no one knows how to predict or reverse
the process.
Concentrated study of oncogenes is
only about 5 years old, although, much
earlier, viruses were found to attach them
selves to normal genes and activate malig
nant behaviour. Bernstein of the Ontario
Cancer Institute pointed out that the
name oncogene derived from cancer re
search but the genes play a role in nor
mal development. Looking at cellular
oncogene expression in normal cells is just
beginning as is the search for people at
high risk for mutant expression. An
understanding of how the proteins func
tion promises to indicate a means to
reverse the process therapeutically.
A m y C h o u in a r d
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Recent Research Suggests...

3.

clindamycin-laden PMN moving
toward the site of infection
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Recent in-vitro research has shown that clindamycin concentrates within
the PMN in amounts greater than are found outside of the PMN.1 The
rates of chemotaxis, phagocytosis and killing of bacteria by PMNs are also
enhanced by the presence of this antibiotic.2*3 These characteristics may
help explain clindamycin’s outstanding record of clinical efficacy in both
anaerobic and gram-positive aerobic infections.
Since host defense factors may be crucial in determining the outcome of
an infection, selection of antibiotics based on host defense parameters
may become a trend in infectious disease therapy.

I

*■

v

1) Klempner MS, et al (Nov 1981) J Infect Dis 144( 5)
2) Johnson JD, et al (March 1980) J Lab Clin Med 95(3)
3) Gemmell C, et al (1980) Current Chemotherapy and Infectious Disease
(eds. J Nelson, C Grassi) Am Soc Microbiol Vol 2
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If colitis is suspected, endoscopy is recommended. Mild cases showing minimal mucosal changes
may respond to simple drug discontinuance. Moderate to severe cases, including those showing
ulceration or pseudomembrane formation, should be managed with fluid, electrolyte, and protein
supplementation as indicated. Corticoid retention enemas and systemic corticoids may be of help
in persistent cases. Anticholinergics and antipenstaltic agents may worsen the condition. Other causes
of colitis should be considered.
Studies indicate a toxin(s) produced by Clostridia (especially Clostridium difficile) may be a princi
pal cause of clindamycin and other antibiotic-associated colitis. These studies also indicate that this
toxigenic Clostridium is usually sensitive in-vitro to vancomycin. When 125 mg to 500 mg of vanco
mycin were administered orally four times a day for 5 -1 0 or more days, there was a rapid observed
disappearance of the toxin from faecal samples and a coincidental recovery from the diarrhea.

Clinical and Laboratory Findings: Patients treated during clinical trials of Dalacin C P h osphat^
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Radionuclide Scintigraphy:
a Valuable Diagnostic Aid in Children with Splenic Trauma
Y

Preserving the spleen in children with
splenic trauma remains a primary con
cern of surgeons. Nonoperative manage
ment has been encouraged in recent
}
years, but this must be balanced against
the risk of delayed rupture of the spleen
;}
and failure to diagnose other causes of
► intra-abdominal bleeding.
The author reviews his experience over
*■ a 10-year period with 36 children who
;
^had a diagnosis of ruptured spleen. The
role of radionuclide scintigraphy of the
spleen has been reviewed recently with
particular reference to its influence on
*- the need for laparotomy. The indications
for laparotomy and the management of
>- splenic injuries are discussed. In the
author's opinion, radionuclide scintigra► phy is a valuable diagnostic aid in chil
dren with suspected splenic trauma.
^ La conservation de la rate chez I'enfant
victime d'un traumatisme splenique
> demeure le premier souci du chirurgien.
Au cours des dernieres annees on a pri►-vilegie un traitement non chirurgical.
Cependant ce choix doit etre pese contre
te risque de rupture retardee de la rate
;
ou le defaut de diagnostiquer d'autres
causes de saignement intra-abdominal.
r
L'auteur revoit son experience de plus
de 10 ans chez 36 enfants ayant eu un
r diagnostic de rupture de la rate. Le role
de la scintigraphie isotopique a ete regvaluee recemment en rapport, particulig-
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rement, avec son influence sur la neces
sity de proceder a une laparotomie. Les
indications de la laparotomie et le traite
ment des blessures de la rate sont
commentes. De I'avis de l'auteur, la
scintigraphie isotopique est un aide
diagnostique utile chez I'enfant chez qui
Ton soupconne un traumatisme
splenique.

Although concerns about the risk of
splenectomy have been voiced over the
past 30 years,1-2 only in the last decade
have these concerns been shown to be
justified.3 Thus, there has been a con
siderable change in thought regarding the
management of all splenic problems, in
cluding splenic trauma. Nonoperative
management of splenic injury has been
advocated for many years,4 but the con
cerns regarding postsplenectomy sepsis
and its associated mortality and morbidity
have certainly helped to make this modal
ity of treatment in children more accept
able. Of equal concern is the risk that un
due conservatism may place the patient
at risk of further morbidity or mortality
because of delayed rupture of the spleen
or missed diagnosis of other intra
abdominal injuries and sources of hemor
rhage. Radionuclide scintigraphy may
help in the diagnosis of a child with sus
pected splenic trauma and in deciding
whether to operate. Our group reviewed
the records of patients with a diagnosis
of splenic trauma treated at Victoria
Hospital during the past 10 years, to as
sess the influence of radionuclide scan
ning of the spleen in the management of
these patients.

mies performed and the influence of the
scanning procedure on the subsequent
need for laparotomy. We reviewed the
incidence of delayed rupture of the spleen
and any associated morbidity or mortal
ity due to nonoperative management.
We also reviewed an additional 19
patients who underwent radionuclide
scintigraphy of the spleen for abdominal
or thoracic trauma but who were not
thought to have splenic injuries on our ini
tial review of the data.
Findings

Of the 36 documented cases of splenic
trauma, 25 were in boys and 11 in girls.
Their ages ranged from 18 months to 16
years, 28 children being between 8 and 16
years of age (Fig. 1).
Cause
A motor vehicle was involved in 20 of
the accidents. In 10 cases the child was
a pedestrian struck by a vehicle, while in
7 the child was an occupant of the motor
vehicle. Three cases involved a bicycle and
car in collision. A fall from a house, horse
or tree accounted for 13 other injuries.
In one case a toboggan collided with a
tree, in another a child was struck by a
train and a third occurred when a child
attempted to make a bicycle become
airborne.
Splenic Scintigraphy
Eleven of the 36 patients underwent
10 -

9-

Patients

No.

?*

°f

From Jan. 1, 1973 to Dec. 31, 1982, 36
children with splenic trauma under the
age of 16 years were treated in our hospi
tal. Eleven underwent radionuclide scin
tigraphy of the spleen. We noted the age
at diagnosis, the cause of the trauma, the
number of laparotomies and splenecto
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FIG. 1—Age of 11 girls and 25 boys with
splenic trauma.
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radionuclide scintigraphy of the spleen.
All demonstrated some defect. An addi
tional 19 patients with suspected trauma
to the abdomen were also scanned; in 16
of these the scan appeared normal and in
3 there was a suggestion of splenic injury.
The defect seen on splenic scanning varied
from decreased uptake in certain areas of
the spleen, suggesting either subcapsular
hematoma or partial disruption of the
blood supply to an isolated area, to frank
disruption of the spleen into two separate
segments (Fig. 2).
Management
O f the 36 patients, 29 had laparotomy
and 28 splenectomy. Twenty-five children
did not undergo splenic scanning and in
this group 24 laparotomies were done. Of
the 11 children who underwent radio
nuclide scanning, 5 had laparotomy. In
the last 4 years of the study (1979 to 1982)
there were 17 children with documented
splenic injury. Nine of 10 children
without scanning had a laparotomy while
only 2 (29%) of 7 children who underwent
splenic scanning had a laparotomy. One
child who underwent laparotomy but not
radionuclide scintigraphy was found to
have a m ajor laceration which was
repaired. This child underwent splenic
scanning postoperatively; the scan
showed excellent healing and return of
function.
Mortality and Morbidity
The mortality for the series of 36 chil
dren was 14% (five deaths). All of these
children had severe neurologic and other
system traum a, with the spleen being
removed because of deteriorating clinical
condition or evidence of continuing
hemorrhage. All of them died of their
head injuries. In children who underwent
splenic scanning, there was no other
source of intra-abdominal bleeding that
caused further difficulties or unsuspected
hemorrhage. One child treated nonoperatively became hypotensive on the 10th
day with a falling hemoglobin level, so a
splenectomy was done for delayed rup
ture of the spleen. So far, none of the
patients who underwent splenectomy has
had an infection, although follow-up in
this group is incomplete. The other 19
patients who had scanning for suspected
splenic traum a were found through our
review of records in the Department of
Nuclear Medicine; 3 of these had sus
pected injuries but were all treated
nonoperatively. In at least two cases the
scanning was done in the outpatient
departm ent by family practitioners
several days after the accident when the
patients were medically stable but con
tinuing to complain of mild left upper
540

quadrant discomfort or chest pain. None
of these patients was admitted to hospital.
Discussion

and partial splenectomy.7 Autotrans
plantation of the spleen has not been
proven to prevent sepsis. None of the-4
procedures should be done if they are
likely to jeopardize the child’s survival. ^
The indications for radionuclide scin
tigraphy fall into two general groups. The*
first includes children with stable vitqj
signs but suspected splenic injury who
have shoulder-tip pain, signs of peritoneal ^
irritation, or unconsciousness and a posi
tive abdom inal lavage. The lastmentioned indication is controversial but
if the unconscious child’s vital signs are'1
stable and scintigraphy gives a positive
result, conservative management can
safely be followed provided a laparotomy
is carried out if the child’s condition
deteriorates. The second group has less r
specific indications; scintigraphy of the
spleen may be a valuable diagnostic aidn
if there are no abnormal findings but the
child has fallen from a considerable
height, suffered severe abdominal or chest
trauma, or has seat-belt marks or other *
bruises and contusions on the upper abdo
men or chest to suggest the possibility of
splenic injury even though abnormal signs 4
are not present. It should be stressed that
splenic scintigraphy is not indicated if
vital signs are unstable.

Splenectomy can no longer be consi
dered the treatment of choice for splenic
injuries secondary to abdominal trauma.
A number of writers have delineated the
importance of the spleen in the immune
response, particularly in children.2'5 Sug
gested causes for the susceptibility to sep
sis include an impaired humoral antibody
response to capsular antigen, a decreased
level of immunoglobulin-M that facili
tates removal of organisms, an overall
decrease in the phagocytic mass that can
not be compensated for by the liver and
remaining reticuloendothelial system and
impaired opsonization. There can now be
no question that sepsis following splenec
tomy is a well-proven entity associated
with substantial morbidity and mortality.
The nonoperative management of
splenic trauma has gained increasing
acceptance; it has been advocated by
many workers over the last 20 years. In
many cases, patients with chest or ab
dominal traum who sustain unsuspected
splenic injury have been treated nonoper
atively because their clinical status did not
warrant laparotomy. Before radionuclide
scintigraphy of the spleen was introduced, Summary
there was no good method of confirming
that the spleen was the source of lessIn 36 children with splenic trauma, the ’’
than-life-threatening blood loss. The incidence of laparotomy was reduced ^
value of this technique to identify the from over 90% in those who did not
!
injury accurately, map its extent and fol undergo radionuclide scintigraphy of tha
low splenic healing has been confirmed.6 spleen to less than 30% in those who did.
It has the added benefit of visualizing the
Radionuclide scintigraphy of the spleen 1
liver and can be done reasonably quickly can play a role in the diagnosis and
with no serious morbidity.
management of suspected splenic injuries; <
The gradual increase in use of this test it can confirm splenic rupture or disrup
over the last 6 to 7 years in our institu tion and is useful for monitoring splenic’*
tion has resulted in a higher incidence of healing. Conservative management is
nonoperative treatment in children with reasonable in the stable patient but close
proven splenic trauma. Twenty-four of 25 observation is needed in hospital for 10 4
patients without splenic scanning under to 14 days and up to 2 months after dis
went laparotomy while less than half who charge. Repair of isolated lacerations, underwent scanning were operated on. In partial splenectomy and splenic artery
the last 4 years laparotomy in those who
underwent splenic scanning was carried
out in less than 30%, compared with 90%
in a similar group treated in this period
who did not undergo scanning.
In reviewing the 24 patients who under
went laparotomy and splenectomy, it was
apparent in 7 that the splenic injury might
have been detected by scanning and
treated without operation. In over two
thirds of the patients who were operated
on, extensive damage to the spleen or the
presence of continued bleeding necessi
tated the splenectomy. Splenic scanning
in these children would not have
influenced their m anagem ent. At
laparotomy, attempts should be made to
preserve the spleen by such methods as
FIG. 2—Radionuclide scintigraphy shows
direct suture, use of hemostatic agents disruption of spleen.
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ligation are all practical approaches to
control hemorrhage in the patient who
►undergoes laparotomy. Overwhelming
sepsis is a real possibility following
r splenectomy. The incidence of sepsis is
lowest following trauma and becomes
much greater in the presence of certain
Ijematologic and immunologic disorders.
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Localized Rigidity and Narrowing of the Antrum:
a Cause of Gastric Outlet Obstruction in Infancy
*in infants with persistent vomiting
without bile staining, in whom congenital
hypertrophic pyloric stenosis has been
excluded, an upper gastrointestinal
roentgenogram may show antral
»• obstruction.
Of four infants with partial gastric out- let obstruction described by the authors,
an antral membrane was demonstrated
^radiologically in two. Other causes of
central obstruction, such as granuloma
tous disease, hour-glass deformity of the
^.antrum, cholecystogastrocolic band and
antral dysmotility, were considered and
-^excluded as the cause of the vomiting.
After medical management failed, gasMroscopy revealed a rigid stenotic circum
ferential area in the antrum in all four
irTfants. An antral membrane was not
^found. Laparotomy confirmed this finding
[ and a pyloroplasty successfully resolved
^ the symptoms.
Localized rigidity and narrowing of the
rpyloric antrum, masquerading as an
antral membrane radiologically, should be

.
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considered among the causes of gastric
outlet obstruction in infancy. Treatment
is determined by the severity of the
symptoms. Pyloroplasty is successful
when medical management fails.
Chez le nourisson presentant des vomissements persistants, avec absence de
teinte de bile, chez qui une stenose con
g en ital et hypertrophique du pylore a
ete exclue, un repas baryta a su demontrer la presence d'une membrane antrale.
Des quatres nourissons souffrant
d'occlusion de I'embouchure gastrique,
des methodes radiologiques ont demontre la presence de telles membranes chez
deux. D'autres causes d'occlusion de
I'antre, telles maladie granulomateuse,
deformation en sablier de I'antre gastri
que, la bandelette cholecystogastrocolique et la trouble de la motilite antrale
ont ete considdrees puis rejetdes comme
cause des vomissements.
Apres I'echec de I'approche medicale,
une gastroscopie dans les quatre enfants
n'a pu demontrer I'existence d'une mem
brane antrale, mais plutot celle d'une
region p£riph£rique de I'antre qui s'avere
rigide et st£nos£e. Une membrane
antrale n'a pas ete trouv6. Une laparotomie a confirme cette decouverte et une
pyloroplastie cura tous les symptomes
associes a un tel etat.
Une rigidity et un retrecissement de
I'antre pylorique, qui apparait comme
une membrane antrale radiologiquement,
doit etre consideres comme les causes
parmi cedes responsables de ('obstruc
tion de I'embouchure gastrique chez le
nourisson. Le traitement approprie a de
telles conditions est determine par la
severite des symptomes. La pyloroplastie

est couronne de succes chez les nouris
sons ou I'approche medicale a failli.

Gastric outlet obstruction in infancy is
usually caused by hypertrophic pyloric
stenosis. Other causes are considered rare.
However, when vomiting is not controlled
by medical treatment and an abdominal
mass is not palpable, further investigation
is indicated.
We describe four patients with
prolonged histories o f vom iting
associated with either failure to thrive or
aspiration pneumonia. Conventional
medical therapy for gastroesophageal
reflux was unsuccessful. In each infant a
partial gastric antral obstruction was
demonstrated. R adiologic studies
appeared to show typical antral webs in
two infants. Endoscopy and operation
revealed a rigid and narrow pyloric
antrum but no membranous web.
Case Reports

Case 1
A 7-month-old girl, weighing 5.9 kg, had
had projectile vomiting since birth. Manipu
lation of feedings and upright posture did not
help. Hospital admission was precipitated by
aspiration pneumonia. Upper gastrointestinal
films showed a distended stomach proximal to
an antral web. Mild gastroesophageal reflux
was noted. Fiberoptic flexible gastroscopy
under anesthesia showed a narrow rigid pyloric
antrum; the gastroscope could not be advanced
from the stomach into the duodenum across
the pyloric antrum. At laparotomy the stomach
was enlarged. A no. 8 Foley balloon catheter
was easily passed by a gastrotomy into the
duodenum. The pylorus was normal but a rigid
ring of tissue was palpable in the antrum. No
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membranous obstruction was found. Full
thickness antral biopsies were taken. The gastroduodenotomy was closed as a pyloroplasty.
The postoperative course was smooth. Histo
logic examination of the gastric biopsy speci
men revealed no abnormality. At 16 months
o f age she weighed 10.3 kg and was
asymptomatic.

obstruction of the gastric antrum (Fig. 2). Gas
troscopy showed gastritis proximal to a rigid
narrow pyloric antrum; the pylorus was not
seen. Laparotomy confirmed these findings
and a pyloroplasty was done. At 1 year of age
he was free of gastrointestinal complaints and
weighed 8.3 kg.

Case 2

Case 4

A 6-month-old boy, weighing 7.9 kg, was
admitted following a prolonged cyanotic spell.
He was noted to have had projectile vomiting
followed by coughing and wheezing since birth.
Upper gastrointestinal films showed a linear
radiolucency in the distal antrum, partial
obstruction of the gastric antrum with a nor
mal pylorus and severe gastroesophageal reflux
(Fig. 1). Under general anesthesia, bron
choscopy and esophagoscopy revealed no
abnormality and the pylorus could not be
visualized. Medical antireflux treatment was
unsuccessful; 3 weeks later, pyloroplasty and
fundoplication were carried out. At 13 months
of age he was free of upper gastrointestinal and
respiratory complaints and weighed 10.7 kg.

Case 3
A 10-month-old boy was admitted, weigh
ing 6.8 kg. Investigations revealed partial

FIG. 1—Case 2. Upper gastrointestinal study
with barium, prone oblique view. Linear
lucency suggests incomplete antral membrane
(arrow) oriented transversely to long axis of
stomach at gastric antrum.

FIG. 2—Case 3. Right decubitus view shows
antral narrowing without lucent membrane
(arrows). Note distended stomach proximally.
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A 19-month-old boy who weighed 9.0 kg was
admitted with chronic projectile vomiting.
Upper gastrointestinal films showed gastric
outlet obstruction caused by an antral web and
gastroscopy revealed a rigid antrum with ste
nosis by a narrow, rigid ring 2 to 3 cm prox
imal to the normal pyloroduodenal junction.
A pyloroplasty was done. For 1 year he has
been free of upper gastrointestinal complaints
and is thriving.

Discussion

Antral webs have been described in
patients of all ages.1'2 Infants present
with nonbilious vomiting without a pal
pable pyloric tumour. The diagnosis is
made by a careful gastrointestinal roentgenographic study. The typical radiologic
sign is a linear filling defect perpendicu
lar to the long axis of the antrum.3 The
web is usually situated within a few cen
timetres of the pyloric canal. The central
aperture of the antral membrane has a
variable diameter. In fact, a central aper
ture diameter greater than 1 cm is gener
ally not associated with obstructive sym
ptoms and is an incidental finding on the
upper gastrointestinal films in older chil
dren and adults.4 Histologically, the
membrane is lined by normal gastric
mucosa, covering the submucosa with a
median common muscularis mucosae.2
The antral web seen in roentgenograms
may have no demonstrable associated
gastric anatomical abnormality.5 Re
peated roentgenographic examinations
may fail to show any antral abnormality
— the findings may be transient. In these
patients signs of obstruction are uncom
mon. Characteristically, the symptoms
are mild and respond to medical
management.
In each of the four infants described,
symptoms were severe and did not
respond to conventional antireflux treat
ment, which included the use of
metoclopramide, 0.1 mg/kg four times
daily, taken during feeding. The upper
gastrointestinal films were important in
localizing the partial antral obstruction.
In cases 1 and 4, an antral web was
demonstrated. Other causes of antral
obstruction in infancy were excluded,
such as the rigid narrowing of the entire
antrum (as seen in chronic granulomatous
disease), a cholecystogastrocolic band,
annular muscular hypertrophy (hour
glass deformity of the antrum) and antral
dysmotility6 characterized by delayed

gastric emptying, a funnel-shaped antrum
and absent antral peristalsis.
Patients demonstrating lack of disten-^
sibility of the prepyloric antrum
associated with partial antral obstruction
on upper gastrointestinal series should
undergo fiberoptic gastroscopy. The*
thickness of the antral web may be 2 mm
or less and thus the web may be miss<St
radiologically unless it is seen tangentially
at fluoroscopy. Gastroscopy failed to~*
show the antral web seen radiologically
in cases 1 and 4 but did demonstrate a
narrow, rigid, stenotic segment of antrum,
2 to 3 cm proximal to the pyloroduodenal
junction. In the first three childraa
described, the rigidity of this segment of
the antrum would not allow visualization^
of the distal normal pylorus at gas
troscopy. Although this endoscopic find- y
ing in the antrum was confirmed at
laparotomy, no characteristic antral wall
abnormality was demonstrated histo
logically.
It is possible that a thin antral mem--*
brane could be ruptured at gastrostomy,
resulting in the erroneous conclusion that 4
no antral abnormality was present.
However, the absence of an antral web*
at both gastroscopy and operation witji
obvious localized antral rigidity suggests
that the pseudomembranous partial
obstruction of the gastric antrum with its
rigid, nondistending characteristics, seen-*
in our patients, constitutes a true entity
and must be considered in the differen- *
tial diagnosis of antral obstruction in
infancy.
y
We concur with previous authors3 th^t
the radiologic diagnosis of partial antral
obstruction must be evaluated further by^
fiberoptic gastroscopy. In the absence of
an antral web, the gastric antrum should —
be carefully examined, looking for local
ized rigidity and narrowing.
^
The indication for operation in these
infants is the clinical severity of the dit
ease and the failure of conventional med-^
ical treatment. The symptoms in such
children have been successfully resolved .,
by pyloroplasty.
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Surgical Management of Persistent Postoperative
Chylothorax in Children
►

Chylothorax occurring postoperatively in
* children is found most commonly after
cardiovascular operations, but may occur
^ after almost any thoracic procedure.
Seven cases of postoperative chylo
thorax seen at the Children's Hospital of
Eastern Ontario in Ottawa from 1976 to
1983 are reported. Two resolved with
nonoperative management and five
required surgical intervention.
>
The authors discuss the clinical
presentation, treatment and outcome.
They describe a simple, safe and effec
tive method of ligation of the thoracic
duct just above the diaphragm.

Le chylothorax postoperatoire chez
*- I’enfant est observe le plus fr6quemment
apres une operation cardiovasculaire,
' mais il peut survenir apres presque
n'importe quelle intervention thoracique.
y Sept cas de chylothorax postoperatoire
<yit 6te observes ci I'Hdpital pour enfants
de Test de I'Ontario, a Ottawa, de 1976
^a 1983. Deux se sont corriges grace a
un traitement non chirurgical alors que
■t cinq necessitaient une operation.
!
Les auteurs commentent le tableau cli►nique, le traitement et I'issue. Ms decrivent une methode simple, sure et efficace de ligature du canal thoracique
^ juste au dessus du diaphragme.

,. Chylothorax occurring postoperatively
has been reported after alm ost every
►known thoracic procedure.1'2 In children
it is seen in 0.25% to 0.5% of cases, most
dbmmonly after cardiovascular opera
tions.3
r Persistent chylothorax may be fatal.4
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The mortality before 1948 was as high as
50% but this rate improved markedly af
ter L am pson5 reported a case of
chylothorax treated by ligation of the
thoracic duct. The availability of
medium-chain triglycerides and total
parenteral nutrition has further decreased
the morbidity and mortality and has per
mitted successful nonoperative manage
ment in most cases.1,3’6
There has been a lack of clear guide
lines with respect to the duration of
nonoperative management and to replace
ment of oral feeding by total parenteral
nutrition. Also, agreement is lacking as
to the timing of surgical intervention and
which procedure is best.
Children with postoperative chylotho
rax are often debilitated and have com
promised cardiovascular function.1,3
There has been a lack of confidence in
surgical management and this has, in
many cases, unduly prolonged nonoper
ative treatment,7 leading to further nutri
tional, metabolic and immunologic de
terioration.1,3
In this paper, we report seven cases of
postoperative chylothorax seen at the
Children’s Hospital of Eastern Ontario,
Ottawa, from 1976 to 1983. In four pa
tients the condition was managed by li
gation of the thoracic duct just above the
diaphragm, using a simple, safe and ef
fective method that we describe.
Case Reports
Case 1
A newborn girl weighing 1.88 kg had
esophageal atresia and distal tracheoesophageal
fistula. The esophageal atresia was repaired
and the fistula divided extrapleurally through
a right thoracotomy without unusual difficulty.
A right pleural effusion appeared 2 days after
operation despite extrapleural tube drainage of
the right side of the chest. The following day,
thoracentesis yielded 60 mL of chylous fluid.
A chest tube was inserted and a total of 90 mL
of chyle drained in 24 hours. The baby was
started on total parenteral nutrition. Over the
next few days, chylous drainage gradually
decreased and then ceased. The tube was
removed 8 days postoperatively.
There was no further recurrence and the
child remains well.

Case 2
This 4-year-old black girl with Noonan’s syn
drome, an endocardial cushion defect and pul
monary artery stenosis, underwent patch
angioplasty of the pulmonary artery, closure
of an atrial septal defect and pulmonary valvotomy through a left thoracotomy. Fifteen
days postoperatively a low grade fever and a
left pleural effusion developed. A pleural tap
yielded 350 mL of chylous fluid. Five days later
chest-tube drainage was required because fluid
had reaccumulated. Chylous fluid, 150 to 355
mL/d, drained for 6 days, then drainage gradu
ally decreased. The chest tube was removed 25
days after operation. Nine days later, a large
pleural effusion developed on the right side;
a right chest tube was inserted and 250 mL of
fluid was removed. For 4 days, daily drainage
was 50 to 125 mL and then it gradually
decreased spontaneously. The right chest tube
was removed 11 days after its insertion. Left
chest drainage was required for 16 days and
drainage of the right side for 11 days.
The baby was treated initially with mediumchain triglycerides given orally for 15 days and
then with total parenteral nutrition for 10 days.
She was discharged home 11 weeks after oper
ation in satisfactory condition on a mediumchain triglyceride diet.

Case 3
This 7-year-old boy underwent a Fontan
procedure for treatment of a single ventricle
and transposition of the great vessels.
Postoperatively, congestive heart and renal
failure developed.
Bilateral precordial chest tubes drained large
amounts of chylous fluid starting 3 days
postoperatively. Between 1000 mL and 3000
mL drained daily for 2 weeks. This required
replacement with intravenous plasma and albu
min. The drainage gradually decreased after
he had been started on a diet of medium-chain
triglycerides. Chest tubes were removed 4
weeks after operation. Gradual reaccumulation
of pleural fluid and increasing dyspnea
required insertion of bilateral chest tubes.
Between 750 and 1200 m L/d of chyle con
tinued to drain despite treatment with total
parenteral nutrition. Thrombosis of the left
subclavian vein further complicated his clini
cal condition and increased the drainage of
chyle.
His metabolic and nutritional status con
tinued to deteriorate. Because of poor cardiac
function, operative treatment was delayed in
the hope that his general condition would
improve. Ligation of thoracic duct through a
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right thoracotomy was finally done 8 weeks
after the initial cardiac operation. Drainage of
chyle completely disappeared immediately after
operation. He was treated postoperatively with
total parenteral nutrition, but his malnutrition,
electrolyte and acid-base imbalances increased
and his immune response deteriorated. Chest
tubes were removed 6 and 8 days after thoracic
duct ligation. He remained in poor general con
dition and died of disseminated candidiasis 16
days after operation.

Case 4
This newborn premature twin girl, who
weighed 910 g, underwent ligation of a patent
ductus arteriosus through a left posterolateral
thoracotomy at 12 days of age. She required
endotracheal intubation and assisted ventila
tion and received total parenteral nutrition
postoperatively.
The endotracheal tube was removed 4 days
after operation. Several attempts to extubate
her failed and a left pleural effusion gradually
developed. Because of the persistent left pleural
effusion, she was treated with daily pleural taps
for 6 days and 27 to 28 mL were aspirated at
each tap. Twenty-five days after operation a
left chest tube was inserted and up to 94 m L/d
of chyle drained.
Her thoracic duct was ligated through a left
thoracotomy 6 weeks after the initial operation.
Postoperatively, very little fluid drained and
the chest tube was removed 4 days after oper
ation. She was promptly extubated and dis
charged home 18 days after thoracic duct liga
tion to continue on a diet of medium-chain
triglycerides for 2 weeks. She has since been
taking breast milk.

Case 5
This boy with Noonan’s syndrome and a sin
gle ventricle underwent a Fontan procedure at
12 years of age.
He did well for 1 year, then he was readmit
ted to the hospital with dyspnea, congestive
heart failure and a left pleural effusion. He was
found to have elevated pressure in the superior
vena cava. A pleural tap yielded 800 mL of
chylous fluid. He was treated with repeated
thoracentesis and a diet of medium-chain
triglycerides for 4 weeks and then was put on
total parenteral nutrition. A right pleural effu
sion developed and so bilateral chest tubes were
inserted. Despite total parenteral nutrition,
large amounts of chylous fluid continued to
drain from both chest tubes (up to 1330 mL/d)
with gradual general deterioration.
After 8 weeks of conservative management
with chest-tube drainage and total parenteral
nutrition, he underwent ligation of the thoracic
duct through a right thoracotomy. In this case,
our technique was not used and attempts were
made to isolate the thoracic duct. Two ducts
were found. These were ligated and metallic
clips were applied. Postoperatively, large quan
tities of chyle kept draining and his condition
continued to deteriorate. He died of staphylo
coccal septicemia 8 days after thoracic duct
ligation.

Case 6
A 9-month-old girl with transposition of the
great vessels and pulmonary outflow obstruc
tion underwent a Senning procedure with resec
tion of the pulmonary infundibulum and liga
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tion o f a patent ductus arteriosus at 8 months
of age. Five days after operation, a right
pleural effusion developed, requiring chesttube drainage o f about 260 m L /d of chyle. She
was treated with medium-chain triglycerides for
4 weeks and then with total parenteral nutri
tion and fasting for 1 week. There was no
reduction in chest drainage.
She underwent low supradiaphragmatic liga
tion o f the thoracic duct through a right
thoracotomy with our technique after 5 weeks
of conservative management. Postoperative
drainage of chyle was negligible and the chest
tube was removed 6 days after operation. She
was discharged home 2 days later.
She was readmitted 2 months later with other
cardiac problems but she showed no recurrence
of the chylothorax.

Case 7
A 1500-g newborn girl with esophageal atre
sia and distal tracheoesophageal fistula under
went division of the fistula through a right
thoracotomy, but anastomosis of the esopha
gus was not possible because of the large gap
between the esophageal segments. At opera
tion, she was found to have a right-sided ao r
tic arch. A small aortic laceration was repaired.
Ten days after operation, a right pleural effu
sion developed. A chest tube was inserted and
110 mL of clear yellowish fluid was removed.
She continued to drain chylous fluid with
volumes up to 196 m L /d despite fasting and
total parenteral nutrition. After 2 weeks of con
servative management, she underwent ligation
of the thoracic duct through a right thoracot
omy with our technique. A feeding jejunostomy was also performed.
Drainage completely disappeared within 24
hours and the chest tube was removed 5 days
after operation.
The chylothorax resolved completely but she
subsequently required abdominal surgery for
intestinal obstruction. She will also require
reconstructive surgery for her esophageal
atresia.

Comments
O f seven children with postoperative
chylothorax, the condition resolved in
two with nonoperative management.
The technique for ligating the thoracic
duct that we shall describe was used in
four of the five patients who required
operative treatment of the chylothorax.
Control of the chylous fistula was com
plete and almost immediate in these four.
In the fifth case, a different surgical tech
nique was used and the chylous fistula did
not close. That patient died of septicemia

{Staphylococcus aureus and S. epidermidis) 8 days after thoracic duct ligation.
This patient had Noonan’s syndrome and .4
his chylothorax appeared 1 year after a
Fontan procedure. We have included this 5
case in our series but the lymphatic abnor
malities are not known and the role of*
Noonan’s syndrome in the etiology o f the
chylothorax is not clear.8
*
One of the four children treated using
our technique died of disseminated can
didiasis 16 days after ligation o f the ^
thoracic duct. His chylous fistula had
closed but he had severe malnutrition, -1
metabolic problems and a poor immuno
logic response to infection.
■*
In all five patients treated surgically, it
had been impossible to control the ^
chylous fistula with either the administra
tion of medium-chain triglycerides or
total parenteral nutrition. The two^
patients who died had severe congenital
heart disease with transposition o f th«
i
great vessels and both underwent a Fon
tan procedure. In both cases, large -*
amounts of chyle drained, a total of 1470
m L/kg in one and 1190 mL/kg in the
other. Nonoperative management was
prolonged — for 8 weeks in both patients.f
All children had chylomicrons in thg. :
pleural fluid but in the newborn with
?
esophageal atresia who had never been
.
fed (case 7), their presence was ques
tionable.
-*
All children had a high chyle lympho
cyte count. The laboratory findings are *
shown in Table I.
?
Ligation of the Thoracic Duct

4

Anatom y o f the Thoracic Duct

^

The statement by Selle and associates9
that the thoracic duct is always single
between the 8th and 12th thoracic ver-^
tebrae has been refuted by others.3’6,10’12
The thoracic duct is the main collecting
vessel of the thoracic system and is a
prolongation of the cisterna chyli. It 4
begins at the level of the first or second
lumbar vertebra and ascends on the right
side of the aorta. After entering the chest
it passes from the right to the left side of
the mediastinum about the level of th§
fifth thoracic vertebra. It continues
upwards to empty into the left innominate -»
vein.10,13' 15

Table 1-Summary of Chyle Drainage and Chyle Examination
Total
Patient Onset after Average daily drainage, Presence of
no.
surgery, d drainage, mUkg
mL
chylomicrons
1
2
24
230
Yes
2
15
8
2 815
Yes
3
3
70
32 822
Yes
4
10
26
94 5
Yes
5
365
24
30 732
Yes
5 697
6
5
19
Yes
7
10
30
1 796
Yes
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;

Fat
Positive
Positive
Positive
Positive
Positive
Positive
Not measured

Total <
Lymphocytes, proteins,
no.lmL
gIL
7 600
5 200
2 650
7 500
1 463
High
2 324

28
74
18
49
46
23
42
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Although this is the anatomy usually
described, there are many variations. For
^example, the level of convergence of the
contributing channels may be thoracic
rather than lumbar. Multiple sacculations
may be seen along the course of two or
►Three converging channels. Cross anasto
mosis can also occur and in the upper
fciest there are communications with pul
monary lymphatic channels via the bron
chomediastinal trunks and the internal
mammary lymph chains. At the diaphrag
matic hiatus the thoracic duct or ducts
^consistently enter the chest on the right
side of the aorta lying on the vertebral
(jolumn.1'3'6'8-16
The duct is provided with valves and
i ►has muscular walls. In the adult, the
volume of chyle produced is about 2.5
L/d on full oral diet. It may fall to 10 to
15 mL/h (240 to 360 mL/d) in the fast’ing state.1'6'10
Surgical Technique
Low supradiaphragmatic ligation of
the thoracic duct has been well described
in the medical literature.6'7'16 We have
^modified the technique of Murphy and
fiper16 and Patterson and colleagues6
who recommended mass ligation of all tis
sue between aorta and azygos vein just
above the diaphragmatic hiatus. Because
we believe that multiple lymph channels
may be present at any level in the thof- rax,3’6'10’11 we mass ligate all tissues lying
to the right of the aorta and in front of
vthe anterior ligaments of the vertebral
column. We also include the azygos vein
in our ligatures. The ligation leaves bare
the ligaments of the vertebral column.
This technique can be performed
through either a right or left thoracotomy
although the right approach is preferable.
►Aposterolateral thoracotomy through the
seventh or eighth intercostal space will
jfrovide adequate exposure. When pleural
adhesions are present, we divide only
those interfering with exposure of the
diaphragmatic hiatus and those in the
supradiaphragmatic area.
y No special attempt is made to find the
chylous fistula. The diaphragm is
detracted inferiorly and the lung superi
orly and anteriorly. It may be necessary
T o divide the inferior pulmonary ligament.
The mediastinal pleura is incised and the
esophagus is identified by a tube passed
^into it from above. After isolation of the
esophagus as inferiorly as possible, it is
retracted anteriorly. The aorta and azygos
vein are identified. All the tissue to the
right side of the aorta, including the
azygos vein, is isolated using a curved
clamp. This tissue is ligated en bloc at
three different levels. The tissue between
^ligatures should not be divided and no
further dissection should be done above
or below the ligatures, to avoid further
injury to the thoracic duct or ducts.

Metallic clips are used only to mark the
thoracic duct between the ligatures for
radiologic identification. Clips should not
be used instead of nonabsorbable liga
tures as recommended by others,1'7
because they may cut through the ducts
or incompletely occlude them. But if
small lymphatic ducts are seen around the
esophagus, these can be clipped.
Since children with persistent chylothorax postoperatively are in critical condi
tion, no time should be wasted in trying
to cannulate the thoracic duct for radiologic identification. It is also unnecessary.
A chest tube should be inserted. If chyle
loculation is suspected, adhesions should
be lysed enough to drain the accumulated
fluid.
Discussion

Postoperative chylothorax has been
reported after almost all thoracic proce
dures,1,2'17 including insertion of central
venous lines by subclavian puncture61819
and translumbar aortography.20'21 It is
most commonly seen after cardiovascu
lar operations.3 Noonan’s syndrome has
been reported to be associated with lym
phatic abnormalities.8
Chylothorax has also occurred with
penetrating and blunt thoracic trauma
and with spinal cord injuries.2,8 It may
be related to congenital lymphatic ab
normalities and may follow birth
trauma.1,2-22 It may occur in association
with neoplasms and mediastinal infection
(e.g., tuberculosis and filariasis) and aor
tic aneurysm.1,2 The condition may be
seen after thymic dissection in cardiac sur
gery. This is especially true when elec
trocautery is used. Vessels should be
ligated instead of cauterized in thymic dis
section.3,7 In our series it is difficult to
blame thymic injury for such a large
volume of chylous drainage. Direct injury
to the thoracic duct is much more likely.
Chylothorax has been reported to occur
spontaneously after thrombosis of the
superior vena cava.2,17'18 This association
was fatal in three newborn babies
reported by Kramer and associates.11
Chylothorax has been produced
experimentally in dogs and cats by Bla
lock and associates23 after ligation of the
superior vena cava distal to the entrance
of the azygos vein. When ligation of the
thoracic duct preceded ligation of the
superior vena cava, chylothorax did not
occur.
In one of our cases, thrombosis of the
left subclavian artery aggravated the
chylothorax and probably contributed to
the patient’s death.11,17
Elevated central venous pressure and
pulmonary edema can increase lymphatic
flow.7-24'25 In five of our patients, this
factor could have contributed to the per
sistence of the chylothorax. The two
patients who died had severely com

promised cardiorespiratory function. It
has been stated that since chyle comes
from the intestinal lymphatics, the
thoracic duct must either be ruptured or
obstructed for chylothorax to occur.8
This is not necessarily true since lymphan
giography has demonstrated retrograde
flow from the thoracic duct to pulmonary
and pleural lymphatics.u '24'26'27 If this is
correct, then chylothorax can also occur
after injury to the thymus and bron
chom ediastinal
trunks
through
anastomosing lymphatics.
Postoperative chylothorax should be
suspected whenever a pleural effusion or
persistent pleural drainage develops after
a thoracic procedure, especially cardi
ovascular surgery. Although it is more
likely to occur from 2 days to 4 weeks
postoperatively, it may rarely occur many
months after operation.1,3'11 In one of
our cases, chylothorax occurred 1 year
after a Fontan procedure. The severity of
the condition is determined by the volume
and rate of the chyle lost. Chronic and
profuse loss will be followed rapidly by
malnutrition, electrolyte, fluid and acidbase imbalances.''3'7'n '25 Prolonged loss
of T cells in chyle will decrease the
patient’s immunologic response to infec
tion.6 When the patient is fasting, the
fluid may be clear but after feedings it will
be milky and a creamy superficial layer
separates on standing. Chyle is alkaline
and creamy, and when fat is extracted by
alkali and ether, it is odourless, sterile and
bacteriostatic. The specific gravity ranges
from 1.012 to 1.025. It contains fat glob
ules (chylomicrons) which stain with
Sudan III. It contains lymphocytes (400
to 6800/mL) and erythrocytes (50 to
600/mL). The protein content is 20 to 60
g/L and the sugar and electrolyte content
is similar to that of plasma.1'3,6'17 Chyle
also contains fat-soluble vitamins and the
thoracic duct is the route of entry of intestinally absorbed vitamin K.7,28
Serum protein levels may fall in the
presence of chylothorax. Lymphocytope
nia may occur and progressively more
immature lymphocytes will appear in the
peripheral blood smear. These changes
may lead to a mistaken diagnosis of
lymphoma.29
The presence of chylomicrons in a
pleural effusion is pathognomonic of
chylothorax. Chyle contains long-chain
triglycerides since medium-chain triglycer
ides are hydrolyzed in the intestine and
pass directly into the portal system as free
fatty acids.3'11'25,30
Lymphangiography has been advo
cated to identify the chylous fistula and
demonstrate any abnormalities of the
lymphatic system.2'6,7,26 We did not per
form this examination because it is tech
nically difficult in small children and
because complications such as oil pulmo
nary embolism may occur.6,31 Above all,
we did not think this investigation would
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change our approach to the problem.
In newborns and small children, the
chylous effusion can mimic segmental
consolidation and atelectasis. This may
delay the diagnosis of chylothorax."
After the diagnosis has been estab
lished, drainage of the pleural cavity is
performed by repeated pleural aspiration
or by chest-tube drainage. There are
advantages in both techniques. In chil
dren it is usually preferable to insert a
chest tube. Repeated taps are difficult and
painful.
Supportive measures are very impor
tant. Chyle must be carefully measured
and replaced with fluids, plasma and
albumin. Medium-chain triglycerides
should be given orally early,32 and con
tinued as long as chylous drainage
decreases. If there is no improvement
after 1 week, total parenteral nutrition
should be started and oral diet stopped.
Some au th o rs3 have advocated
increasing fat, protein, fluid and carbo
hydrates in the diet to replace the loss in
chyle. However, it has been demonstrated
that even oral fluids will increase thoracic
duct flow.1’17 On the other hand, fasting
will decrease it.4,25 Attempts to reinfuse
chyle intravenously are mentioned only to
be condemned since this can lead to severe
anaphylactic reactions and sepsis.2’7,17 If
after 1 week of fasting and total paren
teral nutrition chyle continues to drain at
the same or an increased rate, thoracic
duct ligation should be performed.
In addition to excessive loss of chyle,
there are other indications for operation.
These include intractable nutritional and
metabolic problems caused by the chylo
thorax and problems related to the
administration of total parenteral nu
trition.
The successful use of medium-chain
triglycerides and total parenteral nutrition
in the treatment of chylothorax and some
dissatisfaction with surgical management

have sometimes led to undue prolonga
tion of conservative management with dis
astrous results.3'7,17'25 The two deaths in
our series clearly underline this problem.
Although it is difficult to attribute their
deaths to the chylous fistula alone, it is
unquestionable that the chylothorax
played an important role in the outcome.
Even when the nutritional and metabolic
problems can be corrected, immunologic
depletion will eventually lead to
problems.3,6 Both these patients died of
sepsis.
M ost au thors1,3,4,6,7,17 recommend
thoracic duct ligation after 2 to 3 weeks
if there has been no response to conser
vative management. Pleural symphysis by
either pleurectomy or talc pleurodesis has
been advocated in conjunction with
thoracic duct ligation.25 We found this
procedure unnecessary in our patients but
it may be useful in patients with a malig
nant tumour when recurrence is antici
pated.
In the adult, drainage of over 1000
m L /d for more than 7 days is taken as
an indication for operation.4,6 In chil
dren, daily drainage of 100 mL/year of
age has been quoted as an indication for
operation.12 We found that all our
patients requiring thoracic duct ligation
drained more than 15 m L/kg daily.
Our recommendations, having re
viewed our seven patients and the litera
ture, are shown in Fig. 1. Progression
from a diet of medium-chain triglycerides
to fasting with total parenteral nutrition
is indicated; if no improvement is noticed
after 2 weeks, we recommend low
supradiaphragm atic ligation of the
thoracic duct with the technique
described. This method is a safe, simple
and effective way of controlling the
chylous fistula as demonstrated by almost
immediate cessation of chylous drainage
in the four patients treated by this
technique.

FIG. 1—Proposed therapeutic approach to postoperative chylothorax. MCT = mediumchain triglycerides, TPN = total parenteral nutrition. No improvement = over 15 mL/kg daily
of chylous drainage, over 100 mL/year of age daily and over 1000 m L/d in adult.
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Early diagnosis and adequate suppor
tive treatment are extremely important
since most fistulas will resolve without .
operation.1,6,17,22,25
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Evolution of Intracranial Aneurysm Surgery
In the late 19th and first half of the 20th
centuries, intracranial aneurysms were seldom treated and when they were, Hun
terian occlusion of the carotid artery was
almost always performed. Although a
k few pioneer intracranial procedures were
done in the 1930s, it was not until after
World War II that a major effort was
made to obliterate aneurysms during
1 craniotomy.
Rebleeding before operation and ische*Wiia with vasospasm were the chief
causes of the high morbidity associated
with early surgical attempts and even
now they remain a problem. However,
since the operating microscope was
introduced and with modern neuro
anesthesia, intracranial surgery has
y- become routine and reasonably safe,
especially since simple modification of
The ischemic syndrome by volume expan
sion and hypertension has proved
* effective.
A return to early operation is now
under evaluation. Treatment of
^ aneurysms on the basilar circulation
came later and experience in dealing
ywith giant aneurysms on both the
carotid and basilar systems is now
*■ accumulating.
Vers la fin du 19e siecle et durant la pre^ miere moitte du 20e, les anevrismes
T intracraniens etaient rarement traites et,
»Jorsqu'ils l etaient, une occlusion de Hun
ter de la carotide etait presque toujours
pratiquee. Bien que quelques interven-
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tions intracraniennes aient ete realisees
au cours des annees 30, ce n'est
qu'apres la Deuxieme Grande Guerre
qu'un effort majeur a ete porte a I'obliteration des anevrismes par craniotomie.
Les recidives hemorragiques avant
I’operation et I'isch^mie avec vasospasme sont les principales causes de la
morbidity elevee qui a ete rattachee aux
premieres tentatives chirurgicales et,
meme maintenant, elles demeurent un
probleme, Toutefois, depuis I'avenement
du microscope operatoire et avec I'arrivee de la neuro-anesthdsie moderne, la
chirurgie intracranienne est devenue courante et relativement sure, surtout depuis
qu'une simple modification du syndrome
ischemique par expansion de volume et
hypertension s'est averee efficace.
Un retour vers une operation precoce
fait maintenant I'objet d'une evaluation.
Le traitement des anevrismes de la circu
lation basilaire est arrive plus tard et on
accumule maintenant de ('experience
dans le traitement des anevrismes geants
des systemes carotidien et basilaire.

I am particularly honoured to be asked
to give the Gordon Murray Lecture since,
as a young resident, I had so much ad
miration for Gordon Murray. Dr.
McKenzie* was aware of his genius and
suggested that I watch and listen to him
as much as I could. He was curious,
thoughtful and innovative in his thinking
and experimental work, and that led to
truly remarkable pioneer efforts in blood
vessel, heart and renal disorders in a
doubting medical world. He seemed to
need recognition, but perhaps it was the
character of his genius that caused his
difficulty with the Establishment.
Ravitch1 stated: “ the frequency with
*Kenneth G. McKenzie, Canada’s first neuro
surgeon, was appointed to the Department of
Surgery, University of Toronto in 1923 after
a year of training with Harvey Cushing. He
served as head of the neurosurgical unit at the
Toronto General Hospital until his retirement
in 1952 when he was succeeded by Dr. Harry
Botterell.

which his seemingly far-fetched proposals
proved to have merit may have led him
to be insufficiently critical when late in
his career he was enthusiastic about repair
of the transected spinal cord” . Even so,
he must be one of the most renowned sur
geons in the history of surgery in Canada.
Cerebral Aneurysms

Rupture of a cerebral aneurysm has
likely afflicted mankind since ancient
times. Although references are sparse and
incomplete, historians have suggested a
probable example in the Old Testament:
“ And he said unto his Father, my head,
my head! . . . And when he had taken
him and brought him to his mother, he
sat on her knees till noon, and then died”
(II Kings 4: 18-20). Since this quotation
refers to a child, however, it was more
likely the rupture of an arteriovenous
malformation.
Walton2 provided a detailed historical
review of subarachnoid hemorrhage in
1956 but noted that only towards the end
of the 19th century did the syndrome,
produced by spontaneous bleeding into
the subarachnoid space, begin to emerge
from the heterogenous group of condi
tions known as apoplexy. It was not until
the early 1920s that it was generally recog
nized as a distinct clinical entity, chiefly
as the result of the writings of Fearnsides,3 Collier4 and, particularly,
Symonds.5 Albright,6 reviewing the 30
cases published to 1929, in addition to 2
of his own, wrote: “ It is to be hoped that,
as the diagnosis becomes more exact,
some surgical technique can be developed
to save this unfortunate group of
patients.” He even postulated intracranial
ligation of carotid aneurysms. Only in the
last 20 years has the extent of the problem
become really known — that cerebral
aneurysms exist in about 5% of the popu
lation. Although most are small and less
than the critical size of 5 to 6 mm, when
they become dangerous, about half of
those reaching or exceeding this size,
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untreated, will ultimately destroy the per
son who harbours one.

until succumbing to myocardial infarction
12 years later.
Following Dott’s report, other sur
Carotid Ligation
geons described direct attack on intra
cranial aneurysms. Tonnis,11 in 1934,
Although carotid ligation was used split the corpus callosum to cover the sur
occasionally in the late 17th and through face of an anterior communicating
out the 18th century for injury, particu aneurysm with muscle, and McCon
larly for carotid cavernous fistulas, as well nell,12 in 1937 in Ireland, opened a subas a few cervical aneurysms, there is only chiasmal aneurysm and packed it with
one account of its use for nonfistulous muscle. Walter Dandy of Baltimore
intracranial aneurysm before this century. added immeasurably to intracranial
In 1885, Sir Victor Horsley had exposed procedures when he first trapped a carotid
a middle fossa tumour and found it to be cavernous aneurysm in 193613 and then
an aneurysm. The carotid artery was in 193714 used a McKenzie silver clip to
ligated in the neck and Keen7 reported occlude the neck of a carotid com
that the patient was in “ extremely good municating aneurysm which had pro
health” 5 years later. In 1924, Magnus8 duced third nerve palsy. In 1944,15 he
in Copenhagen had opened a trigeminal was able to report on 64 aneurysms found
tumour for intractable trigeminal neural at operation. In 36 operations designed
gia and a sixth nerve palsy. About half to treat the aneurysm, the mortality was
o f the old clot was removed before “ a 25% but he believed that 55% of the
great gush of blood appeared that could patients were cured. He even described
not be stopped with tamponade” . For coagulating and shrivelling aneurysms
tunately, Magnus had just ligated the with the Bovie electrocautery, which he
external carotid artery because of a tear thought might be the safest way to des
in the middle meningeal artery at the skull troy them!
base, and ligation of the internal carotid
In 1938, German16 reported the first
promptly stopped the bleeding. The excision of an aneurysm of the posterior
remaining contents of the aneurysm were cerebral artery after occipital lobectomy.
removed, and the patient was relieved of Following this, others tackled the
his pain although a paresis of his left hand problem . Jo h n so n 17 described the
developed 3 days after operation. In 1940, difficulty in giving priority to any one of
Schorstein9 reported on 60 cases of the procedures recommended; McKenzie
carotid ligature for the treatment of non- of T oronto mentioned excising an
traumatic saccular intracranial aneur aneurysm; Wilkins described opening an
ysms; 27 were collected from the litera aneurysm in error; Poppen stated that he
ture and 33 from the British experience. preferred to surround an aneurysm with
Eight patients died and eight had hemiple strips of muscle; Lyerly described a case
gia, a 13% incidence of each. Although in which he ligated the artery and
he suggested that Wilfred Trotter was the removed the sac; and Fay related remov
first to ligate a carotid artery without hav ing an aneurysm under the impression it
ing first exposed an intracranial aneurysm was a meningioma. Dandy15 appears to
in 1924, the aneurysm was traumatic in have credited William Cone with the first
origin producing severe epistaxis. In not resection of an aneurysm, but Cone’s
ing Grey Turner’s case in 1928, he was not excision in Montreal of a small anterior
aware that Walter Dandy, in the same communicating aneurysm from a school
year, also had occluded the internal boy that ruptured again intraoperatively
carotid artery for a ruptured intracranial was done in December 1938, obviously
carotid aneurysm;6 both patients had a after German’s operation.18
Dott continued to be innovative,
localizing oculomotor paresis with the
describing in 194110 the opening and
hemorrhage.
stuffing of a large ruptured middle
cerebral aneurysm with muscle while
Intracranial Procedures
using temporary occlusion of the middle
cerebral artery with an artery forceps
The first planned intracranial operation whose handles were proximated gently
was done by Norman Dott in 1931.10 with an elastic band. This must be the first
The stern, crusty chairman of his hospi use of temporary proximal cerebral artery
tal board had had three successive hemor occlusion. In 1944,10 for the first time,
rhages at intervals of only a few days the Hunterian principle of proximal liga
without localizing features except left tion was used intracranially when Dott
periorbital pain. At craniotomy, he fol clipped a dominant anterior cerebral
lowed the left carotid artery up through artery proximal to a ruptured anterior
the subarachnoid clot to define an communicating aneurysm.
aneurysm near its bifurcation and in
vested the sac in muscle. The patient, with Cerebral Angiography
a changed and pleasant demeanour,
perhaps related to the hemorrhages or the
After Roentgen’s discovery of x-rays in
frontal lobe retraction, remained active
1895, a number of investigators carried
550

out experiments to visualize the vascular
system of animals and man. But Egas
Moniz19 and his surgical associate Lima20 mI
are credited with the introduction of
cerebral angiography in 1927. Intracranial J
aneurysms were demonstrated as early as
1932. Norman Dott was the first to use.
arteriography in 1933 as a guide to su rg i-^ B
cal treatment.21 After ligating the caro tid ^H
artery for a carotid aneurysm visualized
with Thorotrast, he reported: “ Arterio- ~^j
graphy has now come to our aid. By this j
means an intracranial aneurysm can be
seen, together with the cerebral arteries.” '
Although Moniz had described carotid
angiography in 1927, it is remarkable howt
slowly its importance and utility were
recognized. Even Dandy, the originator J
of ventriculography, the first method of
imaging the brain, noting the use of it in
1944, said “ It is quite possible . . . that
I may yet come to use it.” In part, this ’
slowness in recognition was due to a lack,
of a nontoxic contrast material. Thorium
j
dioxide (Thorotrast) had been introduced A
in 1930 but soon was unacceptable for
|
intravascular use because of its radioac- *
tivity. In spite of this, it was used for
several years — I can remember restrict- *
ing its use for older patients in the 1940s, \
and even early 1950s because of its toler
ance by the brain and its aging of arterj
ies in contrast to Diodrast which had been
introduced in 1941.
4
Postwar Development of
Aneurysm Surgery

!
•V

The further development of aneurysm
surgery came to a standstill during World
War II and really only began again in the ^
late 1940s. Meanwhile, Richardson and
Hyland22 of Toronto had provided new „
stimulus to the recognition of intracranial
aneurysms when they defined the problem
further in a classic study that correlated
i
the clinical and pathologic findings and1
showed the diverse nature of cerebral i f J
aneurysms and the consequences of their
|
rupture. At that time, however, their atti
tude favoured medical management of
subarachnoid arterial hemorrhage.
4
By 1955, 278 patients had been oper
ated upon for intracranial aneurysm with4
an overall mortality of 28.4% — but in
J
the various small series, the mortality ^
varied from 8% to 8 6 % .23 No doubt this
was the reason why most surgeons
\
preferred to use carotid ligation in which ,
the reported mortality was about 15%. I
recall Sir Geoffrey Jefferson saying about
that time that carotid occlusion was the
sheet anchor for surgical treatment of *1
aneurysms.
But it soon became apparent that
'
carotid artery ligation was useful only for
aneurysms arising from the carotid artery *
itself, for which it did not prevent allf j
rebleeding. This technique was also
associated with considerable risk of mas-
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sive cerebral infarction, especially early
after bleeding, although the risk was les
sened if the common rather than the inter■'-nal carotid artery was occluded.
In Toronto, to my knowledge, planned
direct intracranial approach for an
aneurysm was not carried out until late
949. A 50-year-old man with a subarachoid hemorrhage was referred to Harry
otterell who planned to approach and
clip the middle cerebral aneurysm during
the following week. Unfortunately, the
patient bled again during the weekend
and, as the resident surgeon under Dr.
" G . McKenzie, I removed the right temoral clot and exposed the aneurysm,
emarkably, it was on a temporal branch
of the middle cerebral artery and could
be excised; the patient recovered although
a severe left hemiparesis resulted. Even
so, the interest of the whole service was
Handled. Soon, after watching three
women die of recurrent bleeding under
Conservative management, two of them
^ on the bed pan, we persuaded Drs.
Hyland and Richardson to let us make
„ direct attack on the aneurysms. I remem
ber a few successes and several disastrous
^operating room scenes when the
aneurysm was ruptured prematurely dur
ing its dissection. Harry Botterell used
McKenzie’s silver clip for the neck when
he could, but used Dott’s technique for
anterior communicating aneurysms. But
I saw McKenzie char a carotid aneurysm
with the Bovie cautery, probably because
he knew Dandy who had used this
^method. On another occasion when the
neck of the aneurysm was too large for
his clip, McKenzie tried to suture the neck
with the pin suture technique — with dis* astrous consequences. Nevertheless, when
I left the service in December 1950, Harry
Botterell and I were aflame with the pos
sibilities for treating this calamitous dis
order. McKenzie recognized the future,
tf o, but said he was too old to take it on,
that it was a game for young men. He sent
►me to see Jefferson in Manchester, Dott
in Edinburgh and Olivecrona in Stock
holm. Olivecrona was not only ligating
the neck of aneurysms with linen thread
out resecting arteriovenous malforma
tions for the first time. These men were
the contemporary pioneers of the first
. forays into the stroke field.
Surgery early after a rupture was the
l mark of that day in an anxious effort to
( prevent the disaster of recurrent bleeding;
it is important to remember the circum
stances of those operations. The brain
was swollen with a red and angry look,
little was known about anesthesia for
brain operations and the anesthetists were
all too often uninterested, and usually not
dedicated. To glimpse the circle of Willis
-♦meant tapping the ventricle and even then
firm, even harsh, retraction of the fron
tal lobe was required. Removal of a clot
made things a little easier. These

aneurysms proved to be very fragile, often
On Lougheed’s return, Botterell began
bursting with the least manipulation. to use the technique for aneurysms dur
Application of the small silver clip fre ing which both carotid and vertebral
quently tore the neck, often because of arteries might be shut off temporarily in
the blunt nose of the appliers, which were the neck for up to 15 minutes. Their pub
difficult to manipulate in the narrow con lication in 195625 aroused the neurosur
fines on either side. The bleeding gical world, for here at last was a means
obscured the field and these closed clips of preventing complications of cerebral
could not be removed. Frantic clip appli ischemia while operating on a soft
cations could not be accurate and often aneurysm in a dry field under a slack
the parent artery or an important branch brain. An interesting sidelight to that
was occluded, sometimes deliberately to paper was the introduction of the first
prevent the patient from bleeding to widely accepted grading scale for
death.
subarachnoid hemorrhage for which the
Temporary closure of the carotid artery Botterell name is now most widely used.
exposed at the same time in the neck, or Moderate hypothermia, to 28°C, was
by the anesthetist’s thumb, was helpful used for more than 400 operations on
in making the sac softer or in controlling cerebral aneurysms at the Toronto
hemorrhage. In 1946, Gardner24 in General Hospital over a decade. It was
Cleveland had introduced deliberate sys also used for some head injuries and other
temic hypotension for brain procedures disorders. Gradually, as microsurgical
by withdrawing large quantities of blood techniques improved, it was found
into a reservoir, a form of hypovolemic unnecessary in most situations, particu
shock. Soon after, reduced blood pressure larly when deeper levels of artificial
with pharmacologic ganglionic blockade hypotension, down to 40 mm Hg, were
became available and this was used in the found to be safe at normal temperature.
early 1950s for aneurysm operations.
Deep hypothermia to 15°C or lower,
with cardiac arrest and exsanguination
Use o f Hypothermia
under cardiopulmonary bypass, was tried
in New York,27 Rochester28 and London,
Botterell and colleagues in 195625 in Ontario29 in the early 1960s. But there
Toronto first used hypothermia for oper were bleeding problems in the brain and,
ations on intracranial aneurysms. It began like moderate hypothermia, it did not pre
with Lougheed who had just finished 6 vent vasospasm and ischemia. Hypother
months with Dr. Murray and was on his mia was, therefore, abandoned in the
way to Boston. He knew, of course, early 1960s in favour of deeper levels of
about Bigelow’s experimental results on hypotension and delayed operations.
hypothermia in animal models. He had
seen the catastrophes in the operating Arterial Spasm
room, with inadvertent rupture of fragile
aneurysms and felt that, as the cardiac
Gradually, a new phenomenon was
surgeons were doing for the heart, so the recognized, peculiar to early direct oper
neurosurgeons had to do for the brain to ation on a ruptured aneurysm. It occurred
control the inflow and outflow of the par even when the operation went smoothly,
ent artery while the aneurysm was being the brain being reasonably slack with
dissected and occluded. In Boston, in accurate application of clips. Initially, the
1954, William Sweet supported Lough patient would recover well without deficit
eed’s research, which at first was directed only to deteriorate a few hours or days
towards cooling only the animal’s brain later. This deterioration often would be
with a primitive perfusion pumping sys signaled by confusion and the complaint
tem.26 In order to maintain perfusion of a tingling or weak arm that showed
pressure, the cerebral vascular resistance postural drifting. Within a few hours the
rose to dangerously high levels. Further patient would be stuporous and hemi
more, most of the animals died from plegic. A postoperative clot was usually
fibrillation when the cold blood reached suspected, but when urgent reoperation
the heart. Turning to general body was undertaken, only a swollen, softened
hypothermia with surface cooling in ice brain would be found. As a consequence,
water, he showed in animals that there death or severe neurologic deficit was
was some protective effect during tem commonplace. It did not take much per
porary cerebral ischemia. The results were suasion for my neuroradiologic colleague,
promising enough that two procedures John Allcock,30 to do angiography
were done by Dr. Sweet on patients under postoperatively on these patients. This
general hypothermia at the Massachusetts puzzling sequence was shown to be
General Hospital before Lougheed’s associated with severe arterial narrowing,
return to Toronto — one for glioblastoma the vessels irrigating the hemisphere often
and the other for a cerebral arteriovenous being no larger than threads. The brain
malformation, in both of which tem showed swelling and infarction. This
porary interruption of a portion of the arterial spasm became dreaded and was
cerebral circulation was used without blamed for the poor results in otherwise
infarction.
uncomplicated aneurysm surgery.
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During the same period it was learned
that in operations carried out a week or
more after bleeding, the brain could be
made slack, the dissection was easier,
hypotherm ia was unnecessary, the
ischemic phenomenon with arterial spasm
seldom occurred and the results were
satisfactory. Consequently, operation
tended to be delayed until the acute reac
tion of the brain and its vessels had sub
sided, for few surgeons would accept the
high morbidity of early operation which
in most instances equalled or exceeded the
risk of rebleeding. During the 1950s, some
clinical observers were appalled at the
mortality and morbidity of early opera
tions and then at the disasters that
occurred from rebleeding while the sur
geon waited for the patient to become a
good risk. Wide acceptance of the emerg
ing intracranial operations was slow. In
1960, McKissock and associates31
reported the only controlled study of the
surgery of aneurysms, which suggested
that surgical treatment was no better than
the conservative measure of bed rest for
a few weeks. This study, in my view,
deterred for a while the development of
intracranial techniques and experience in
many centres.
In 1968, Mullan and Dawley32 used an
antifibrinolysin, epsilon aminocaproic
acid systemically to preserve the clot, seal
ing the rent in the aneurysm for 1 to 2
weeks until the patient became a good risk
for surgical treatment. In initial studies,
it appeared to reduce rebleeding by about
50%. This was seen as a remarkable
accomplishment and surgeons, under this
safety umbrella, were even more inclined
to delay operation for about 1 week.
There was some concern that more
ischemic calamities would occur but the
real extent of this was not known until
1983.33,34
Because of the lethal effect of arterial
spasm and its prohibition of life-saving
early operation, there was an extraordi
nary amount of research, both clinical
and experimental, on its nature and relief.
It is now known to occur to some degree
in most patients who, on computerized
tomography, show evidence of blood in
the basal cistern; the degree of narrow
ing and subsequent ischemia seem to be
directly and predictably related to the
thickness of the clot around the basal
arteries. Correlation of cerebral blood
flow in vasospasm and ischemia has only
recently been established by Ferguson and
associates.35 One of the difficulties is
that the brain tolerates a reduction in
blood flow to nearly half its normal value
before neuronal function decays. This
explains why some patients are neurologically well in spite of severe narrowing
exhibited by angiography, even though
they were probably teetering on the brink
o f ischemic disaster with any insult such
as craniotomy.
552

Initial attempts at relief were centred
on altering the vasospastic state. Every
conceivable vasoactive drug, given alone
or in combination, systemically or locally,
was tried without consistent success. In
the 1960s, low-molecular-weight Dextran
showed promise in improving perfusion
but was not widely favoured because
prolonged use led to a bleeding disorder.
Only recently36 has it become known
how effective the improvement of perfu
sion can be from blood-volume expan
sion, with albumin and artificial hyper
tension if necessary. Sustained reversal of
hemiplegia and aphasia are now common,
dramatic events.
The fragile nature of the intracranial
aneurysm, the problems associated with
limited exposure and accurate clip appli
cation in tears of its neck have led to the
development of other means for its con
tainment that do not require wide
exposure and prolonged meticulous dis
section. These include coating with gauze
or plastic (muscle was shown to be of no
use) and promoting intraluminal throm
bosis by injecting animal h air37 or
thrombogenic wire38 into the sac. Even
iron filings have been injected into
anterior com m unicating aneurysms
through a fine needle placed through a
burrhole into the sac and held there by
a magnet until thrombosis occurs.39
The initial appeal of intraluminal
thrombosis was tempered because often
the neck was not included and this could
expand into a new and dangerous sac.
Encasement to be effective demands fairly
complete dissection so that a clip can be
applied instead. Gauze is an insecure re
straint during the months required for a
firm fibrous sheath to form but plastic
coating is still used for otherwise
unmanageable complex aneurysms. A few
aneurysms have grown out of the plastic
encasement at the base and have ruptured
again.
Magnification
Magnification has been an obvious
need, and in the late 1950s, 2.5 x loupes
were first used which, with the subsequent
development of near coaxial fiberoptic
light sources, gave the first good magni
fied view of the depths of the exposure.
The surgical microscope, which first saw
neurosurgical use in the mid-1960s, was
not widely used until about 1970. Lougheed was certainly the first to use it in
Canada and one of the first in the world.
This increased greatly the scope o f mag
nification, providing not only much
higher magnification, perfect coaxial
lighting and side-arm viewing for the
assistant, but also television monitoring
for the other operating staff and for
teaching. It was a whole new world in
which to operate with extreme accuracy
and gentleness; occlusion o f the neck of

the aneurysm is now the safer, surer treat
ment of choice. This advance meant that
new clips and finer instrumentation were _4
required. The introduction o f the spring
clip to neurosurgery by Schwartz and
Mayfield was a landmark in that it could
be removed if imperfectly placed or used
temporarily,40 and neurosurgeons have^
designed much finer clips with modified
tions of this principle. As a consequence
of these technical advances, the morbidity
of intracranial operations on aneurysms
of the carotid circulation has lessened dra
matically so that now a satisfactory out
come is to be expected in over 90% in the
hands of experienced surgeons as long a;
the brain has not been irreparably injured
by hemorrhage.
Vertebral and Basilar Aneurysms

The history of surgical treatment of
aneurysms on the vertebral and basilat*
circulations is much shorter, probably
because of their lower incidence (10% to ■*
15%), the later development o f vertebral
angiography and the belief that because
of their hidden position in front of and ^
embedded in the brain stem, little could
be done about them.
In 1958, a 50-year-old farmer was
admitted after two subarachnoid hemor
rhages. An aneurysm, projecting forward
from the basilar artery at the origin of the fi
superior cerebellar arteries, was disco- j
vered at angiography. Although it was
considered an inoperable area, the more '
I thought that if any such aneurysm could *
be managed successfully, this was the one^
Working on cadavers to find a suitable
approach to the aneurysm, I decided that ^
the subtemporal would be best, perhaps
with division of the tentorium. Dr. ^
McKenzie thought I should try it but the :
family refused. Another coma-producing-t
hemorrhage occurred suddenly, leaving
the patient drowsy and confused with af?
upward-gaze palsy. The family were now ^.j
anxious that something be done. I was j
able to clip the aneurysm uneventfully
and the patient recovered completely in
3 weeks and farmed thereafter f o r years. 4
Had a catastrophe occurred, m y views
might have been different but I was theri
convinced that the region was approach
able. W ithin 2 years, f o u r more
aneurysms in the region of th e basilar
bifurcation were obliterated, b u t three
patients died, although for ottier than
technical reasons.41 F o u rteen cases
would be reported in 196542 a n d it waj»
during this time that the importance of
the perforating arteries was recognized
and means to preserve them developed.
A new clip43 was developed for th e bifur
cation aneurysm with an aperture in its
base to accommodate the posterior
cerebral artery in order to avoid the critt
ical and dangerous dissection of this
artery from the fragile base °f
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aneurysm. The clip has largely solved the
technical aspects of basilar bifurcation
^aneurysms but it has seen much wider use.
Literally every artery or its branches and
the optic and oculomotor nerves44 have
been accommodated in the aperture. Its
se in tandem and in parallel has proved
to be the answer for most open giant
eurysms.45
Today our experience with vertebral
and basilar aneurysms encompasses more
than 1100 cases. It appears that those of
ordinary calibre are as safely treatable as
those of the anterior carotid circulation.
For example, the overall morbidity for the
ordinary basilar bifurcation aneurysm,
which was the most difficult to treat in
the beginning, is now down to about 5%.
The problem of larger aneurysms, up to
2.5 cm in diameter, took longer to solve
but with the use of a temporary proximal
clip, accurate clipping of the neck of the
softened aneurysm can be carried out so
as to spare the large branches and vital
perforators. There are some remaining
difficulties with giant basilar aneurysms,
particularly when the neck is firm with
atheroma or mural thrombus or involves
*a substantial segment of the basilar artery
tLat gives rise to vital branches.

culation appeared to be marginal. In the
case of occlusion of the middle cerebral
artery, the tourniquet was used to test the
efficiency of the bypass.45 Externalinternal carotid artery bypass has been
used in the Hunterian treatment of over
60 giant aneurysms of the carotid and
middle cerebral arteries. Other major
intracranial arteries have also been
occluded without bypass: anterior
cerebral, 5 cases; posterior cerebral, 25;
basilar artery, 50 and vertebral arteries
bilaterally, 16.
Delayed versus Early Operation

Neurosurgeons in the 1960s and 1970s
became reasonably content with the
results of delayed operation for ruptured
aneurysm, many assuming that antifibrinolysins retarded rebleeding safely
for the operation in a majority of cases.
However, it became apparent in about
1980 that the overall management success
in those series considering all patients in
whom an aneurysm had ruptured, regard
less of their condition, was little better
than 50%.47 It was estimated that only
one in three patients having a subarach
noid hemorrhage due to an aneurysm ever
came to operation! This stunning revela
Giant Aneurysms
tion has prompted a review of the causes
of this huge morbidity and a re-evaluation
Except for giant aneurysms found on of early surgery in many centres.
the carotid artery where treatment by
What has become apparent is that
carotid ligation was possible, little has aneurysms in many patients go unrecog
been recorded for the surgery of huge nized until catastrophic bleeding occurs
♦-aneurysms elsewhere in the cerebral cir and that antifibrinolysins, while truly
culation. Because of a special interest, our retarding rebleeding, appear to be asso
Service now has an experience with nearly ciated with more vasospasm and brain
500 such aneurysms.45 What has been ischemia so that the morbidity after 2
learned is that many have necks small weeks is the same whether or not
enough for clipping or necks that can be antifibrinolysins are given.33'34 On the
made so, particularly using the Drake clip other hand, evidence is accumulating that
rin tandem or in parallel. Where neck early operation with modern neuro
occlusion is not possible, the use of the anesthesia, with a slack brain and using
Hunterian principle of proximal ligation microsurgical techniques, is reasonably
of the major artery giving rise to the safe in certain circumstances. This at once
aneurysm has been expanded from the removes the threat of rebleeding and
carotid artery alone to include all the allows vigorous anti-ischemic measures,
major arteries of the brain.46 These have including induced hypertension to control
proved to be very effective procedures brain ischemia if it develops. These have
when the collateral circulation is ade been remarkably effective in sustaining
quate. No surgeon had dared to occlude reversal of ischemic deficit in about 80%
the middle cerebral artery deliberately, of patients. But the optimum timing of
but when external-internal carotid artery operation has not been established. A
bypass became available in 1969, it multicentre international study of early
seemed an obvious way of providing col surgery is now under way and will be
lateral circulation for middle cerebral reported in Toronto in July 1985 at the
artery occlusion or isolation in the treat World Congress of Neurosurgical Socie
m ent of certain inoperable giant carotid ties. If early operation improves the out
and middle cerebral artery aneurysms. look appreciably, then it will place an
Our initial experience with Hunterian enormous responsibility on physicians for
ligature and bypass was reported in public education and to recognize the ini
Toronto in 1977, and subsequent experi tial, often minor, warning hemorrhage
ence has supported the use of this meth which indicates that a state of emergency
od. The application of a snare or tour exists. It will require more organization
niquet around the artery to be occluded within neurosurgical units to deal with
was introduced to test the collateral cir these problems on a continuing emer
culation after the patient was awake if cir gency basis.
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Whenever anaerobic infection cannot be ruled out

FLAGYL 5 0 0

(metronidazole)

A selective anaerobicide
ACTIONS
Flagyl (metronidazole) is bactericidal against
anaerobic bacteria, it exerts trichomonacidal activity
and is also active against Giardia lamblia and
Entamoeba histolytica. Its exact mechanism of action
has not been entirely determined as yet. It has been
proposed that an intermediate in the reduction of
metronidazole, produced only in anaerobic bacteria
and protozoa is bound to deoxyribonucleic acid and
proteins, and inhibits subsequent nucleic acid
synthesis.

INDICATIONS AND CLINICAL USES
Bacterial Infections: The treatment of serious
anaerobic abdominal infections due to susceptible
anaerobic bacteria, such as Bacteroldes fragilis (and
other species of Bacteroides), Clostridium,
Fusobacterium, Peptococcus, and Peptostreptococcus
species.
Culture and susceptibility studies should be
performed to determine the causative organisms and
their susceptibility to metronidazole. Based on clinical
judgment and anticipated bacteriological findings,
therapy may be started while awaiting the results of
these tests. In mixed aerobic and anaerobic infections,
consideration should be given to the concomitant
administration o f an antibiotic appropriate for the
treatment of the aerobic component of the infection.
(See Warnings).
Flagyl (metronidazole) has also been used in the
treatment of a small number of cases of brain or lung
infections (some with abscesses) caused by anaerobic
bacteria.

CONTRAINDICATIONS
Flagyl (metronidazole) is contraindicated in
patients with a prior history of hypersensitivity to
metronidazole or other nitroimidazole derivatives.
Flagyl should not be administered to patients with
active neurological disorders or a history of blood
dyscrasia, hypothyroidism and hypoadrenalism.

WARNINGS
Flagyl (metronidazole) has no direct activity
against aerobic or facultative anaerobic bacteria. In
patients with mixed aerobic/anaerobic infections,
appropriate concomitant antibiotics active against the
aerobic component should be considered.
Known or previously unrecognized moniliasis may
present more prominent symptoms after treatment
with Flagyl.
Studies in rats and mice have provided some
evidence that metronidazole may cause tumors in
these species when administered orally for a long
period at high doses. The relevance of these findings
in humans is not known.
Severe neurological disturbances (i.e. convulsive
seizures and peripheral neuropathy) have been
reported in patients treated with Flagyl (administered
orally or intravenously). These have oeen observed
very infrequently.

PRECAUTIONS
Patients taking Flagyl (metronidazole) should be
warned against consuming alcohol, because of a
possible disulfiram-iike reaction. For the same
reason, patients receiving Flagyl should not be
administered disulfiram concomitantly.
Transient eosinophilia and leukopenia have been
observed during treatment with Flagyl. Regular total
and differential leukocyte counts are advised if
administration for more than 10 days or a second
course of therapy is considered to be necessary.
Metronidazole crosses the placental barrier.
Although Flagyl has been given to pregnant women
without apparent complication, it is advisable that
oral administration be avoided in pregnant patients
and Flagyl be withheld during the first trimester of
pregnancy. In serious anaerobic infections, if the
administration of Flagyl to pregnant patients is
considered to be necessary, its use requires that the
potential benefits be weighed against the possible
risks to the fetus.

Metronidazole is secreted in breast milk in
concentrations similar to those found in plasma.
Intravenous or oral administration of Flagyl should be
avoided in the nursing mother.
Metronidazole has been reported to potentiate the
anticoagulant effect of warfarin resulting in a
prolongation of prothrombin time. This possible drug
interaction should be considered when Flagyl is
prescribed for patients on this type of anticoagulant
therapy. Clinical experience in children is very limited.
The monitoring of this group of patients is particularly
important. The safety and effectiveness of intravenous
Flagyl in children has not been established.
A rare case of reversible but profound neurological
deterioration has been reported following a single oral
dose of Flagyl; it is therefore advisable that a patient
taking Flagyl for the first time not be left unattended
for a period of two hours. The appearance of abnormal
neurologic signs demands prompt discontinuation of
Flagyl therapy and, when severe, immediate medical
attention. Gastric lavage may be considered if no
more than two or three hours have elapsed since
administration of the drug.
Treatment with Flagyl should be discontinued if
ataxia or any other symptom of CNS involvement
occurs.
Patients with severe hepatic disease metabolize
metronidazole slowly with resultant accumulation of
metronidazole and its metabolites in the plasma.
Accordingly, for such patients, doses of Flagyl below
those usually recommended should be administered
and with caution. The determination of serum
glutamic oxaloacetic transaminase (SGOT) by the
Technicon SMA 12/60 system in blood samples from
patients receiving Flagyl may give abnormally low
values. This abnormality is artifactual and caused by
the absorption of metronidazole at the wavelength
where the enzymatic reaction is monitored
spectrophoto metrically.

ADVERSE REACTIONS
Gastrointestinal: diarrhea, nausea, vomiting,
anorexia, epigastric distress, dyspepsia, constipation.
Month: furred tongue, dry mouth, unpleasant
metallic taste.
Hem atopoietic: transient eosinophilia or
leucopenia.
Derm atologic: rash and pruritus.
Cardiovascular: palpitation and chest pain.
Central Nervous System: convulsive seizures,
peripheral neuropathy, transient ataxia, dizziness,
drowsiness, confusion, insomnia and headache.
Peripheral neuropathies have been reported in a few
patients on moderately high to high-dose prolonged
oral treatment with metronidazole. It would appear
that the occurence is not directly related to the daily
dosage and that an important predisposing factor is
the continuation of oral and/or I.V. medication for
several weeks or months. Profound neurological
deterioration, within 2 hours after Flagyl
administration has been reported. The occurrence is
not directly related to the dosage level.
MctaboHc: An antithyroid effect has been reported
by some investigators but three different clinical
studies failed to confirm this.
Local Reactions: Thrombophlebitis has occurred
with I.V. administration.
Other: Proliferation of Candida albicans in the
vagina, vaginal dryness and burning; dysuria;
occasional flushing and headaches, especially with
concomitant ingestion of alcohol; altered taste of
alcoholic beverages. Darkening of the urine has been
reported. This is probably due to a metabolite of
metronidazole and seems to have no clinical
significance.

SYMPTOMS AND TREATMENT OF
OVERDOSAGE
Symptoms
Massive ingestion may produce vomiting and slig
disorientation.
Trsatmsnt
There is no specific antidote. Early gastric lavag
may remove a large amount of the drug; otherwise,
symptomatic treatment.

DOSAGE AND ADMINISTRATION
TREATMENT OF ANAEROBIC
INFECTIONS
Treatment should be initiated by the I.V. route. Or
medication may be substituted when it is feasible
and/or practical. Duration of therapy depends upon
clinical and bacteriological assessment. Treatment fo
seven days should be satisfactory for most patients.
However in cases where infection sites cannot be
drained or which are liable to endogenous
recontamination by anaerobic pathogens, a longer
treatment may be required.

I.V. ADMINISTRATION:
100 mL (500 mg) by intravenous infusion every 8
hours. The injection should be infused intravenously
at the rate of 5 mL per minute.
Flagyl injection is compatible in a volume ratio of
1:5 with normal saline, dextrose-saline, dextrose 5
cent w/v or potassium chloride injections (20 mmo
and 40 mmol). It should not be mixed with sodium
lactate injection 5% w/v, or dextrose injection 10%
w/v.

AVAILABILITY
Injection 0.5% w/v in Viaflex* plastic bags of
100 mL (500 mg) for intravenous infusion.
FULL PRODUCT MONOGRAPH AVAILABLE ON
REQUEST.
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Pancreatic Carcinoma: Surgical Treatment
There is controversy in the literature over
the surgical treatment of pancreatic
carcinoma, especially whether gastro
enterostom y should be performed
prophylactically when palliative biliary
bypass is done. The authors report a
retrospective study of 184 patients with
pancreatic carcinoma treated at the
Hotel-Dieu Hospital in Montreal between
1970 and 1982. Of these, 106 patients
had cancer of the head of the pancreas.
In this group, 15 had a Whipple proce
dure. Median survival was 512 days
with no 5-year survivors. Forty-nine
patients had biliary bypass alone and 3
needed gastroenterostomy later for duo
denal obstruction. Eleven patients had
both biliary —enteric bypass and gastroen
terostomy. Biliary bypass using the com
mon duct gives the same result as that
using the gallbladder. Considering their
reoperation rate of only 7.3% , the
authors do not believe that prophylactic
gastroenterostomy is indicated in these
patients.

•* La literature diverge sur le choix du traitement chirurgical du cancer du pan
creas, specialement en ce qui concerne
le besoin d'effectuer une gastroenterostomie quand une derivation
biliaire palliative est pratiquee. Les
auteurs font etat d'une etude retrospecv tive portant sur 184 patients qui ont <§te
traites a I'Hdtel-Dieu de Montreal, entre
1970 et 1982, pour un cancer du pan
creas. Dans 106 cas, il s'agissait du can-

From the Department o f Surgery, HotelDieu de Montreal, Montreal, PQ
Presented at the 88th annual meeting o f the
Canadian Association o f Clinical Surgeons,
Eastern Division, Hamilton, Ont., May
24-26, 1984
Accepted fo r publication June 20, 1984
Reprint requests to: Dr. D. Bourbeau,
Division o f General Surgery, Hotel-Dieu de
Montreal, 3840, rue St-Urbain, Montreal,
PQ H2W 1T8

cer de la tete du pancreas. Dans ce
groupe, 15 ont subi une operation de
Whipple. La survie mediane a ete de 512
jours; on ne compte aucun survivant a 5
ans. Quarante-neuf patients ont eu une
derivation biliaire seule et 3 ont neces
sity par la suite une gastro-enterostomie
pour obstruction duodenale. Onze
patients ont subi simultanement une
anastomose entero-biliaire et une gastroenterostomie. Une derivation biliaire via
le choledoque donne des resultats similaires a ceux qu'on obtient en passant
par la vesicule biliaire. Compte-tenu d'un
taux de reoperation de seulement 7.3% ,
les auteurs ne croient pas qu'une gastroenterostomie prophylactique soit indiquee chez ces patients.

those with islet cell carcinoma were
excluded. There were 106 men with a
mean age of 63 years and 78 women with
a mean age of 64 years.
Of the 184 patients, 150 (82%)
presented with an average weight loss of
10 kg. A history of pain (abdominal, dor
sal or both) was recorded in 122 (66%)
and 85 (46%) had jaundice on admission.
Sixty-nine (38%) had a palpable abdomi
nal mass; in 21 of them, the mass was
considered to be a distended gallbladder.
Five patients (3%) had palpable lymph
nodes. One was in the left inguinal region
and four were in the left supraclavicular
region. Six patients (3%) were hospital
ized for lower-limb phlebitis.
Pathologic Findings

The results of surgical treatment for pan
creatic carcinoma are disappointing.
Much controversy exists over the various
choices of procedure, since they involve
important morbidity and mortality. Even
curative surgery results in poor long-term
survival. Moreover, there is no agreement
as to which type of biliary bypass should
be done and whether or not gastroen
terostomy is indicated for prophylaxis
when palliative surgery is performed.
In a retrospective analysis of our
experience, we examined the survival and
effectiveness of biliary diversion and
evaluated the need for prophylactic gas
troenterostomy.
Follow-up was verified with the tumour
registry through which long-term evolu
tion of the disease and survival were
established. Results were analysed using
the x2 test and analysis of variance.1 Sur
vival curves were constructed using actu
arial methods.2

Autopsy, operation or laboratory
investigation enabled us to locate the
cancer in the head of the pancreas in 106
patients and in the body and tail in 66
others. Because of the spread of the
cancer or lack of information, we could
not locate the tumour in the other 12
patients.
The diagnosis was confirmed by cyto
logic or histologic examination in 178 of
the 184 patients. Of these, 60 had fineneedle biopsy of the pancreas, percutaneously or operatively, without morbidity.
There were 175 adenocarcinomas and 3
cystadenocarcinomas. Because of termi
nal illness or extensive tumour spread, no
palliative procedure was performed in 95
patients. However, in all, a diagnosis was
made from tissue obtained by different
procedures such as laparotomy, skin,
lymph-node or percutaneous biopsy, aspi
ration of ascitic fluid or at autopsy.
Surgical Treatment

Patients

The records of 184 patients with pan
creatic carcinoma treated at the HotelDieu de Montreal between 1970 and 1982
were reviewed. Patients with cancer of the
ampulla, bile duct and duodenum and

Eighty-nine patients underwent resec
tion for cure or palliation. The diagnosis
was confirmed by examination of tissue
in 83 of these patients. In the other six
the diagnosis was made on clinical
grounds alone.
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Four patients underwent distal pan hospital death occurred at 23 days due to
createctomy and splenectomy for tumour terminal illness. Median survival after
of the body and tail of the pancreas. diagnosis was 175 days.
Three of them had a cystadenocarcinoma.
Six patients underwent gastrojejun
There were no hospital deaths in this ostomy for duodenal obstruction. None
group. Two patients were alive and well died but one patient had prolonged gas
5 and 9 years postoperatively. One patient tric retention due to atony, despite gas
died of massive abdominal recurrence 48 trostomy. Median survival was 88 days.
days after resection and the patient with
Three patients required a colocolic or
adenocarcinoma was lost to follow-up.
ileocolic bypass for intestinal obstruction
Fifteen patients underwent a Whipple secondary to carcinomatosis. They sur
procedure. All had adenocarcinoma of vived an average of 112 days. One
the head of the pancreas. One patient in 87-year-old patient underwent simple
this group underwent a regional pan cholecystostomy for jaundice that was
createctomy. Only one patient was not tem porarily successful in relieving
jaundiced. The average serum bilirubin symptoms.
level among the 15 patients was 160
/nmol/L. One or more complications Survival (Fig. 1)
occurred in six patients. Among these
were three patients with pancreatic
Actuarial survival curves demonstrated
fistulas, all requiring reoperation. Three no statistical difference between biliary
patients died in hospital including the enteric bypass alone and the Whipple
patient who had undergone regional pan procedure done for cure.
createctomy. Mesenteric thrombosis was
the primary cause of death in this patient. Biliary Bypass
Pancreatic fistula was a contributing
cause of death in the two others who died.
Biliary-enteric bypass without gastro
O f the remaining 12 patients, 7 died of enterostomy was performed using the
recurrent disease, 4 are alive with recur common duct in 29 patients. This proce
rence and 1 has been lost to follow-up. dure failed to relieve jaundice in three
The median survival after diagnosis patients. Morbidity was 17% and hospi
among the 12 patients who were dis tal mortality 7%.
charged was 512 days.
Gallbladder was used in 20 patients
Forty-nine patients underwent biliary who underwent biliary-enteric bypass
bypass operations without gastroen operations. Five patients failed to be com
terostomy. The average serum bilirubin pletely relieved of jaundice. In this group,
level was 200 ^mol/L. Jaundice was com morbidity was 15% and hospital mortal
pletely relieved in 37 patients, as meas ity 10%. There was no statistical differ
ured by biochemical levels and physical ence between the two methods with
examination. Seven patients had at least respect to effectiveness in relieving jaun
one complication, of which four con dice, and to mortality, morbidity or
tributed to the hospital mortality of 8%.
survival.
Three patients in this group required
reoperation for duodenal obstruction, 3, Duodenal Obstruction
8 and 10 months respectively after the
biliary bypass procedure. The median sur
Of the 45 patients who survived biliary
vival for this group was 91 days.
bypassing, 3 required reoperation for
Eleven patients had a biliary-enteric symptomatic duodenal obstruction, 3, 8
bypass with gastrojejunostomy for con and 10 months respectively after the first
comitant or imminent duodenal obstruc procedure. If one eliminates the four
tion. Ten of them had jaundice (mean patients lost to follow-up, this results in
a 7.3% reoperation rate.
serum bilirubin value of 180 /rmol/L).
Jaundice was completely relieved in eight
patients. There was no morbidity and one Comments

FIG. 1—Comparison of survival after duodenopancreatectomy (black squares) and
biliary bypass (white squares).
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Some authors have reached the conclu
sion that palliative operations give results
similar to, if not better than, radical resec
tion in terms of survival.3'4 In our
experience, the Whipple procedure failed
to effect a cure but provided acceptable
palliation. Generally, this operation was
equivalent to simple biliary bypass with
respect to survival. It resulted, however,
in some longer term survival partly
because the procedure was done at an
earlier stage of the illness. We believe that
a patient with localized disease should
have a resection for cure because it is
difficult sometimes at laparotomy to dis

tinguish between a carcinoma of the head
of the pancreas and one of the ampullary
region.
4
Despite reports in the literature to the
contrary,5 biliary bypass operation using
the common duct was more successful in
relieving jaundice than a bypass operation *
using the gallbladder. We think either^
procedure can be used, depending on
local conditions. In addition, prophylac
tic gastrojejunostomy, suggested as a rou
tine procedure by some,5'6 is not indi
cated, considering our reoperation rate of
7.3% and the fact that these patients sur
vived an average of only 3 months after
biliary bypass.
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NOTICES
Clinical and Basic Factors
Influencing Bone Growth
The Second International Conference on
Clinical and Basic Factors Influencing
Bone Growth will be held Jan. 3-5, 1985
at the University of California in Los
Angeles. This interdisciplinary conference^
will be a follow-up to the one held in
January 1982. Again, a primary objective
of the conference is to update and inte
grate our understanding of bone growth
with new knowledge and to offer direc
tions for future research. Clinical
experimental approaches to bone growth
will be emphasized as well as basic scien
tific aspects. The content will cover fac
tors and mechanisms which influence nor
mal and abnormal pre- and postnatal
bone growth, both general and craniofa
cial, from the subcellular to the gross
level. The proceedings of the conference
will be published.
For registration information write to:
Dr. Andrew D. Dixon or Dr. Bernard G.
Sarnat, Schools of Dentistry and Medi
cine, Dental Research Institute, Center
for the Health Sciences, University of
California Los Angeles (UCLA), Los
Angeles, CA 90024, USA.
continued on page 585

VOLUME 27, NO. 6, NOVEMBER 1984 / THE CANADIAN JOURNAL OF SURGERY

<

M. Abecassis, md; L. Makowka, md, ph d ;
B. Langer , md, frcs[C], facs; B. Taylor , md , frcsic]

*<*

*

Sclerotherapy for Esophageal Varices:
Preliminary Experience
There has been a resurgence of interest
in injection sclerotherapy as a means of
controlling and preventing variceai
hemorrhage. This report reviews and
evaluates the early experience with this
procedure at the Toronto General
+ Hospital.
From May 1979 to January 1983, 39
f
patients underwent 73 separate treat
ment sessions (rigid 23, flexible 50), dur
ing active bleeding (3), during hospitali
zation for variceai hemorrhage but after
cessation of bleeding (35) and during
k elective admission to hospital expressly
for sclerotherapy (35). Follow-up w as
obtained for 38 patients (9 8 % ). The
overall rate of rebleeding w as 2 7 % .
iComplications occurred in 13 patients
(3 3 % ). Ten patients died; in 2, death
was directly attributable to a complica
tion of sclerotherapy.
^
From this preliminary experience the
v authors conclude that complications of
sclerotherapy are frequent and poten*
tially life-threatening, so more prospec
tive randomized trials are needed before
its role in the treatment of bleeding
varices is clear.
^
[

r

I r On note un renouveau d'interet pour la
'
sclerotherapie dans le controle et la pret
vention des h6morragies variqueuses.
Cet article revoit et evalue les premiers
recours & cette intervention au Toronto
.
General Hospital.
De mai 1979 a janvier 1983, 39
► patients ont subi 73 seances de traitement (23 rigides et 50 flexibles) en cours
1
d'hemorragie (3), durant une hospitalisa-

*
v
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tion pour hemorragie variqueuse mais
apres I'arret des saignements (35) ou
durant une hospitalisation diff£r£e specialement pour sclerotherapie. Les suites
therapeutiques ont pu etre verifiees chez
38 patients (9 8 % ). Le taux global de
recidives hemorragiques a ete de 2 7 % .
Des complications sont survenues chez
13 patients (3 3 % ). Dix patients sont
decedes dont 2 directement des compli
cations de la sclerotherapie.
De cette experience preliminaire, les
auteurs concluent que les complications
de la sclerotherapie sont frequentes et
mettent en danger la vie du malade. En
consequence, des etudes prospectives
randomisees sont necessaires si Ton
veut clarifier son role dans le traitement
des hemorragies variqueuses.

Bleeding from esophageal varices con
tinues to be associated with high mortal
ity, because of the difficulty in control
ling the hemorrhage, and because of a
wide variety of multisystem problems that
develop in patients with chronic liver dis
ease. Portosystemic shunting is the most
reliable way of stopping the bleeding and
preventing further hemorrhage. However,
the mortality and morbidity associated
with major operations for portal decom
pression is substantial,1'4 in both emer
gent and elective situations. Because of
these deterrents to portacaval shunting,
many alternative procedures have been
used to control hemorrhage and to avoid
major complications.
Endoscopic injection sclerotherapy was
introduced as long ago as 19355 and has
recently been repopularized. This paper
reports our experience with the use of
endoscopic sclerotherapy at the Toronto
General Hospital as a means of control
ling variceai hemorrhage and preventing
further bleeding. Its efficacy in 39 patients
over a 44-month period was reviewed
retrospectively and its complications were
assessed.

Toronto General Hospital between May
1979 and January 1983 were reviewed.
Thirty-nine patients (10 women, 29 men)
aged 24 to 81 years (mean 55 years), with
endoscopically proven esophageal varices
and documented variceai hemorrhage,
underwent 73 separate treatments. In 34
of these patients, percutaneous liver
biopsy specimens documented the liver
disease (Table I). Of the 39 patients, 23
had alcoholic cirrhosis, 10 nonalcoholic
cirrhosis, 4 had portal vein thrombosis of
varying causes and 2 had extensive liver
metastases from colonic carcinoma. The
patients were also categorized according
to Child’s classification6 of liver disease
(Table I).
Twelve patients had undergone one or
more operations for portal hypertension.
These were distal splenorenal shunting
(two patients), portacaval shunting (one),
mesocaval shunting (one), coronary vein
to left renal vein grafting, devasculariza
tion of stomach and ligation of splenic
artery (one), esophageal devascularization
and ligation of left gastric veins and tribu
taries (one) and transjugular embolization
o f varices, with insertion of a Gruntzig
balloon to form an intrahepatic shunt
(one). Seven patients, including two from
the previous group, had undergone
splenectomy.
These operative procedures had all
failed to prevent variceai bleeding in the
long term.
The indications for sclerotherapy (as
opposed to other forms of treatment)
included, in addition to failure of previ
ous shunting procedures, prohibitive sur
gical risks, portal vein thrombosis and the

Table 1-Cause of Esophageal Varices
According to Child's Classification
of Liver Disease
Child's classification
Cause

Accepted fo r publication Aug. 20, 1984

Patients

Reprint requests to: Dr. B. Langer, 9-236
Eaton Bldg., Toronto General Hospital,
101 College St., Toronto, Ont. MSG 1L7

Alcoholic cirrhosis
Monalcoholic cirrhosis
Portal vein thrombosis
Metastatic (liver) cancer

The records of all patients on whom
sclerotherapy had been performed at the

Totals
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A

B

C

6
5
4
2

5
3
0
0

12
2
0
0

17

8

14
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patient’s refusal to undergo further
surgery.
Methods
The tech n iq u e o f sclerotherapy
changed during the study period. Initially
in 23 treatment sessions, we employed a
rigid esophagoscope (Pilling Co., Fort
Washington, Pa.) with a proximal light
ing system, performing the procedure
with complete muscle relaxation under
general anesthesia. A rigid flanged nee
dle was used to inject 3% sodium
tetradecyl sulfate (Thrombovar) intravascularly and tamponade of the injected
varix was achieved by direct pressure of
the scope on the varix. Later scleroses
were done using a fiberoptic endoscope
(Olympus GIF-Q; Olympus Corp of
America, New Hyde Park, NJ) with a
flexible needle inserted through the biopsy
channel. Injection was made usually into
each distended varix using 2 mL of
sclerosing solution at two levels: circum
ferential injection first at the level of the
gastroesophageal junction and again 4
to 5 cm proximally. If brisk bleeding
occurred during flexible or rigid endo
scopy, tamponade wa achieved with
the Sengstaken-B lakem ore balloon
catheter.
After injection, the patient was
observed for symptoms such as chest pain
or dyspnea, clear fluids were given for 1
day and the patient was discharged 2 or
3 days after the procedure. No routine
radiologic investigations were done, but
symptoms suggestive of complications
were usually investigated with plain roent
genography o f the chest or after Gastrografin swallow, or both.
Three patients were treated with
sclerotherapy at the time of active bleed
ing (acute). Thirty-five scleroses were per
formed during the same hospitalization
as the bleeding episode, but an average
of 5.8 days (varying from 1 to 23 days)
after bleeding had stopped (semielective).
Thirty-five sessions were performed dur
ing a planned elective admission to hospi
tal for sclerotherapy (elective).
The planned treatment protocol con
sisted of repeated monthly injections to
obliterate the varices as determined at
endoscopy. However, it was sometimes
difficult to adhere to this protocol for a

variety of reasons, including reliability of
patients and geographically prohibitive
follow-up conditions.
Overall, 73 separate treatment sessions
were performed on 39 patients. This
varied from 1 to 10 sessions per patient,
with a mean of 2 (Fig. 1). One patient
who had two sclerotherapy sessions at our
institution had undergone several sessions
as a child elsewhere.
The patients were followed up through
periodic visits to our outpatient liver
clinic. For those not residing in geogra
phically suitable areas, follow-up was
arranged through the referring physician.
Liver disease and evidence of bleeding
were monitored clinically and biochem
ically.
Results
Follow-up was obtained in 38 of the 39
patients (98%). The mean period of
follow-up after the first treatment session
was 12.5 months (from 1 to 43 months).
Effect on Bleeding
A cute sclerotherapy.—Of the three
patients who underwent sclerosis while
actively bleeding, two required immedi
ate devascularization procedures, 1 and
2 days after the session respectively, as
bleeding continued uncontrolled. One
patient continued to bleed and died of
hepatorenal syndrome 6 days after injec
tion; he was never considered a candidate
for operation. For all three patients, this
was their first session of sclerotherapy.
Nonacute sclerotherapy. —Thirty-six
patients underwent sclerosis during the
nonacute phase of bleeding (semielective
and elective). We analysed the rebleeding
rate in these patients.
Ten patients were excluded from our
calculations; 5 died of causes unrelated
to rebleeding (2 had not had any further

bleeding at 3 and 9 months following their
first and third injections respectively), 4 ,
patients underwent some type of devas- ^
cularization or shunt procedure follow
ing their last injection and 1 patient was '
lost to follow-up.
Of the remaining 26 patients, 7 (27% )^
experienced further bleeding following^
their last recorded injection; of these, 5
had received only one injection, 1 had
received three and 1 patient had been
injected four times. Two of the patients ~
bled again within 24 hours of injection;
both died as a result of the bleeding.
Three other patients bled again at 10 days,.,
15 days and 6 weeks respectively after the
last injection. Of these, one died as a.; ^
result of the bleeding. The two remain-^ ,
ing patients bled again after 1 year. All *
seven patients required transfusion for
rebleeding. None were operated on.
tr
Thus, in all, 21 of the 39 pa-+
tients had not rebled at the time of
review. Of these 21, 7 patients received I
only one injection, 8 had been injected
twice, 5 had undergone three injections
and 1 patient had been injected 10 times.
The period of follow-up for these patients 4
varied from 1 to 56 months (mean 10.6^,
months).
Complications
H

Thirteen patients (33%) had complica
tions directly attributable to sclerotherapy
(Table II).
Dysphagia developed in three patients;
in one, radiologic investigations were nor--»
mal and the symptoms resolved spontane
ously. In another, painless dysphagia *
developed 2 days after treatment and a
barium swallow demonstrated a linear

T a b le I I — C o m p lic a tio n s o f
S c le r o th e r a p y
No. of
C o m p lic a tio n s

p a tie n ts

R a d io lo g ic
P u lm o n a r y
In filtr a te

1

E ffu s io n

6
3

A te le c ta s is
Esophageal
U lc e r a tio n
S tr ic tu r e
P e r fo r a tio n
P e r ie s o p h a g e a l a b s c e s s

3
1
1*
1*

C lin ic a l
P l e u r i t i c c h e s t p a in
Fever
D y s p h a g ia
R e t r o s t e r n a l p a in

FIG. 1—Number of sclerotherapy sessions
per patient.
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4
6
3
2

’ P a t i e n t d ie d a s a r e s u l t o f c o m p l i c a t i o n .

FIG. 2—Esophagogram after barium swal
low shows 2-cm segment of narrowing, about
4 cm proximal to gastroesophageal junction.
|
Narrowed lumen has diameter of 1.5 cm and
there is minimal linear mucosal ulceration ,
(arrow) just distal to narrowed segment. There
is also small hiatus hernia with gastro
esophageal reflux.
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toms resolved spontaneously. A third
i patient was seen in the emergency depart^ ment 3 days after discharge (5 days after
injection), complaining of right pleuritic
r- chest pain, dysphagia, fever and chills.
Roentgenograms showed a small right
pleural effusion and a large ulcer in the
•distal esophagus (Fig. 3a). With conser
v a tiv e management the symptoms les. ^ sened, even though the ulceration had
progressed on repeat roentgenograms
after barium swallow carried out 5 days
later (Fig. 3b). Fie has, however,
h- remained well and asymptomatic.
Esophageal perforation and mediasti^nitis occurred in two patients. The first
experienced pleuritic pain with mild short^ ness of breath, cough and fever, which
developed 1 day after injection. A chest
film showed consolidation in the right
y, lower lobe and a small right pleural effu
sion. Initially, Gastrografin swallow

showed no esophageal leak (Fig. 4a), but
a repeat Gastrografin swallow 5 days later
(Fig. 4b) showed a large leak from the dis
tal esophagus into the right pleural cavity.
This was treated aggressively with closed
thoracostomy drainage. Initially the
patient’s condition improved, but then
progressive multisystem failure developed
secondary to sepsis and the patient died
39 days after treatment. Because o f con
tinued bleeding, the second patient under
went distal splenorenal shunting 2 days
after sclerotherapy. He died of septicemia
and infected ascitic fluid; periesophageal
abscess and mediastinitis were found at
autopsy. He had experienced pleuritic
chest pain, but Gastrografin studies
showed no abnormality.
Another accompaniment of endoscopic
sclerosis was retrosternal pain in two
patients with normal radiologic findings.
Pyrexia occurred in four others, includ-

*

ing the one who received 10 treatments
and was febrile on three separate occa
sions. Fever was associated in each
instance with demonstrable roentgenographic chest abnormalities (pleural effu
sions, pulmonary infiltrates or atelecta
sis), except for one episode of pyrexia
which was attributed to an infected
central-venous-pressure catheter. Re
sponse to conservative management was
rapid.
One patient died of exsanguination
from persistent bleeding after sclerother
apy and was found at autopsy to have
large esophageal ulcerations.

Mortality
Of the 39 patients who entered our
study, 10 died. Five died o f sepsis; of
these, four had undergone further emer
gency surgery after sclerotherapy failed
to control bleeding. Causes of sepsis
included: infected ascitic fluid (two), aspi
ration pneumonia (one), intraperitoneal
abscess (one). In one patient already dis
cussed, sclerosis caused esophageal per
foration, mediastinitis and eventually
death. Another patient died of hepato
renal syndrome 1 month after undergoing
his second treatment session.
Uncontrolled variceal hemorrhage was
the cause of death in two patients, 6 days
after the first session of sclerotherapy in
one patient, and 1 year after the first
treatment in the second.
Two patients died of metastatic colonic
carcinoma, the cause of the bleeding
varices.

Discussion
Fig. 3a
t

FIG. 3—(a) Esophagogram after barium swallow 4 days after injection of sclerosing agents.
Large ulcer (arrow) measuring 2.5 X 0.5 cm is seen in distal esophagus, at site o f injection,
(b) Repeat esophagogram 5 days later shows slight deepening of distal esophageal ulcer.

Fig. 4a

-t

Fig. 3b

Fig. 4b

FIG. 4—(a) Esophagogram after Gastrografin swallow 3 days after endoscopic injection
of sclerosing agent into lower esophageal varices. There is no ulceration or leakage, (b) Repeat
esophagogram 5 days later shows extensive leakage into right pleural cavity from lower esopha
gus, 4 cm from gastroesophageal junction. Right chest drain lies within cavity and drains away
contrast material.

N um erous uncontrolled, nonrandomized reports have been published
recently describing patients who under
went variceal sclerosis by a variety of
techniques. The results have been
encouraging. The number of randomized
controlled trials, however, is small and
their conclusions are not yet firm .713
Evaluation of this procedure must include
an assessment of rebleeding rates, survival
and complications. MacDougall and
associates8 reported a 43% incidence of
rebleeding in a study group of 51 ran
domly selected patients who received
sclerotherapy, versus 75% in the control
group who were treated conservatively.
Terblanche and associates9 in a ran
domized study noted recurrent variceal
bleeding in 36% of the sclerotherapy
group versus 69% in the control group.
The rebleeding rate of 27% in our group
was comparable. Paquet11 quoted rates
of 6% and 66% respectively in the
sclerotherapy group versus the control
group.
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Injection sclerotherapy, which has been
considered a minor therapeutic procedure
compared with shunting, is associated
with serious complications. The difficulty
of carrying out the procedure and the risk
of complications are greater when there
is active bleeding. 14 Complications are
more frequent when the endoscopist is
less experienced, and when a rigid
esophagoscope is used.8'14 Currently
used sclerosing solutions can cause differ
ent tissue reactions, depending on such
factors as concentration and quantity
used and injection technique.15 These are
constantly undergoing modification, and
there has been no standardization yet.
Esophageal ulceration, perforation and
stricture have occurred in small numbers
in most series and sometimes result in
death. 14'16’22 Five o f our patients had
esophageal complications; one had per
foration and eventually died. Early recog
nition and diagnosis o f such complica
tions cannot be overstressed. It has been
clearly shown that early recognition of
esophageal perforation and prompt sur
gical therapy are associated with a
markedly reduced mortality.23 If eso
phageal perforation is suspected, roent
genography after a water-soluble (Gastrografin) swallow should be carried out and,
if negative, should be followed by barium
studies.24
Fever, dysphagia and retrosternal dis
comfort are reported frequently in most
series, as in our group o f patients.
Pleuritic chest pain was reported by four
of our patients, associated in each
instance with an abnormal chest roent
genogram. The pain resolved with
appropriate conservative therapy.
Conclusions

From this preliminary experience we
can draw limited but important conclu
sions. First, injection sclerotherapy can
be undertaken safely in most cases but
requires a skilled endoscopist experienced
in its use. Complications may be lifethreatening, but most are minor and can
be treated conservatively with good
results. A cute awareness o f these
problems is essential in the early detec
tion and prevention o f serious and fatal
complications. More importantly, the role
o f sclerotherapy in the management of
active variceal hemorrhage as a temporiz
ing measure before portosystemic shunt
ing and as an alternative to shunting in
patients who are surgical candidates
remains to be defined. Rebleeding rates
after single injections are high, and
repeated injections are required in most
patients in whom control o f rebleeding is
obtained. Prospective randomized trials
are necessary to determine better the place
of sclerotherapy in the treatment of bleed
ing varices.
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Prophylactic Use of Antibiotics in Pancreatic Sepsis:
a 25-Year Reappraisal
The efficacy of antibiotics given
prophylactically in cases of acute pan
creatitis is controversial. The authors
►
carried out a retrospective review of 528
y, cases of pancreatitis seen between 1955
and 1980 and noted a marked increase
•Jn the number of septic complications
and in the mortality related to sepsis. In
^ most cases, infection was due to organ
isms sensitive to the antibiotics used,
Suggesting that they are not effective in
^ preventing sepsis. The authors suggest a
new approach to prophylactic administra».tion of antibiotics, based on bioactive tis
sue levels in pancreatitis.

W

L'efficacite de lantibiotherapie prophylactique dans les cas de pancreatite
aigue demeure incertaine. Les auteurs
’bnt revu retrospectivement 528 cas de
pancreatite survenus entre 1955 et 1980
et constate une augmentation dramati^.que du nombre de complications infectieuses et du taux de mortality en cas
d'infection. De plus, les microorganismes impliques dans ces infections
eont generalement sensibles aux antibiotiques choisis. Ceci suggere que les regiy mes antibiotiques utilises couramment
sont inefficaces a titre prophylactique.
Les auteurs proposent une nouvelle
approche pour la selection d'antibiotiques dans les cas de pancreatite. basee
,sur leur niveau de bioactivite tissulaire
lors de I'inflammation aigue.

r

Patients and Methods
Between 1955 and 1980, 528 patients
with acute pancreatitis were admitted to
the Montreal General Hospital. Data
were analysed on three separate occasions
(1966, 1972 and 1981), hence the division
into three periods and the varying avail
ability of data. The 1955 to 1965 period
covered 153 admissions while the 1966 to
1971 and 1972 to 1980 periods included
200 and 175 patients respectively.
The diagnosis of acute pancreatitis was
made on the basis of (a) a serum amylase
level below 600 Somogyi units/L (1110
U /L) with typical clinical findings, in ad
dition to an elevated urinary amylase level
or a depressed serum calcium level or (b)
a serum amylase level above 600 Somogyi

x The efficacy of prophylactic antibiotics
in acute pancreatitis is still controversial.
Several authors1-7 have concluded that
they are useless in preventing septic com
plications such as abscesses and infected

1955-1965
1966-1971
1972-1980

Results
♦

Table II summarizes the changes !n
mortality, the overall complication rate,
the percentage of septic complications
and mortality in the presence o f sepsis
over the 25 years. The mortality decreased
steadily over this period, while the over
all complication rate, although improv-

Antibiotics used
Ampicillin or tetracycline
Penicillin and kanamycin
Ampicillin or penicillin or
cephalosporin ± kanamycin
or gentamicin

From the Department o f Surgery, Montreal
General Hospital, Montreal, PQ
Table 11-Mortality and Complication Rate, and Mortality in Sepsis
from Acute Pancreatitis (1955-1980)
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units with supportive clinical findings. Se
vere pancreatitis was diagnosed in the
presence o f shock, persistent hypocalce
mia, respiratory failure, gastrointestinal
hemorrhage, nutritional depletion or
overt sepsis at any time in the period of
hospitalization.
The baseline treatment regimen con
sisted of nasogastric suction, intravenous
hydration and analgesia. Since the onset
o f the study, other modalities of treat
ment, such as aggressive nutritional sup
port (with elemental feedings or intra
venous hyperalimentation), peritoneal
irrigation and respiratory care, have been
added to our standard protocol for
m anagem ent of acute pancreatitis.
Approximately half of the patients were
given antibiotics prophylactically. These
were usually administered on an empiri
cal basis, depending on the surgeon’s
choice. Clinical indications for their
administration also included the presence
o f severe pancreatitis and an unequivo
cal diagnosis of gallstone pancreatitis.
The regimens used during each period are
shown in Table I.
Bacteriologic typing o f infectious
agents was performed in all cases of infec
tion. Detailed breakdown of responsible
bacteria and their sensitivity patterns was
done for the 1972 to 1980 period only.

Table 1—Baseline Antibiotic Regimens Used in
Acute Pancreatitis
Period

►

^

pseudocysts. Despite these findings, the
serious nature of the complications has
led to the persistent use and recommen
dation of various antibiotic regimens.8-13
This paper represents the third chapter of
a 25-year retrospective study carried out
at The Montreal General Hospital8,14
and reviews our experience with antibi
otics and septic complications in acute
pancreatitis.
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Period
1 955-1965
1966-1971
1972-1980

Mortality,
%

Overall
complication
rate, %

Complications
related to
sepsis, %

Mortality in
sepsis, %

9.2
6.0
4.5

39.2
41.5
20.0

5.0
18.0
45.0

21.0
33.3
50.0
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ing appreciably, remained exceedingly
high. Septic complications (i.e., infected
pseudocyst, subhepatic abscess, and
wound, respiratory and urinary tract
infections) accounted for an increasing
portion of all complications (from 5% to
45%). Despite antibiotic coverage, the
mortality directly related to sepsis rose
proportionally from 21% to 50%.
The breakdown of bacteria responsible
for the infections during the 1972 to 1980
period is shown in Table III. Enteric
gram-negative aerobic or facultative aer
obes, such as Escherichia coli, Pseudo
monas aeruginosa, Klebsiella sp. and Pro
teus sp. were present in 41 of 74 infections
(55%) and 15 of 22 (68%) subhepatic
abscesses and infected pseudocysts. Other
enteric gram-negative organisms such as
Bacteroides sp. and Fusobacterium
accounted for all but one instance of
abscess or pseudocyst. When considered
together, gram-negative organisms,
whether aerobes or anaerobes, were iso
lated in three quarters of infectious cases
(55 of 74). Gram-positive bacteria were
encountered mainly in wound infections
and in blood cultures.
All the organisms identified were sen
sitive to the baseline combinations of
antibiotics chosen. In 40% of the cases,
however, failure to control sepsis (i.e., no
clinical response after 24 hours of treat
ment) was evident and the regimen had
to be altered to include metronidazole,
chloramphenicol or clindamycin. In 10%
of the cases, surgical debridement of the
abscess had to be performed on an urgent
basis to control the sepsis.
Discussion
Controlled clinical trials have shown
that prophylactic antibiotics can lower the
incidence of infection in selected high-risk
populations. An effective prophylactic
regimen should therefore be administered
to identified high-risk groups, be directed
against the most likely infecting organ
isms and should be present in adequate
concentration in the blood or tissues at
tlfe time of clinical insult.
The clinical presentation in acute pan

creatitis ranges from a mild, self-limiting
illness to a dramatic, rapidly lethal dis
ease that defies all attempts at treatment.
Until Ranson’s efforts to identify early
prognostic signs of major complica
tions,9'15 clinicians estimated the severity
o f the disease by such imprecise
parameters as those described earlier in
the “ Patients and Methods” section. The
definition of objective criteria of severity
will help recognize the patients at risk of
septic complications, who would most
likely benefit from antimicrobial therapy.
As emphasized by Cameron and associ
a te s,5 most series have reported
appreciable improvement in the mortal
ity over the years, while sepsis accounts
for an ever-increasing proportion of the
residual mortality. When we originally
reviewed our experience,14 hypovolemic
shock was the major cause of death in
patients with pancreatitis. Between 1966
and 1971,8 nutritional depletion emerged
as a critical problem. This aspect of our
management has since been altered and
now seldom accounts for any morbidity
or mortality. The current prominence of
septic complications in pancreatitis
deserves all our attention. Gram-negative
organisms, particularly E. coli, have been
identified by several authors2,7’14,16'17 as
the most frequent offending species. This
has led to recommendation that broadspectrum parenteral antibiotics such as
ampicillin or cephalosporin, alone or in
combination with an aminoglycoside, be
given prophylactically.8"10,12
The rationale for such recommendation
is apparently flawless: these antibiotics
show antibacterial activity against most
involved organisms and they have been
shown to reach satisfactory levels in the
bile and pancreatic juice.18,19 However,
this study confirms previous work1-7 and
clearly demonstrates that these antibiotics
are not effective in preventing the onset
of septic com plications in acute
pancreatitis.
We postulated that unless the antibi
otics were present in the pancreatic tissue
itself during pancreatitis, their use was of
no therapeutic value. A canine model was
developed to study bioactive tissue levels

Table III—Organisms Producing Septic Complications in Acute Pancreatitis (1 9 7 2 -1 9 8 0 )
Organisms

Subhepatic

Pseudocyst

Gallbladder

Wound

Urinary
tract

Respiratory

4

11

12

5

3

1

5

41

2

4

1

1

3

2

1

14

Blood Totals

Gram-negative
aerobes
Gram-negative
anaerobes
Gram-positive
aerobes
Gram-positive
anaerobes
Fungi

0

1

1

3

1

0

10

16

0
0

0
0

1
0

1
0

0
1

0
0

0
0

2
1

Totals

6

16

15

10

8

3

16

74

568
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MARCAINE* NERVE BLOCK OR INFILTRATION
BEFORE CLOSURE GIVES UP TO 15 HOURS OF
POST-OPERATIVE PAIN RELIEF1

:" POST-OPERATIVE STRESS can be
substantially reduced by preventing
post-operative pain in those critical
„ first hours after surgery.2

Marcaine blocks this pain, giving an
easier, quicker recovery; often without
the need for narcotic analgesics.3

MARCAINE

FOR PAIN RELIEF THAT
STARTS IN THE O.R.
Winthrop Laboratories
Division of Sterling Drug Ltd.**
Aurora, Ontario L4G3H6
*Reg. Trade Mark
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Prescribing Information

Marcaine*
(bupivacaine hydrochloride injection U.S.P.).
Indications:
Peripheral nerve block including retrobulbar block, infiltration, sympa
thetic blockade, caudal, epidural, and pudendal blocks.
Contraindications:
Bupivacaine is contraindicated in persons with known sensitivity to
local anesthetics of the amide type.
The use of bupivacaine is contraindicated in the presence of sepsis
near the site of proposed injection, in severe shock and in heart block.
Warnings:
Usage in Pregnancy: There are no adequate and well-controlled studies
in pregnant women of the effect of bupivacaine on the developing
fetus. Decreased pup survival in rats and an embryocidal effect in rab
bits have been observed when bupivacaine hydrochloride was adminis
tered to these species in doses comparable to nine and five times
respectively the maximum recommended daily human dose (400 mg).
Bupivacaine hydrochloride should be used during pregnancy only if the
potential benefit justifies the potential risk to the fetus. This does not
exclude the use of Marcaine 0.25% or 0.50% at term for obstetrical
anesthesia or analgesia.
Obstetrics: The highest (0.75%) concentration is not recommended for
obstetrical anesthesia. There have been reports of cardiac arrest with
difficult resuscitation or death following its use for epidural anesthesia
in obstetrical patients.
Due to the high risk to the fetus, paracervical block is no longer recom
mended.
The obstetrician is warned that severe persistent hypertension may
occur after administration of certain oxytocic drugs, if vasopressors
have already been used during labor (e.g. in the local anesthetic solu
tion or to correct hypotension).
Until further experience is gained in children younger than 12 years,
administration of bupivacaine in this age group is not recommended.
Precautions:
Marcaine (bupivacaine) should be used cautiously in persons with
known drug allergies or sensitivities, particularly to the amide-type local
anesthetics.
Caution is advised in administration of repeat doses of bupivacaine to
patients with severe liver disease.
The lowest dosage that gives effective anesthesia should be used, to
avoid high plasma levels and serious systemic side effects. Injection of
repeated doses of bupivacaine may cause a significant increase in
blood levels due to accumulation of the drug or its metabolites or slow
metabolic degradation.
Tolerance varies with the status of the patient. Debilitated, elderly and
acutely ill patients may require reduced doses commensurate with age
and physical condition.
It should be remembered that solutions containing a vasopressor
agent, e.g. epinephrine, should be used with caution, if at all, in patients
who are receiving monoamine oxidase inhibitors or anti-depressants
of the triptyline or imipramine type, because severe, prolonged hyper
tension may result. Dose-related cardiac arrhythmias may occur if
preparations containing epinephrine are employed in patients during or
immediately following the administration of chloroform, halothane,
cyclopropane, trichloroethylene or other related agents. In deciding
whether to use these products concurrently in the same patient,
the combined action of both agents upon the myocardium, the concen
tration and volume of vasoconstrictor used, and the time since injec
tion, when applicable, should be taken into account.
The decision to use a local anesthetic containing a vasoconstrictor in
areas with a limited blood supply or in patients with peripheral vascular
disease, will depend on the physician's appraisal of the relative advan
tages and risks.
Local anesthetics which contain preservatives, i.e. those supplied in mul
tiple dose vials, should not be used for caudal or epidural anesthesia.
Epidural Use: It is advised that a test dose, generally 2-3 mL of 0.5%
bupivacaine (or other amide anesthetic) containing 1:200,000 epme.phrme (10-15 micrograms) be administered to check that the spinal
canal or a blood vessel has not been entered while locating the epidural
needle or catheter.
In the event of spinal injection clinical signs of spinal block would
become evident in a few minutes.
In the event of intravascular injection a transient increase in pulse rate
and possibly momentary increase in systolic blood pressure are
usually detectable with a monitor. The other symptoms and signs of
“epinephrine response" are less dependable. The effects of other medi
cation the patient has received may modify this response.
When reinforcing doses are required the test dose should be used
again to check the catheter location.
Use in Ophthalmic Surgery: When Marcaine 0.75% is used for retrobulbar block, complete corneal anesthesia usually precedes onset of clini
cally acceptable external ocular muscle akinesia. Therefore, presence
of akinesia rather than anesthesia alone should determine readiness of
the patient for surgery.
Adverse Reactions:
Reactions to bupivacaine are characteristic of those associated with
amide-type local anesthetics. A major cause of adverse reactions to
this group of drugs is excessive plasma levels, which may be due to
over-dosage, inadvertent intravascular injection, or slow metabolic
degradation. Other causes of reactions to these local anesthetics may
be hypersensitivity, idiosyncrasy, or diminished tolerance.
Excessive plasma levels cause systemic reactions involving the central
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nervous system and the cardiovascular system. The central nervous
system effects are characterized by excitation or depression The first
manifestation may be nervousness, dizziness, blurred vision, or tre
mors, followed by drowsiness, convulsions, unconsciousness, and pos
sibly respiratory arrest. Since excitement may be transient or absent,
the first manifestation may be drowsiness, sometimes merging into
unconsciousness and respiratory arrest.
Other central nervous system effects may be nausea, vomiting, chills,
constriction of the pupils, or tinnitus. The cardiovascular manifesta
tions of excessive plasma levels may include depression of the myocar
dium, blood pressure changes (usually hypotension), and cardiac
arrest. Recent clinical reports and animal studies suggest this may be
more likely to occur with the long acting amide local anesthetics such
as bupivacaine.
Allergic reactions are characterized by cutaneous lesions (e.g. urticaria,
edema) and other manifestations of allergy.
Reactions following epidural or caudal anesthesia may include: high or
total spinal block, urinary retention; fecal incontinence, loss of perineal
sensation and sexual function; persistent analgesia, paresthesia, and
paralysis of the lower extremities; headache and backache; and slow
ing of labor and increased incidence of forceps delivery.
It should be noted that reactions due to systemic absorption may be
slow or rapid in onset. Those of rapid onset include respiratory depres
sion, cardiovascular collapse and cardiac arrest. This type of reaction
necessitates a high degree of preparedness since it can occur with little
warning.
In co-ordinated studies of 3200 procedures carried out by 15 investiga
tors, there were 2 severe systemic reactions. Both patients experienced
convulsions as a result of inadvertent vascular injection.
Fetal bradycardia has been observed with the use of bupivacaine. Most
cases, including a few fatalities, occurred when the paracervical route
was used (see “Warnings”).
In some subjects bupivacaine may produce marked peripheral vaso
constriction in unanesthetized areas which may last for several hours.
Treatment of Overdose and Severe Reactions:
Toxic effects of local anesthetics require symptomatic treatment; there
is no specific cure. The physician should be prepared to maintain an
airway and to support ventilation with oxygen and assisted or con
trolled respiration as required. Supportive treatment of the cardiovas
cular system includes intravenous fluids and, when appropriate, vaso
pressors (preferably those that stimulate the myocardium).
Convulsions may be controlled with oxygen and intravenous adminis
tration, in small increments, of a barbiturate or muscle relaxant, as
follows: preferably, an ultra short-acting barbiturate such as thiopental
or thiamylal; if this is not available, a short-acting barbiturate (e.g. seco
barbital or pentobarbital) or a short-acting muscle relaxant (succinylcholine). Intravenous muscle relaxants and barbiturates should only be
administered by those familiar with their use.
Dosage and Administration:
The duration of anesthesia with bupivacaine is such that, for most pro
cedures, a single dose is sufficient. Maximum dosage limit must be indi
vidualized in each case after evaluating the size and physical status of
the patient, as well as the usual rate of systemic absorption from a par
ticular injection site. Most experience to date is with single doses of
bupivacaine up to 225 mg with epinephrine 1:200,000, and 175 mg
without epinephrine; more or less drug may be used depending on indi
vidualization of each case.
At present there is insufficient clinical evidence with multiple dosage or
intermittent dose techniques to permit precise recommendations for
such procedures to be given. However, limited clinical experience in this
area of use indicates that bupivacaine may be repeated in 3 to 6 hours
up to a maximum dose of 400 mg in 24 hours. In most cases the dura
tion of anesthetic effect is prolonged by the addition of epinephrine.
The following doses have generally proved satisfactory for the average
adult. They may require adjustment in relation to age and the physical
condition of the patient.
Local infiltration: up to a maximum dosage of 0.25% solution.
Peripheral nerve block: 5 to 30 mL of 0.50% or 5 to 60 mL of 0.25%
solution.
Sympathetic: 20 to 50 mL of a 0.25% solution.
Epidural: 10 to 20 mL of a 0.25%, 0.50%, or 0.75%t solution.
Caudal: 15 to 30 mL of a 0.25% or 0.50% solution.
tO.75% not recommended for obstetric use.
Supplied:
Each 20 mL single dose vial contains: bupivacaine 0.25%, 0.50% or
0. 7 5 . with or without epinephrine 1:200,000. Boxes of 5 vials.
Each 50 mL multiple dose vial contains: bupivacaine 0.25% or 0.50%.
Boxes of 1 vial.
Note: Bupivacaine solutions without epinephrine may be autoclaved.
Product Monograph available on request.
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o f antibiotics in the normal gland and
after induction of bile/trypsin hemor
rhagic pancreatitis. Significant differences ^
were found in bioactive levels o f antibi
otics between blood and pancreatic tissuS 1
during pancreatitis.20 We now recom- ^
mend that, in pancreatic sepsis, the antibi
otics of choice be appraised on the basis*
of their tissular bioavailability rather than
on blood levels alone. Based on this, we <
have been using either clindamycin,
metronidazole or chloramphenicol in such
instances and we shall soon be reviewing
the impact of this modification on our H
sepsis rate in pancreatitis.
^

Conclusions
\

*

This study emphasizes the growing
importance o f septic complications in M
acute pancreatitis. It confirms that cur-,. <
rent antibiotic regimens are not effective
)
in preventing pancreatic sepsis. We sug- ^
gest that antibiotics to be given
prophylactically should be appraised on*
the basis o f their tissular bioavailability
rather than on the blood or bile level *
alone.
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Left Main-Stem Coronary Artery Disease:
Surgical versus Medical Management
The survival of surgically and medically
treated patients with left main-stem
coronary artery stenosis has been ana
lysed in detail. From 1978 to 1981, 85
patients with stenosis of the left main
coronary artery greater than 50% were
^divided into two groups; 47 were treated
surgically and 38 medically.
Left ventricular function, previous
myocardial infarction, associated right
(coronary artery occlusion and extent of
the left main coronary artery disease
^ were analysed using the x2 and independent Student's /-tests. These important
variables were comparable in both
' ji'ps. Severity of angina in the two
groups both pre- and postmanagement
were compared using the x2 test and
Stuart-Maxwell test. These showed that
(the majority of surgically treated patients
improved markedly as compared with the
medically treated group. Survival was
examined using the Kaplan-Meier
product limit estimate. The difference
between the survival curves was statisti
cally significant (p < 0.0 05, generalized
yVilcoxon and Savage tests), with the
surgical group having the more favoura
ble outcome. One-year and 2-year sur
vival for the surgically treated group was
* 97 .8% and 9 1 .3 % , compared with
79 .9% and 74 .9% for the medically
treated group.
-

La survie consecutive aux traitements
chirurgical et medical de la stenose du
tronc de I'artere coronaire gauche a ate
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analysee en detail. Entre 1978 et 1981,
85 patients ayant une stenose du tronc
de I'artere coronaire gauche superieure a
50% ont ete divises en deux groupes;
47 furent traites chirurgicalement et 38
medicalement.
La fonction ventriculaire gauche, ('inci
dence d'un infarctus myocardique pream
ble, la presence simultanee d'une occlu
sion de I'artere coronaire droite et
I'etendue de la stenose de la coronaire
gauche ont ete analysees au moyen du
test du x2 et du test du / de Student
pour variables independantes. Ces varia
bles importantes etaient comparables
pour les deux groupes. La severite de
I'angine avant et apres traitement a ete
comparee entre les deux groupes au
moyen du test du x2 et du test de
Stuart-Maxwell. Ces analyses ont revele
que la majorite des patients du groupe
chirurgical se sont ameliores sensiblement par rapport au groupe traite medi
calement. La survie a ete evaluee par
I'estimation du produit limite de KaplanMeier. La difference des courbes de sur
vie etait statistiquement significative (p
< 0 .0 0 5 , aux tests de Wilcoxon et de
Savage), le groupe chirurgical ayant le
meilleur pronostic. La survie a 1 an et 2
ans etait de 97 .8% et 91.3% respectivement pour le groupe chirurgical comparativement a 79 .9% et 74.9% pour le
groupe traite medicalement.

Survival characteristics of surgically and
medically treated patients with stenosis of
the left main coronary artery have been
analysed in detail. Operability, modern
medical therapy, left ventricular function,
degree of stenosis and associated distal
coronary artery disease all play important
roles in the management of these patients.
We conducted a retrospective, nonrandomized study to assess the quality of life
and survival pattern of patients who
underwent surgical and medical manage
ment. In order that the two groups be
comparable, inoperable patients were
excluded from our study, leaving only
operable patients in the medically treated
group for comparison with the surgical
group.

Patients and Methods

From 1978 to 1981, 85 patients with
stenosis of the left main coronary artery,
greater than 50%, were divided into two
groups. Patients with left main-stem ste
nosis requiring associated aneurysm resec
tion or valve replacement were excluded
as were patients with left main-stem
equivalent. Of the 85 patients, 47 were
treated surgically (group 1) and 38 medi
cally (group 2). Group 2 was subdivided
into 27 operable and 11 inoperable
patients. These 11 patients were deemed
inoperable because of recent myocardial
infarction or severe distal coronary artery
disease, as assessed angiographically by
two independent observers, or both. The
remaining 27 patients were considered
candidates for operation after review of
their coronary anatomy and left ven
triculogram, again by two independent
observers. Information regarding left
main-stem disease was retrieved from the
coronary angiography data bank. The
results of operations of one surgeon
within the Division of Cardiovascular and
Thoracic Surgery were compared with
those of all medically treated patients. In
the medically treated group, therapy was
instituted and continued after cardiac
catheterization with conventional medi
cal therapy or instituted after catheteri
zation.
The variables analysed were previous
myocardial infarction, extent of the lesion
in the coronary vessels, valvular heart dis
ease and left ventricular function.
Follow-up was performed by question
naire, office visits and by correspondence
with family physicians.
The x2 test and the independent f-test
were used to compare baseline values of
the two groups. Changes in the New York
Heart Association angina grade were exa
mined using the Stuart-Maxwell test. To
interpret events over time, survival curves
were analysed with the biomedical com
puter data package (BMDP; Biomedical
Computer Programs, P-series, 1981,
University of California, Los Angeles,
Calif.). Survival functions were based on
the Kaplan-Meier product limit estimates.
Generalized Wilcoxon and generalized
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Savage tests were used to test the equal
ity of the survival distributions for the
two groups. The generalized Wilcoxon
test is sensitive to early losses and the
generalized Savage test to later losses. A
computer data control (CDC CYBER
835; Control Data Corp., Minneapolis,
Minn.) was used to analyse the material.
Results
The possible differences in important
variables between the two groups are
summarized in Table I. Also, left mainstem stenosis was compared across groups
using the independent f-test. No signifi
cant difference was found (p = 0.1641).
On the basis of this, we believed that the
two groups were comparable with regard
to these variables.
Of the 47 patients in group 1, 44 sur
vived.
Table II compares the severity of
angina in the two groups before and after
treatment. Before operation none of the
group 1 patients had grade 0 or 1 angina
but postoperatively 34 of the 44 survivors
became grade 0 or 1.
In group 2, there was little change in
angina grading after medical manage
ment. This difference was statistically sig
nificant (p < 0.001). To examine the sur
gical group further, the Stuart-Maxwell

test was performed (Table III). This test
showed significant lessening (p < 0.005)
of symptoms after operation.
Generalized Wilcoxon and generalized
Savage tests were utilized to analyse the
equality of the survival distributions for
the two groups (Fig. 1). Both tests indi
cated a significant difference in the per
centage of patients surviving between the
groups (p < 0.005). There was 97.8%
survival at 1 year and 91.3% survival at
2 years in group 1, compared with 79.9%
at 1 year and 74.9% at 2 years in group 2.
Discussion
There is consensus that aortocoronary
bypass grafting in patients with left mainstem disease greatly improves survival and
the quality of life.115 However, patients
with left main disease are not a homo
geneous group.16,17 Some investigators
have shown that improved survival is
limited to the subgroup of patients with
left main-stem stenosis greater than 75%
and associated right coronary artery dis
ease, particularly when left ventricular
function is impaired.1,3,11
In order to make the medical and sur
gical groups comparable in this study,
possible differences in important variables
between the two groups were examined
and found to be comparable. Campeau

Table 1—Comparability of Study Groups on Important Variables, Using x 2 Test
Variable
Ventricle
Aortic valve
Left anterior descending
coronary artery
Circumflex artery
Right coronary artery
Myocardial infarction

X2 value

Degree of
freedom (df)

p value

2 .2 9 0
4 .4 6 7

4
2

NS
NS

3 .2 9 5
5.151
0 .8 8 3
0 .0 1 0

2
2
2
1

NS
NS
NS
NS

and associates3 compared the survival of
subsets of medically and surgically treated
patients in a nonrandomized retrospective *•'
study and found significantly improved
survival after surgery in patients with left ■
main-stem stenosis greater than 50% and I
associated stenosis of the right coronary I
artery greater than 70%. However, sur? I
vival remained significantly higher in I
patients who underwent operation than J
in those treated medically. Hence, in our
study only those patients with left main <
stenosis greater than 50% were included
and further categorization according to '
degree of obstruction was not made.
j
In the randomized controlled study car-*
ried out by the European group,2 signifi
cantly improved survival was reported at
3 years in surgically treated patients witlj
left main stenosis greater than 50%, and
a left ventricular function ejection fraction greater than 50%. In that study, no
subgroup analysis was reported, proba-’
bly because only 59 patients had left
main-stem disease. In the Veterans
Administration cooperative study18 there^
was significant improvement in survival
after surgery in patients with left main- 4
stem stenosis greater than 75%, abnor
mal left ventricular function and high"*
noninvasive risk. However, surgery had
benefited even those patients with lesser
left main-stem disease and normal left
ventricular function, although not to a
statistically significant degree.
In our study, the operative mortality
was 2.1%, with survival at 1 year being 4
97.8% and at 2 years 91.3%. In the med
ically treated group, however, the survival ■*
rates were 79.9% and 74.9% respectively.

Table III-Angina Grade, Group 1 Using the
Stuart-Maxwell Test
Grade
pretreatment

I IG• 1 Comparison of survival in operable patients with left main-stem coronary artery
disease treated surgically (•) and medically (x ).
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Grade post treatment
0,1

2

3,4

No. of
patients

0,1
2
3,4

0
19
15

0
0
2

0
2
6

0
21
23

No. of patients

34

2

8

44

X2 - 34, df = 2. p < 0.005.
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In the Veterans Administration cooper
ative study of the medical and surgical
^treatment of patients with left main dis
ease,1 the operative mortality was 14%.
£he total mortality was 36% for medi^ cally and 20% for surgically treated
patients during the mean follow-up of 30
tponths. The cumulative survival was
approximately 65% for medically and
y 82% for surgically treated patients. The
high operative mortality could be
attributed to the early period of the study
because overall surgical mortality has
^decreased over the last decade, for many
jeasons.19
In the collaborative Coronary Artery
l . Surgery Study (CASS), the operative
W mortality was 4.2%.20 The first- and
k $econd-year survival rates of 95% and
I 93% respectively appear to be comparam* ble to those of our surgical group. The
first- and second-year survival rates of
'medically treated patients in this study
were 85% and 76%, again similar to those
in our study.
k In the clinical study performed at
Emory University of Medicine,21 the
. operative mortality was 4% in patients
with left main-stem disease and the 2-year
►survival was 88%. However, in the med
ically treated group, the 2-year survival
was only 66%.
Improvement in survival, concomitant
with improved quality of life, is the goal
that one tries to achieve for any form of
therapy. We have shown that not only is
survival longer in surgically treated
patients with left main-stem disease but
►there is also significant improvement in
the grade of angina.
We conclude from this study that
patients with left main-stem stenosis
greater than 50%, with or without right
coronary artery disease, have a better
quality of life and improved survival folY-lowing aortocoronary bypass grafting
than medically treated patients.
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Textile Teflon Arterial Prostheses: How Successful Are They?
,

Today the woven and knitted Teflon vascular prostheses developed over 25
i years ago by Edwards are of only minor
clinical interest. The literature contains a
chronology of postoperative complica
tions critical of textile Teflon as a
'prosthetic material, and this led to its
discontinuance as a commercial product.
* Recent evidence from pathologic and
material analyses of three grafts
removed from patients after implantation
k . for 11, 19 and 19 years, respectively,
suggests that the previously reported
►complications were more likely to have
been related to the use of silk sutures,
the fraying and ravelling of the
woven and weft-knitted constructions
and local or systemic reactions than to
degradation of the Teflon. Experimental
studies of grafts implanted in the
k thoracic and abdominal aortas of dogs
for periods of up to 6 months support
*>!hese findings. Because of the apparent
long-term stability of textile Teflon as an
r implantable material, the authors see
merit in its reintroduction as a warpknitted vascular prosthesis.
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Les protheses arterielles textiles en
Teflon developpees par Edwards voici
plus de 25 ans ne presentent plus
actuellement d'interet Clinique. Au debut
des annees 70, la litterature medicale a
rapporte des complications evolutives
graves associees & ce type de materiau;
la commercialisation des protheses arte
rielles textiles en Teflon fut alors abandonnee. L'examen de trois protheses de
ce type apres leur exerese 11, 19 et 19
ans apres la mise en place, suggere que
les complications rapportees anterieurement dependent essentiellement de I'utilisation de la soie comme suture, de
types de construction (tisse et tricot
trame) susceptibles de s'effilocher aux
extremites et de reactions locales ou
systemiques plutot que de la degradation
du Teflon. Les etudes sur les protheses
implantees dans I'aorte thoracique ou
dans I'aorte abdominale de chiens pen
dant des periodes s etendant jusqu'a 6
mois le confirment. La stabilite du Teflon
a long terme est exceptionnelle et les
auteurs croient a I'interet de le reintroduire sous forme de tricot chaine.

In 1971 and 1973, Boyd and Midell1'2
reported a high percentage of complica
tions following the use of textile Teflon
(polytetrafluoroethylene) grafts in
patients who underwent aortoiliac sur
gery. These consisted of disruption of the
suture line and occlusion of some grafts.
In a group of 48 patients operated upon
for abdominal aneurysm and occlusive
disease, the authors stated that “the long
est period a graft is known to have func
tioned is 86 months after resection for
abdominal aortic aneurysm” . There was
a much lower frequency of complications
and a lower mortality when Dacron (poly
ester) grafts were used. The authors con
cluded that Teflon in a textile form was
unsatisfactory as a prosthesis and its use
should be abandoned.
Earlier, Teflon had been used exten
sively, following experimental studies to
evaluate its performance as a vascular
substitute. In 1957, Harrison3 reported
the results of a laboratory study in which
he evaluated 250 prostheses of different
synthetic materials. In his opinion, Teflon

performed satisfactorily with rapid heal
ing and good resistance to degradation
over extended periods. Such a conclusion
was corroborated by the Committee for
the Study of Vascular Prostheses of the
Society for Vascular Surgery,4 although,
at the same time, Deterling, one of the
coauthors, and Bhonslay indicated their
preference for Dacron.5 After an exten
sive 8-year study of various prostheses
Szilagyi and associates,6 in 1964, showed
that all textile implants exhibited the same
pattern in regard to arteriogenesis, but
that woven Teflon was defective in incor
porating connective tissue and thus was
inferior to Dacron.6 Wesolowski and
associates7 have also influenced its
acceptability by suggesting that the tight
ness of the weave prevented the organi
zation of fibrous tissue and that Teflon
was responsible for precipitating calcium
salts within the lumen. In 1965,
Wesolowski8 proposed that graft failures
could be related to systemic causes as well
as to deficiencies in the physical proper
ties of Teflon.
Consequently, the experimental and
clinical experience with Teflon in the
1950s and 1960s lent support to the state
ments made by Boyd and Midell in 1971
and 1973, that the prosthetic material
itself was responsible for the high percen
tage of complications. This concept has
also been shared by many clinicians
interested in this question, including our
group. However, following the analysis
of explanted textile Teflon grafts obtained
through our implant retrieval program,
we have revised our thinking.9 Our
attention has been drawn to the case his
tories of three patients in particular —
one who was reoperated upon 11 years
after receiving a textile Teflon prosthesis
and two who died 19 years after implan
tation. Because of the unexpected results
from the analysis of these explants, we
undertook a series of animal experiments
to support our clinical findings. This
paper reports our experience with textile
Teflon arterial prostheses.
Methods

Tubular textile Teflon prostheses used
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to be manufactured by USCI (C.R. Bard,
Inc.), formerly of Glenn Falls, NY and
Murray Hill, NJ, in straight and bifur
cated designs in both weft-knitted and
woven constructions.10 Sold under the
trade name Edwards Seamless Teflon
Graft, each style was available in a range
of sizes. Since 1981 this product has been
discontinued. Unused samples were made
available to us by Bard Im plants
(Billerica, Mass.).
Following macroscopic examination,
microscopic analysis of the human and
animal explants was conducted by light
and scanning electron microscopy on
representative sections, according to a
previously established protocol.9
The tissue adhering to the remaining
sections of the grafts retrieved from
humans was removed and the samples
were cleaned by boiling in a 5% sodium
bicarbonate solution, immersing in a
peroxide bleach at room temperature,
washing thoroughly with distilled water
and drying. Certain material properties
(fabric structure, fibre morphology, usa
ble length, diam eter and bursting
strength) of the grafts retrieved from our
cases 2 and 3 were analysed by methods
previously described.11 The size of the
sample retrieved from case 1 was too
small to enable these tests to be com
pleted. In order to determine the extent
and nature of changes in the prostheses
during im plantation, virgin grafts

manufactured more than 20 years ago
were also analysed by the same techniques
(Figs. 1 and 2).
Case Reports
Case 1
A 55-year-old man was operated upon 11
years after implantation of a woven textile
Teflon graft for left aortofemoral bypass. His
symptoms had included rest pain associated
with segmental obstruction due to arterioscle
rosis. In spite of a good recovery, the reoper
ation was required because a false aneurysm
developed at the distal anastomosis. A small
segment of the prosthesis was resected with the
aneurysm, and a Dacron graft was inserted end
to end to the Teflon and end to side to the deep
femoral artery to restore blood flow.
The specimen was 2 cm long and had a thin
internal capsule. It was poorly incorporated
into the graft structure and contained closely
packed fibrous tissue made up of collagen and
fibroblasts. The flow surface was smooth and
glistening and contained flattened cells (Fig.
3). No external capsule was evident, but it may
have been lost during the reoperation.

Case 2

A 77-year-old man died from generalized^"
atherosclerosis with bilateral cerebral infarc
tion. Nineteen years earlier a ruptured abdon% i
nal aortic aneurysm had been successfully
treated by the implantation of a knitted tex- 4
tile Teflon bifurcated graft which was sutured
with silk. Three weeks after the operation h#
had had small-bowel obstruction and acute
cholecystitis and subsequently had returned to A
the hospital on many occasions because of reti-

FIG. 3—Case 1. Scanning electron pho-*4
tomicrographs of explanted graft. (A) Smooth
and glistening flow surface of thin internal cap- .
sule which is poorly attached to substratum
(reduced by 52% from x 54). (B) Capsule con
sisting of packed fibrin, collagen and flattened
cells (reduced by 52% from x 720).

FIG. 1—Scanning electron photomicro
graphs of virgin woven prosthesis. (A) Fabric
under low magnification (reduced by 52%
from x 54). The internal and external views
are similar. (B) Individual fibres appear rough
and non-uniform, while fine fibrils are seen
bridging adjacent fibres (reduced by 52% from

x 1000).
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PTG. 2—Scanning electron photomicro
graphs o f virgin knitted prosthesis. (A) Inter
nal and (B) external views of weft-knitted con
struction (reduced by 52% from X 54). (C)
Fibrils are seen between fibres (reduced by 52%
from x 1000).

FIG. 4—Case 2. Graft in situ. Proximal ^
anastomosis has ruptured and silk sutures are
absent. Fibrous tissue proliferation across 4-cm
gap between prosthesis and host aorta.
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nal artery embolism, a herniated disc, osteoar
thritis, depression and primary affective
-'■‘disorder.
Examination of the Teflon graft showed that
; t^ie proximal anastomosis had failed and that
the silk sutures had disappeared (Fig. 4). A disfr tance of 4 cm separated the prosthesis from the
host aorta, and only the presence of surround
ing fibrous tissue had prevented hemorrhage.
The internal capsule contained concentric
►' layers of thrombus laid down at different times
with fibrin present on the luminal surface.
KExcept for some ravelling near the proximal
anastomosis, the weft-knitted structure of the
►-cleaned sample appeared well preserved. No
fibre degradation could be seen since the Teflon
fibres retained their virgin appearance (Fig. 5).
Even the delicate microfibrils that join adjay cent fibres were still intact (compare Figs. 3 and
5). Table I indicates the increase in length
1 (10%) and diameter (17% to 20%) of the graft
that occurred during the 19 years of implan
t a t i o n . During this period the graft lost 11%
of its original bursting strength,

v

Case 3
i

A 74-year-old man had received a woven tex►

tile Teflon graft 19 years previously. He had
presented with aortoiliac obstruction and renal
hypertension. An aortobifemoral graft with a
limb to the right kidney was implanted during
a 6-hour procedure and he had required numer
ous blood transfusions. As in case 2, silk had
been used as the suture material. He was exa
mined regularly throughout the 19 years
postoperatively until he died because of suddent rupture o f the anastomosis between the
body of the graft and the limb to the right
kidney.
On macroscopic examination, the limb to the
kidney was separated from the body of the
prosthesis. No suture material could be found
(Fig. 6). There was virtually no internal cap
sule and what did exist appeared to be poorly
organized, discontinuous and of variable thick
ness. The external capsule was very thin and
appeared to separate easily from the prosthesis.
The cleaned prosthesis showed a wellpreserved woven fabric structure (Fig. 7),

Animal Experiments
Protocol
Four series of implantations were con
ducted on adult mongrel dogs, selected
according to the Canadian Council on
Animal Care Regulations, for scheduled
periods of 4 hours, 24 hours, 1 week, 1
month and 6 months. The first two ser
ies involved the insertion of 8- or 10-mm
diameter woven and knitted Teflon grafts
to bypass the thoracic aorta in 11 male

Table 1-Textile Analysis of Knitted Teflon Prostheses. Virgin Prosthesis
versus Prosthesis Retrieved from Case 2, 19 Years after Implantation
Prosthesis
19 years after
Virgin
implantation
prosthesis
Characteristic
Dimensional stability
Usable length, cm
Diameter
Body, mm
Limbs, mm
Dilatation at 120 mm Hg
Body, %
Limbs, %
Bursting strength, kPa
Water permeability,
mL/cm2- min"1

FIG. 5—Case 2. Scanning electron pho
tomicrographs show well-preserved fabric. (A)
Internal and (B) external surfaces (reduced by
52% from x 54). (C) Delicate fibrils were still
joining adjacent fibres (reduced by 52% from
X 1000).

except for some tearing and fraying near the
suture lines (compare Figs. 1 and 7). There was
no evidence of fibre degradation. The test
results (Table II) indicate that during its 19
years of implantation, this woven Teflon graft
retained its original dimensions and virtually
all its original bursting strength.

Change,

11.3

12.4

+ 1U

19.7
10.4

23.6
12.2

+ 20
+ 17

-

—
—
-11

3.7
6.8
863

—

771

1970 ± 100

FIG. 6—Case 3. Graft showing absence o f silk sutures. (A) Anastomosis of prosthetic limb
to kidney with body of prosthesis. (B) Anastomosis of distal limb with femoral artery. (C and
D) Scanning electron photomicrographs show luminal surface covered with poorly organized
fibrin deposits entrapping blood cells (reduced by 51% from C, x 180; D, x 7000).
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dogs. The last two series involved the
insertion o f 6-mm diameter woven and
knitted grafts to bypass the infrarenal
abdominal aorta in 11 female dogs.
Details o f these protocols have been pub
lished p reviou sly.12'13 A ngiographic
studies o f the grafts implanted for 6
months were performed 48 hours before
the scheduled sacrifice.
Results

abdominal or thoracic aorta). The woven
graft with its smoother, non-wettable sur
face and smaller interstices (Figs. 1 and

2) retained only a sparse, discontinuous
thrombotic matrix concentrated mainly
between the threads after 4 hours o f * --------------------- *

T a b le I I — T e x t ile A n a ly s is o f W o v e n T e f lo n P r o s th e s e s . V ir g in P r o s th e s is
v e r s u s P r o s t h e s is R e tr ie v e d f r o m

C a s e 3 , 1 9 Y e a rs a f t e r I m p la n ta tio n
P r o s t h e s is

C h a r a c te r is t ic

1

V irg in

1 9 y e a rs a fte r

p r o s th e s is

im p la n t a t io n

Change, %

1 1 .8

1 1 .7

-1

1 8 .8

1 9 .3

+ 2

9 .4

9 .7

+ 3

D im e n s io n a l s t a b i l i t y

In all, 21 grafts were available for study
because one dog died postoperatively
from a cause unrelated to the graft.
Angiography indicated that after 6
months o f implantation all grafts were
patent and free from dilatation or other
complications.
M icroscopic exam ination o f the
removed grafts revealed differences in the
early thrombotic response between the
woven and knitted constructions but not
between the sites o f implantation (i.e., the

U s a b le le n g th , c m
D ia m e te r
Body, m m
L im b s , m m

^

D ila t a t io n a t 1 2 0 m m H g
Body, %

2 .5

L im b s , %
B u r s t in g s t r e n g t h , k P a

0 .9

__

743

705

_
-5
t

W a t e r p e r m e a b ilit y ,
m U c m 2- m in

1

75

±

20

-

FIG. 8—Scanning electron photomicrographs of grafts removed from thoracic aorta of
dogs after 4 hours of implantation: (A) woven graft near proximal anastomosis (left); (B) knifted graft (right). After 6 months: (C) knitted prosthesis has flow surface coated with thin inter
nal capsule; (D) woven prosthesis with flow surface covered with endothelial-like cells. Both <
types of prosthesis had similar degrees of healing regardless o f location (reduced bv 51% from
A, x 48; B and C, X 54; D, x 2000).
V,

T a b le I I I - - M ic r o s c o p ic A n a ly s is o f T e x t ile T e f lo n P r o s th e s e s R e tr ie v e d f r o m

Dogs

j

L e n g th o f
im p la n t a t io n
4 h

W o v e n c o n s t r u c tio n
F e w th ro m b i. F ib rin s u f fic ie n t

K n it t e d c o n s t r u c tio n
H e a v y t h r o m b o t ic d e p o s its

t o o c c lu d e in t e r s tic e s
24 h

FIG. 7—Case 3. Explanted and cleaned
prosthesis. (A) Specimen cut into three pieces
for analysis showing extent of fraying at prox
imal and limb (hole) anastomotic regions. (B
and C) Scanning electron photomicrographs
showing woven structure (B) and (C) that
individual fibres maintained their integrity
(reduced by 52% from B, x 54; C, X 440).
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Pfizer Introduces

AN IMPORTANT INNOVATION
IN HOSPITAL ANTIBIOTIC THERAPY
Prescribing Information
CEFOBID*
(cefoperazone sodium)

For Intravenous or Intramuscular Injection

Antibiotic
ACTION
In vitro studies indicate that the bactericidal action of CEFOBID (cefoperazone sodium) results from the
inhibition of bacterial cell wall synthesis.
INDICATIONS AND CLINICAL USES
CEFOBID (cefoperazone sodium) may be indicated for the treatment of the following infections when
caused by susceptible strains of the designated microorganisms:
LOWER RESPIRATORY TRACT INFECTIONS caused by Streptococcus pneumoniae, Haemophilus in
fluenzae, Staphylococcus aureus. Streptococcus pyogenes, Klebsiella species (including Klebsiella
pneumoniae), Pseudomonas aeruginosa. Escherichia coli, Proteus mirabilis, indole-positive Proteus
species and Enterobacter species
URINARY TRACT INFECTIONS caused by Escherichia coli. Pseudomonas aeruginosa, Enterobacter
species. Klebsiella species. Enterococcus. Proteus mirabilis. Staphylococcus aureus. Staphylococ
cus epidermidis and indole-positive Proteus species.
Due to the nature of the underlying conditions which usually predispose patients to Pseudomonas
infections of the lower respiratory and urinary tracts, a good clinical response accompanied by
bacterial eradication may not be achieved despite evidence of in vitro sensitivity.
ACUTE BILIARY TRACT INFECTIONS ASSOCIATED WITH CHOLECYSTITIS OR CHOLANGITIS caused
by Escherichia coli.
SEPTICEMIA caused by Staphylococcus aureus. Streptococcus pneumoniae. Streptococcus agalactiae, Escherichia coli and Klebsiella species.
WOUND INFECTIONS (SURGICAL AND TRAUMATIC) caused by Staphylococcus aureus, Streptococ
cus pyogenes and Pseudomonas aeruginosa.
GYNECOLOGICAL INFECTIONS (SUCH AS PELVIC INFLAMMATORY DISEASE AND ENDOMETRITIS)
caused by Streptococcus agalactiae. Neisseria gonorrhoeae, Escherichia coli, Bacteroides species
(including Bacteroides fragilis), Peptococcus species and Peptostreptococcus species
Specimens for bacteriologic culture should be obtained prior to therapy in order to identify the causative
organism and to determine its susceptibility to CEFOBID (cefoperazone sodium) Therapy may be in
stituted before results of susceptibility testing are known: however, modification of the treatment may be
required once these results become available.
CONTRAINDICATIONS: CEFOBID (cefoperazone sodium) is contraindicated in patients with known
allergy to the cephalosporin class of antibiotics.
WARNINGS: Before therapy with CEFOBID (cefoperazone sodium) is instituted, careful inquiry should be
made to determine whether the patient has had previous hypersensitivity reactions to cephalosporins,
penicillins or other drugs. CEFOBID (cefoperazone sodium) should be administered with caution to
penicillin-sensitive patients or to any patient who has demonstrated some form of allergy, particularly to
drugs If an allergic reaction to CEFOBID (cefoperazone sodium) occurs, discontinue administration of
the drug and treat the patient with the usual agents (e g. epinephrine, antihistamines, pressor amines or
corticosteroids).
Pseudomembranous colitis has been reported to be associated with the use of CEFOBID (cefoperazone
sodium). Therefore, in those patients administered CEFOBID (cefoperazone sodium) who develop diar
rhea, it is important to consider such a diagnosis.
Treatment with broad-spectrum antibiotics, including CEFOBID (cefoperazone sodium), alters the
normal flora of the colon and may permit overgrowth of Clostridia. Studies indicate that a toxin produced
by Clostridium difficile is one primary cause of antibiotic-associated colitis
Mild cases of colitis may respond to drug discontinuance alone Moderate to severe cases should be
managed with fluid, electrolyte, and protein supplementation as indicated When the colitis is not reliev
ed by the discontinuance of CEFOBID (cefoperazone sodium) or when it is severe, consideration should
be given to the administration of oral vancomycin.
PRECAUTIONS
General: The concomitant administration of aminoglycosides and some cephalosporins has caused
nephrotoxicity Although transient elevations of BUN and serum creatinine have been observed, there is
no evidence that CEFOBID (cefoperazone sodium) when administered alone causes significant
nephrotoxicity. However, the effect of administering CEFOBID (cefoperazone sodium) concomitantly
with aminoglycosides is not known
CEFOBID (cefoperazone sodium) is excreted in both the bile and urine. In normal volunteers. 19 to
41 /o of the dose is excreted in the urine, the remainder being excreted by the hepato-biliary system. The
serum half-life of CEFOBID (cefoperazone sodium) is usually prolonged and urinary excretion of the drug
increased in patients with hepatic disease and/or biliary obstruction Serum concentrations of
cefoperazone should be monitored in these patients treated with doses in excess of 2 grams daily and
dosage should be adjusted as necessary
Because renal excretion is not the main route of elimination of cefoperazone, adult patients with renal
failure usually require no adjustment in dosage when daily doses of 2 to 4 grams (1 to 2 grams every 12
hours) are administered. If higher doses of CEFOBID (cefoperazone sodium) are used, serum concentra
tions of cefoperazone should be monitored. If there is evidence of accumulation, dosage should be
decreased accordingly
In one study in patients w ith chronic renal failure, the half-life of CEFOBID (cefoperazone sodium) was
reduced from 4 17 to 1.67 hours during hemodialysis. Thus, dosing should be scheduled to follow a
dialysis period
In patients with both hepatic dysfunction and renal impairment, the initial dosage of CEFOBID
(cefoperazone sodium) should not exceed 1 to 2 grams daily and serum concentrations of cefoperazone
should be monitored closely.
Vitamin K deficiency has occurred in a few patients treated with CEFOBID (cefoperazone sodium). The
mechanism is most probably related to the suppression of gut flora which normally synthesizes this
vitamin Those at risk include patients with poor diet or malabsorption states (e g cystic fibrosis) and
patients on prolonged intravenous alimentation regimens. Prothrombin time should be monitored in
these patients and exogenous vitamin K administered as indicated.
A reaction characterized by flushing, sweating, headache, and tachycardia has been reported when
alcohol is ingested during and as late as the fifth day after CEFOBID (cefoperazone sodium) administra
tion Patients should be cautioned concerning ingestion of alcoholic beverages in conjunction with ad
ministration of CEFOBID (cefoperazone sodium). For patients requiring artificial feeding orally or
parenterally. solutions containing ethanol should be avoided
CEFOBID (cefoperazone sodium) should be administered with caution to individuals with a history of
gastrointestinal disease, particularly colitis.
Overgrowth of nonsusceptible organisms may occur during prolonged use of CEFOBID (cefoperazone
sodium) Patients should be observed carefully during treatment. If superinfection occurs, appropriate
measures should be taken

Drug Laboratory Test Interactions
j
A false-positive reaction for glucose in the urine may occur with Benedict's or Fehling's solution
^
Pregnancy: The safety of CEFOBID (cefoperazone sodium) in pregnancy has not been established. The
use of CEFOBID (cefoperazone sodium) in pregnant women requires that the likely benefit from the drug
be weighed against the possible risk to the mother and fetus
Reproduction studies have been performed in mice, rats and monkeys at doses up to 10 times the
human dose and have revealed no evidence of impaired fertility or teratogenic effects due to cefoperazone sodium Animal reproduction studies, however, are not always predictive of humair
response
Nursing Mothers. Cefoperazone is excreted in low concentration (0 4 to 0.9 /*g/m L) in human mji|(
Caution should be exercised when CEFOBID (cefoperazone sodium) is administered to a nursing mother
Children: The safety and efficacy of CEFOBID (cefoperazone sodium) in children have not been
established
^
ADVERSE REACTIONS
Hypersensitivity: Macuiopapular rash, urticaria, pruritis, eosmophilia. drug fever
Hematology - Decreases in hemoglobin and/or hematocrit have occurred Slight decreas^-m ^
neutrophil count have been reported, and reversible neutropenia may occur with prolonged administra
tion Transient eosinophilia has occurred Hypoprothrombmemia has been observed Some individuals
have developed positive direct Coombs' test during treatment
Liver — Transient elevations in SGOT, SGPT and alkaline phosphatase levels have been noted. One pa
tient with a history of liver disease developed significantly elevated liver function enzymes durinc
therapy with CEFOBID (cefoperazone sodium). Clinical signs and symptoms of nonspecific hepatitis £■
companied these increases After CEFOBID (cefoperazone sodium) therapy was discontinued, the pa
tient's enzymes returned to pre-treatment levels and the symptomatology resolved
j
Kidney — Transient elevations of blood urea nitrogen and serum creatinine have been noted
;

Gastrointestinal — Altered bowel habits (loose stools or diarrhea) have been reported Most of these
events have been mild or moderate, but some have been severe. In all cases, these symptoms respond
ed to symptomatic therapy or ceased when cefoperazone therapy was stopped Nausea and vomiting 1
have been reported rarely
Pseudomembranous colitis has been reported rarely in patients administered CEFOBID (cefoperazone
sodium). Symptoms of pseudomembranous colitis can appear during or for several weeks subsequent to I
antibiotic therapy
Disulfiram-iike Reaction
^
Disulfiram-like reactions have been reported when alcohol was ingested during and as late as the fifth ^
day after CEFOBID (cefoperazone sodium) administration.
Central Nervous System — Headache and dizziness occur rarely.
^
Local Reactions — CEFOBID (cefoperazone sodium) is well tolerated following intramuscular administra
tion Occasionally, transient pain may follow administration by this route. When CEFOBID (cefoperazone
sodium) is administered by the intravenous route, some patients develop phlebitis at the site of ad ^
ministration
Other — Diaphoresis/chills
SYMPTOMS AND TREATMENT OF OVERDOSAGE
"
Since no case of overdosage has been reported to date with CEFOBID (cefoperazone sodium), no
specific information on symptoms or treatment of overdosage is available Treatment should be symp ,
tomatic.
^
Hemodialysis is not effective in the removal of cefoperazone
DOSAGE AND ADMINISTRATION
DOSAGE
CEFOBID (cefoperazone sodium) may be administered intravenously or intramuscularly
Dosage and route of administration should be determined by severity of infection, susceptibility of the
causative organism, and condition of the patient.
Adult
v
The recommended daily dose of CEFOBID (cefoperazone sodium) is 2 to 9 grams administered in equal
ly divided doses every 8 to 12 hours (See table below). The usual duration of treatment is 7 to 14 days
Adult Dosage
<
Type of Infection
Daily Dose
Frequency and
Mild to moderately severe
2 to 4 grams
1 to 2 grams
infections such as pneumonia,
every 12 hours
acute urinary tract infection,
I.M or I V
wound infection
Severe infections or infections
4 to 8 grams
2 to 4 grams
caused by less sensitive
every 12 hours
organisms
IV
Infections commonly requiring
9 grams
3 grams every
antibiotics in higher dosage
8 hours I V
(e.g septicemia and lifethreatening infections)
The maximum adult daily dose should not exceed 9 grams.
For infections caused by Streptococcus pyogenes, therapy should be continued for at least 10 days^
Impaired Renal Function
Because renal excretion is not the main route of elimination of cefoperazone, adult patients with renal
failure usually require no adjustment in dosage when daily doses of 2 to 4 grams (1 to 2 grams every 12
hours) of CEFOB'D (cefoperazone sodium) are administered. If higher doses of CEFOBID (cefoperazone
sodium) are used, serum concentrations of cefoperazone should be monitored If there is evidence of
accumulation, dosage should be decreased accordingly For patients whose glomerular filtration rate is
less than 18 mL/min or whose serum creatinine level is greater than 3.5 m g/dL, the maximum
CEFOBID (cefoperazone sodium) dosage should be 4 grams per day
In patients undergoing hemodialysis, dosing should be scheduled to follow a dialysis period
Hepatic Disease and Biliary Obstruction
The serum half-life of cefoperazone is increased 2 to 4 fold in patients with hepatic disease and/or
biliary obstruction Serum concentrations of cefoperazone should be monitored in patients treated w itlj
doses in excess of 2 grams daily and dosage should be adjusted as necessary
Hepatic Dysfunction and Renal Impairment
In patients with both hepatic dysfunction and concomitant renal impairment, the initial dosage of
CEFOBID (cefoperazone sodium) should not exceed 1 to 2 grams daily and serum concentrations of
cefoperazone should be closely monitored
Children
The safety and efficacy of CEFOBID (cefoperazone sodium) in children have not been established

ADMINISTRATION
Intramuscular:
CEFOBID (cefoperazone sodium) should be administered by deep intramuscular injection into a large
muscle mass such as the gluteus maximus or anterior thigh. The maximum dose of CEFOBID
(cefoperazone sodium) should be two (2) grams
Intravenous:
Direct Intravenous (bolus) Injection: The reconstituted solution should be injected slowly over a
period of no less than three (3) minutes. The maximum dose of CEFOBID (cefoperazone sodium)
should be two (2) grams.
Intermittent Intravenous Infusion: The reconstituted solution may be infused over a period of 15
minutes to 1 hour through the tubing of an administration set while any of the intravenous solutions
(See Solutions for I.V. Infusion) are being infused. During infusion of the solution containing
CEFOBID (cefoperazone sodium), it is desirable to temporarily discontinue administration of the other
solution.
Continuous Intravenous Infusion: CEFOBID (cefoperazone sodium) may also be administered over a
longer period of time.
Noto: If therapy with CEFOBID (cefoperazone sodium) is carried out in combination with an
aminoglycoside antibiotic, each should be administered at different sites because of a physical in
compatibility. An aminoglycoside should not be mixed with CEFOBID (cefoperazone sodium) in the
same container.
PHARMACEUTICAL INFORMATION
CHEMISTRY
Trade Name: CEFOBID
Proper Name: Cefoperazone sodium
Chemical Name:
Sodium (6R,7R)-7-[(R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-(p-hydroxyphenyl)
acetamido]-3 T[(1-methyl-1 H-tetrazol-5-yl)thio]methyll-8-oxo-5-thia-1-azabicyclo[4.2.0]
oct-2-ene-2-carboxylate
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Molecular Formula: C25H20NgOgS2Na Molecular Weight: 667.65
Description:
Cefoperazone sodium is a white powder, soluble in water, sparingly soluble in methanol, poorly soluble
in ethanol, and insoluble in ethyl ether, acetone, chloroform, or n-hexane.
Composition:
CEFOBID vials contain cefoperazone sodium (expressed in terms of free acid). The sodium content of
each gram of CEFOBID is approximately 34 mg (1.5 mEq sodium ion). The pH of a 25% (w /v ) solution
is 4.5 to 6.5 and the solution is colorless to straw yellow depending on the concentration.
RECONSTITUTION
For Intramuscular Uso:
Solution for Reconstitution
Sterile Water for Injection
or, if required
Bacteriostatic Water for Injection
0.5% Lidocaine Hydrochloride Injection
Reconstitute as follows:
Volume to be
Vial Size
Added to Vial
(g)
(mL)

Approximate
Available
Volume (mL)

Approximate
Average Concentration
(mg/mL)

1.0
3.5
4.0
250
2.0
7.0
8.0
250
Shake well until dissolved. Solutions should be allowed to stand after reconstitution to allow any foaming to dissipate in order to permit visual inspection for complete solubilization. Vigorous and prolonged
agitation may be necessary to solubilize CEFOBID (cefoperazone sodium).
For Intravenous Use.
Solutions for Reconstitution and Dilution
Sterile Water for Injection
or, if required
Bacteriostatic Water for Injection
Reconstitute as follows:
Volume to be
Approximate
Approximate
Vial Size
Added to Vial
Available
Average Concentration
(mL)
Volume (mL)
(mg/mL)
(9)
1
9.5
10.0
100
2
19.0
20.0
100
Shake well until dissolved. The prepared solution may be further diluted to the desired volume with any
of the solutions for I.V. infusion listed below.
For direct intravenous (bolus) injection: Reconstitute as directed above.
For intermittent intravenous infusion: Reconstitute as directed above
For continuous intravenous infusion: Reconstitute with Sterile Water for Injection. The-reconstituted
solution may be added to an appropriate intravenous bottle/bag containing any of the solutions for I.V.
infusion listed below:
Solution for I.V. Infusion
5% Dextrose Injection (USP)
10% Dextrose Injection (USP)
5% Dextrose and Lactated Ringer's Injection
Lactated Ringer's Injection (USP)
0.9% Sodium Chloride Injection (USP)
5% Dextrose and 0.9% Sodium
Chloride Injection (USP)
Normosol® M and 5% Dextrose Injection
Normosol® R
5%Dextrose and 0.2% Sodium
Chloride Injection (USP)
Stability of Solutions
Storage:
Reconstituted solutions for intramuscular injection should be used within 24 hours if kept at room
temperature, or 72 hours if stored under refrigeration (5°C).
Reconstituted solutions for I.V. injection or infusion should be used within 24 hours if kept at room
temperature, or 72 hours if stored under refrigeration (5°C).
Incompatibility
CEFOBID (cefoperazone sodium) should not be added to blood products, protein hydrolyzates, or amino
acids. CEFOBID (cefoperazone sodium) should not be mixed together with an aminoglycoside.
DOSAGE FORMS
Availability.
CEFOBID (cefoperazone sodium) is available as a lyophilized powder
1 0g vial — cefoperazone 1 0 g as sodium salt
2 0g vial — cefoperazone 2.0 g as sodium salt
Storage
CEFOBID (cefoperazone sodium) should be stored protected from light and refrigerated (2 to 8°C).
References:
1. Official product monograph.
2. Data on file.
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implantation. In comparison, the rougher
and more porous surface of the knitted
graft retained a thicker and continuous
thrombotic matrix that completely
covered the luminal surface (Fig. 8, A and
B). This discrepancy, however, became
less evident after longer periods of
implantation (Table III) due, we believe,
to the absorption of blood species that
improve the wettability of the Teflon and
to lvsis of the thrombotic deposits with
the onset of fibrinolytic activity. After 1
week in situ, the extent and rate of heal
ing appeared comparable, with both types
of grafts containing a thin thrombotic
matrix that did not completely cover the
textile structure. After 1 month, collagen
was visible near the anastomoses. After
6 months, the entire length of the luminal
surface contained collagen. It had a
smooth, glistening appearance with
endothelial-like cells progressing a few
millimetres beyond the anastomoses (Fig.
8, C and D).
Discussion

The results of microscopic examination
from this animal study are important in
that they demonstrate the similarities in
sequence and rate of healing between
Teflon and Dacron textile prostheses.
Within the first 24 hours of contact with
blood, some differences between these
two materials can be recognized. Teflon
is more hydrophobic, so that its water
permeability is lower for woven grafts and
more variable for knitted structures than
equivalent Dacron prostheses (Tables I
and II). Consequently, Teflon produces
a smaller amount of thrombotic matrix
and less inflammatory response14 than
equivalent Dacron structures. However,
in the medium and long term, we
observed the same sequence and a simi
lar rate of healing.12 The only notewor
thy difference is that the internal and
external capsules of the textile Teflon
prostheses are thinner than their Dacron
counterparts.
These general statements, based on the
results of our animal study, need to be
interpreted in the light of our clinical find
ings. Of particular interest is the large var
iation found in the degree of encapsula
tion between the three cases we have
reported. This confirms our earlier claim
that the extent of healing is more hostdependent than graft-dependent,9 and is
in agreement with our previous laboratory
observations that acute thrombosis in
grafts is related mostly to the thrombohematologic properties of the recipient.15
One particular concern arising from the
observation of incomplete encapsulation
in some patients is that the exposed fibrin
network acts as a potential site for bac
terial colonization. As a consequence,
antibiotics should be given during any
subsequent operation on such patients.
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The results of material testing of the or complete aneurysms at the anasto
clinical specimens indicate that the Teflon moses.
grafts themselves are remarkably stable,
Factors other than those of the graft
maintaining their integrity far better than material itself play a crucial role in deter
equivalent Dacron structures.16 The mining the fate of implants. The progres
retrieved woven Teflon prosthesis has sion of the disease is of major impor
exhibited the most impressive stability tance. In addition, local and systemic
with 5% or less change in dimension and factors associated with the insertion of the
strength during its 19 years in situ. This artificial organ remind us to be cognizant
evidence sup p o rts the claim s o f of the new physicopathology defined by
Edwards17 and Botzko and associates18 Galletti as “ the physiology of dependence
for Teflon’s long-term stability. The on the prosthesis” .28 For these reasons
major limitation of this type of construc the importance of patient follow-up
tion is that it frays easily and cannot be procedures to identify complications of
cut at sharp angles.
prosthetic instability cannot be overem
The observed differences between the phasized.29 Graft failures can now be
woven and knitted samples point to the recognized early, using reliable noninvainherent inferior dimensional stability of sive techniques such as ultrasonogra
the weft-knitted construction. Even so, phy30 and computerized tomography.31
the observed increases in length (10%)
and diameter (17% to 20%) are about
Conclusions
half the changes expected with weftknitted Dacron prostheses after the same
Our observations have confirmed the
period of implantation.9 This superior
findings of others,18-20 namely, that tex
dimensional stability over Dacron is also
tile Teflon vascular prostheses can main
evident when comparing the dilatation
tain their integrity over long periods. The
data for virgin prostheses. Table I gives
previously reported complications are
values of 3.7% and 6.8% whereas Nunn
more likely to have been caused by fray
and associates19 and Edw ards and
ing and ravelling of the woven and weftassociates20 reported values between
knitted structures, the use of silk sutures,
10% and 17% for equivalent Dacron
as well as local and systemic reactions,
grafts tested under the same conditions.
than by biodegradation of the Teflon
A loss of 11% of the original bursting
material. Because of its long-term stabil
strength after 19 years of implantation is
ity as an implantable material, we suggest
small compared with that of Dacron weftthat consideration be given to a textile
knitted prostheses which usually lose the
Teflon graft of warp-knitted construc
same amount of strength after only 18
tion. Such a design would overcome the
months in vivo.21 As well as having
fraying and ravelling disadvantages of the
inferior dimensional stability, weftprevious models.
knitted constructions have a tendency to
ravel, especially when cut on the diagonal.
We are indebted to J. Bastien, S. Bourassa,
These deficiencies can be overcome by M. Corriveau, A. Dion, D. Lafreniere, D.
using a warp-knitted rather than weft- Martel, L. Martin and G. Mongrain for their
knitted construction. In addition, warp skilful technical assistance. We acknowledge
knits are less likely to dilate and lose the continuing interest and support of our col
leagues Drs. J.F. Girard, H.P. Noel, S.A.
strength in vivo, regardless of the type of Brown, C. Gosselin and G. Wilson.
material used.22
We believe that these clinical and
experimental observations demonstrate
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Tracheal Sleeve Pneumonectomy
for Carcinomas of the Proximal Left Main Bronchus

>

I
1 1'

c
Although most primary cancers of the
r f left main bronchus extending to the
carina are inoperable, some patients with
such a tumour may benefit from an
extended, curative surgical procedure.
r This type of resection presents specific
problems in reconstruction and physio
logic management during operation,
n
Between 1977 and 1983, five such
patients were managed by left pneujnonectomy followed by resection of the
carina. They ranged in age from 49 to
65 years. None were irradiated before
the procedure. In all cases, an end-toend anastomosis was made between the
right main bronchus and the mediastinal
trachea. The high-flow catheter tech
nique was used for ventilation during
reconstruction.
, There were no operative deaths.
Excessive bronchorrhea was noted in all
^ patients and was aggravated by left
recurrent nerve palsy in two.
This report indicates that modern tech
niques of tracheobronchial reconstruction
can be successfully applied in patients
with locally advanced carcinoma of the
proximal left main bronchus. This type of
y resection may be the treatment of choice
in selected cases.
»-

^

V

Meme si la plupart des patients presentant un cancer de la bronche souche
gauche avec envahissement de I'eperon
tracheal sont consideres inoperables, certains malades peuvent beneficier d'une
resection chirurgicale etendue. Ce genre
de chirurgie presente des problemes specifiques relies a I'anesthesie et a la tech
nique de reconstruction.
Entre 1977 et 1983, cinq patients ont
Subi une pneumonectomie gauche (pre-
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mier stage) suivie d'une resection de
I'eperon tracheal par thoracotomie droite
(deuxieme stage). L'age des patients
variait entre 49 et 65 ans et aucun
n'avait recu de radiotherapie preoperatoire. Dans tous les cas, une anastomose
termino-terminale a ete faite entre la trachee mediastinale et la bronche souche
droite. La ventilation par catheter et oxygene a haut debit a ete utilise durant la
reconstruction.
II n'y a eu aucun deces operatoire.
Une bronchorrhee importante a ete notee
en postoperatoire chez tous les malades.
Dans deux cas, cette complication a ete
aggravee par une paralysie de la corde
vocale gauche.
Cette etude demontre que les techni
ques modernes de reconstruction
tracheo-bronchique peuvent s'appliquer
avec succes dans la resection des can
cers de la bronche souche gauche localement invasifs. Ce type de resection peut
representer le traitement de choix pour
certains patients selectionnes.

Bronchogenic carcinomas presenting with
local invasion of the carina extend out
side the anatomical limits of standard pul
monary resection. Since most of these
tumours are considered incurable, pallia
tive radiotherapy is generally accepted as

the treatment of choice. In some cases,
however, surgical resection is possible and
could be beneficial to the patient.
On the right side, the technique of
sleeve pneumonectomy1-3 is well de
scribed and the results suggest that some
patients can be cured of their disease fol
lowing this operation. On the left side, the
aortic arch limits exposure to the carina
and makes resection technically difficult.
This report reviews our experience with
left tracheal sleeve pneumonectomy and
analyses the important implications of the
surgical and anesthetic techniques.
Patients
In the 6 years from 1977 to 1983, 213
patients underwent pneumonectomy for
cure of primary bronchogenic carcinoma.
In five men ranging in age from 49 to 65
years (mean 54 years), a sleeve resection
of the trachea was added to the left pneu
monectomy. All five had squamous car
cinomas and only one patient had hilar
metastases (Nl).
In three patients, the indication for
carinal resection was disease at the resec
tion line after proximal left pneumonec
tomy; two patients had a local recurrence
1Vi and 6 years (Fig. 1) after pneumonec
tomy. No patient had received radiother
apy preoperatively.

Fig. lb
FIG. 1—(a) Chest roentgenogram showing bronchial stump (arrows), (b) Line drawing of
stump recurrence 6 years after left pneumonectomy.
Fig. la
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Operative Technique
The procedure is done in two stages.
First, a proximal left pneumonectomy is
carried out. If tissue from the resection
line is malignant, the carina is resected
through a right posterolateral thoracot
omy 3 to 5 weeks later.
When the carina is resected, the
tracheal bifurcation and bronchial stump
must be fully mobilized before dividing
the airways. To avoid injury to the left
pulmonary artery or left recurrent nerve,
the dissection must be kept close to the
bronchial stump. The trachea is divided
circumferentially 2 cm above the carina
and the right main bronchus near its ori
gin (Fig. 2a). If frozen sections of tissue
from both resection lines are positive for
cancer, the resection is extended
accordingly.
Anesthesia
During reconstruction, all patients were
ventilated by the high-flow catheter tech
nique.2'4 Oxygenation is achieved with
100% oxygen drawn from a wall source
and directed through a no. 14 French
nasogastric catheter inserted through the
endotracheal tube.
The trachea and right main bronchus
are anastomosed using interrupted sutures
(Fig. 2b). Since the membranous part of
the anastomosis is susceptible to dehis
cence, it is completed last and special care
is taken to avoid suture tension. Perfect
mucosal approximation must be achieved
around the entire anastomosis. In order
to relieve tension, it is sometimes neces
sary to mobilize the right hilum by open
ing the pericardium.

that in stage III disease the local extent
of the tumour (T3) does not have the
same prognostic implications as involve
ment of the .superior mediastinal nodes
(N2) or distant metastases (Ml). Some
patients may benefit from extended sur
gical resection especially if there is no
nodal involvement and histologic findings
are favourable.
The problems associated with carci
noma of the right upper lobe extending
to the carina have been well recognized
and the results of operation suggest that
some patients can be cured of their dis
ease.1'3 Abbott5 in 1950 was the first to
describe the technical difficulties encoun
tered when resecting carcinomas of the
upper lobe extending into the trachea. In
1972, Jensik and associates1 reported a
series of 14 cases, involving resection of
the right lung and carina followed by cir
cumferential anastomosis of the left lung
to the trachea. We reported in 19826 on
a similar series of 26 patients with an
absolute 5-year survival rate of 23%.
On the left side, proximal extension of
the cancer is rare, probably because of the
extra length of the main bronchus. In
most cases, the carinal involvement is
related to metastatic mediastinal nodes
growing into the tracheal lumen. The
technique of left pneumonectomy fol
lowed by carinal resection therefore
applies to a minority of cases and remains
an alternative to conventional stump
radiotherapy.7,8
Several factors must be taken into con
sideration before deciding to carry out
this procedure. The ideal patient should
have a well-differentiated squamous cell
carcinoma with no lymph-node metas

tases. Neoplastic involvement of the
superior mediastinal nodes is an absolute
contraindication.
v
The planning of resection is done dur
ing the bronchoscopic examination. Biops
sies are taken in the trachea 2 cm above .
the carina and if cancer cells are found *
at that level, the procedure is contraindi
cated. Bronchoscopy should also be done~
to rule out a synchronous occult carci- „
noma in the right lung. In this series, one
patient died of a second lung cancet
which may have been missed at the time
of initial examination.
-*
Since the procedure is done in two
stages, the postoperative period of the'*
first operation (left pneumonectomy)
must be relatively smooth. A complicated *
course would make the second stage
hazardous and inadvisable. The cardio
pulmonary status must be reassessed ^
between the two operations to ensure that
the patient can tolerate a d d itio n a l
surgery.
The technique of left tracheal sleeve
pneumonectomy in one stage has been
described by Grillo9 and Smith and
Nigam10 but is most commonly done in #
two stages.1'11 Mobilization of the carina
and particularly of the left bronchial-*
stump is difficult, not only because of
local scarring but also because of the
mediastinal shift that follows pneumonec
tomy. One must always be aware of the
proximity of the left pulmonary artery
stump and left recurrent nerve.
Division of the trachea 1.5 cm above
the carina is generally sufficient but it is
essential to have an expert opinion from-i
a pathologist so that the cancer can be
completely removed. The maximal length -

Results
There were no operative deaths related
to the procedure. All patients had bronchorrhea; in two cases this was aggravated
by left recurrent nerve injury and paral
ysis of the left vocal cord. One patient had
an acute respiratory distress syndrome
and needed reintubation with respiratory
assistance for 8 days.
The follow-up of these five patients is
interesting although the small number of
cases does not allow statistical analysis.
Three patients lived for 2 years; two of
them were still alive in June 1984, 2'h and
41/2 years following operation. Two
patients died early, one of a local recur
rence 3 months postoperatively and the
second 6 months after operation of a
small cell carcinoma that developed in the
lower lobe of the right lung.
Comments
Although involvement of the carina
defines the lung cancer as stage III (TNM
classification), it is important to recognize
584

Fig. 2a

Fig. 2b

FIG. 2—Operative technique, (a) Division of trachea and right main bronchus, (b) Cir
cumferential anastomosis.
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of trachea that can be safely removed is
3.0 to 3.5 cm. To prevent dehiscence or
p la te r stenosis, good mucosal approxima
tion must be obtained all around the
► piastomosis. If additional blood supply
is needed, an intercostal muscle pedicled
• graft can be applied around the
anastomosis.
*** Aggressive physiotherapy must be
instituted early after operation.
^ Endotracheal aspiration or bronchoscopy
. should be done at the earliest sign of
retained secretions. In this series, all
F patients had transient postoperative bronchorrhea probably related to interruption
haf lymphatics and ciliary epithelium.
Vocal cord paralysis on the left side with
r decreased ability to cough increased the
bronchorrhea in two patients.
v Conclusions

y It is difficult to reach definitive conclusions about the merits of this extended
procedure for the management of bron
chogenic carcinoma of the left lung with
: local extension to the carina. Our short*. term results are comparable to those
reported for similar groups of patients
l and the one long-term survivor (4Vi years)
indicates that perhaps this operation is
beneficial to selected patients.
.

NOTICES
continued fro m page 560
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G en e ra l S u rgical S ym p o s iu m
The Division of General Surgery of the
University of Ottawa School of Medicine
will hold its annual General Surgical Sym
posium on Feb. 15 and 16, 1985 at the
Westin Hotel in Ottawa, Ont. It will deal
with management of a variety of com
monly encountered surgical problems. In
addition to local faculty, guests will
include Dr. Andrew Warshaw, Associate
Professor of Surgery at Harvard Medi
cal School and Dr. Zane Cohen, Assis
tant Professor of Surgery at the Univer
sity of Toronto.
For further information contact Dr.
J.L. Wellington, Chairman, Program
Committee, General Surgical Sympo
sium, Department of Surgery, Ottawa
General Hospital, 501 Smyth Rd.,
Ottawa, Ont. K1H 8L6.

P o stg ra d u a te A s s e m b ly
in S u rg e ry
The eighth annual San Diego Postgraduate
Assembly in Surgery will be held Jan.
21-25,1985 at the Sheraton Harbor Island
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Fracture of the Hook of the Hamate
t
r
Fracture of the hook of the hamate most
often occurs in athletes in the hand that
v holds a club, racket, bat or hockey stick,
when the end abuts against the palm of
the hand. The authors report six patients
with this rare fracture, including the only
\n o w n case of spontaneous healing.
^ Because this fracture is associated with
nonunion, surgical excision of the hook
through the fracture site is recommended
in most cases.

t

r

Les fractures de la pointe de I'os crochu
surviennent souvent chez des athletes
fquand le bout de I'instrument utilisee
(raquette, batte ou crosse de golf ou de
hockey) frotte contre la paume de la
main. Les auteurs commentent les cas
de six patients victimes de cette fracture
rare, dont le seul cas connu pour qui la
guerison fut spontanee. Comme cette
fracture est associee a une absence de
soudure de I'os, I'exicision chirurgicale
de la pointe au foyer de fracture est
recommandee dans la plupart des cas.

over 2 years. We report six such cases seen
over a 4-year period. Included in this
group is the only known case in which
there was clinical and radiologic evidence
of healing. The anatomy, etiology, clini
cal presentation, diagnosis and treatment
are reviewed.
Anatom y

The hook of the hamate is a bony
projection arising from the anteroulnar
aspect of the distal part of the triangular
hamate bone. It is 4 to 5 mm wide,
projects 8 to 10 mm from the body of the
hamate and is about the same length
along its rounded crest. Attached to the
crest are the pisohamate ligament, flexor
brevis and opponens digiti minimi mus
cles and the distal half of the ulnar attach

ment of the flexor retinaculum. The radial
surface of the hook forms part of the
ulnar wall of the carpal tunnel (Fig. 1).
The flexor tendons to the ring and little
finger are close against the radial surface.
The deep motor branch of the ulnar nerve
runs along the ulnar side of the base of
the hook and the sensory branch lies close
to the crest. A variation in the motor
branch that could be important in this
injury and its treatment is reported by
Lassa and Shewsbury.12 They described
a case in which the nerve splits to send
a branch around each side of the hook.
The hook can be palpated through the
hypothenar cushion of the palm of the
hand in an area 1.5 to 3 cm distal to the
pisiform bone along a line projected to
the centre o f the head of the index
metacarpal (Fig. 2).

Fracture of the hook of the hamate has
been regarded as a rare injury.1'4 Most
reports have been of only one to three
cases.1-8 In 1977, Stark and associates9
reported 20 cases in athletes over an
8-year period (this did not include those
| r that occurred as a result of a fall or a
j crushing inju ry ) and C arter and
: associates10 reported 9 cases seen over 4
years. One patient appeared in both ser
ies. Egawa and Asai11 described the use
of computerized tomography in six
patients with this fracture who were seen
From the Department o f Surgery, Sunnybrook Medical Centre, Toronto, Ont.
*Fellow in Plastic Surgery; f Director o f
Hand Unit, Sunnybrook Medical Centre
Accepted fo r publication Mar. 19, 1984
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FIG. 1—Section through base of metacarpals. Hook of hamate forms distal half of ulnar
wall of carpal tunnel.
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Cause and Clinical Presentation

All but one11 of the reported cases
have occurred in men, about half of
whom were in the third decade of life.
The youngest patient was a 14-year-old
girl.11 The hamate has two ossification
centres, one in the body and one in the
hook, that may not fuse until the age of
15 years. Ossification may fail to take
place, presenting a roentgenographic pic
ture similar to that of a fracture. It is
usually bilateral.6
Fracture of the hook of the hamate
may occur as part of a multiple car
pometacarpal fracture-dislocation that is
caused by major trauma to the hand and
wrist.7 An isolated fracture of the hook
usually results from a direct blow to the
palm of the hand at the base of the
hypothenar eminence. Symptoms may
date from a fall on the outstretched hand,
a blow to the region of the hamulus or
a crush injury to the proximal portion of
the palm. The history varies depending on
the cause. Patients who have fallen or
have a severe crush injury will have a his
tory of severe pain, swelling and bruis
ing of the proximal part of the palm and
diffuse tenderness around the base of the
hypothenar eminence. Standard roent
genograms of the wrist do not show any
abnormality and the injury is reasonably
labelled as a bruise or a sprain. In the ath
lete, Stark and associates9 have described
how the injury is caused by the end of a
club, bat or racket that is suddenly forced
against the hook when the centrifugal
force of the swing overcomes the grasp
ing power of the hand. This will occur
with a dubbed shot and at the end of the
swing in golf, a checked swing in base
ball or a difficult shot in a racket sport.
When such a fracture occurs, swelling and
bruising are not prominent features. The
patient may experience an immediate
sharp pain in the wrist that is propagated
and aggravated by attempts to keep play
ing. There are also cases in which the
patient does not recall a specific incident
but is aware of recurring and increasing
pain and tenderness around the ulnar half
o f the base of the palm when a handle
that abuts against the hook is gripped.
The history is similar to that of a stress
fracture.
Regardless of how the symptoms start,
the diagnosis is usually made weeks,
months or even years later and usually
after much treatment. In this late stage,
pain is not a complaint except when pres
sure is exerted against the base of the
hypothenar eminence. On examination,
there is a point of tenderness over the
hook in the palm of the hand. Firm pres
sure over the dorsum of the hamate elicits
pain on the volar surface in the region of
the hook and forced ulnar deviation with
dorsiflexion of the wrist is painful.
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M anske13 reported a patient who
presented with symptoms of carpal tun
nel syndrome. One patient in our series
had exploration of the ulnar nerve in
Guyon’s canal. There are five reported
cases in which the diagnosis was made
after rupture of the tendons to the small
or ring fingers.14'16 In three cases there
was involvement of the motor or sensory
branch of the ulnar nerve.7'17,18
Diagnosis

An isolated fracture of the hook of the
hamate is suggested by the history and by
the physical examination. The diagnosis
is made by radiologic examination. The
fracture may be seen with carpal tunnel
views of the wrist done by the method
described by Hart and Gaynor17 (Fig.
3a). In some cases, however, a good view
of the carpal tunnel is difficult to obtain
because of painful, limited dorsiflexion
of the wrist. Andress and Peckar1
demonstrated the fracture with an oblique
anteroposterior projection. The condition
was diagnosed in most of our patients by
lateral tomograms of the hamate (Fig.
3b). It was the only method by which the
fracture could be demonstrated in three
of them . M urray and associates8
reported a similar experience in their ser
ies of three patients. They believe tomo
graphy is the preferred method. They
pointed out that the margins are more
accurately defined by tomography, and
that helps to distinguish those fractures
that may cause tendon or nerve compli
cations and to differentiate the fracture
from an unfused ossification centre.
Egawa and Asai11 used computerized
tomography to diagnose the fracture in
six cases.

Our Experience

The clinical features of the patients in
our series are outlined in Table I.
Selected Cases
Case 1.—A 41-year-old, right-handed man
had experienced a sudden sharp pain at the
base of the hypothenar eminence of his left
hand after a dubbed golf shot. Pain and tender
ness had gradually subsided, but recurred,
whenever he tried to play golf. Roentgeno
grams of the wrist, including carpal tunnel
views, obtained initially, had shown no abnor
mality. The ulnar nerve in Guyon’s canal had
been explored, but symptoms had persisted.
When he was first seen by us 16 months after
the onset of symptoms, he had tenderness over
the hook of the hamate, pain on pressure over
the hamate dorsally and on ulnar deviation of
the wrist. Tomograms o f the hamate showed
a fracture of the hook with some sclerosis along
the fracture line. He stopped playing golf. His .
symptoms subsided but repeat tomography 2
months later showed no change in the fracture.
Six months from the time of diagnosis the
patient was completely free of pain and repeat^
tomography showed that the fracture had
healed.
Case 2.—This 27-year-old man was an
ardent tennis and squash player. He could

Fig. 3b
FIG. 2—Hook of hamate can be palpated
3 cm distal to pisiform along line joining it and
head of index metacarpal.

F IG. 3—F racture through hook of hamate,
(a) Carpal tunnel view, (b) Lateral tomogram.
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recall no specific incident that precipitated his
symptoms but for 9 months he had suffered
■pain at the base of the hypothenar eminence
o f his right hand. He persisted in playing racket
games with a wrist gauntlet in spite o f the dis
comfort it caused. Any flexion movement of
the wrist, while holding a racket, gave him
acute pain in the hypothenar region. Tomo
gram s of the hamate showed a fracture through
the hook with marked rarefaction along the
fracture site. The hook was excised. Less than
2 months later the patient was able to resume
playing tennis.
Case 3.—A 28-year-old man had a 2-year
history o f pain at the base o f the hypothenar
eminence of his left hand. He first noticed it
“playing hockey as a right-handed shooter with
the end o f the stick held in his left hand. There
was tenderness on palpation over the hook and
dorsally over the body of the hamate. The frac
ture was not seen in carpal tunnel views, but
it was clearly evident on tomograms. Symp
toms subsided completely after the hook was
excised.

Treatment
Due to repeated stresses on the hook
and its ligamentous attachment, these
fractures frequently do not unite. Surgi
cal excision of the hook through the frac
ture site is the preferred treatment. Five
of the six patients in this series were
treated in this way. The operation
requires care but is not complicated.
In four patients the incision was done
through a 6-cm sinuous incision in the
hypothenar eminence overlying the hook.
The palmaris brevis muscle is incised and
the sensory branch of the ulnar nerve and
branches of the ulnar artery are gently
retracted towards the ulna. The ligamen
tous attachments are carefully dissected
from the crest of the hook and the peri
osteum is stripped from the body of the
fractured fragment with a sharp elevator.
Damage to the motor branch of the ulnar
nerve is avoided by staying close to the
bone. The fragment is easily lifted free at
the fracture site and any remaining rough
edges at the base are smoothed with a ron
geur. In one patient, the hook was
removed through a carpal tunnel incision
that ran parallel to and just ulnar to the
thenar crease. It was exposed by a lon

gitudinal incision through the synovium
and periosteum down the ulnar wall of
the carpal tunnel directly over the hook.
Postoperatively, the hand is supported
by a light plaster cast over a padded dress
ing. Light use of the hand can be started
when the wound is healed. Softening of
the tissues in this area of the palm is
sometimes prolonged but most patients
can resume full activities in 6 to 8 weeks.
Discussion

of the fracture. The patient in our series
whose fracture healed 22 months after the
onset of symptoms is the first one to do
so.
More widely disseminated knowledge
of the clinical manifestations of fracture
of the hook of the hamate and the spe
cial roentgenographic views required to
show it may prove that this injury is not
particularly rare but rather is rarely
diagnosed.
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A patient who presents with pain and
tenderness in the wrist and a normal
roentgenogram creates a diagnostic
dilemma for the treating physician. Wrist
pain associated with tenderness over the
base of the hypothenar eminence and over
the dorsal aspect of the hamate is sugges
tive of an isolated fracture of the hook
of the hamate. Aggravation of symptoms
and impaired function when there is
impingement on the hook demands roentgenographic investigation that will clearly
show the full length of the hamulus. Diag
nosis is made by a combination of clini
cal suspicion and radiologic persistence.
Negative carpal tunnel views should be
supplemented by lateral tomograms
before ruling out this fracture. Computer
ized tom ography may be justified
occasionally.
The papers of Stark and associates9
and Carter and associates10 have drawn
attention to the frequency of this injury
in athletes who use a racket, bat or club.
In 40 fractures reported in the combined
series of Stark and associates,9 Carter
and associates,10 Egawa and Asai11 and
ourselves, 34 occurred in athletes. We add
two hockey players to the baseball
players, racket enthusiasts and golfers.
The delay in diagnosis is a frustration for
the amateur athlete and a potential loss
of livelihood for the professional.
All of the previously reported cases
were associated with nonunion. Two
patients in the series of Stark and
associates9 and the patient reported
by Andress and Peckar1 had clinical
resolution of the symptoms without union
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Spontaneous Perforation of the Common Bile Duct in Infancy
Detected by "-Tc HIDA Scanning
Bile ascites is a rare cause of mild
icterus and abdominal distension in the
newborn. An indirect inguinal hernia may
also occur. The authors report such a
case in a 5-week-old infant. Proof was
obtained by abdominal ultrasono
graphy followed by scanning with
N-(2,6-dimethyl phenyl carboxymethyl)
iminodiacetic acid labelled with tech
netium 99m ( " mTc HIDA) and
paracentesis. Laparotomy was carried
out at 7 weeks of age and the opening
in the common bile duct was closed with
excellent results.

Pendant la periode neo-natale, I'ictere
faible et distention abdominale peuvent
etre causes par la bile ascitique. II peut
aussi y avoir une hernie inguinale indirecte. Le cas que les auteurs presentent
est celui d'un bebe age de 5 semaines
avec la bile ascitique. La preuve de celuici a ete obtenue par une ultrasonographie abdominale suivit d'une tomographie " mTc HIDA et d'une paracentese.
A I'age de 7 semaines une laparotomie a
ete effectuee pour verification et
traitement.

Case Report
A third child was born to a healthy mother,
at term, by cesarean section for cephalopelvic
disproportion. The pregnancy had been
uncomplicated except for an influenza-like ill
ness at 2'A months. At birth the child weighed
3 kg and was delivered without asphyxia. Fin
dings on physical examination of the baby were
normal. A staphylococcal skin infection deve
loped in the diaper region at 10 days; it was
treated with cloxacillin. Over the first month
the baby breast fed well and he gained weight
satisfactorily. The parents noted a vague abdo
minal fullness, mild icterus, an occasional expi
ratory grunt and described him as a little fussy
at times.
He was referred at 5 weeks because of a
swelling in his right scrotum. On examination
he appeared happy and well nourished; he
weighed 3.48 kg. On later questioning, the
parents described his urine as dark, and his
stools were intermittently acholic. He was
mildly icteric (serum bilirubin 80.4 /unol/L,
conjugated 44.5 /rmol/L) with a vaguely full
abdomen but no hepatosplenomegaly. The
contents of the right inguinal hernia could be
easily reduced without the usual feel of small
intestine. There also appeared to be a blocked
left tear duct.
At inguinal herniotomy the next day, the
abdomen was distended and could not be
relieved by gastric decompression. The soft tis
sues of the groin appeared jaundiced. An inad

vertent but fortuitous opening was made into
the sac at the external ring yielding a large
amount o f bile-stained ascitic fluid which, on
later analysis, showed a bilirubin content of 752
/rmol/L.
Postoperatively, despite good breast feeding,
the infant was irritable and had increasing,
abdom inal distension. U ltrasonography
showed appreciable ascites and an absent right
kidney. The serum bilirubin was 65 nm ol/L,
conjugated 63.3 /tmol/L. Tests for hepatitis B,
a j-antitrypsin deficiency and Torch organisms
were negative.
With the bilirubin content of the ascitic fluid,
the diagnosis of perforation of the biliary tree A
was suspected, so scanning was carried out
to confirm the diagnosis by injecting intra
venously 1 pCi of technetium 99m-labelled N(2,6-dimethyl phenyl carboxymethyl) iminodi
acetic acid (99raTc HIDA). Abdominal imag
ing was performed every 10 minutes for 1 hour
(Fig. 1). Normal accumulation of activity in*
the liver was seen with the gallbladder appear
ing at 20 minutes. Immediately following this,
activity was seen diffusely throughout th e.
abdomen. No activity was seen in the duodenal
loop nor in any bowel lumen. Lateral decubi
tus and erect images (Fig. 2) showed free
activity within the abdomen suggesting spillage
of bile into the peritoneal cavity. A high level
of radioactivity was measured in 20 mL of bilestained fluid obtained during abdominal
paracentesis; 1 /iCi/ml was recovered. This
again confirmed that radioactive material had

FIG. 1—At 10 minutes * T c HIDA scan
shows scintillation free in abdominal cavity
(arrow).

FIG. 2—At 30 minutes radioactivity is con
centrated in pseudocyst and scintillation is free
in lower peritoneal cavity.

Bile ascites, o r bile p erito n itis, is a rare
condition o f early infancy. It presents as
vague ab d o m in al distension, a m ild p e r
sistent hyperbilirubinem ia, varying a c h o 
lic stools a n d som etim es a fluid-filled
inguinal h e rn ia .1'2 Since th ese findings
m ay be su b tle and th e in fa n ts o ften
a p p e a r well, th e diagnosis is n o t alw ays
obvious. In th e follow ing case rep o rt, o ur
suspicions w ere confirm ed by scanning
w ith " “ te c h n e tiu m H ID A b e fo re
operation.
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passed from the biliary system into the free
ascitic fluid.
j- *
At laparotomy, a right subcostal incision was
made and 195 mL of bilious fluid (bilirubin
.content 530 /imol/L) were removed. A pseu
docyst was found in the area bounded by the
duodenum, the neck of the gallbladder and the
area of the common bile duct. The cyst, which
►was green, thick and leathery enough to hold
sutures, was opened. In the depths of the cyst
f-j there was a 3-mm slit in the common bile duct
through which bile was leaking. The opening,
.which was closed with two Lembert sutures of
5-0 silk, was just below the cystic duct entrance.
y A cholecystoduodenostomy was done to take
' the pressure off the duct system, and a small
■>-Penrose drain was placed in the area of the
common bile duct.
..
Postoperatively, there was considerable bile
drainage but this had almost ceased at 5 days.
^Repeat ultrasonography at 11 days postoper
atively showed no ascitic fluid. A repeat HIDA
^
scan obtained at 4 months (Fig. 3) showed no
leak and normal passage of radioactivity into
t the small bowel. The baby has since been well
and has progressed normally.
►

Discussion
A

Although uncommon, chronic bile
ascites with mild abdominal distension,
acholic stools, fluctuating mild jaundice,
^ ascites and inguinal hernia is well
described.1,2 The review by Lilly and
associates3 of 53 cases showed that delay
k in treatment often leads to complications
and conservative management often to
t death.
Most documented cases of biliary
K ascites have resulted from an opening in
the anterior wall of the common bile duct
just distal to the entrance of the cystic
duct. It is possible that there could be a
congenital defect in the duct, but with the
intense reaction in the area it is difficult
''to prove this. The fact that in our patient
^ a kidney position anomaly (crossed renal
ectopia) and blocked left tear duct were
r present might lend some support for a
congenital origin. The right inguinal her
nia resulted only because of the increase
in the intra-abdominal pressure.
r The use of 99mTc HIDA scanning has
^

not previously been described in the liter
ature for detecting bile leakage in infancy.
Rose Bengal labelled with iodine 131 has
been used.1'3 Drawbacks to the use of
this agent include the higher radioactivity
required, the inefficient detection by
gamma cameras of the main gamma emis
sion at 364 KeV and the local damage
without added imaging capabilities of the
emitted beta particles. On the other hand,
99mTc HIDA provides rapid blood clear
ance and liver transit and 1% reabsorp
tion from the intestine; it also requires a
lower radiation dose.
The noninvasive 99mTc HIDA scan can
pictorially demonstrate bile leaks in vivo.
The HIDA is excreted in the bile and thus
follows its excretory pathway. In our
patient the liver and gallbladder accumu
lated activity in a normal sequence, but
subsequently radioactivity appeared in the
left lower quadrant and pelvis in the
ascitic fluid, confirming a bile leak.
Paracentesis substantiated this, yielding
bile-stained ascitic fluid with a high radi
oactivity level.
Most often the lower end of the com
mon bile duct is not obstructed but is con
sidered by Lilly and associates3 to be a
phantom obstruction. To explore the duct
because of concern that an obstruction
might be present would have been consi
dered meddlesome. Anastomosis of the
pseudocyst to an intestinal loop has led
to death.3 Draining by simple cholecystostomy has proven adequate in some
cases, but deaths have been reported fol
lowing this method of treatment. Fitzger
ald and associates4 reported three suc
cessful cases in all of which the common
bile duct perforation was closed with fine
silk or catgut and a cholecystojejunostomy and distal jejunojejunostomy
performed.
We believed that the simplest internal
decompression of the biliary tree was
most reasonable (Stephens C: Personal
communication, 1982). Therefore, in our
patient the body of the gallbladder was
anastomosed to the adjacent proximal
portion of the second part of the duode
num. This does not appear to be
associated with an increased frequency of
cholangitis. If the lower common duct is
patent, then the duodenocholecystostomy
may close spontaneously. An internal
shunt to the common bile duct with the
intense reaction present would have been
most difficult.
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FIG. 3—Repeat scan at 4 months shows nor
mal distribution of radioactivity in liver, small
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Treatment of Femoral Fractures with the Cast Brace
The authors report a retrospective review
of 82 patients with femoral fractures
treated nonoperatively by skeletal trac
tion and cast bracing at the University of
Alberta Hospital between 1975 and
1979. Fractures were classified as stable
or unstable and the position of the frac
ture was assessed at the time of applica
tion of the cast brace and at the time of
removal, using angulation, shortening and
healing time as criteria for classification
of results. Satisfactory results were seen
in 88% of patients. At the time of cast
brace removal, average knee flexion was
9 7 ° , thigh atrophy was 2.5 cm and
shortening was 1.4 cm. The unsatisfac
tory results are analysed and a protocol
for successful use of the cast brace is
suggested.

Les auteurs rapportent les resultats
d'une analyse retrospective de 82 fractu
res du femur traitees de facon non chirurgicale par traction et contention platre
fonctionnel a I'Hopital de I'universite de
I'Alberta entre 1975 et 1979. Les fractu
res ont ete classifiees stables ou insta
bles, la position de la fracture a ete evaluee au moment de la pose et de
I'enlevement du contention platre fonc
tionnel et les resultats ont et6 classifies
d'apres I’angulation, le raccourcissement
et le temps de guerison. Des resultats
satisfaisants ont ete constates chez
8 8 % . A I'enl&vement du contention pla
tre fonctionnel, la flexion moyenne du
genou 6tait de 9 7 ° , I'atrophie de la
cuisse de 2.5 cm et le raccourcissement
de 1.4 cm. Les resultats insatisfaisants
sont analyses et un protocole est suggere visant a obtenir le succes de
I'immobilisation par un contention platre
fonctionnel.

Fractures of the femoral shaft are rela
tively common injuries, particularly in the
young adult. The problem posed by this
fracture is not healing but the long hospi
tal stay and rehabilitation necessary when
conventional closed methods are used.1
Internal fixation has been shown to
shorten hospital stay and speed return to
work2 but is unsuitable for many com
minuted fractures. This method also car
ries risks of infection and failure of fixa
tion. The conventional method of skeletal
traction, with or without supplemental
plaster immobilization, results in joint
stiffness, muscle atrophy and osteoporo
sis, necessitating a long course of phys
iotherapy. This poses economic burdens
on both the patient and the health-care
system.
Early ambulation with weight-bearing
has only recently become accepted as a
result of the work of Dehne, Sarmiento,
Brown and others on tibial fractures. This
concept was extended to femoral fractures
more than 10 years ago by Mooney and
associates.3 Total contact orthotic prin
ciples were used to design a cast brace.
Their initial results were encouraging, with
reports of faster fracture union and fewer
problems with plaster disease.3'4 There
was some resistance to the concept based
on the idea that rigid immobilization was
necessary for fracture union, but the
device gained acceptance in many centres.
The cast brace has been used exten
sively in our centre since 1974, not only
in the closed treatment of femoral frac
tures, but also to protect internal fixation
of the femur and following tibial plateau
fractures and knee-ligament repairs.
Application of a cast brace has been
described previously,4’5 but several
points should be emphasized. Elastic
plaster is applied over minimal padding
to maintain total contact. If polycentric
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Traction
Hospital stay
Healing time

knee hinges are used, they must be care
fully positioned to avoid limiting knee '
motion. If there is malalignment of the
fracture, the cast brace is wedged or4
replaced. In distal fractures, knee exten
sion is limited by 20° to 30° to diminish 4
the deforming force of the gastrocnemius t
muscle. The device is not meant to be
ischial weight-bearing and usually slides <
distally after several weeks. Although the
femur may be unloaded initially up to*
50%, this falls rapidly to only 10% to
20%.5-6 Position of the fracture is main- 4
tained by the compressed soft tissues A
encased in a rigid cylinder. All cast braces
are applied by trained prosthetists in our
institution.
Patient Data

The records of all patients with femoral
fractures treated by closed methods *•
between 1975 and 1979 were reviewed; 82
patients had sufficiently detailed records
to be included in the study. Intra-articular ,
fractures were excluded. There were 17
children and 65 adults; their ages ranged,,
from 6 to 89 years. Seven fractures were
open. There were 32 stable and 50 unsta- -i
ble fractures. Stable fractures were
defined as transverse or short oblique 4
with minimal comminution, whereas
unstable fractures were defined as spiral,
long oblique or comminuted. Thirty-four
fractures were in the middle one third and"
48 in the distal one third of the femur.
Time spent in traction and in hospital was
recorded (Table I). The healing time was ^
defined as the time elapsed from injury
to removal of the cast brace (Table I). The
brace was removed when the patient
could bear full weight and there was evi-“
dence of reasonable callus development
on roentgenograms. Removal was de
layed in unreliable patients.
--t

Table 1-Mean Time (and Variation) in Traction,
Hospital Stay and Healing Time in Weeks
Child
3.611.1-5.1)
4.3
9.6(7.1-16.0)

L

Adult
4.6(1.6-12.7)
5.6
16.7(8.4-29.3)
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Findings
The result was satisfactory if there was
less than 15° angulation in any plane, if
' -healing occurred by 26 weeks, if there was
, more than 75° of knee flexion at time of
removal and if there was less than 2 cm
kOf shortening. Based on these criteria, 72
(88%) of the 82 patients had a satisfacr tory result. In this group, the average
knee flexion at time of removal was 97°,
average thigh muscle atrophy was 2.5 cm
and average shortening measured clini7" cally was 1.4 cm. Patient acceptance was
good; the only common complaints were
knee effusion shortly after application
I and dermatitis beneath the plastic quad
rilateral socket in hot weather.
Ten patients, all adults, had unsatisfac
tory results. Nine had unstable fractures,
v There were two cases of nonunion, both
in distal fractures. These two patients had
t satisfactory alignment and minimal short
ening (Fig. 1). Both fractures required
operative intervention. Three patients had
^delayed union of unstable, open frac
tures. All three fractures ultimately healed
in the cast brace in satisfactory position.
There were three malunions; two of the
*■fractures were in an unsatisfactory posi
tion at the time the cast brace was applied.

Two of these patients required subsequent
osteotomy for varus deformities of more
than 30°. In the other patient posterior
angulation of 20° was accepted. There
were two failures due to displacement of
unstable fractures after application of the
cast brace, with shortening greater than
2.5 cm. No refractures occurred.

Case 2
A 45-year-old man sustained a comminuted
fracture (Fig. 3a). Satisfactory position was
obtained in skeletal traction and 25 days after
injury a cast brace was applied and walking
started. There was no appreciable change in
position after weight-bearing (Fig. 3b).

Discussion
Case Reports
The following cases illustrate the use of
the cast brace.
Case 1
A 17-year-old boy sustained a stable trans
verse fracture which was too distal for optimal
intramedullary fixation (Fig. 2a). He was
placed in skeletal traction and satisfactory
reduction was obtained. Ten days following his
injury a cast brace was applied and weight
bearing begun. Satisfactory position was main
tained and the fracture healed without com
plication (Fig. 2b).

The cast brace has proven to be a use
ful device for the nonoperative manage
ment of certain femoral fractures. Con
ventional traction is associated with
nonunion and malunion in 11% to 29%
and shortening greater than 2 cm in 4%
to 17%.4 In this series the rate of malun
ion was 3.7% and of nonunion 2.4% .
There were no patients in this series with

Fig. la
Fig. 2a

Fig. lb

Fig. 2b

Fig. 3b

FIG. 1—(a) Comminuted distal shaft frac
ture. (b) Established nonunion after 6 months
in cast brace.

FIG. 2—(a) Stable fracture in satisfactory
position in traction before application of cast
brace, (b) Position remains acceptable in cast
brace following partial weight-bearing.

FIG. 3—(a) Comminuted fracture in accept
able position in traction, (b) Position remains
acceptable in cast brace with partial
weight-bearing.
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fractures in the proximal one third of the
femur but it has been reported that these
fractures can be managed successfully
with modifications of the cast brace.7
To achieve optimal results, the follow
ing steps should be followed:
• Skeletal traction should be estab
lished and a satisfactory reduction
obtained.
• The cast brace may be applied when
pain and swelling subside, when there is
sufficient stability clinically and when
early callus formation is evident on
roentgenograms.
• Application of the device is an exact
ing procedure and ideally should be per
formed by an experienced prosthetist.

• If the fracture reduction remains
satisfactory after application of the cast
brace, the patient can begin weight
bearing walking as tolerated. Periodic
roentgenograms should be taken to check
the position of the fracture and assess
callus formation. When the patient is able
to bear weight fully without pain and
there is evidence of healing by roent
genography, the device may be removed.

ment by intramedullary nailing and by traction and a spica
cast. J Bone Joint Surg [Am] 1973; 55: 690-700
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Clinical Comparison of Michel and Proximate Clips
Used for Abdominal Wound Closure
For many years Michel clips (Down Sur
gical, Mississauga, Ont.) have been used
to close wounds and results have been
good, but several newer clips are now
available (e.g.. Proximate; Ethicon
Sutures Ltd.), which are said to be easier
to use and produce a better scar.
However, they are much more expen
sive. The authors carried out a prospec
tive controlled study in which 30
patients with abdominal incisions had
half of the skin incision closed with
Michel clips and the other half with
Proximate clips. They assessed ease of
insertion and removal, and appearance of
the wound immediately after removal
and 2 months later.
Ethicon Proximate clips were, in
general, slightly easier to insert, less
uncomfortable to remove in 8 of the 30
patients and gave a better immediate
cosmetic result in 9 patients. However,
there was no difference in the appear
ance of the wound 2 months later. The
authors do not consider that Ethicon
Proximate clips offer an advantage over
the much less expensive Michel clips.

Depuis plusieurs annees, les agrafes
Michel (Down Surgical, Mississauga,
Ont.) ont ete utilisees pour la fermeture
des plaies avec de bons resultats.
Plusieurs nouvelles agrafeuses (par
exemple, la Proximate de Ethicon
Sutures Ltee) sont disponibles que I'on
dit plus faciles d'emploi et capables de
produire de plus belles cicatrices. Toutefois, elies sont beaucoup plus couteuses. Les auteurs ont mene une etude
prospective contrdlee chez 30 patients
ayant subi une incision abdominale; la
moitie de I'incision cutanee fut refermee
avec des agrafes Michel, I'autre moitie a
I'aide de I'agrafeuse Proximate. Ils ont
evalues la facilite de pose et de I'enl6vement, ainsi que I'apparence de la plaie
juste apres I'enlevement et 2 mois plus
tard.
Les agrafes Ethicon Proximate etaient,
regie generate, legerement plus faciles &
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poser, moins inconfortables a enlever
pour 8 des 30 patients et ont donne de
meilleurs resultats cosmetiques
*
immediats chez 9 patients. Toutefois, 2
mois plus tard, on n'a constate aucune
difference dans I'apparence de la plaie.
Les auteurs considerent que I'agrafeuse
Ethicon Proximate n'offre pas d'avantage
par rapport aux agrafes Michel beaucoup
moins dispendieuses.
y

There are many ways in which a skin incision may be closed. Traditionally, this has
been accomplished with cuticular sutures
but metal clips or staples have become
popular because of the ease of insertion
and removal and quality of the scar..
Wound healing appears to be equally
good with either method of closure1 but
it has been claimed that staples give a bet- .
ter scar, especially if they are removed *
soon after operation. Certainly the

Table I—Operation Performed
Operative procedure
Cholecystectomy

From the Division o f General Surgery,
Ottawa General Hospital, University o f
Ottawa, Ottawa, Ont.

4

Small-bowel obstruction
Anterior resection of rectum
Gastroplasty for morbid obesity
Incisional hernia repair
Vagotomy and antrectomy
Panniculectomy following
planned weight loss

No. of
patients
14
2
2
6
2
1
3

"T
Incision
Kocher (8)
Midline (6)
Paramedian
Paramedian
Midline
Midline
Midline
Combined midline
and transverse
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rtM efbxiri moves
w to the front line
Broad spectrum bacteri
cidal activity against the
causative pathogens nor
mally found in communityacquired intra-abdominal
sepsis, e.g. E. coli, Proteus
mirabilis, Klebsiella or
B. fragilis.]

■ Ruptured appendix
■ Diverticulitis
■ Abdominal trauma
■ Pelvic inflammatory
disease
Clinically proven efficacy
in community-acquired
intra-abdominal sepsis,
comparable to the com
bination of gentamicin
and clindamycin.2
Safety profile comparable
to cephalothin.
MEFOXIN* is not active against
Pseudomonas spp., most strains
of enterococci, many strains of
Enterobacter cloacae, Listeria
monocytogenes, and methicillinresistant staphylococci.

(sterile cefoxitin sodium, Frosst Std.)

QjMefoxiri
ANTIBIOTIC
ACTION
In vitro studies dem onstrate that the
bactericidal action of cefoxitin, a cephamycin
derived from cephamycin C, results from the
inhibition of bacterial cell wall synthesis.
Evidence suggests that the methoxy group in
the 7 o p o s itio n is responsible fo r the
resistance of cefoxitin to degradation by
bacterial beta-lactamases.

INDICATIONS AND CLINICAL USES
TREATMENT

The treatment of the following infections when
due to susceptible organisms:
1 - Intra-abdominal infections such as
peritonitis and intra-abdominal abscess
2 - G ynecological in fe ction s such as
endometritis and pelvic cellulitis
3 - Septicemia
4 - Urinary tract infections (including those
caused by Serratia marcescens and
Serratia spp.)
5 - Lower respiratory tract infections
6 - Bone and joint infections caused by
Staphylococcus aureus
7 - Soft tissue infections such as cellulitis,
abscesses and wound infections
Appropriate culture and susceptibility studies
should be performed to determine the
susceptibility of the causative organism(s) to
MEFOXIN*. Therapy may be started while
awaiting the results of these tests, however,
modification of the treatment may be required
once these results become available.
Organisms particularly appropriate for
therapy with MEFOXIN* are:
Gram positive

Staphylococci, penicillinase producing and
non-producing
Streptococci excluding enterococci
Gram negative (beta-lactamase producing
and non-producing strains)

E. coli
K le b s ie lla s p e c ie s ( in c lu d in g
pneumoniae)
Proteus, indole positive and negative
Haemophilus influenzae
Providencia species

K.

Anaerobes

Bacteroides fragilis
MEFOXIN* may also be appropriate for the
treatment of infections involving susceptible
strains of both aerobic and anaerobic bacteria.
Clinical experience has demonstrated that
MEFOXIN* can be administered to patients
who are also receiving c a rb e n ic illin ,
gentamicin, tobramycin, or amikacin (see
PRECAUTIONS and ADMINISTRATION).
Intravenous Administration

The intravenous route is preferable for
p a tie n ts w ith ba cte re m ia , b a c te ria l
septicemia, or other severe or life-threatening
infections, or for patients who may be poor
risks because of lowered resistance resulting
from such d e b ilita tin g c o n d itio n s as
malnutrition, trauma, surgery, diabetes, heart
failure, or malignancy, particularly if shock is
present or impending.
PROPHYLACTIC USE

MEFOXIN* may be administered perioperatively (preoperativeiy, intraoperatively and
postoperatively) to patients undergoing
vaginal or abdominal hysterectomy and
abdominal surgery when there is a significant
risk of postoperative infection or where the
occurrence of postoperative infection is
considered to be especially serious.
In patients undergoing cesarean section,
intraoperative (after clamping the umbilical
cord) and postoperative use of MEFOXIN*
may reduce the incidence of surgery related
postoperative infections.
Effective prophylactic use depends on the
time of administration. MEFOXIN* usually
should be given one-half to one hour before
the operation. Prophylactic administration
should usually be stopped within 12 hours. It
has been generally reported that continuing
administration of any antibiotic beyond
*®Trademark

24 hours following surgery increases the
possibility of adverse reactions but, in the
majority of surgical procedures, does not
reduce the incidence of subsequent infection.
If signs of postsurgical infection should
appear, specimens for culture should be
obtained for identification of the causative
organism(s) so that appropriate therapy may
be instituted.

CONTRAINDICATIONS
MEFOXIN* is contraindicated in persons who
have shown hypersensitivity to cefoxitin or to
the cephalosporin group of antibiotics.

WARNINGS
Before therapy with MEFOXIN* is instituted,
careful inquiry should be made to determine
whether the patient has had previous hypers e n s itiv ity re a c tio n s to MEFOXIN*,
cephalosporins, penicillins or other drugs.
MEFOXIN* should be given with caution to
penicillin-sensitive patients.
There is some clinical and laboratory evidence
of partial cross-a lle rge nicity between
cephamycins and the other beta-lactam
antibiotics, penicillins and cephalosporins.
Severe reactions (including anaphylaxis) have
been reported with most beta-lactam
antibiotics.
Pseudomembranous colitis has been reported
with virtually all antibiotics. This colitis can
range from mild to life threatening in severity.
Antibiotics should therefore be prescribed
with caution in individuals with a history of
gastrointestinal disease, particularly colitis. It
is important to consider a diagnosis of
pseudomembranous colitis in patients who
develop diarrhea in association with antibiotic
use. While studies indicate that a toxin
produced by Clostridium difficile is one
primary cause of antibiotic-associated colitis,
other causes should also be considered.
Any patient who has demonstrated some form
of allergy, particularly to drugs, should receive
antibiotics including MEFOXIN* with caution.
If an allergic reaction to MEFOXIN* occurs,
a d m in istra tion of the drug should be
discontinued. Serious hypersensitivity
reactions may require treatm ent with
epinephrine and other emergency measures.

PRECAUTIONS
The total daily dosage should be reduced
when MEFOXIN* is administered to patients
with transient or persistent reduction of
urinary output due to renal insufficiency (see
DOSAGE AND ADMINISTRATION) because
high and prolonged serum a n tib io tic
concentrations can occur from usual doses.
In patients treated with MEFOXIN* a false
positive reaction to glucose in the urine may
occur with Benedict's or Fehling’s solutions
but not with the use of specific glucose
oxidase methods.
Using the Jaffe Method, falsely high creatinine
values in serum may occur if serum
concentrations of cefoxitin exceed 100 /vg/mL.
Serum samples from patients treated with
MEFOXIN* should not be analyzed for
creatinine if withdrawn within two hours of
drug administration.
Increased nephrotoxicity has been reported
following concomitant administration of
c e p h a lo s p o rin s and a m in o g lyco sid e
antibiotics.
The safety of MEFOXIN* in the treatment of
infections during pregnancy has not been
esta blished . If the a d m in istra tio n of
MEFOXIN* to pregnant patients is considered
necessary, its use requires that the anticipated
benefits be weighed against possible hazards
to the fetus. Reproductive and teratogenic
studies have been performed in mice and rats
and have revealed no evidence of impaired
fertility or harm to the fetus due to MEFOXIN*.
Cefoxitin has been observed in the milk of
nursing mothers receiving the drug.
Prolonged use of MEFOXIN* may result in the
overgrowth of non-susceptible organisms.
Repeated evaluation of the patient's condition
is essential and if super-infection occurs
during therapy, appropriate measures should
be taken. Should an organism become
resistant during antibiotic therapy, another
antibiotic should be substituted.
In children 3 months of age or older, higher
doses of MEFOXIN* (100mg/kg/day and
above) have been associated with an
increased incidence of eosinophilia and
elevated SGOT.

The safety and efficacy of MEFOXIN* for the
treatment of infections in infants from birth to
three months of age have not yet been
established.
ADVERSE REACTIONS
j
MEFOXIN* is generally well tolerated. Adverse
reactions rarely required cessation of
treatment and usually have been mild'end
transient.
Local Reactions

4/

T h ro m b o p h le b itis has occu rred with
intravenous administration. Some degree of
pain and tenderness is usually experienSSd
after intramuscular injections using water.
Induration has occasionally been reported. •,
Allergic

Maculopapular rash, urticaria, pruritus,
eosinophilia, fever and other allergic reactions
have been noted.
Gastrointestinal

H

Symptoms of pseudomembranous colitis can
appear during or after antibiotic treatment.
Nausea and vomiting have been reported
rarely.
Blood

^

T ra n s ie n t e o s in o p h ilia , le u ko p e n ia ,
neutropenia, hemolytic anemia, and thrombo
cytopenia have been reported. Some
individuals, particularly those with azotemia,
may develop positive direct Coombs test*
during therapy with MEFOXIN*.
Liver Function

t

Transient elevations in SGOT, SGPT, serum
LDH, and serum alkaline phosphatase have
been reported.
j

Kidney

Elevations in serum creatinine and/or bland
urea nitrogen levels have been observed. As
with the cephalosporins, acute renal failura
has been reported rarely. The role c f
MEFOXIN* in changes in renal function tests
is d iff ic u lt to assess, since fa c to rs
predisposing to prerenal azotemia or to
impaired renal function have often been
present.
TREATMENT OF OVERDOSE
\
Other than general supportive treatment, nc
specific antidote is known. MEFOXIN* can be
eliminated by dialysis in patients with repa
insufficiency.
j

DOSAGE AND ADMINISTRATION
TREATMENT DOSAGE

1

MEFOXIN* may be administered intra
venously or intramuscularly when required.
(See monograph for Preparation of Solution.)
Adult Dosage

The usual adult dosage is 1 g or 2g of
MEFOXIN* every 6 to 8hours. Dosage and
route of administration should be determined
by severity of infection, susceptibility of the
causative organisms, and condition of the"
patient. The usual adult dosages are shown in
the Table below.
1
Usual Adult Dosage
T y p e of
of infection

Daily
Dosage

l
Frequency
and Route

Uncomplicated
forms* of in
fections such as
pneumonia,
urinary tract
infection, soft
tissue infection

3-4 g

Moderately
severe or severe
infections

6-8 g

1 g every 4 h
or
2g every 6-8 h4 V.

Infections
commonly
needing anti
biotics in higher
dosage (e g. gas
gangrene)

12 g

2 g every 4 h
or
3 g every 6 h I.V.

1 g every 6-8 h
I.V. or I.M.
V

"Including patients in whom bacteremia is
absent or unlikely
Therapy may be started while awaiting the
results of susceptibility testing.
Antibiotic therapy for group A beta-hemolytic
streptococcal infectionsshould be maintained*,
for at least 10 days to guard against the risk of
rheumatic fever or glomerulonephritis. In
staphylococcal and other infections involving
a collection of pus, surgical drainage should
be carried out where indicated.

Dosage in Adult Patients with Impaired Renal
Function
MEFOXIN* may be used in patients with
reduced renal function but a reduced dosage
should be employed and it is advisable to
monitor serum levels in patients with severe
impairment.
In adults with renal insufficiency, an initial
loading dose of 1 g to 2 g should be given.
A fte r a lo a d in g dose, th e fo llo w in g
recommendations for maintenance dosage
may be used as a guide:
RENAL
FUN CTION

C REATININE
CLEARANCE
m L /m in

M ild
im p a ir m e n t
M o d e ra te
im p a ir m e n t
S e v e re
im p a ir m e n t
E s s e n t ia lly
n o fu n c t io n

DOSE

FREQUENCY

5 0 -3 0

1 -2 g

e v e r y 8 -1 2 h

2 9 -1 0

1 -2 g

e v e ry 1 2 -2 4 h

9 -5

0 .5 -1 g

e v e ry 1 2 -2 4 h

<5

0 .5 -1 g

e v e ry 2 4 -4 8 h

In the patient undergoing hemodialysis, the
loading dose of 1 - 2g should be given after
each hemodialysis, and the maintenance dose
should be given as indicated in the Table
above.
Infants and Children
The recommended dosage in children three
months of age and older is 80 to 160 mg/kg pf
body weight per day divided into four to six
equal doses. The higher dosages should be
used for more severe or serious infections.
The total daily dosage should not exceed 12 g.
At this time no recommendation is made for
children from birth to three months of age (see
PRECAUTIONS).
At present there is in s u ffic ie n t data to
recommend a specific dosage for children
with impaired renal function.THowever, if the
administration of MEFOXIN’ is deemed to be
essential the dosage should be modified
consistent with the recommendations for
adults (see Table above).
PROPHYLACTIC USE
Forprophylactic use, a three-dose regimen of
MEFOXIN4 is recommended as follows:
Vaginal or abdominal hysterectomy and
abdominal surgery
2 g a d m in is te r e d in tra m u s c u la rly or
in tr a v e n o u s ly ju s t p r io r to s u rg e ry
(approximately one-half to one hour before
initial incision).
The second and third 2g doses should be
administered at 2-6hour intervals after the
initial dose.
Cesarean Section
The first dose of 2 g should be administered
intravenously as soon as the umbilical cord
has been clamped. The second and third
2a doses should be given intravenously or
intramuscularly four hours and eight hours
after the first dose.

AVAILABILITY
Sterile MEFOXIN’ is a dry white to off-white
powder supplied in vials containing cefoxitin
sodium as follows:
No. 3356 1 g cefoxitin equivalent in boxes of
10 vials
No. 3357 2 g cefoxitin equivalent in boxes of
10 vials.

PRODUCT MONOGRAPH AVAILABLE
ON REQUEST
1.

Quintiliani, R.: Overview of cephalosporin
a n tib io tic s in the 1980’s, in “ C o n 
s id e ra tio n s in the se lection of a n ti
microbial chemotherapy, a round-table
discussion on treatment concepts” , Merck
& Co. Inc., 1982, pp 6-25.
2. T runkey, D.D.: C ephalosporin in the
management of trauma. Ibid, pp 44-52.

“ cross-hatches” commonly seen on skin
closed with sutures are avoided when sta
ples are used.
Michel clips (Down Surgical, Missis
sauga, Ont.) have been used for many
years with excellent results, especially on
transverse neck incisions. Interest in the
use of clips at other operative sites has
been renewed with the introduction of
newer stapling devices. These newer clips
are said to be easier to insert and remove
and give an even better scar than do
Michel clips. These factors are often
quoted as justification for the much
higher cost of the newer staples. Michel
clips cost $3.20 for 35 clips and may be
resterilized whereas Proximate 35 W clips
(Ethicon Sutures Ltd., Peterborough,
Ont.) cost $14.00 for 15 and are only
available in a single-use cartridge which
may not be resterilized.
The purpose of this study was to assess
the abqve claims in a prospective and con
trolled manner.

Patients and Methods
Thirty patients who required closure of
an abdominal wound were included in the
study. The operations performed and the
incisions used are shown in Table I. All
closures were performed by one surgeon.
In each patient, the fascia was closed with
continuous Prolene sutures, but the sub
cutaneous layer was not sutured.
One half of the skin incision was closed
with Michel clips and the other half with
Proximate clips. This order was reversed
in alternate patients. The surgeon
recorded his impression of the ease of
insertion for each type of clip. All clips
were removed 4 days after operation and
the wounds reinforced with Steristrip
(Surgical Products Division, 3M Canada
Ltd., London, Ont.) for 9 or 10 days.
Each patient was then asked which type
of clip was less uncomfortable to remove
and which half of the incision they con
sidered to have a better cosmetic result.
All patients were seen 2 months
postoperatively when the subjective and
objective assessments were repeated. The
objective examination of the wound was
carried out by one of the two authors who
did not know which clips had been used
for each half of the incision. After record
ing our observations, we referred to the
operative note.

less uncomfortable to remove; one patient
preferred the Michel clips. The remain
ing 21 patients could detect no difference.
Nine patients thought that the Ethicon
clips gave a better cosmetic result immedi
ately after removal; in these, the skin
closed with Michel clips was more ery
thematous. However, when the patients
were reassessed 2 months later, neither
patient nor clinician could detect a sub
stantial difference between the two wound
halves.
Discussion
In this study, we have demonstrated
that Proximate clips were slightly easier
to insert. Michel clips may also be inserted
easily and quickly if the assistant holds
the skin edges with two toothed forceps
and the surgeon applies clips using a
Kocher forceps in one hand while hold
ing a band of clips with a second Kocher
forceps in the other. The study also
showed that Proximate clips were some
times less uncomfortable to remove and
gave a better immediate cosmetic result
in almost one third of the patients. Michel
clips are removed with a standard, reus
able remover that can easily be kept on
the ward. On the other hand, Ethicon
clips must be removed with a special
instrument that is supplied with the clips.
Quite often this instrument is kept in the
operating suite rather than on the ward
where it is needed. Probably more impor
tant than the ease of insertion and
removal or immediate cosmetic result is
the fact that there was no important
difference in the two halves of the inci
sion 2 months postoperatively.
Recently, there has been a proliferation
o f devices for mechanical wound closure
and their use is clearly expanding in all
fields of surgery.2'3 In a hospital with an
average of 50 wounds closed with clips a
week, the use of Michel clips rather than
Ethicon Proximate clips would represent
an annual saving of over $28 000.
Michel clips have been well tried and
tested. Experimental evidence suggests
that they produce a wound as strong as
or even stronger than a wound closed with
sutures.4 Proximate clips offer marginal
short-term and no long-term benefits over
Michel clips. We do not consider that the
extra cost of Proximate clips justifies their
use in place of Michel clips.
References
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The Proximate clips were easier to
insert in all cases but the difference was
m inim al. Insertion of both types
improved with practice and there was no
difference in the speed of insertion. Eight
patients thought the Proximate clips were
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Pleuroperitoneal Shunt for Intractable Pleural Effusion
Intractable pleural effusion secondary to
malignant disease is often managed by
thoracentesis or sclerotherapy, painful
time-consuming procedures that may be
ineffective. An alternative technique is to
place a pleuroperitoneal shunt as in a
73-year-old man, described in this paper,
who had recurrent right and left pleural
effusions secondary to inoperable squa
mous cell carcinoma of the right lung. In
his case, sclerotherapy was not
attempted on the left side because a
pericardial window was functioning. The
left pleural effusion was successfully
managed by inserting a pleuroperitoneal
(LeVeen) shunt.
Un epanchement pleural irreductible
secondaire a une maladie maligne est
souvent traite par thoracentese ou scldrotherapie, des interventions douloureuses et longues qui s'averent parfois inefficaces. Une autre technique consiste a
placer une derivation pleuro-peritoneale.
C'est a celle-ci qu'on a eu recours chez
un homme de 73 ans souffrant d'epanchements pleuraux droit et gauche consecutifs a un epithelioma malpighien ino
perable du poumon droit. La sclerodermie
n'a pas ete tentee du cote gauche pour
ne pas nuire au fonctionnement d'une
fenetre pericardique. L'epanchement
pleural gauche a cedd a I'insertion d’une
derivation pleuro-peritoneale (LeVeen).

Intractable pleural effusion can be a
serious problem in patients with malig
nant disease. It is often managed by
thoracentesis or sclerotherapy, or both.
In addition to being time-consuming and
painful, these procedures may be ineffec
tive. The following report describes the
use o f a LeVeen shunt (Becton Dickinson,
Rutherford, NJ) as a pleuroperitoneal
shunt in a patient with an intractable

pleural effusion secondary to terminal
malignant pulmonary disease.
Case Report
A 73-year-old man with inoperable squa
mous carcinoma of the right lung was admit
ted to hospital for management of recurrent
left pleural effusion. Three months previous
ly he had undergone sclerotherapy of the right
pleural space for recurrent right pleural effu
sion and a pericardial window had been made
to manage a large malignant pericardial effu
sion. Subsequently, he was relatively well un
til 3 weeks before admission, when he ex
perienced increasing shortness of breath due
to left pleural effusions. These were managed
by thoracentesis as required. After admission
to hospital, chest-tube drainage was institut
ed (Figs. 1 and 2). Initial drainage produced
about 2 L of serous fluid. Over the following
7 days, chest drainage was 500 to 600 mL/d.
Sclerotherapy was not attempted because of the
functioning pericardial window. Pleuroperito
neal shunting was carried out. A LeVeen
peritoneovenous shunt was placed subcutane
ously between the pleural space and the
peritoneal cavity in a reversed position.
Postoperatively, the patient did well (Fig. 3)
and was discharged from hospital after 6 days.
The shunt functioned well. About 1 month af
ter insertion of the shunt, the patient died of
his carcinoma.

Discussion

malignant disease.1 The shunt has a one
way valve and is designed to allow
unidirectional flow o f ascitic fluid from
the abdomen to the vascular system. In
our case it was used to shunt pleural fluid
into the abdominal cavity. During expi
ration, the intrapleural pressure can
exceed the intraperitoneal pressure. At the
beginning o f expiration, the intrapleural
pressure reaches 4 cm H20 or more.2
The valve of the shunt opens at a pres
sure of 3 cm HjO. In the presence o f a
pleural effusion, the differential pressure

FIG. 2—Drainage of pleural effusion afler
insertion of left chest tube.

The LeVeen peritoneovenous shunt has
been used in patients with intractable
ascites secondary to intra-abdominal
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FIG. 1—Left lateral decubitus view show
ing left pleural effusion.

FIG. 3—Posteroanterior view 5 days after
insertion of LeVeen shunt.
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between the pleural space and the intra
abdominal cavity can be even larger.

1

ing of the shunt helps to maintain
patency. In addition, the valve of the
shunt opens at a positive pressure of
about 1 cm HzO.
T horacentesis with or w ithout
sclerotherapy remains an acceptable form
of management for patients with intrac
table pleural effusion secondary to malig
nant disease. Selected patients, however,

may easily be managed with a pleuro
peritoneal shunt.
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Although not a problem in our case,
the LeVeen shunt can become obstructed
rb y malignant cells. An alternative is the
Storz-Denver shunt (Storz Instrument
Co., St. Louis, Mo.). This shunt has a
manual pumping chamber that can be
' compressed percutaneously. Daily pump
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Resection of a Metastatic Sternal Carcinoma and
Reconstruction of the Chest Wall: a Case Report
A large metastatic squamous carcinoma
of the anterior chest wall was managed
' by en-bloc resection of the thoracic wall.
The extensive defect resulting from the
resection was bridged with Marlex mesh
. superimposed on an omental flap that
served as recipient to partial-thickness
skin grafts.
This composite reconstruction restored
r- an efficient bellows action to the chest
cage, manifested by the lack of anterior
flailing and postoperative spirometry
values, measured at the bedside, that
were 75% of those obtained preoperatively. During the initial postoperative
period, however, mechanical ventilatory
r assistance was required to treat an adult
respiratory distress syndrome that
together with mild anterior flailing made
early extubation impossible.

Un large epithelioma malpighien metastatique de la paroi anterieure du thorax a
*■ ete traite par resection monobloc de la
paroi thoracique. La large breche laissee
par la resection a et6 couverte par une
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toile de fibres Marlex surimposee sur un
lambeau d'epiploon servant de siege
pour la greffe de lambeaux cutanes
partiels.
Cette reconstruction composite a retabli Faction de soufflet de la cage thoraci
que comme en temoignaient I'absence de
volet anterieur ainsi que les valeurs de
spirometrie postoperatoires, mesurees au
lit du malade, lesquelles atteignaient
75% des valeurs mesurees avant ('opera
tion. Cependant, une assistance ventilatoire mecanique a ete necessaire durant
la periode postoperatoire initiale pour
traiter un syndrome de detresse respiratoire de I'adulte qui, de concert avec un
leger volet thoracique anterieur, empechait I'extubation precoce.

Neoplasms of the thoracic skeleton are
rare. Ochsner and associates1 reported
134 cases, representing only 5% of all
neoplasms of bones and joints studied
over 4 years. Of these patients, 84 (63%)
had primary (48 benign and 36 malignant)
tumours.
Metastatic lesions involving the ster
num most frequently originate in the
breast, thyroid or lung, probably due to
involvement of the internal mammary
nodes with subsequent extension through
the chest wall.
In addition to tumour involvement of
the thoracic skeleton, the chronic inflam
matory reaction with ensuing dense fibro
sis caused by radiotherapy, which is fre

quently used in an initial attempt to
control the lesion, and local superimposed
sepsis make resection and reconstruction
of the chest wall a complicated procedure.
A multidisciplinary approach is required.
We report such a case that illustrates
some of the problems that may arise.
Case Report
A 53-year-old white man was referred
because of a large, fungating sternal ulcer,
present for 2 years.
The patient had undergone a left upper
lobectomy for a squamous cell carcinoma of
the anterior segment 3 years before referral.
The parietal pleura in the anterior chest wall
was grossly involved but the hilar nodes and
resection line were free of tumour. Radiother
apy (Table I), delivering approximately 7760
rad, was given in two 14-day sessions after the
operation. One year later, the patient noted the
gradual development of a painful ulcer in the
left sternal border at the second intercostal
space. Biopsy o f the ulcer showed metastatic
squamous cell carcinoma. The lesion was
unresponsive to radiotherapy (2000 rad),
increasing gradually in size. Chronic local pain,
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suppuration and intermittent bleeding led to
referral.
On admission to our institution, a large fun
gating mass was found to extend superiorly
from the sternal angle to the third sternebra
of the corpus sterni inferiorly and to the
costochondral joints bilaterally. A halo of
erythema, induration and edema extended
superiorly from the lower half of the sternal
manubrium to the xiphoid process inferiorly
and laterally from the left midclavicular line
to just medial to the right midclavicular line.
The ulcer was tender, bled easily on touch and
was covered by a creamy purulent exudate (Fig.
1

).

A chest roentgenogram showed loss of
volume of the left lung and changes compati
ble with radiation fibrosis. The sternum was
destroyed from the manubriosternal joint to
the lower corpus sterni (Fig. 2). A computer
ized tomogram demonstrated a large mass
extending deep into the pericardium (Fig. 3).
Samples o f the purulent exudate grew

immediately after operation was unsuccessful
because of flailing of the reconstructed area.
Twenty-four hours after operation, respiratory
distress syndrome required intensive medical
and ventilatory support. A tracheostomy was
performed 15 days after operation and during
the next 10 days with a combination of con
tinuous positive airway pressure and decreas
ing intermittent mandatory ventilation, the
condition resolved.
The reconstructed area oozed approximately
250 m L /d of serous fluid during the first 7 days
after operation. Frequent changes of saline
dressings were necessary but subsequently the
area remained dry. The meshed split-thickness
skin grafts established themselves without dis
placement, breakdown or local sepsis.
At the time o f discharge from hospital, 35
days after operation, there was no flailing of

the reconstructed segment of chest wall and the
defect had contracted 3 cm vertically and 4 cm
horizontally (Fig. 6). Bedside spirometry
showed an FVC of 1.4 L and an FEV, of 1.2
L.

Discussion
Chest-wall defects usually result from
surgical resection o f tumours or indolent
ulcers secondary to radiotherapy (radi
onecrosis), trauma or repair o f congeni
tal abnormalities. Reconstruction of the
thoracic wall aims to protect intrathoracic
organs, restore continuity to maintain an
efficient bellows action and to achieve an
acceptable appearance.
Several reconstructive procedures have

Staphylococcus aureus.
Spirometry performed at the bedside showed
a forced vital capacity (FVC) of 1.8 L and
forced expiratory volume in 1 second (FEV,)
of 1.6 L, suggesting restrictive lung disease with
a superimposed noncompliant chest wall.
Before operation, the patient was given cloxacillin (4 g/d) intravenously for 10 days.
Operation was carried out in conjunction
with the plastic surgery division. It consisted
of en-bloc resection of the anterior chest wall,
extending superiorly from the middle portion
of the sternal manubrium to the xiphoid
process and anterior diaphragmatic insertion
inferiorly. Laterally the resection followed the
margins of indurated erythematous skin. The
resection included the anterior pericardium
extending just medial to each phrenic nerve.
The estimated blood loss was 2600 mL, mostly
from damage to the main pulmonary artery
which was encased in dense fibrotic tissue.
The resulting chest-wall defect measured 21
x 23 cm (Fig. 4). A single sheet of Marlex
mesh attached firmly to the bone ends and
muscular fascia served to support an omental
flap (Fig. 5) covered superficially with meshed
split-thickness skin grafts harvested from the
right thigh. Flemovac drains were placed
between the heart and visceral pleura and the
Marlex mesh.
An attempt to remove the endotracheal tube

FIG. 1—Sternal ulcer.
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FIG. 3—Tomogram shows chest-wall mass extending into anterior pericardium.
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been advocated,2 varying from primary
closure of the defect to the use of an
• assortment of grafts (skin, myodermal,
rib, omental). Synthetic materials, such
~as Marlex mesh and tantalum plates, have
also been used.3'4 In our patient, the
problem of reconstruction was due to the
ylarge defect resulting from en-bloc resecdon of the anterior chest wall. The resec
tion included almost the entire sternum,
except for the upper half of the
manubrium and the sternoclavicular and
first sternochondral joints, bilateral excision of cartilagenous plates, a moderate
^portion of pectoralis major muscle on
both sides and the anterior pericardium,
leaving exposed the heart and both lungs.
Both internal mammary arteries were

resected precluding the use of bilateral
rectus abdominis muscle flaps to obliter
ate the anterior chest-wall defect.
Although the main blood supply of both
pectoralis major muscles was intact, the
amount of muscle mass included in the
specimen made the use of pectoralis
major muscle flaps hazardous.
Direct covering of the intrathoracic
organs with meshed split-thickness skin
grafts has been mentioned in the litera
ture,2 but we considered that direct
covering of the anterior aspect of the
heart with skin grafts was risky because
of possible dislodgement or breakdown
of the skin grafts secondary to cardiac
motion.
Preservation of the sternal manubrium

and its sternoclavicular and first sternochondral joints maintained support of
the thoracic inlet and even though flail
ing of the Marlex mesh repair precluded
early removal of the endotracheal tube,
we believe that the solidity of the repair,
which allowed us to withdraw mechani
cal ventilation once the acute pulmonary
infiltration had subsided, was due to the
firm medial anchorage of the clavicles and
first ribs.
In the presence of local sepsis, the use
of knitted Marlex mesh, instead of
autografts to stabilize the anterior chest
wall, may be criticized since infection is
a major complication and when it occurs,
the synthetic material must be removed
completely. However, the omental graft,
with its great vascularity, covering the
Marlex prosthesis, prevented local sepsis
and served at the same time as an excel
lent base for the skin grafts.
The Marlex reconstruction restored an
efficient bellows action, manifested by the
lack of an anterior flail chest and
postoperative bedside spirometry values
that were 75% of those obtained
preoperatively.
The management of these cases
demands cooperation between thoracic
and plastic surgeons as well as interaction
with other discipline, anesthesia and acute
care medicine, to obtain satisfactory
results.
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The Evolution of Management of Pilonidal Sinus Disease
y

Pilonidal sinus disease has for too long
k been treated by radical methods, proba
bly on the assumption that these were
1 the only ways to prevent recurrence. A
review of the literature reveals a sprin’ kling of papers indicating that simpler
^ methods not only carry less morbidity,
but also are associated with a lower
> recurrence rate.
With a detailed 10-year review, the
author reports a series of 72 consecutive
patients with pilonidal sinus treated suc
ce ss fu lly as outpatients by conservative
^ methods under local anesthesia. This
review, along with the similar experience
of others, makes it clear that only simple
conservative methods are acceptable in
the management of pilonidal sinus.

La maiadie du sinus pilonidal a, pendant
trop longtemps, fait I'objet de traitef ments agressifs et radicaux. Et ceci,
base sur I'impression que seulement de
telles methodes pouvait eviter le haut
taux de rgcidive. En faisant une revue de
la litterature medicate, on trouve quel,
ques articles qui suggerent que des
methodes plus simples portent avec
.elles, non seulement moins de morbidity,
mais aussi une recidive moins frequente.
►
L'auteur presente une etude retrospec
tive sur 10 ans, faisant 6tat de 72 cas
consecutifs de patients atteints de la
maiadie du sinus pilonidal. Ces patients
ont tous ete traites de facon conserva^trice, en externe, avec anesthesie locale.
En raison de resultats similaires chez
d'autres auteurs, il semble apparent
qu'une approche conservative soit la
seule acceptable.

Pilonidal sinus is generally treated by rad
i c a l excision to reduce the high recurrence
rate associated with this debilitating dis
ease. However, satisfactory results and
lower recurrence rates have been report
ed,1' 10 using conservative methods.
In the past 10 years, I have treated 72
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consecutive patients (ranging in age from
16 to 48 years) with pilonidal disease, in
cluding those with simple sinuses, recur
rences after as many as three previous sur
gical procedures and many with abscesses.
All were managed as outpatients under lo
cal anesthesia. Six were lost to follow-up,
66 were re-examined.

Methods
Whether the patient presents with an
acute pilonidal abscess or a chronic drain
ing sinus, the management is always as
follows:
• Premedication is given if required.
• The skin is prepared, with careful
shaving of the area.
• The skin is infiltrated with 1°7o Carbocaine without epinephrine over the
main sinus and its lateral ramifications.
• The area is incised, taking care to
search for all sinus openings, and the con
tents are evacuated, including hair if any
is found.
• Hemostasis is achieved by pressure
and a suitable pack soaked in a topical
disinfectant (usually povidone-iodine) is
inserted into the sinus.
• The patient is instructed to change
the pack daily, shave the area twice a
week, bathe or shower the area daily and
return for review once a week.
The local care of the wound is usually
done by a relative or friend, frequently
a home-care nurse, and sometimes by the
patient. It is essential that the wound be
inspected at least once a week, so that any
skin bridging, which usually results
because the pack has not been inserted
properly into the wound, can be divided.
In this series every patient was
instructed to follow a regimen of local
shaving and careful cleansing for a mini
mum of 3 months, but compliance was
poor. Patients often failed to return for
their weekly check soon after the opera
tion. This must be guarded against; while
the patients feel completely recovered,
skin bridging will likely already have
recurred ensuring a late recurrence.
Results
Morbidity was minimal. The majority
of the patients missed only 1 or 2 days

from work, while a very few were absent
from work as long as 1 week. One who
was hospitalized for further skin care was
away from work for 2 weeks. Healing
time ranged from 10 days to 6 weeks, but
most sinuses were healed in 4 weeks. Mor
bidity after the first 2 or 3 days was
minimal and almost every patient
resumed normal activities by then.
Of the 72 patients treated, 6 were lost
to follow-up and 66 (25 women, 41 men)
were interviewed and examined. O f the
66 cases I reviewed, 8 (12.1%) had recur
rence. Only one patient who had had
previous surgery elsewhere had a recur
rence. All recurrences were minor; they
were treated conservatively and all sinuses
healed. It is noteworthy that one patient
cured herself by removing the hair and
applying a small disinfectant pack as had
been done initially. Another experienced
three small recurrent midline sinuses but
was unaware of any problem. He was
instructed to return to the routine of
twice-weekly shaving of the area, careful
washing and daily application of a small
disinfectant pack. All three sinuses dis
appeared within 4 weeks.
One woman was hospitalized postoperatively because of prolonged delay in
healing. (This is consistent with the patho
genesis of this disease; occasionally, the
patient must be hospitalized to clean the
sinus thoroughly to allow healing.) A few
days of hospital care with constant
exposure of the wound to a heat lamp and
regular topical applications of a mild skin
disinfectant led to rapid healing. It may
be that the success of this method is due
to the same principles of exposure of the
wound with reversed strapping outlined
by Rosenberg.8 Even the most compli
cated cases were managed in the same
way, opening all the lateral sinuses under
local anesthesia and trimming the skin
only at the junction of these incisions to
allow greater ease of packing and
smoother healing.
Discussion
The literature on the treatm ent of this
minor but very debilitating disease is
extensive. Herbert Mayo is reported to
have published the first case of pilonidal
disease in 1833.3 In 1847, Anderson11
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described his management of a young
man with an abscess containing matted
hair near the os coccygis. No anesthesia
was mentioned, but the treatment con
sisted o f incision and drainage, removal
o f debris and application of topical dis
infectants. It is a pity that his methods
were not adopted widely. One of my vivid
memories as a medical student is the sight
o f a soldier lying face-down in his bed to
display to the assembled class the area of
healthy granulations around his gluteal
fold, covering an area approximately the
size of his hand, after radical surgery for
“ Jeep Disease” . During World War II
progress was made when the American
army prohibited primary closure after
excision of pilonidal sinus because of a
very high recurrence rate and prolonged
morbidity.
Patey and Scarff12 were among the
first to challenge the congenital theory of
pathogenesis for pilonidal sinus. They
believed that the condition was acquired.
This theory was widely accepted but now
there is a swing back to the congenital the
ory. Abcarian13 believed that recurrence
was due to the skin closing faster than the
tissues underneath. He stressed that the
patient must shave the area until the
wound healed, then monthly, perhaps for
1 year, “ until their mother, wife or girl
friend gets tired of it” .
A t least one standard text14 recognizes
conservative ambulatory methods but still

recommends marsupialization or excision
and primary closure.
As early as 1956, Klass1 managed 45
patients conservatively; their combined
hospital stay totalled only 4 days. Wat
ters and MacDonald2 described marsupi
alization of pilonidal sinus abscesses, but
used general anesthesia. Miller3 reported
his military experience with 362 patients
and eliminated pilonidal disease as an
inpatient problem. Lord and Miller4
used simple treatment for pilonidal sinus
disease and provided an interesting solu
tion to the problem of lateral branches;
they excised a small ellipse of skin around
the openings and removed any possible
foreign material from these side tracts by
passing a small electric razor cleaning
brush through them. Thus, they avoided
opening wide areas of tissue and confined
the conservative surgery to the midline
crease. In 1971 in this jo u rn al,5 I
described a conservative approach to this
problem with an emphasis on minimal
surgery, outpatient management and local
anesthesia. Broadrick and associates6
reported a simplified outpatient treatment
and recommended a regimen of hygiene
to be followed in order to prevent recur
rence. Rickies,7 as a result of extensive
experience with 227 patients treated since
1950 with a recurrence rate of 4%,
stressed the importance of a conservative
approach, eliminating hospitalization. He
treated patients with abscesses in two

stages. In cases in which the wound did
not heal after a prolonged period,
Rosenberg8 pointed out the value of j
reversed bandaging in order to separate
the buttocks to allow easier cleansing. _
Ortiz and associates9 described 96
patients treated by marsupialization, incision or excision without primary closure.
They found that simple incision of thef^
sinus tract under local anesthesia allowed
the patient to return to work sooner. Jor
dan and Meinecke10 stated that the
procedure should be tailored to each
lesion. They used minor incisions and
local anesthesia on an outpatient basis.
They stressed home-care instructions, 4
including regular repacking of the wound
up to four times daily after sitz baths or
showers. Postoperative follow-up was
scrupulous and at each examination local4
hair was clipped until the wound had ^
healed. Great emphasis was placed on
hygiene to prevent recurrence.
<
Perhaps the most discerning comment
about this condition in recent literature '
comes from Peter Goodall,15 who noted
the high recurrence rate in patients fol-4
lowed up for more than 1 year. In his col
lected series of 197 patients, 38% had <
recurrence after wide excision and a
primary suture, 21% after wide excision
and healing by granulation, 20% after
excision and Z-plasty and only 8% after
incision and healing by granulation. This
clearly demonstrates that incision rather

COLORLESS
<

Rational therapy for hemorrhoids,
proctitis and pruritus ani+
+Darke, A.C., Rudd, W.W.H.: Reformulation ofTwo Hemorrhoidal Ointment Preparations: Double-blind Clinical
Comparison with Existing Formulations; Curr. Therap. Res. 30; 6:880-885,1981.

-

than excision provided a more satisfac of abscesses is unnecessary. Simple
tory result. However, he pointed out that
sinuses will heal spontaneously without
^ these results had not been measured
operation with suitable shaving and toi
against the natural history of the disease
let of the gluteal cleft. Any surgery per
^ which can be one of spontaneous cure.
formed should be as simple as possible,
He described a series of 26 patients in with the emphasis on midline incision,
> < whom a policy of conservative treatment
minimal excision of skin and no suturing
was adopted at the first outpatient visit;
or cautery of any kind. One is not trying
patients were advised to bathe each day,
to destroy a malignancy and there is no
to shave the surrounding skin and to
congenital cyst. Midline pits tend to foster
remove protruding hair. Of these 26
further recurrence and should be
patients, 4 subsequently required surgical
managed by local incision and use of dis
f treatment for persistent discharge or
infectant packs with regular shaving; they
recurrent abscesses, 5 had minor symp may disappear with simple regular toilet
toms requiring little or no treatment and
alone.
► patients lost no time from work. Of 20
It has been observed, and I concur, that
patients with an untreated sinus followed
the milder form of this disease, consist
up for more than 1 year, only 2 required
ing only of recurrent discharge from a
surgical treatment for recurrent infection.
small sinus, needs only local hygiene and
* This compared favourably with excisional regular topical disinfectant to resolve the
^ methods of surgical treatment and was
problem. This regimen must become part
similar to the success rate found in inciof the patient’s daily routine. In the more
v sional surgery. He recommended that the
severe form, including pilonidal disease
initial management of pilonidal disease
with abscess, minor incision and evacua
should be conservative, as in most cases
tion should be carried out, as an outpa
the disease was neither progressive nor
tient procedure and without general
►persistent. He stated that only 1 in 10 anesthesia.
patients was likely to require operation.
Many papers have been published
From a review of the literature, impordescribing every conceivable type of skinh tant principles emerge. Radical proce shift procedure and using all manner of
dures are not only unnecessary but carry
sutures in attempts to shift the gluteal
appreciable morbidity. General anesthe cleft to either side or from the vertical to
sia has been used frequently even with
the horizontal and adding electrical or
conservative surgery, but is not needed
chemical cautery, silicone sponges, ten
even for abscesses. Two-stage treatment
sion sutures, strappings, cryosurgery and
»

B

*0

laser surgery, and almost always under
general anesthesia on an inpatient basis.
Many days, weeks or months may be lost
from work. In view o f the success of con
servative measures, such techniques will
likely soon disappear.
References
1. Klass AA: The so-called pilo-nidal sinus. Can M ed
Assoc J 1956; 75: 737-42
2. W atters N, M a c d o n a ld IB: Marsupialization of pilo
nidal sinus and abscess: a report o f 50 cases. Can M ed
Assoc J 1958; 79: 236-40
3. M iller RJ: Pilonidal disease, a logical approach. Post
grad M ed 1967; 41: 382-5
4. LORD PH , M illa r DM: Pilonidal sinus: a simple treat
ment. Br J Surg 1965; 52: 298-300
5. HURST DW: Pilonidal sinus: an overtreated disease. Can
J Surg 1971; 14: 98-9
6. Broadrick GL, E h r lic h FE, Kram er SG: Simplified
treatment of pilonidal disease on an outpatient basis. Sur
gery 1971; 70: 635-7
7. RICKLES JA: Ambulatory surgical management o f pilon
idal sinus. A m Surg 1974; 40: 237-40
8. Rosenberg I: The dilemma o f pilonidal disease: reverse
bandaging for cure of the reluctant pilonidal wound. Dis
Colon Rectum 1977; 20: 290-1
9. ORTIZ HH, M arti J, Sitges A: Pilonidal sinus: a claim
for simple track incision. Ibid: 325-8
10. J ord a n M H, M ein eck e HM: Ambulatory surgery for
pilonidal disease. A m Surg 1979; 45: 360-3
11. A nderson A W : H air extracted from an ulcer Boston
M ed Surg J 1847; 36: 74
12. P atey DH, Sc a r f f RW: Pathology o f postanal pilo
nidal sinus: its bearing on treatm ent. Lancet 1946- 2484-6
13. ABCARIAN H: In discussion o f ROSENBERG I: The
dilemma of pilonidal disease: reverse bandaging for cure
of the reluctant pilonidal wound. Dis Colon Rectum 197720: 292
14. Sabiston DC JR: Davis-Christopher Textbook o f Sur
gery: the Biological Basis o f Modern Surgical Practice,
12th ed, Saunders, Philadelphia, 1981: 1683-6
15. GOODALL P: Management o f pilonidal sinus. Proc R Soc
M ed 1975; 68: 675

-f S

pl)SOL*-HC... Ointment & Suppositories
Ijti-inflammatory...helps relieve pain and itching
tibricating petrolatum base...cosmetically elegant
ow incidence of side effects
3. t .M. Parke, Davis & Company Parke-Davis Canada Inc., auth. user

PARKE-DAVIS
Parke-Davis Canada Inc., Scarborough, Ontario

J . HALPENNY, MD; C .H . RORABECK, MD, FRCS[C]

Supracondylar Fractures of the Femur:
Results of Treatment of 61 Patients
A retrospective study of 61 fractures (60
patients) involving the supracondylar and
intercondylar areas of the femur was
made. All patients were younger than 60
years and sustained their injuries in
motor vehicle accidents. Follow-up was
from 1 to 9 years (mean 30 months).
Clinical results of operative and
nonoperative treatment were compared
with respect to knee motion, pain and
function. Extra-articular (type A) frac
tures had superior clinical ratings if
treated operatively (45% excellent and
30% unsatisfactory). Intra-articular
(type B) fractures had a substantial
number of unsatisfactory ratings
(45%) and results of operative and
nonoperative treatment were compara
ble. Fractures of one condyle only did
best with open reduction and internal
fixation.
Rates of nonunion were low (7%);
malunion in varus led to poorer overall
function. The most important factor for
acceptable function was early knee
mobilization. Early motion of the knee
and quadriceps rehabilitation are facili
tated by operative management or use of
the cast brace.
On a realise une etude retrospective de
61 fractures (chez 60 patients) des
regions sus-condylienne et intercondylienne du femur. Tous les patients
etaient ages de moins de 60 ans et
avaient subi leurs blessures dans des
accidents de la route. Les examens de
surveillance se sont etales sur de 1 a 9
ans (moyenne de 30 mois).
Les resultats cliniques des traitements
chirurgicaux et non chirurgicaux ont ete
compares en rapport avec la limitation
des mouvements du genou, la douleur et
la fonction. Les fractures extra-
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articulaires (de type A) ont obtenu une
meilleure evaluation clinique lorsqu'elles
ont eta traitees chirurgicalement (45%
d'excellents resultats et 30% de resul
tats insatisfaisants). Les fractures intraarticulaires (de type B) ont obtenu un
nombre important devaluations insatisfaisantes (45% ) et les resultats des
traitements chirurgicaux et non chirurgi
caux etaient comparables. Dans les cas
de fracture d'un condyle, les bons resul
tats n'ont ete obtenus que par reduction
chirurgicale et fixation interne.
Le taux d'echec de soudure de I'os a
ete faible (7%); une mauvaise soudure
en varus a donne les plus mauvais resul
tats du point de vue de la fonction. Le
facteur le plus important pour I'obtention
d'une fonction acceptable est la mobili
sation precoce du genou. La mise en
mouvement pr6coce du genou et la rea
daptation du quadriceps sont facilites par
la chirurgie ou I'emploi d'un contention
platre fonctionnel.

The treatment of choice for supracondy
lar fractures of the femur is still evolving
and the results of different methods are
still incomplete and controversial. An
interest in the end result of comminuted
supracondylar fractures of the femur was
the original impetus for this study.
Studies of long-term results of femoral
fractures and particularly supracondylar
fractures reveal unsatisfactory function in
a substantial number of cases evaluated
in the earlier decades of this century.
Delorme and associates1 noted poor
results for femoral fractures closer to the
knee joint, but improved results with
early ambulation and resisted quadriceps
exercise. Stewart and associates2
reported on 213 fractures of the distal one
third of the femur and documented bet
ter results with closed methods. Neer and
colleagues3 reviewed 110 fractures of the
distal one third of the femur and reported
similar results. The introduction of the
blade plate (ASIF; American Society for
Internal Fixation) in the 1960s increased
enthusiasm for the operative approach,
particularly in younger patients. Schatzker and Lambert4 compared operative
and nonoperative methods in two groups,

carefully selected to have the same type
and degree of comminution. They reported 75% good or excellent results
using the blade plate and 32% using trac- *
tion. In the opinion of Zickel and associ
ates,5 results of operative and nonoper
ative methods were similar. They designed T
special condylar rods that are still
experimental.
Cast bracing has been suggested by
some6'9 as the treatment of choice for *
supracondylar fractures of the femur.
They found it particularly suitable for dis
tal femoral fractures providing adequate
stability and still allowing knee motion.
Meggitt and associates10 and Wardlaw
and colleagues11 noted similar results
with the use of traction and cast bracing.
These treatment modalities and their
efficacy are still being evaluated. The aim <
of this study was to compare operative
and nonoperative treatment of supracon
dylar fractures of the femur and to ana
lyse various treatment parameters.

Patients
We reviewed the charts and roentgeno
grams of 60 patients (42 men, 18 women)
who sustained supracondylar fractures of
the femur from 1973 to 1980. Supracon
dylar fractures through osteoporotic bone
in elderly patients were excluded. One t
patient had bilateral fractures, making a
total of 61 fractures. Follow-up included
telephone interview with the patient to
assess subjective function.
The patients’ age ranged from 18 to 59
years (mean 42 years). The left lower
extremity was involved in 35 patients and
the right in 26. Fractures were classified
according to site (Fig. 1). There were 40
type A, 15 type B and 6 type C fractures.
The follow-up ranged from 1 to 9 years
(mean 30 months).
Seven patients had open fractures and
15 had associated injuries. Results were
classified into three categories on the basis t*
of pain, knee motion and function (Table
I).

Results were tabulated to compare
operative and nonoperative treatment,
and the following parameters were ana-
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lysed: period of immobilization, time to
union, delayed and nonunion, and
jjialunion.
^Results
Fifty-five patients sustained type A or
B fractures. Twenty-nine were treated
Operatively and 26 nonoperatively. At
operation a 90° angled plate was used
(Fig. 2). Nonoperative methods included
fraction alone, traction with a cast or trac
tion with cast bracing (Fig. 3). Patients
treated by these methods were divided
into two groups — traction or cast brac
ing (after traction). The results of both
methods of treatment are tabulated in
Tables II and III. Overall, operatively
, treated type A and type B fractures had
66% excellent or satisfactory results.
Of all patients treated without opera
tion, those receiving a period of traction
*■.followed by application of a cast brace
had superior results to those treated by
•traction alone. Overall, 63% of these
patients had excellent or satisfactory
results.
Six patients had type C fractures. Five
of these were treated operatively (four by
^operation alone and one with cancellous
screw fixation and a cast) and one patient
was treated in a cast alone. This patient
had an excellent result and, of those

FIG. 2—Type A fracture treated with blade-plate.

FIG. 1—Fracture types: A is extra-articular,
involving distal one third of shaft and
supracondylar area; B is intra-articular, involv
ing both condyles (displaced or undisplaced)
'and often supracondylar area (T-fractures) and
Jype C involves one condyle only.

. Rating
►

Table 1—Rating System
Criteria

Excellent

Satisfactory
►

Unsatisfactory

t

No pain
Knee flexion greater than
130°
No extension lag
Full activity
Occasional pain not requiring
medication
Knee flexion greater than 90°
Partial restriction of activity,
but no interference w ith
activities of daily Jiving
Pain requiring medication
Knee flexion less than 90 °
Instability requiring external
aids, inability to work or
interference w ith daily
activities

FIG. 3—Type B fracture treated with cast brace (top) (previous patellar fracture). Healed
fracture (bottom).
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treated operatively, two had excellent and
three satisfactory results.
Seven fractures were initially open;
three were treated by debridement and
internal fixation and four by debridement
and traction. Two patients with type A
and two with type B fractures had satis
factory healing, and one with type A and
two with type B fractures had unsatisfac
tory healing.
The period of immobilization is shown
in Table IV. The time to mobilization was
also compared to the final range of knee
motion (Table V). This shows that a
larger percentage of patients who took
less than 4 weeks to achieve their final
range of motion had an excellent and
satisfactory range than those who took
longer than 4 weeks.
The time to clinical union was recorded
(Table VI). It was approximately the same
for each group. Primary bone grafting
was used in four patients.
One patient had delayed union and
three nonunion. Of these four patients,
three had been treated in traction and one
by internal fixation. Final results after sal
vage procedures (operation, internal fix
ation and bone grafting) were generally
unsatisfactory because of decreased range
of motion and symptoms of chondro
malacia.
The incidence of malunion was also
compared to the method of treatment
(Table VII). For purposes of this study,
varus greater than 5°, as compared with
the opposite side, was considered a
malunion. Using this criterion, three
patients had genu varum greater than 5°;
all three had an unsatisfactory result. Six
had angulatory deformities in the
anteroposterior plane greater than 10°.

Discussion

The results of this study show that
operative treatment of type A fractures
of the femur is superior to nonoperative
methods. Although the number of
unsatisfactory results in both groups was
substantial (30% and 31%), a higher per
centage of operatively treated patients
had an excellent result (45% vs. 13%). In
type B fractures, unsatisfactory results
were frequent (44% and 50%), and
neither treatment modality proved
superior. Patients with type C fractures
all did well with both methods of
treatment.
Schatzker and Lambert4 reported sim
ilar findings. They found that type B frac
tures had a poorer result than type A.
The length of time the knee was
immobilized was an important factor in
predicting the end result, particularly with
respect to range of motion. Patients
treated operatively, irrespective of the
fracture type, began knee mobilization
earlier than those treated nonoperatively
and had a superior result. Others1’12,13
have demonstrated the importance of
early mobilization and its correlation with
good results.
Late pain influenced the final result in
25% of cases, and was more frequent in
patients with type B fractures. Damage
to the articular surface at the time of
injury may result in later degenerative
joint changes. Also, a decreased range of
motion may magnify the compression
stresses across the patellofemoral joint
and contribute to chondromalacia.1’14
Both of these factors may be responsible
for late pain.
The time to union was approximately

Totals
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patients

Excellent

Satisfactory

0
0

3
1

4
4

8
5
1

2
1
1

5
4
0

1
1
0

4(15%)

13(48%)

Table IV--Period of Immobilization in Weeks
Fracture
type
Operative
Nonoperative
A
3
Traction, 7
Cast brace, 5
B
3
Traction, 8
Cast brace, 5
C
3
3

»

Table V-Period of Immobilization Related
to Range of Motion, % of Patients
Range of motion, 0
Immobilization,
wk
30-69 70-109 >110
1 to 2
0
20
80
3 to 4
48
8
46
5 to 6
21
70
9
7 to 10
25
75
0
>11
33
67
0

Unsatisfactory

8
5

27

.

Table VI -Time to Union in Weeks
"
Fracture
type
Operative
Nonoperative
A
13
15
B
14
16
1
C
11
11

Table III—Results of Nonoperative Treatment
Result
Treatment
Traction
Type A
Type B
Cast brace
Type A
Type B
Type C

the same irrespective of the method of
treatment. Similar healing rates have been
noted by others.2'12'15
♦ ”*
The incidence of delayed union
nonunion was 7%. It was more frequent
(although not significantly) in patients not
operated on. This incidence compared
favourably with that of other series.,''
Stewart and associates2 found nonunion
in 30% of their operatively treated
patients and Schatzker and Lambert4
noted a similar incidence in those whose"
fractures were treated operatively. Recent ^
studies of cast bracing showed nonunion
rates of 10% or less.
j
Malunion in general, and genu varum*
in particular, was more common in frac-,
tures treated nonoperatively than in those
treated operatively and both werg'
associated with poor results. An analysis
of the comminuted fractures and those "*
that developed varus illustrated the ,
importance of the medial cortical buttress"
in these fractures. Neer and associates3A !

10(37%)

L
Table VII—Malunion
Deformity
Operative Nonoperative .
Genu varum
1
2
Anterior
angulation > 10°
1
2
Posterior
angulation > 10°
0
3
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noted that comminuted fractures in trac
tion tended to fall into varus and inter
n a l rotation because of lack of medial
support and the pull of the adductor mus
culature. In patients who were operated
on, Schatzker and associates15 noted the
importance of providing medial support
with bone grafting in comminuted frac
tures. The current study suggests that this
^observation is correct.
In patients not operated on, the best
^results were obtained from traction fol
lowed by a cast brace. Others10-14 have
reported acceptable results using the cast
brace. They showed that when properly
^applied this device adequately supports
the fracture fragments and that no angu
lation develops while the limb is braced,

SESAP IV Question
The high postoperative mortality for children with congenital diaphrag
matic hernia is due to
316.

(A)
(B)
(C)
(D)
(E)

increased intra-abdominal pressure
persistent patent ductus arteriosus
failure of the collapsed lung to expand
mediastinal shift with impaired venous return
abnormal pulmonary microvasculature

v-

Conclusions

* Type A fractures showed better results
with operative than with nonoperative
management. Operative methods in
cluded open reduction and rigid internal
fixation with a blade-plate device. A
period of traction followed by the use of
a cast brace is an acceptable alternative.
'In type B fractures, operative and non
operative management gave similar re
sults. Early mobilization of the knee and
exercising the adjacent musculature are
important in obtaining a good result.

For the incomplete statement above select the one answer that is best of the
five given. For the critique of Item 316 see page 622.

(Reproduced by permission from SESAP I V Syllabus: Surgical Education and
Self-Assessment Program No. 4. For enrolment in the Surgical Education and
Self-Assessment Program No. 4, please apply to the American College of Sur
geons, 55 East Erie St., Chicago. IL 60611.)
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Congenital Posterolateral Diaphragmatic Hernia in the AdultBochdalek's hernia, congenital posterola
teral diaphragmatic hernia, is common in
children but rarely occurs in adults. The
authors report two such adult cases.
One of the hernias was on the left and
the other on the right. Both patients had
gastrointestinal symptoms. The approach
was abdominal in one and thoracoabdo
minal in the other. There were no opera
tive or postoperative complications.
The possibility of congenital posterola
teral diaphragmatic hernia must be consi
dered in the differential diagnosis of
patients who have recurrent gastrointes
tinal and respiratory complaints. A com
plete roentgenologic examination is
necessary in order to make an accurate
diagnosis preoperatively. Because of the
danger of strangulation of the hernia,
operation should be carried out as soon
as the diagnosis is made.
La hernie de Bochdalek, une hernie
diaphragmatique posterolaterale congenitale, est frequente chez I'enfant mais
rarement observee chez I'adulte. Les
auteurs decrivent deux cas chez I'adulte.
Une des hernies affectait le cote gauche
alors que I'autre etait du cote droit. Les
deux patients souffraient de symptomes
gastro-intestinaux. On a utilise un abord
chirurgical abdominal dans un cas et
thoraco-abdominal dans I’autre. II n'y eut
aucune complication operatoire ou postoperatoire.
On doit songer a la possibility d'une
hernie diaphragmatique posterolaterale
congenitale dans le diagnostic differential
des troubles gastro-intestinaux recidivants. Un examen radiographique complet est necessaire pour etablir le diag
nostic preoperatoire de facon sure. A
cause du danger d'dtranglement de la
hernie, I'operation doit etre pratiquee des
que le diagnostic est connu.
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Congenital posterolateral diaphragmatic
hernia — Bochdalek’s or pleuroperitoneal
hiatal hernia — is the commonest conge
nital hernia o f the diaphragm in infants
and children. B a ffes1 reported the
following frequency of congenital diaph
ragmatic hernias in 116 infants and chil
dren: posterolateral 59.5%, parasternal
(Morgagni) 2.6% and hiatal 23.3%.
Eventration occurs in 14.6% but phrenic
paralysis is rare.
In contrast, this lesion is rare in adults.
In 1959, Kirkland2 first called attention
to the special diagnostic problems in the
few patients whose congenital posterola
teral diaphragmatic hernia escaped diag
nosis during their first years of life. He
collected 35 such patients, reported from
1853 to 1958, between the ages o f 12 and
72 years. Fingerhut and associates3 col
lected 114 cases o f postinfancy congeni
tal posterolateral diaphragmatic hernia up
to 1978.
We have had the opportunity to study
and operate upon two adults with Boch
dalek’s hernia.

Six years later she was asymptomatic. The
chest roentgenogram was normal.

Case 2

»■»

A 33-year-old white man suddenly suffered
severe epigastric pain on physical exertion. He
j
was treated with antispasmodic agents in his ^
local hospital and some hours later he was*
asymptomatic. During the following 7 months,
less severe but similar bouts of pain recurred*
triggered by running or other physical exercise,
j
The epigastric pain then became more severe
and persistent and he was admitted to hospital 8 months after the first episode of epigas$
trie pain. No breath sounds were heard in the
right lower thorax.
'
j
A chest roentgenogram showed elevation of
the right hemidiaphragm and atelectasis of the
base of the right lung. Roentgenogram after
a barium meal did not give a clear diagnosis f
)
A thoracotomy through the right seventh,
:
intercostal space and a midline laparotomy
were p erform ed. There, was a right

Case Reports
Case I
A 20-year-old white woman was admitted to
the hospital 10 days after experiencing severe
crampy abdominal pain that was more mar
ked on the left, postprandial vomiting and
dyspnea. During the previous 12 months she
had complained of recurrent pain in the upper
left abdomen. There was no history of trauma
qr previous operation.
Physical examination revealed tenderness in
the upper abdomen on the left side. Bowel
sounds but no breath sounds were heard in the
left lower thorax.
A chest film showed a mass, measuring 5 x
10 cm, with multiple air-fluid levels above the
left diaphragm (Fig. 1). A roentgenogram after
barium enema confirmed the presence of a loop
of the colon above the left hemidiaphragm.
A midline laparotomy was performed. There
was a 6-cm diaphragmatic defect posterolaterally on the left side (Fig. 2), through which the
greater omentum and splenic flexure had her
niated. No hernial sac was present. After
replacing the abdominal viscera, the defect was
closed with interrupted Mersilene sutures. The
patient made a smooth recovery and was dis
charged 2 weeks after operation.

-

FIG. 1—Posteroanterior film showing mas?
laterally above left hemidiaphragm with airfluid levels.
■*

FIG. 2—Hernial defect (arrow) in left
hemidiaphragm seen from below after replace
ment of bowel.
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posterolateral diaphragmatic defect, 21 cm
wide (Fig. 3), through which two thirds of the
— ^liver had herniated. No hernial sac was found.
The liver was easily repositioned in the
A b d o m in al cavity. The hernial defect was
closed in two layers.
►
Recovery was smooth and the patient was
discharged 12 days after operation. Nine
i - ' ^months later he was asymptomatic and the
chest roentgenogram was normal.

j

Discussion

The diaphragm derives from four
► different sources.4,5 Its central tendinous
portion is formed from the septum trans►j/ersum, the mediodorsal portion from the
mesoesophagus and the lateral portions
rfrom the musculature of the lateral body
wall and pleuroperitoneal membrane.
r The ventral septum transversum grows
dorsally during gestational weeks 4 and
5 to envelop the gut, inferior vena cava
*■ and aorta. This leaves the abdominal and
pleural cavities connected by only the
* .paired posterolateral pleuroperitoneal
canals. Normally, these canals are closed
►*by a two-layer membrane derived from
pleura and peritoneum (pleuroperitoneal
membranes) during gestational week 8
>. and are later buttressed by ingrowth of
‘skeletal muscle. Incomplete closure of the
pleuroperitoneal canal will result in her
niation of abdominal viscera into the tho
rax through this space.
Posterolateral defects in the diaphragm
^*are relatively common, constituting at
least 40% of all embryologic defects of
the diaphragm.6
l.
Compromised diaphragmatic breath
ing, atelectasis and respiratory acidosis
make Bochdalek’s hernia a true surgical
emergency in the newborn, being
^associated with a high mortality. This is
why the lesion is rarely reported in adults.
' Prompt recognition and surgical treatment are lifesaving.7
► In adult2,3,7 as well as in infant series1
the defect occurs more commonly (80%
to 90%) on the left. This is probably due
r to narrowing of the right pleuroperitoneal
canal by the caudate lobe of the liver.8
These hernias usually have no sacs and
the contents are thus in direct contact with
the thoracic viscera. However, in some

* FIG. 3—Hernial defect in right hemidiaphragm viewed from below after replace
ment of liver.

cases (29%) a hernial sac is observed.3 In
these cases the posterolateral portion of
the diaphragm did not become muscularized before the herniation occurred,
although the pleuroperitoneal membrane
met the septum transversum, closing the
posterolateral portion of the diaphragm.
Osebold and Soper7 believe that long
term survival of patients with congenital
posterolateral diaphragmatic hernia may
be due to persistence of a confining
pleuroperitoneal sac. Rupture of this sac
in later life may coincide with onset of the
characteristic symptoms. Others9 believe
that the congenital posterolateral defect
is relatively common but remains asymp
tomatic unless trauma or increasing
abdominal pressure from such causes as
obesity and pregnancy supervenes.
The most commonly herniated organs
are the colon, stomach and spleen.2,3'7 In
contrast, the liver has been associated in
only 7 of 114 cases collected from the
literature by Fingerhut and associates.3
In one of our cases the liver was displaced
into the pleural cavity.
The sudden intense distress, essentially
cardiorespiratory, that characterizes the
clinical picture in the infant is very differ
ent from the more chronic and recurrent
gastrointestinal and respiratory symptoms
in adults.
Of the 50 patients reviewed by Ahrend
and Thompson4 one quarter were
asymptomatic. The remainder had vague
remitting gastrointestinal symptoms,
most frequently intermittent abdominal
pain with or without intestinal obstruc
tion. It is natural that signs and symptoms
of the complications are the same as those
of other hernias. If there is free movement
of the viscera between the pleural and
peritoneal cavities, symptoms will arise
periodically, whereas the symptoms will
be progressive and the condition possibly
fatal should the intestine become incar
cerated or strangulated.4
Of the 114 cases reviewed by Fingerhut
and associates,3 38 were seen in acute
distress because of acute gastric dilata
tion,10 volvulus of the stomach,11 perfo
ration of appendix12 or intestinal
obstruction.13 Hematemesis and melena
also occurred.3,14
Chest roentgenograms are adequate to
diagnose large herniations that contain
gas-filled viscera. If the hernia is small or
of moderate size and if it contains no gasfilled organs, it may simulate a pleural
effusion.15
In infants, roentgenograms after a bar
ium meal and barium enema are rarely
necessary and may be dangerous if they
delay treatment.7 However, in older
patients gastrointestinal contrast studies
are most helpful and in many cases they
confirm the diagnosis of Bochdalek’s
hernia.
Because of the danger of strangulation,
operation is recommended immediately

following diagnosis. However, the choice
of surgical approach is controversial. Of
the 81 patients reviewed by Fingerhut and
associates,3 40 had a thoracotomy and
31 a laparotomy. In the remaining 10
patients, a thoracoabdominal operation
(laparotomy plus thoracotomy or thoracophrenolaparotomy) was used.
The surgical approach in our patients
was abdominal in case 1 and thoracoab
dominal in case 2. We favour an abdomi
nal approach but thoracotomy is equally
satisfactory. For right-sided hernias we
believe that a combined approach
(laparotomy plus thoracotomy) is more
satisfactory for replacing the herniated
viscera and closing the diaphragmatic
defect.
In the collective review of Fingerhut
and colleagues,3 the overall mortality
was 12%. It was higher following emer
gency surgical repair (32%) than follow
ing elective surgical repair (3%).
Recurrence after repair is rare.
Nevertheless, reports have indicated that
eventration can occur. Of the five cases
reported in the literature2,16-19 two were
fatal.

References
1. BAFFES TG: Diaphragmatic hernia. In MUSTARD WT,
Rav itch MM, S nyder WH j r , et al (eds): Pediatric
Surgery, 2nd ed, vol 1, Year Bk Med, Chicago, 1969: 342
2. KIRKLAND JA: Congenital posterolateral diaphragmatic
hernia in the adult. Br J Surg 1959; 47: 16-22
3. F ing erh ut A, p o u r c h e r J , P e lletier JM , Be r TEAUX D, et al: Deux observations de hernie diaphragmatique postero-laterale congenitale (dite de Bochdalek)
revel&s a Page adulte par des complications severes. Inter
vention et guerison. Revue de la litterature. J Chir (Paris)
1978; 115: 135-43
4. AHREND TR, THOMPSON BW: Hernia of the foramen
o f Bochdalek in the adult. A m J Surg 1971; 122: 612-5
5. K etonen P, M a ttila SP, H a r jo la P-T, J a rv inen
A, M attila T: Congenital posterolateral diaphragmatic
hernia in the adult. Acta Chir Scand 1975; 141: 628-32
6. G ray SW, S kandalakis JE: Embryology fo r Sur
geons, Saunders, Philadelphia, 1972: 359
7. O sebold WR, So per RT: Congenital posterolateral
diaphragmatic hernia past infancy. A m J Surg 1976; 131:
748-54
8. WELLS LJ: Development of the human diaphragm and
pleural sacs. Contrib Embryol 1954; 35: 107-34
9. M a c DOUGALL JT , A bbot AC, GOODHAND TK: H er
niation through congenital diaphragmatic defects in
adults. Can J Surg 1963; 6: 301-16
10. SEIDENVERG NF: Foramen o f Bochdalek hernia with
acute tension o f displaced organs. Calif M ed 1971; 114(2):
39-41
11. POWERS RC, Se jd in a j I, OBERSCHNEIDER PB: Stran
gulated foramen o f Bochdalek hernia in the adult. A m
J Surg 1966; 111: 749-51
12. FOLKMAN J: Discussion. In DlBBlNS AW: Neonatal
diaphragmatic hernia: a physiological challenge. A m J
Surg 1976; 131: 410
13. R aichoudhury RC, P atnaik SC, Sa h o o M, P a n d a
K, P atnaik BK: Foramen of Bochdalek hernia in adults.
Chest 1973; 64: 259-62
14. C arter R, Brewer LA in.- Strangulating diaphragmatic
hernia. A nn Thorac Surg 1971; 12: 281-90
15. H aines JO, COLLINS RB: Bochdalek hernia in an adult
simulating a pleural effusion. Radiology 1970; 95: 277-8
16. DELIGNY M: Aplasie congenitale de la coupole gauche,
bien toleree pendant vingt ans (hernie de Bochdalek).
Chirurgie 1969; 95: 461-6
17. H ackwood JF: Complete congenital diaphragmatic her
nia in an adult: operation. Br M ed J 1934; 1: 1030-1
18. R ives JD, Bak er DD: Anatomy o f the attachm ents of
the diaphragm: their relation to problems o f surgery of
diaphragmatic hernia. Ann Surg 1942; 115: 745-55
19. SKINNER EF, C a r r D, DUNCAN JT, H a l l JR: S tran
gulated diaphragmatic hernia. J Thorac Surg 1958; 36:
102-11

VOLUME 27, NO. 6, NOVEMBER 1984 / THE CANADIAN JOURNAL OF SURGERY

611

N ow ,
control
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interactions.
INJECTION.
(RANITIDINE HC1)
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t e \ Effective in the prophylaxis of acid aspira* * * tion syndrome with fewer patients at risk.1)

f?S

“This study suggests that (Zantac)...increases
the mean gastric pH and decreases
the number of ‘at risk days’ in seriously ill
patients.”12)

.

Prevents acid aspiration syndrome without
the hepatic drug interactions found with
other H2 antagonists.
Effectively inhibits gastric acid secretion one of the major factors involved in the
pathogenesis of stress ulcers.
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Prescribing Information
ZANTAC® INJECTION (ranitidine hydrochloride)
PHARMACOLOGICAL CLASSIFICATION
Histamine H 2-receptor antagonist

ACTION

v

1*

r

Ranitidine is a selective antagonist of histamine at gastric H2-receptor sites. Thus
ranitidine inhibits both basal gastric secretions and gastric acid secretion induced
by histamine, pentagastrin and other secretagogues. On a weight basis, ranitidine is
between 4 and 9 times more potent than cimetidine. Inhibition of gastric acid secre
tion has been observed following intravenous, intraduodenal and oral admin
istration of ranitidine and it is dose related, a maximum response being achieved at
an oral dose of 150 mg.
Pepsin secretion is also inhibited but secretion of gastric mucus is not affected.
Ranitidine does not alter the secretion of bicarbonate or enzymes from the pancreas
in response to secretin and pancreozymin.
Ranitidine is rapidly absorbed after oral administration, peak plasma concentra
tions being achieved within 2 to 3 hours. These plasma concentrations are not
significantly influenced by the presence of food in the stomach at the time of the
oral administration nor by regular doses of antacids.
Bioavailability of ranitidine administered orally is approximately 50%. Serum
protein binding of ranitidine in man is in the range of 10% to 19%. The elimina
tion half-life is approximately 3 hours. The principal route of excretion is the urine
(40% recovery of free and metabolised drug in 24 hours).
Intramuscular ranitidine is fully bioavailable in comparison to intravenous
ranitidine. The median elimination half-life of ranitidine injection 50 mg, adminis
tered intravenously or intramuscularly was found to be 140 minutes (range 120 to
160 minutes.) The half-life of ranitidine in patients with renal dysfunction is
prolonged. However, in a study of 27 patients with varying degrees of renal impair
ment therapeutic plasma levels of ranitidine were shown to be achieved without
risk of drug accumulation, using half the normal dose of ranitidine in patients with
plasma creatinine concentration greater than 300 /rmols/litre.
There is a significant linear correlation between the dose administered and the
inhibitory effect upon gastric acid secretion for doses up to 150 mg orally.
A plasma ranitidine concentration of 50 ng/mL has an inhibitory effect upon stimu
lated gastric acid secretion of approximately 50%. Estimates of the ICS0 range from
36 to 94 ng/mL. Following the administration of 150 mg ranitidine orally, plasma
concentrations in excess of this lasted for more than 8 hours and after 12 hours the
plasma concentrations were sufficiently high to have a significant inhibitory effect
upon gastric acid secretion. In patients with duodenal ulcer, 150 mg ranitidine
given by mouth every 12 hours significantly reduced mean 24 hour hydrogen ion
activity by 69% and nocturnal gastric acid output by 90%.
Following intramuscular injection of 50 mg ranitidine, plasma concentrations
in excess of 100 ng/mL were achieved within five minutes of administration and
remained above this level for 4 to 6 hours.
Intravenous infusion of ranitidine in seriously ill patients at a rate of
0.125 mg/kg/hour produced a rise of intragastric pH between 5.6 and 7.0 after two
hours and maintained this level over the test period. The volume of gastric secre
tion was reduced by more than 55%. Doubling the infusion rate to
0.25 mg/kg/hour produced no further increases in gastric acid inhibition.
A single 50 mg intravenous bolus dose of ranitidine produced significant acid
inhibition 8 to 9 hours after administration. When 13 seriously ill patients with two
or more risk factors (shock, sepsis, respiratory failure, jaundice, renal insufficiency
and peritonitis) were treated with a 50 mg intravenous bolus dose of ranitidine
followed by a continuous infusion of 0.2 mg/kg/hour the number o f‘at risk’ days
when gastric pH was less than 3.5 on three consecutive four-hourly aliquots, was
approximately half that for placebo treated patients.
Furthermore, in respect of both 24 hour acidity and nocturnal acid output,
ranitidine, 150 mg twice daily was superior to cimetidine 200 mg three times daily
and 400 mg at night (P <0.001 and <0.05, respectively).
Ranitidine injection is well tolerated following intravenous administration at
dose levels of up to 100 mg four times daily for ten days. These levels are in excess
of those recommended for normal clinical use.
Treatment of volunteers with ranitidine 150 mg twice daily for 7 days did not
cause bacterial overgrowth in the stomach.
Volunteers treated with ranitidine have reported no significant gastrointestinal
or central nervous system side effects; moreover, pulse rate, blood pressure, electro
cardiogram and electroencephalogram were not significantly affected in man
following ranitidine administration.
In healthy human volunteers and patients, ranitidine did not influence plasma
levels of the following hormones: cortisol, testosterone, estrogens, growth
hormone, follicle stimulating hormone, luteinizing hormone, thyroid stimulating
hormone, aldosterone or gastrin - although like cimetidine, ranitidine reduced
vasopressin output. Treatment for up to 6 weeks with ranitidine 150 mg twice
daily by mouth did not affect the human hypothalamic-pituitary-testicular-ovarian
or -adrenal axes.
At 50 mg intravenously, ranitidine had no effect on prolactin levels. Only at
the 300 mg i.v. dose level was an increase in prolactin secretion, equivalent to that
produced by 200 mg of cimetidine i.v., observed.
At the high dose levels used in the tolerance studies, minor, transient increases
in serum alanine transaminase (ALT/SGPT) and aspartate transaminase
(AST/SGOT) levels were observed in some patients. No other liver function tests
were abnormal for these subjects and the cause and clinical significance of these
findings are unknown.
Laboratory studies have shown that ranitidine has negligible affinity for the
cytochrome P4S0-linked hepatic mixed function oxidase system. In man, ranitidine
treatment has been shown not to impair the metabolism of antipyrine,
aminopyrine, warfarin or diazepam.

PRECAUTIONS
Use in pregnancy and nursing mothers - The safety of Zantac in the treatment
of conditions where a controlled reduction of gastric secretion is required during
pregnancy has not been established. Reproduction studies performed in rats and
rabbits have revealed no evidence of impaired fertility or harm to the fetus due to
Zantac. If the administration of Zantac during pregnancy is considered to be neces
sary, its use requires that the potential benefits be weighed against possible hazards
to the patient and to the fetus. However, therapeutic doses of Zantac administered
to obstetric patients in labour or undergoing caesarean section have been without
adverse effect on labour, delivery, or subsequent neonatal progress.
Ranitidine is secreted in breast milk in lactating mothers but the clinical
significance of this has not been fully evaluated.
Use in impaired renal function - Ranitidine is excreted via the kidney and in
the presence of severe renal impairment, plasma levels of ranitidine are increased
and prolonged. Accordingly, in the presence of severe renal impairment, clinicians
may wish to reduce the oral dose to half of the usual dose taken twice daily, simi
larly it is recommended that ranitidine injection be administered in doses of 25 mg
to patients with renal dysfunction.
Children - Experience with Zantac in children is limited and such use has not been
fully evaluated in clinical studies. It has however been used successfully in children
aged 8-18 years in doses up to 150 mg orally twice daily without adverse effect.

ADVERSE REACTIONS
No serious adverse effects have been reported to date in patients treated with
Zantac. There has been no clinically significant interference with endocrine,
gonadal or liver function, nor has the drug adversely affected the central nervous
system even in elderly patients.
The incidence of adverse events among Zantac-treated patients (8.1%) was very
little greater than that among placebo-treated patients (7.7%). Only five adverse
events, namely, tiredness (0.38%), headache (0.90%), dizziness (0.32%), diarrhea
(0.52%) and skin rashes (0.52%) had a greater incidence in the ranitidine treated
group than in the control group.
A small proportion (1.99%) of patients treated with ranitidine injection experi
enced itching or burning at the injection site. This reaction was mild and usually
subsided within 10-15 minutes.
Headache was experienced by 2.54% of patients receiving ranitidine injection.
The majority of these cases were not thought to be treatment-related. In some in
stances the headache was thought to be due to over-rapid injection of ranitidine,
and did not recur on rechallenge with slow intravenous injection. Similarly, some
patients experienced nausea after rapid injection of the drug, but on subsequent
occasions with slow-intravenous injection, experienced no ill-effects.

OVERDOSAGE
Zantac is very specific in action and accordingly no particular problems are
expected following overdosage with the drug. Symptomatic and supportive therapy
should be given as appropriate. If need be, the drug may be removed from the
plasma by haemodialysis.

DOSAGE AND ADMINISTRATION
Adults: Zantac injection may be given either as a slow (over one minute) intra
venous injection of 50 mg, which may be repeated every six to eight hours; or as an
intravenous infusion at a rate of 25 mg per hour for two hours; the infusion may be
repeated at six to eight hour intervals.
In the prophylaxis of haemorrhage from stress ulceration in seriously ill
patients or the prophylaxis of recurrent haemorrhage in patients bleeding from
peptic ulceration, parenteral administration may be continued until oral feeding
commences. Patients considered to be still at risk may then be treated with Zantac
tablets 150 mg twice daily.
In patients considered to be at risk of developing acid aspiration syndrome
Zantac injection 50 mg may be given intramuscularly or by slow intravenous injec
tion (over one minute) 45-60 minutes before induction of general anaesthesia.
Experience with Zantac in children is limited and it has not been fully eval
uated in clinical studies - see PRECAUTIONS.

AVAILABILITY
Zantac Injection is available as 2mL ampoules each containing 50 mg ranitidine
(as hydrochloride) in 2mL solution for intravenous or intramuscular administra
tion. Packages of 10 ampoules.
Zantac Tablets are available as white film-coated engraved ZANTAC 150 on
one face and GLAXO on the other containing 150 mg ranitidine (as the
hydrochloride), in packs of 28 & 56 tablets.
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INDICATIONS AND CLINICAL USE
Zantac injection is indicated for the treatment of duodenal ulcer, benign gastric
ulcer, post-operative ulcer, reflux esophagitis, Zollinger-Ellison syndrome and
other conditions where reduction of gastric secretion and acid output is desirable.
These include the prophylaxis of gastrointestinal haemorrhage from stress ulcera
tion in seriously ill patients, the prophylaxis of recurrent haemorrhage in patients
with bleeding peptic ulcers and before general anaesthesia in patients considered to
be at risk of acid aspiration (Mendelson’s) syndrome, particularly obstetric patients
during labour.
For appropriate cases Zantac Tablets are also available.

THE BETTER

ANTAGONIST.

CONTRAINDICATIONS
There are no known contraindications to the use of Zantac (Ranitidine).

WARNINGS
Gastric ulcer - Treatment with a histamine H 2-antagonist may mask symptoms
associated with carcinoma of the stomach and therefore may delay diagnosis of the
condition. Accordingly, where gastric ulcer is suspected the possibility of malig
nancy should be excluded before therapy with Zantac is instituted.
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ZOVIRAX'
(ACYCLOVIR SODIUM)
IV INFUSION

dosing regimen. In other instances, renal function improved following increased hydration,
dosage adjustment, or discontinuation of ZOVIRAX therapy.
When dosage adjustments are required they should be based on estimated creatinine
clearance (See DOSAGE AND ADMINISTRATION).
It is not known whether acyclovir is excreted in human milk. Because many drugs are
excreted in human milk, caution should be exercised when ZOVIRAX is administered to a
nursing mother.
All animal studies carried out to date on reproduction and teratology have been negative. ^
However, since animal reproduction studies are not always predictive of human response.
ZOVIRAX should be used during pregnancy only if the physician feels the benefit will outweigh
the possible harm to the fetus.
^ '
There exists no data, at this time, which demonstrates that the use of ZOVIRAX will
prevent transmission of herpes simplex infection to other persons.
Consideration should be given to an alternative treatment regimen if after 5 days of treaty
'
ment there is no expected clinical improvement in the signs and symptoms of the infection.
Strains of herpes simplex virus which are less susceptible to ZOVIRAX have been isolated
from herpes lesions and have also emerged during intravenous treatment with ZOVIRAX.

ADVERSE REACTIONS

(ACYCLOVIR SODIUM)
I.V. INFUSION

The most frequent adverse reactions reported during controlled clinical trials of acyclovir
were inflammation or phlebitis (14%) at the injection site following infiltration of the I.V. fluid,
and rash or hives (4.7%). Ofthe patients receiving placebo, 4.8% experienced the same reactions
(inflammation/phlebitis, rash or itching).
Less frequent adverse reactions were diaphoresis, hematuria, hypotension, headache antf '
nausea, each of which occurred in 1.6% of the patients. Hematuria and nausea were experienced
by placebo recipients at the same frequency. These reactions were observed in severely
immunocompromised patients who often have multisystem diseases unrelated to herpes 4
infections and, therefore, it is difficult to state conclusively that these reactions were caused
by ZOVIRAX therapy.
Additional adverse reactions were reported in uncontrolled trials. The most frequent
A4
adverse reaction was elevated serum creatinine. This occurred in 9.8% of patients, usually
but not always following rapid (less than 10 minutes) intravenous infusion. It is not known
whether this phenomenon is drug related but in view of the fact that the drug is known to
crystallize in urine there exists a possibility that this occurred due to inadequate hydration of
the patients. Less frequent adverse experiences were thrombocytosis (0.4%) and jitters (0.4%) *

ACTIONS

SYMPTOMS AND TREATMENT OF OVERDOSAGE

Now, the first effective anti-herpes therapy is
available in an I.V. infusion form: Indicated for immuno
compromised adults and children with initial or recur
rent mucosal or cutaneous herpes simplex infections
...and for normal patients with severe initial episodes
of herpes simplex infections.
ZOVIRAX

ZOVIRAX (acyclovir), an acyclic nucleoside analog, is a substrate specific for herpesvirusspecified thymidine kinase. It inhibits replication of these viruses. Normal cellular thymidine
kinase does not effectively utilize acyclovir as a substrate. Herpesvirus-specified thymidine
kinase transforms acyclovir to its monophosphate which is then transformed by cellular
enzymes to acyclovir diphosphate and acyclovir triphosphate. Acyclovir triphosphate is both
an inhibitor of, and a substrate for, herpesvirus-specified DNA polymerase. Although the cellular
oc-DNA polymerase in infected cells may also be inhibited by acyclovir triphosphate, this occurs
only at concentrations of acyclovir triphosphate which are higher than those which inhibit the
herpesvirus-specified DNA polymerase. Acyclovir is preferentially taken up and selectively
converted to its active form by herpesvirus-infected cells. Thus, acyclovir has a very much lower
toxic potential for normal uninfected cells because.- 1) less is taken up; 2) less is converted to
the active form; 3) cellular oc-DNA polymerase has a lower affinity for the active form of the drug

INDICATIONS AND CONICAL USE
ZOVIRAX Sterile Powder is indicated for treatment of initial and recurrent mucosal and
cutaneous herpes simplex infections in immunocompromised adults and children. It is also
indicated for severe initial episodes of herpes simplex infections in patients who may not be
immunocompromised. It is not recommended for use in herpes encephalitis or other herpes
group infections all of which are still the subject of ongoing investigations.
The indications are based on the results of a number of double-blind, placebo-controlled
studies which examined changes in virus excretion, total healing of lesions, and relief of pain.
Because of the wide biological variations inherent in herpes simplex infections, the following
summary is presented merely to illustrate the spectrum of responses observed to date. As in
the treatment of any infectious disease, the best response may be expected when the therapy
is begun at the earliest possible moment.
In patients experiencing initial episodes of herpes genitalis, virus excretion had ceased
in 100% of initial lesions within 3 days after the start of a 5-day course of intravenous ZOVIRAX
therapy. Only 20% of placebo recipients were virus-free at this time, as well as when therapy
was discontinued. ZOVIRAX therapy arrested virus excretion in over 90% of immunocompromised
patients with mucocutaneous disease at the end of 7 days of therapy, while only 26% of placebotreated patients were virus negative at the same time.
Because complete re-epithelialization of herpes-disrupted integument necessitates recruit
ment of several complex repair mechanisms, the physician should be aware that the dis
appearance of visible lesions is somewhat variable and will occur later than the cessation of
virus excretion. In spite of these limitations, 100% of ZOVIRAX-treated patients with initial
episodes of herpes genitalis healed within 15 days after initiation of treatment. Only 50% of
placebo recipients were healed at this same interval. The lesions of 61% ofimmunocompromised
patients who received ZOVIRAX were healed within 15 days after the initiation of a 7-day course
of therapy; only 38% of placebo patients had healed their lesions at that point.
Pain associated with herpes infections is highly variable in frequency and intensity. These
clinical studies, however, demonstrated that ZOVIRAX therapy plays a significant role in reduc
tion of pain in cutaneous herpes infections in immunocompromised patients. For example.
61% of ZOVIRAX-treated immunocompromised patients were pain-free by day 10, whereas
44% of placebo-treated patients were pain-free in the same period of time.
Whereas cutaneous lesions associated with herpes simplex infections are often pathogno
monic. Tzanck smears prepared from lesion exudate or scrapings may assist in diagnosis.
Positive cultures for herpes simplex virus offer the only absolute means for confirmation of
the diagnosis.

CONTRAINDICATIONS
ZOVIRAX Sterile Powder is contraindicated for patients who develop hypersensitivity to
the drug.

WARNINGS
ZOVIRAX Sterile Powder should not be administered by any route [i.e. topically (skin or
eye), intramuscularly, orally or subcutaneously] other than by intravenous infusion.

PRECAUTIONS
Precipitation ofZOVIRAX crystals in renal tubules can occur if maximum solubility (1.3 mg/mL
in water) is exceeded. This phenomenon is reflected by a rise in serum creatinine and blood
urea nitrogen and a decrease in creatinine clearance. With sufficient renal tubular compromise,
urine output decreases
Acute increases in serum creatinine and decreased creatinine clearance have been observed
in hum ans receiving ZOVIRAX and: (1) who were poorly hydrated; (2) who were receiving
concomitant nephrotoxic drugs (e.g., amphotericin B, and aminoglycoside antibiotics); (3) who
had pre-existing renal compromise or damage; and (4) in whom the dose was administered
by rapid intravenous injection (less than 10 minutes). Observed alterations in renal function
have been transient, in some instances resolving spontaneously without change in ZOVIRAX
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No acute massive overdosage of the intravenous form has been reported.
Doses administered to humans have been as high as 1200 m g/m 2 (28 mg/kg) three
times daily for up to two weeks. Peak plasma concentrations have reached 80 ng/m L. Possible
evidence of central nervous system (CNS) toxicity (coarse tremors, confusion and agitation)
and/or bone marrow toxicity were seen in four patients at 2100 and 2700 m g/m 2/day. The
CNS side effects resolved upon lowering the dosage or discontinuing ZOVIRAX therapy. Pre- <
cipitation of acyclovir in renal tubules may occur when the solubility (1.3 mg/mL) in the intratubular fluid is exceeded. Precipitation may be avoided or overcome by adequate hydration qL
the patient. Acyclovir is dialyzable. In the event of acute renal failure and anuria, hemodialysis"^
should be initiated until renal function is restored.

DOSAGE AND ADMINISTRATION
CAUTION - RAPID OR BOLUS INTRAVENOUS AND INTRAMUSCULAR OR SUBCUTANEOUS
INJECTION ARE TO BE AVOIDED.
Therapy is recommended for at least 5 days for immunocompetent patients and for at
least 7 days for immunocompromised patients.
i
Adults: 5 mg/kg infused at a constant rate over a 1-hour period, every 8 hours (15 mg/kg/day)
in patients with normal renal function.
Children Under 12 Years: In children under 12 years of age, more accurate dosing can blr
attained by administering 250 m g/m 2 infused at a constant rate over a 1-hour period, every
8 hours (750 m g/m 2/day).
^
Patients with Acute or Chronic Renal Impairment: Use the recommended doses and
*
methods of administration; and adjust the dosing interval as indicated in the following table.
Creatinine Clearance
Dose
Dosing Interval ,
(mL/min/1.73m2)
(mg/kg)
(hours)
>50
5
8
25-50
5
12
j
10-25f
5
24
*
0-1 Of
2.5
24-48
tHemodialysis: For patients who require hemodialysis, the mean plasma half-life of
acyclovir during dialysis is approximately 5 hours, which results in a 60% decrease in plasma*
concentrations following a 6-hour dialysis period. Recommended doses should be administered
every 24-48 hours, and after hemodialysis.
_

PHARMACEUTICAL INFORMATION
Reconstitution
Solutions for Reconstitution

*

Reconstitute as follows:

Sterile Water for Injection
Reconstitution Table
Volume to be
Approximate Available
Approximate Average
Vial Size
Added to Vial
______ Volume______
Concentration
500 mg
10 mL
10 mL
50 mg/mL
SHAKE WELL UNTILDISSOLVED. ASSURE COMPLETE DISSOLUTION BEFORE MEASURING
AND TRANSFERRING EACH INDIVIDUAL DOSE.
Intravenous Infusion: The calculated dose of the reconstituted solution should be removed
and added to an appropriate intravenous solution listed below at a volume selected for ad
ministration during each 1-hour infusion. Infusion concentrations exceeding 10 mg/mL are
4
not recommended. Since the vials do not contain any preservatives any unused portion of
the reconstituted solution should be discarded.
Solutions for I.V. Infusion
5% Dextrose Injection
Ringer's Injection
5% Dextrose and 0.9% Sodium Chloride Injection
Normal Saline Injection
5% Dextrose and 0.2% Sodium Chloride Injection
Lactated Ringer s Injection
Stability o f Solution
Storage: Reconstituted solutions at a concentration of 50 mg/mL should be used within
12 hours if kept at room temperature. Refrigeration may result in the formation of a precipitate
which will redissolve at room temperature.
Once diluted, the admixtures are to be administered within 24 hours of the preparation.
The admixtures are not to be refrigerated.
*Incompatibility: ZOVIRAX should not be added to biologic or colloidal fluids (e.g. blood
products, protein hydrolysates or amino acids, fat emulsions, etc.)

DOSAGE FORMS
Availability: ZOVIRAX is available as sterile powder in 10 mL vials, each containing acyclovir
sodium equivalent to 500 mg of acyclovir.
Storage: ZOVIRAX should be stored at 15°-30°C.
^
Product Monograph available on request.
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^ Unusual Snowmobile Injury of the Penis: a Case Report
Snowmobiles have been responsible for
a variety of characteristic injuries. The
authors report a most unusual injury —
fitegloving of the penis. A 49-year-old
man was thrown against the handlebars
of his machine. The penis was traumatically circumcised, degloved and forced
through the subcutaneous peritoneal tisi sue to exit through a gash in the left
thigh. At operation, the area was debri
efed and irrigated. The penis was easily
returned to its normal position, into the
* intact but detached penile skin which
was then sutured in place.

in a snowmobile accident in which he was
thrown against the handlebars of the machine.
The penis had been traumatically circumcised,
completely degloved, forced into the perineal
subcutaneous tissue and had exited through a

r

Les motoneiges ont etd la cause d'une
variete de blessures caracteristiques. Les
auteurs decrivent une blessure des plus
inhabituelles — I'extraction du penis de
»ja gaine cutanee. Un homme de 49 ans
a ete projete sur le guidon de son vehicule. Sur le coup, le penis a ete circoncis, est sorti de sa gaine cutanee pour
f4netrer dans le tissu perineal sous: cutane et ressortir par une dechirure
dans la cuisse gauche. A i'operation, la
region a ete debridee et irriguee. Le penis
a pu etre facilement replace dans sa
position normale, dans sa gaine cutanee
I intacte mais detachee, laquelle a ete
'
s*Jturee en place.

10- to 12-cm gash in the deep subcutaneous tis
sue of the posteromedial aspect of the left thigh
(Fig. 1). The scrotum and testicles were intact
and uninjured, but the suspensory ligaments
of the penis had been torn. There was a per
sistent priapism. The urethra was uninjured
and a retrograde urethrogram appeared nor
mal. There was urinary retention. The patient
had not sustained any other injuries.
After meticulous debridement and irrigation
with normal saline, the penis was quite easily
pushed from the thigh into the perineum and
into the intact but detached penile skin. A no.
14 French Foley catheter was gently passed into
the bladder without difficulty and the circum
cision was repaired with 4-0 chromic catgut.
The laceration of the left thigh was drained and
repaired (Fig. 2).

Discussion

FIG. 1—Circumcision and complete degloving of penis which exited through laceration
of left thigh.

We believe that there were probably
two injuring forces acting simultaneously:
the force that circumcised, degloved and
forced the penis into the perineum, and
one responsible for the bursting injury of
the thigh, creating a subcutaneous tunnel.
In the presence of priapism, it would

Since the introduction of snowmobiles, a
variety of injuries characteristic of these
’machines have been recognized.1Various
mechanisms have also been reported. To
our knowledge never before has a case of
genital injury been documented. We
report an unusual snowmobile degloving
injury of the penis, with no associated
trauma.
Case Report
A 49-year-old man sustained penile injuries
From the Division o f Urology, Department
p f Surgery, Memorial University o f
Newfoundland, St. John’s, Nfld.
Accepted fo r publication Mar. 19, 1984
Reprint requests to: Dr. H.G. Kiruluta,
Department o f Surgery (Urology), Health
Sciences Centre, St. John's, Nfld. A1B 3 V6

Fig. 2a
Tig- 2b
FIG. 2—(a) Penis pushed back into intact penile skin, (b) Appearance 1 week after operation.
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have been easy for the penis to exit
through the laceration which appeared to
have been the line o f least resistance;
however, we do not know if the penis was
erect at the time o f the injury.
The penis is commonly involved in
accidental injuries such as entrapment of
the foreskin by a zip fastener ,2 trauma

tic amputation 3 and complete or partial
denudation o f its skin .4 Surgical man
agement depends on the type and seve
rity o f the injury, the aim being to pre
serve a functioning penis.
We thank Mrs. C. Breen for her secretarial
assistance.
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Human Bite Injuries of the Hand
-S

The charts of 24 patients admitted to
Victoria Hospital, London, Ontario with
human bite injuries were analysed. Two
clinical groups were found. One group of
patients had evidence of septic arthritis.
They required operative treatment and
experienced complications. The second
group was made up of patients with cel
lulitis who responded to antibiotic ther
apy and had an uncomplicated course.
No resistance to cephalosporins was
found. Patients seen soon after injury
without evidence of joint penetration
should be managed by irrigation and
open management of the wound,
immobilization in a hand dressing, eleva
tion, tetanus prophylaxis, oral administra
tion of a cephalosporin and re
examination within 24 hours. Those who
fail to respond to this treatment should
be admitted to hospital and given antibi
otics intravenously. Clinical evidence of
septic arthritis warrants early operative
incision and drainage combined with
antibiotics given intravenously.
Les dossiers medicaux de 24 patients
regus a I'hopital Victoria de London,
Ontario, a la suite de morsures humaines
ont ete analyses. Deux groupes distincts
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quant au tableau clinique ont ete identi
fies. Le premier manifestait des signes
d’arthrite aigue. Un traitement operatoire
fut necessaire et ils ont eprouves des
complications. Le second etait constitue
de patients qui souffraient de cellulite
repondant aux antibiotiques et qui ont
evolue sans complication. Aucune resis
tance aux cephalosporines na ete constatee. La conduite a tenir devant les
patients qui sont vus tot aprfes la blessure et qui n'ont pas de signe de pene
tration des articulations consiste a irriguer la blessure et a la traiter a ciel
ouvert, puis a immobiliser la main dans
un pansement, a tenir le membre eleve,
a administrer une prophylaxie antitetanique, a donner une c£phalosporine
par voie orale et a reexaminer le blesse
dans les 24 heures. Si le malade ne
repond pas a ce traitement, il devrait
etre hospitalise et recevoir un antibiotique par voie intraveineuse. Des manifes
tations cliniques d'arthrite aigue suppuree justifient une incision immediate avec
drainage suivie d'une antibiotherapie
intraveineuse.

In a recent review o f hand infections
requiring hospitalization, Glass1 reported
that 21 % were due to human bites. In the
preantibiotic era, one third o f patients
suffering human bite injuries whose treat
ment was delayed for longer than 24
hours required amputation .2 Even as late
as 1977, an amputation rate o f 4% was
reported. Osteomyelitis and stiffness were
frequent sequelae o f human injuries.
These facts underscore the need for care
ful management o f all human bite inju
ries to the hand.

Patients

j

The management of all patients admit- 4
ted between 1974 and 1982 to Victoria
Hospital in London, Ontario with a
human bite injury to the hand was
reviewed by examining the hospital, emer* j
gency and outpatient department charts.
Of 24 such patients, 15 returned for *
follow-up. The charts were analysed with
respect to: sex and age, cause, location,
associated conditions, physical findings, ^
leukocyte count, Gram’s staining, culture
and sensitivity, radiologic findings, time
from injury to treatment, emergency and
definitive treatment, and outcome.
♦,
Morbidity was assessed by the duration j
of hospitalization, the duration of outpa- 1
tient follow-up and complications.

Findings
Sex and A ge
There were 23 men and 1 woman, a
much greater preponderance o f men t«
women than the 4 to 1 ratio reported in
the literature.2’5 Fourteen o f the patients
were between 20 and 30 years old.
Cause
In 20 patients a laceration of the hancl
resulted from a blow to an opponent’^
teeth in a fight; in the other 4, the injury
was due to an actual human bite.
*■'*•
Location
Seventeen lacerations were on the right
hand and 10 on the left (Fig. 1). The most
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frequent location was over the dorsum of
the metacarpophalangeal joints.
Associated Conditions
Associated conditions included alco
holism in four cases and diabetes mellitus in one. Diabetes mellitus has been
previously reported1 to be associated
►with a higher amputation rate and inci
dence of infection with gram-negative
v organisms and slower healing.
Physical Findings
Review of the physical findings at the
v- time of admission revealed that swelling,
heat and erythema were always present.
Eleven patients had purulent drainage.
Exquisite pain on passive motion of a
joint, indicative of septic arthritis, was
*present in nine patients. Lymphangitis
was present in only one and lymphadenitis in two. In general, there were two clin
ical groups: those with clinically evident
* septic arthritis (9 patients) and those with
a clinical picture of cellulitis (11 patients).
In the other four patients the physical
i
findings were nonspecific.
Leukocyte Count
*- The leukocyte count was elevated in 8
^of 23 patients, but this did not help to
differentiate between cellulitis and septic
arthritis. The differential count was
abnormal in only three patients.
Gram’s Staining
►-

r

„ Gram’s staining in 19 cases showed that
leukocytes were present in 16, no organ
isms were seen in 8, gram-positive cocci
were present in 10, gram-negative rods in
r 6 and gram-positive rods in 5.

Culture and Sensivitity
On culture, 17 patients had mixed
infections and in 3 others no organisms
were grown after aerobic and anaerobic
incubation. Alpha-hemolytic streptococci
were present in 17 cases, Staphylococcus
epidermidis in 7 and Staphylococcus
aureus in 5. In addition, the gamut of
mouth organism was cultured. In the ser
ies reported by Mann and colleagues,2
there was a 43% incidence of mixed infec
tion and a-hemolytic Streptococcus was
the most frequently cultured organism.
Fifty percent of cases with poor results
were associated with S. aureus infection.
Gram-negative organisms accounted for
30% in their series. In four out of five
cases, the staphylococci in our series were
resistant to penicillin. In cases in which
sensitivities were obtained, there were no
instances of resistance to cephalosporins.
Radiologic Findings
Roentgenograms were available in 18
patients; 12 were normal and the other 6
demonstrated soft-tissue swelling only.
None of the films showed bone or joint
injury or osteomyelitis.
Time from Injury to Treatment
The delay before treatment was classi
fied as follows: early — treatment within
24 hours (13 patients), delayed — treat
ment from 1 to 7 days after injury (10
patients) and late — treatment after 7
days (1 patient). Analysis of the morbidity
by groups demonstrated no difference in
outcome, as reported by others.3
Emergency Treatment
Before referral to the plastic surgery
service, 18 of the patients were treated in

the emergency department, 10 from the
early group, 7 from the delayed group
and 1 from the late group. The treatment
generally consisted of irrigation of the
wound with sterile saline, application of
a bulky hand dressing with a splint, teta
nus prophylaxis and prescription of an
oral antibiotic. It is disturbing to note that
in four cases the wounds were closed by
suturing or application of Steristrips.
Some of these patients lied about the
cause of the injury.
The antibiotics prescribed in the emer
gency department are noted in Table I.
Definitive Treatment
All 24 patients were eventually referred
to the plastic surgery service for definite
treatment. Operations were performed in
11 cases; in 8, incision and drainage of
septic arthritis of the metacarpophalan
geal joints was performed. Two patients
underwent incision and drainage of
lesions of the thumb; one had septic
arthritis and the other a paronychia.
Another had debridement of an abscess
on the dorsum of the hand and subse
quently underwent skin grafting. All
wounds were left open. Postoperatively,
the management consisted of elevation,
splinting and dressing.
All patients were given antibiotics
intravenously. Cloxacillin and ampicillin
in combination were the antibiotics
adm inistered most frequently (14
patients), for an average of 2.6 days.
Other antibiotics administered included
Keflin alone and combined with ampicil
lin, penicillin G alone and combined with
cloxacillin, cloxacillin and gentamicin,
and floxacillin.
Review of the culture and sensitivity
results revealed that in five cases the
organism cultured was resistant to the
antibiotic prescribed. In spite of a failure
to change the antibiotic, the infection
resolved in all cases, suggesting that
antibiotic therapy itself does not neces-

Table 1-Antibiotics Prescribed in the
Emergency Department (n = 18)*
No. of
Antibiotic
patients
Cloxacillin
11t
Sensitive
6
Sensitivity not available
3
Resistant to Eikenella corrodens
1
Cloxacillin + amoxicillin
2
Sensitive
1
Culture negative
1
Penicillin
2
Sensitive
1
Resistant
1
Unknown
1
*2 patients did not receive antibiotics.
t1 patient did not comply with treatment.
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Thrombostat Prescribing Information
(Thrombin, USP) Bovine Origin—
formerly: Thrombin, Topical

sarily determine the outcome. In five
other cases, two antibiotics were
INDICATIONS: Thrombostat is indicated as an
administered in combination where one
aid in hemostasis wherever oozing blood from
would have been sufficient. In all cases,
capillaries and small venules is
j
oral
antibiotics were prescribed after the
accessible.
I parenteral antibiotics were discontinued.
In various types of surgery,
However, duration of therapy could not
solutions of Thrombostat may /
be used in conjunction with
be assessed because of incomplete
absorbable gelatin sponge
[ records.
USP for hemostasis,
Outcome was evaluated by the duration
CONTRAINDICATION:
J of hospitalization, the duration of outpaThrombostat is contra
j tient follow-up and the number of com
indicated in persons
plications. The average hospital stay was
known
4.8 days. For patients who did not require
to be
sensitive
operation (those with cellulitis), the aver
to any of
age stay was 3.9 days. The 11 patients
its components and/or to material of bovine origin.
who required operation (9 with septic
WARNING: Because of its action in the
arthritis) had an average hospitalization
clotting mechanism, Thrombostat must not be
of 5.9 days. The difference is statistically
injected or otherwise allowed to enter large blood
significant (p < 0.05, unpaired Student’s
vessels. Extensive intra-vascular clotting and even
/-test). The average duration of outpatient
death may result. Thrombostat is an antigenic
substance and has caused sensitivity and allergic
follow-up was 12.4 days. For those who
reactions when injected into animals.
did not undergo operation, it was 9.8 days
PRECAUTIONS: Consult the absorbable gelatin
and for those who did, it was 19.4 days.
sponge product labelling for complete informa
This difference also was significant (p <
tion for use prior to utilizing the Thrombostat
0.01). Thus, those who required opera
saturated-sponge procedure.
tion had a longer duration of hospitali
ADVERSE REACTIONS: An allergic type reaction
zation and a longer duration of outpatient
following the use of thrombin for treatment of
follow-up. They also suffered the most
epistaxis has been reported. Febrile reactions
have also been observed fdllowing the use of
complications: five out of seven. Joint
thrombin in certain surgical procedures but no
stiffness accounted for six of the compli
cause-effect relationship has
cations and skin loss requiring skin graft
been established.
ing accounted for one.
Discussion
DOSAGE AND
ADMINISTRATION:
Solutions of Thrombostat
may be prepared in sterile
distilled water or isotonic
saline. The intended use determines the strength
of the solution to prepare. For general use in
plastic surgery, dental extractions, skin grafting,
neurosurgery, etc. solutions containing approx
imately 100 units per mL are frequently used. For
this, 10 mL of diluent added to the 1000 unit
package (Bio 2077) is suitable. Where bleeding is
profuse, as from cut surfaces of liver and spleen,
concentrations as high as 1000 to 2000 units per
mL may be required. For this the 5000 unit vial
(Bio 2073) dissolved in 5 mL or 2.5 mL respectively
of the diluent supplied in the package is convenient.
Intermediate strengths to suit the needs of the
case may be prepared by selecting the proper
strength package and dissolving the contents in
an appropriate volume of diluent. In many situations,
it may be advantageous to use Thrombostat in
dry form on oozing
surfaces.
Caution: Solutions
should be used the day
they are prepared. If
several hours are to elapse,
the solution should be refrigerated,
preferably frozen, and not used
. after 48 hours.
Complete dosage and administration for topical
application of Thrombostat is available upon request.
Supplied: 10mL vials of 1000 N.I.H. units; packages
containing a 5,000 N.I.H. vial and a 5 mL vial of
diluent; 10 mL vials of 10,000 N.I.H. units.
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In previous series,2'5 human bite inju
ries from blows have resulted in a higher
incidence of complications because of
delay in treatment and penetration into
deeper structures such as joints.
This study demonstrates that the
patients who had clinical findings of sep
tic arthritis (exquisite pain on passive
m otion) were hospitalized longer,
required longer outpatient follow-up and
had more complications than patients
who did not. Laboratory investigations
such as leukocyte and differential counts
and roentgenographic examination did
j not help to decide whether an operation
was required.
Separate analysis of outcome for
patients in early, delayed and late treat
ment groups failed to show any differ
ence. There was no difference in outcome
in those patients whose wounds were ini
tially closed in the emergency department.
It is possible that the small size of this
group (four patients) was responsible for
this.
In reviewing the culture and sensitiv
ity results, it was apparent that
cephalosporins covered the spectrum of
organisms most completely. There were
no organisms resistant to cephalosporins.
Bilos and associates6 have suggested that
cephalosporins be given as the initial
I antibiotic in human bite injuries because

they were effective against the commonest
organisms in their series: a- and 0hemolytic streptococci, S. aureus and _
Eikenella corrodens.
*
On the basis of this study and a litera-**
ture review, human bite injuries seen soon
after injury (within 24 hours) may be *
treated on an outpatient basis if there is
no clinical evidence of septic arthritis. The
wound should be copiously irrigated with
sterile saline and left open, a swab of the ■>
wound should be obtained for culture and
sensitivity, tetanus prophylaxis should be
administered according to the recommen/
dations of the American College of Sur
geons and a bulky hand dressing with a ^
splint should be applied to rest the hand.
The patient should be advised to elevate -»
the hand above heart level (a sling is not
recommended as it keeps the hand depen- **
dent) and be given antibiotics orally. The
preferred antibiotic is Keflex (500 mg
every 6 hours). The patient should be re- >
examined in 24 hours, preferably by the '
physician who examined the patient ini- „ I
tiaily. If there is no improvement, the
patient should be admitted to hospital and * *
given antibiotics intravenously and should
be followed closely. A patient who shows 4
clinical evidence of septic arthritis at any A
time following a human bite injury to the A
hand requires immediate incision and
drainage of the infected joint under con
trolled conditions in the operating room.
Postoperatively, parenteral antibiotics,
dressing changes, rest and elevation are
needed. In spite of early, aggressive
management, patients who have septic
arthritis will have the most morbidity.
^
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Improved Neurologic Function following Repair of Type I
Aortic Dissection with an Intraluminal Prosthesis
~
t-

|

Repair of type I dissection of the aorta
v- by suturing is often complicated by
intraoperative and postoperative bleed* T ing. To avoid these complications, the
_
authors use a sutureless ringed intralumi
nal prosthesis. They describe the case of
y- a 62-year-old woman who had paralysis
r of the lower extremities with acute type
I dissection of the aorta. Emergency sur
gical intervention 14 hours after onset of
►^ symptoms and repair with the intralumi
nal graft resulted in minimal aortic
insufficiency and almost complete functional recovery.
* An aggressive surgical approach to
patients with profound neurologic
deficits due to aortic dissection is justi* fied. Repair with the sutureless intralumi
nal prosthesis is simple and safe and
may allow recovery of neurologic
function.
La reparation par suture des dissections
f de I'aorte de type I est souvent compliquee par des h6morragies per- et postoperatoires. Afin d'eviter ces complicay^tions, les auteurs ont utilise une prothese
intraluminale annulaire sans suture. Ils
'
decrivent le cas d'une femme de 62 ans
souffrant de paralysie des extrem es
» inferieures ainsi que d'une dissection
aigue de I'aorte de type I. Une operation
r d'urgence pratiquee 14 heures apres le
fr d6but des symptomes, avec reparation a
I'aide du greffon intraluminale. a laisse
une insuffisance aortique minimale et
donne une guerison fonctionnelle quasi
» complete.
Une approche chirurgicale agressive
*■est justifiee chez les patients qui presen. tent un deficit neurologique profond du a
f
.
une dissection de I'aorte. La reparation a
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I'aide d'une prothese intraluminale sans
suture est simple, sure et peut permettre
de recouvrir la fonction neurologique.

The sutureless ringed intraluminal
prosthesis1,2 is now our method o f choice
for the management o f type I dissection3
of the aorta. The technique is simple
and avoids the complications o f suturing
friable tissue, nam ely, intra- and
postoperative bleeding. In most cases the
aortic valve can be resuspended and
preserved. We recently operated upon a
patient who had complete paralysis of the
lower extremities due to type I dissection.
Because the prognosis for functional
recovery was poor, there was considera
ble discussion about proceeding with

FIG. 1—Angiogram demonstrates type I dis
section of aorta.

operation. However, the patient made a
remarkable neurologic recovery and 3 !A
years after operation was leading an ac
tive life.
C ase R eport

A 62-year-old woman had sudden onset of
pain in the middle of her back with weakness
of the lower extremities. Her symptoms
progressed and she became unable to move her
legs or feet. Because of a history of breast car
cinoma 10 years previously, it was initially
thought that her symptoms might be due to
spread of the disease. A myelogram, however,
appeared normal. On admission to hospital,
the blood pressure was 60/30 mm Hg and the
heart rate was 45 beats/min. Dopamine was
infused intravenously in the emergency room;
a systolic murmur was heard over the left ster
nal border as her blood pressure increased to
90/50 mm Hg. The pedal and brachial pulses
were normal and a carotid bruit was heard.
Neurologic examination revealed flaccid
paralysis of the lower extremities with
decreased sensation and no reflex activity; the
plantar response was absent. The spinal fluid
glucose level was 4.6 mmol/L (normal 2.2 to
3.9 mmol/L) but there was no other abnormal
ity. A chest roentgenogram revealed unfold
ing of the aorta. The aortogram (Fig. 1)
showed type I dissection with minimal aortic
insufficiency.
Operation was carried out 14 hours after the
onset of symptoms. The dissection was found
to extend to the right femoral artery, which was
cannulated. After sternotomy a single double
stage venous cannula was inserted into the right
atrium . C ardiopulm onary bypass was
instituted at normothermia. The aorta was then
cross-clamped and cardioplegic arrest was
induced. After longitudinal aortotomy, the
aortic valve was resuspended at the commis
sures with pledgetted sutures. The dissection

Table l-Sum m aty of Neurologic Findings after Operation_______________
Time after operation
2d
3 wk
8 mo
14 mo
L
R
L
L
R
R
L
R
Test
4
4
2
3+
2
3
1-2
1-2
Hip flexion
4
4
3
2
2
1
1
1
Quadriceps strength
2
2
3
2
2
2
1
1
Hamstring strength
2
3
2
2
3
3
1
1
Plantar flexion
?
3
1
3
3
0
1
1
Dorsiflexion
R - right, L - left.
Grading is from 0 (no recovery) to 5 (full recovery).
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was repaired with a 26-mm intraluminal graft
(USCI, Billerica, Mass.). The cross-clamp time
was 19 minutes and the total pump time was
36 minutes. Postoperatively the patient did
well. The cardiovascular findings remained
unchanged and there was no evidence o f gross
aortic insufficiency. Initially, the neurologic
examination revealed absent deep tendon
reflexes, absent motor activity below T12 to
L I, complete sensory loss below T12 and an
initial expressive dysphasia that resolved within
6 hours. Two days postoperatively she had
return of the ankle jerk on the right and full
return of sensation o f deep pain but no fine
sensation below T12. The summary o f her neu
rologic status postoperatively is shown in Table
I. Three and a half years after operation she
can walk and carry out full household activi
ties. She has decreased sensation to pinprick
below LI but has normal light touch, vibra
tion and proprioceptive sensation. She is con
stipated but is continent. She voids using
Crede’s method and has had several urinary
tract infections that required treatment with
antibiotics. There was no evidence o f heart
failure or increase in aortic insufficiency at 3 'h
years.

Discussion
Aortic replacement with a cloth graft
was first reported in 19553 for the treat
ment of type I dissection of the aorta. A
new method has recently been introduced

that allows repair by insertion of a suture
less ring prosthesis into the true lumen of
the ascending aorta.1'2 In this manner,
bleeding is minimized and the native aor
tic valve is preserved. We favour this
method of treatment for all types of aor
tic dissection because of its simplicity and
excellent short-term results in our hands
and favourable long-term follow-up of
these patients reported by others.4
There have been no reports in the liter
ature dealing with neurologic improve
ment in the case of type I dissection
treated by the intraluminal prosthesis.
One could question whether surgery is
justified in the face of profound neuro
logic deficits. In addition, in our patient,
14 hours had elapsed between the onset
of symptoms and the time of diagnosis
and surgical treatment. It was postulated
that the spinal cord injury was due to dis
ruption of the blood supply by the dis
section and that the chances of recovery
were negligible. We also believed that
operation was indicated only because the
m ortality in untreated patients is
extremely high.
We can only speculate as to why the
patient’s neurologic condition improved
after operation; perhaps it was because
of the development of collateral circula
tion. More likely, however, blood flow to

the spinal cord was restored through the
true lumen of the aorta, albeit 14 hours
after the onset of paralysis.
^ ~
From this unusual case, we advise an
aggressive approach to the treatment of
patients with type I dissection, regardless
of neurologic sequelae. Because the '*■
procedure is simple, insertion of the
sutureless ringed prosthesis appears to be *
the technique of choice. Functional recov
ery is possible, despite profound neuro-'
logic abnormalities and delay in diagno- y,
sis and treatment.
*
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NOTICES

continued from page 618

Stereotactic and
Functional Neurosurgery

PUBLICATIONS AVAILABLE FROM CMA

Report of the Task Force on Allocation of
Health Care Resources, chaired by Joan
Watson ($15) and Woods Gordon Report on
impact of demographic change on the health
care system ($20). Enclose cheque or money
order. Five or more copies of the task force
report will be $15 for the first copy, $5 any
additional copies.
Write to:
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REPORTS
Canadian Medical Association
PO Box 8650
Ottawa, ON
K1G 0G8

*-

The 9th meeting of the World Society for
Stereotactic and Functional Neurosurgery
will be held July 4-7, 1985 at the Chelsea ,
Hotel and the University of Toronto,
Toronto, Ont. It will be immediately fol- -<
lowed by the International Congress of^
Neurological Surgery.
i
For further information please write
,
Mrs. Rae Ryan, Administrative Coordi
nator, Division of Neurosurgery, Eaton r
Building North 7-221, Toronto General
Hospital, 101 College St., Toronto, Ont. ->
M5G 1L7 or call (416) 595-3443.
^

International Congress on
Craniofacial Anomalies

j!
■f

The fifth international congress on cleft
palate and related craniofacial anomalies -* j
will take place in Monte Carlo Sept. „
2-7, 1985 at the Congress Center. The "
congress chairman is Dr. Rene Malek.
This important meeting will be of parti\
cular interest to plastic, dental pediatric 4 and maxillofacial surgeons, to orthodon||
tists, otorhinolaryngologists and speech v
pathologists, and all others working in
j
this field. The deadline for the submis- * *"
sion of abstracts is Nov. 15, 1984. For
further information contact Dr. Rene
Malek, 6, rue Erlanger, 75016 Paris,
France or SOCFI, 14, rue Mandar, 75002 *'
Paris, France.
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'CORONARY ARTERY SURGERY: APPLICATION OF NEW TECHNOL
OGIES. Arthur J. Roberts. 475 pp. Illust.
Year Book Medical Publishers, Inc.,
Chicago, 1983. $71.25 (US). ISBN
0-8151-7302-2.

^.This text summarizes technologic advances in
the investigation of patients with cardiac dispease. The emphasis is on noninvasive tech
niques. Although the title gives the impression
i~ that the book contains a great deal about
cardiac surgery itself, this is not the case.
V-f a t h e r , it is a concise, well-written review of
current technology, such as perfusion scinti
g rap h y , computerized transmission tom ogra
phy and digital subtraction angiography. A few
*. chapters deal with cardiac surgery itself, such
as the one by Wilkinson and associates on
anesthesia for patients who undergo cardiac
surgery and the chapter by Roberts on
-^myocardial protection. The contribution of
|
leading experts in the field is evident in each
chapter, where the different investigative tech
\
niques for the patient with heart disease are
^summarized.
This book is worth reading and should be
,* in libraries of institutions where cardiac
patients are being investigated. The cardiac sur
geon will find little in it to aid him with tech
niques in the operating room but will gain a
better understanding of preoperative, nonin'vasive methods that are commonly used.

BOOK REVIEWS

surgery of benign strictures, the treatment of
carcinoma of the main hepatic duct and
postoperative jaundice, and will find them
informative. Fewer will be interested in liver
preservation and orthotopic liver grafting and
the detailed and well-illustrated final chapter
on primary tumours and tumour-like condi
tions of the liver.
The book is well illustrated, with pictures
taking up more space than words. It is not
overloaded with detail about nonoperative
aspects of liver surgery, nor is it concerned with
presenting alternative views from the literature.
As a result, it is quick and easy to read and
all general surgeons will have some interest in
most of the chapters. As the editor states, the
book is an anthology rather than a comprehen
sive text of liver surgery.
J.H . D u f f , m d , fr c s [C]
Department of Surgery,
University Hospital,
London, Ont.
N6A 5A5

NONCARDIAC SURGERY IN THE
CARDIAC PATIENT. Assessment and
Management. Edited by Stephen P.
Glasser. 402 pp. Illust. Futura Publishing
Company, Mount Kisco, NY, 1983. $49.50
(US). ISBN 0-87993-183-3.

’'T om a s A . S a l e r n o , m d , fr c sic ]
y Head, Division of Cardiovascular Surgery,
k St. Michael’s Hospital,
Toronto, Ont.
M5B 1W8
%•

LIVER SURGERY. Roy Y. Caine. 288 pp.
Illust. Piccin Medical Books, Padua, Italy,
>Jf.
1983. Price not stated. ISBN 88-212-0743-9.
’

t

This multiauthored book contains illustrated
descriptions of operations on the liver. Proce
dures for the treatment of portal hypertension
are excluded. The authors present their per
sonal approaches to specific liver operations
and, thus, readers may disagree with some of
* their policies. Even the editor, Professor Caine,
differs with the authors of the chapter on liver
trauma in regard to the use of packing — Mad
ding and Kennedy condemn the use of pack
ing whereas Caine believes that there is a
definite place for it and that good results have
been achieved under certain circumstances. The
book would be improved by similar editorial
comments at the end of each chapter, since
there is room for disagreement in such areas
as the use of U tubes, the treatment of bileduct strictures and the management of liver
cysts.
* Most general surgeons will be interested in
the chapters on liver trauma, biliary atresia,

Assessing cardiac patients for noncardiac sur
gery can be difficult. Although several articles
have been published in different journals, text
books on this subject are few. This book
attempts to fill the gap. It is directed towards
the surgeon, internist, cardiologist and
anesthetist looking after such patients.
The book is divided into three major sec
tions. The first is an overview o f the physio
logic response to surgery, the effect of anesthe
sia on myocardial function and the cardiac
medications that might be used. The second
section gives a broad overview of a variety of
noninvasive and invasive investigations that
may be used in the preoperative assessment of
such patients. The third section involves the
perioperative management of patients in
specific disease categories.
The first section is quite brief. The informa
tion provided on anesthetics and cardiac medi
cations represents the bare minimum. These
chapters cannot replace the standard texts on
their respective subjects. I found the chapters
on exercise testing and invasive testing to be
the highlights of the second section, especially
with respect to risk assessment. The one on
invasive testing gives state-of-the-art informa
tion on the contribution of coexisting coronary
artery disease to the risk of carotid, aortic and
peripheral vascular surgery. The third section
includes chapters on the elderly patient, the

pregnant patient and on specific cardiac con
ditions. The chapter on cardiac arrhythmias is
superficial and insufficient for the cardiologist
dealing with such problems. The rest of the sec
tion, for the most part, is sufficiently detailed
and quite useful.
I found this textbook to be quite helpful in
clinical practice. It is well referenced and there
are excellent tables throughout the text that
summarize the world literature. I think this
textbook should be on the shelf of any inter
nist, cardiologist or anesthetist involved with
the perioperative management o f cardiac
patients. It is complete without being verbose
and has only minor flaws.
J am es E. C a l v in , m d , fr c pic j
University of Ottawa
Heart Institute,
Ottawa Civic Hospital,
1053 Carling Ave.,
Ottawa, Ont.
K1Y 4E9

PAGING DOCTORS. MESSAGES FROM A
MEDICAL JOURNALIST. David Woods.
179 pp. Epigram Publishing, PO Box 6044,
Station J, Ottawa, Ont., 1984. $20. ISBN
0-9691765-0-3.
Few of the books reviewed in these pages lend
themselves to curling up with — by fireplace
or in bed. Most require a desk, a pen and notepaper and the upright posture. David W oods’s
book can be read in any position. He has put
together a collection of his columns, interviews
and articles on a variety o f topics — literature,
politics, the economy, defence o f patients
(when appropriate), defence of doctors (when
appropriate) and, above all, defence of the
English language (always appropriate). He is
the advocate not only of clear thinking, but of
clear presentation, the enemy o f befuddlement
by obscuration. He quotes Orwell in one of his
essays: “ Directness, simplicity, sincerity, logic,
humanness and humour are the principal ingre
dients for clear communication” . All o f these
are embodied in his own writings. Add a nice
turn of phrase, apt use o f just the right word
and you have a small gem. Not all the pieces
preach good communication directly, although
many do. Some give hints on running an office
practice, others concern the history o f medi
cine, medical ethics, medical publication and
much more. But in every instance, the clarity
of the writing comes through and the lessons
are learned without pain.
Norman Cousins, a literary editor who is on
the medical faculty of the University of Califor
nia at Los Angeles, is the subject of an inter
view reported in the book. A professor in the
program of medicine, law and human values,
he teaches courses in language and communi
cation. It would be super if David Woods were
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on the faculty of one of our own medical
schools to teach communication skills. Mean
while, read the book — you’ll find it a pleasure.

J oseph L. Shugar , md , frcs[C]
Senior Associate Editor

SI UMTS. A Practical Guide for Health
Professionals. M .J. McQueen. 204 pp.
Dlust. Simole Consultants Ltd., Burlington,
Ont., 1982. $8, paperbound.
This pocket-sized book, which contains over
200 conversion tables, is a practical reference
for every physician who wishes assistance in
converting imperial measurements and stan
dard metric units into SI units. In the introduc
tion, McQueen describes the SI system, the
base and the derived units. He outlines the mul
tiples and submultiples, the accepted abbrevi
ations and how they should be used.
Following the introduction are several short
chapters that cover areas of special interest.
One chapter deals with the pharmacy and the
nomenclatures of drugs followed by informa
tion about the aqueous fluids available for
either oral or intravenous administration, with
their contents in standard terms and molar
terms. Diabetes and ionizing radiation are two
areas needing special attention and both are
treated carefully and clearly. Hematology and
clinical chemistry receive special attention
because of particular problems that arise when
using the new terminology.
This manual will be a source of reference for
some time to come since its tables convert
figures from the standard metric system into
the SI system. It provides the means whereby
this may be done easily and simply. All of us
will learn some new terms that are generally
useful.

C. Barber M ueller , md , facs, frcs[C]
Coeditor

SURGICAL ONCOLOGY. Edited by Edward
M. Copeland III. 723 pp. Illust. John Wiley
& Sons, Inc., Somerset, NY, 1983. $58.95
(US). ISBN 0-471-07997-9.
This collection of individually authored chap
ters, each dealing with a separate organ sys
tem, runs into a problem common with all such
anthologies — there is no consistency in the
approach to the subject matter. Some chapters,
especially those on malignant tumours o f the
head and neck, seem well balanced and cover
the material adequately. The best chapter deals
with the salivary gland; it defines the problem
well, presents some of the biologic and patho
logic aspects of the disease and gives a worth
while discussion of surgery and combined
modality treatm ent. The section on ovarian
cancer presents good background data on anal
ysis of staging and grading.
Unfortunately, many chapters are brief and
superficial. Some are too didactic and fail to
present a broad or fundamental look at the
problem; they are more like long summaries
prepared for student notebooks. The section
on breast cancer appears to have been written
20 years ago with a few small paragraphs
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tacked on to give it some currency. The basic
concepts are out of date, with no apparent
justification for the lines of thought, little or
no presentation of alternative ideas and no dis
cussion of current controversies. An unin
formed reader o f this chapter would be una
ware that the majority of the surgical world
has different ideas from those presented here.
On the other hand, some chapters give a
strong cross-section of the topic, with empha
sis on a multidisciplinary approach and good
discussions of secondary issues. The chapter
on apudomas is an example of a well-balanced
contribution with good discussion of patho
physiology and surgical principles. Regretta
bly, the chapters on the more common diseases
such as breast and colonic cancer do not share
this depth of information.
One would expect a book aimed at a
specialty group to raise issues of importance
and discuss them adequately, even if some
issues remain unresolved. But it appears that
controversies and uncertainties in the surgical
world are less important to most presenters in

this book. Rather, they have presented a ser
ies of instructions with an approach resembling
that of a cookbook. While this idea provide^ t~
guidelines for people entering a specialty, i r
fails to provide them with the view that science^'
is a process, not just a collection of facts.
The title suggests that this book is aimed at -J
specialists or trainees in surgical oncology. It
straddles the line between a standard surgical • *
text and a specialty book. True, there is m ore'
information here than appears for cancerrelated subjects in a standard surgical textT I
however, this book does not approach enough*,
of the real issues in current surgical oncology
to make it of much use to anyone wishing to
acquire some expertise on the topic.
j

-*

Richard G. M argolese, md, frcsic]
r

Associate Director,
McGill Cancer Centre,
McGill University,
Montreal, PQ
H3G 1Y6

—
*

SESAP IV Critique
ITEM 316
Children with congenital diaphragmatic hernia can do well if the pulmonary
vasculature is normal. In many, however, the pulmonary microvasculature has
numerous characteristics o f a persistent fetal circulation. The high resistance
to flow through the pulmonary vascular bed causes the persistent high mortal
ity (still about 50%) in these patients. Increased intra-abdominal pressure, per
sistent patent ductus arteriosus, failure o f the collapsed lung to expand, and
mediastinal shift with impaired venous return can cause trouble in specific pa
tients, but the underlying abnormality in the pulmonary vasculature is the main
cause of failure of treatment. The persistent patent ductus may actually help
some children by allowing adequate systemic perfusion despite the high
resistance in the lungs. The collapsed lung rarely expands acutely to normal
size. Drugs and procedures to lower the resistance to flow in these patients are
being sought. The success of prolonged partial bypass with a membrane oxy
genator in a few patients indicates that this lethal vascular lesion is probably
reversible in a few days if life can be sustained in the interim.

Reference

316/1.

Shochat SJ, Naeye RL, Ford W DA, et al: Congenital diaphragmatic
hernia: New concept in management. Ann Surg 190:332-341, 1979
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PIPRACIL

lepcillin sodium

p«ral Antibiotic for Intravenous and Intramuscular Use
TflONS AND CLINICAL USES: Treatment of serious infections caused by susceptible strains of the designated
usms in the conditions listed beiow.
!n!a-aMominal Infections including hepatobiliary and surgical infections caused by Escherichia coli, Pseudo>s as*rginosa, enterococci. Clostridium sp., anaerobic cocci, and Bacteroides sp., including B fragilis
Urinary Tract Infections (complicated and uncomplicated) caused by Escherichia coli, Klebsiella sp., Pseudomonas
pnosa, Proteus mirabilis and enterococci. Also uncomplicated urethritis caused by Neisseria gonorrhoeae
aynectlogical Infections including endometritis and pelvic inflammatory disease caused by Bacteroides sp
Jing B, fragilis, anaerobic cocci, Neisseria gonorrhoeae, and enterococci (Streptococcus faecalis)
Sepfjwnla caused by Escherichia coli, Klebsiella sp., Serratia sp., Proteus mirabilis, S. pneumoniae enterococci
tomonas aeruginosa, Bacteroides sp., and anaerobic cocci.
Lower Respiratory Tract Infections caused by Escherichia coli, Klebsiella sp., Enterobacter sp.. Pseudomonas
jmoja, Serratia sp., Haemophilus influenzae. Bacteroides species and anaerobic cocci Although improvement
Jen noted in patients with cystic fibrosis, lasting bacterial eradication may not be achieved
ikiri and Skin Structure Infections caused by Escherichia coli, Klebsiella sp., Serratia sp., Acinetobacter sp
tbacier sp.. Pseudomonas aeruginosa, indole-positive Proteus sp., Proteus mirabilis, Bacteroides sp including
jibs, anaerobic cocci and enterococci.
•jjj®
Jj ' nl Infections caused by Pseudomonas aeruginosa, enterococci, Bacteroides sp., and anaerobic cocci
'IPRACiL* is useful for the treatment of mixed infections and presumptive therapy prior to the identification
causative organisms; infections produced by organisms resistant to other penicillins, some aminoglycosides
epha^sporins; and infections at various sites caused by streptococcus species including Group A beta-hemoitreptococcus and Streptococcus pneumoniae.
IPRACIL* may be administered as single drug therapy in some situations where normally two antibiotics
i e employed. In vitro synergism has been shown between Piperacillin and some aminoglycosides in some
Tal strains PIPRACIL* has been used clinically with aminoglycosides, especially in patients with impaired host
ces. Both drugs were used in full therapeutic doses.
iPftACIL" can be used safely in combination with a penicillinase-resistant penicillin, e.g. oxacillin in mixed
ons when beta-lactamase-positive Staphyloccus aureus is isolated along with piperacillin-susceptible
sms. It may be administered concomitantly with a cephalosporin, provided that an additive or synergistic
cte rijl action of the two antibiotics is ascertained through in vitro tests. Based on in vitro data cefoxitin should
given with piperacillin when Pseudomonas infections are suspected or confirmed
.ecause PIPRACIL* is excreted not only renally, but also by the biliary route, it can be used in patients with
ibihbiy infections, or severely restricted kidney function, and in patients who have had nephrotoxic reactions
tr drugs, with appropriate adjustment of dosage (See DOSAGE).
ppropriate cultures should be made for susceptibility testing before initiating therapy and therapy adjusted
opriate, once the results are known.
(INDICATIONS: A history of allergic reactions to any of the penicillins and/or cephalosporins.
.165: Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients
;ig tlferapy with pencillins. These reactions are more apt to occur in persons with a history of sensitivity to
a allergens.
oss-sensitivity of patients to penicillins and cephalosporins has been reported. Before initiating therapy with
ILT careful inquiry should be made concerning previous hypersensitivity reactions to penicillins cephalospod other allergens.
in anergic reaction occurs, the antibiotic should be discontinued
RIOUS ANAPHYLACTOID REACTIONS REQUIRE IMMEDIATE EMERGENCY TREATMENT WITH EPINEPHRINE
N. INTRAVENOUS STEROIDS, AIRWAY MANAGEMENT, INCLUDING INTUBATION, SHOULD ALSO BE ADMINISAarntLEoSARY.
ITIONS: Bleeding manifestations have occurred in some patients receiving beta-lactam antibiotics including
■illin. These reactions have sometimes been associated with abnormalities of coagulation tests such as
I time, platelet aggregation and prothrombin time and are more likely to occur in patients with renal failure
bleeding manifestations or significant leukopenia occur, PIPRACIL* should be discontinued and appropriate
t instituted.
[e possibility of the emergence of resistant organisms and the development of superinfections should be
mind, particularly during prolonged treatment.
w ithother penicillins, patients may experience neuromuscular excitability or convulsions if higher than
nended doses are given intravenously,
isage adjustment should be made in renal insufficiency.
3RACSl * is a monosodium compound containing 1.98 milliequivalents (45.5 mg) of Na+per gram based on
itent which includes the U.S.P. allowed average. The calculated value, based on molecular weight is 1.85
(42.55 mg.). Periodic electrolyte determinations should be made in patients with low potassium reserves
possibility of hypokalemia should be kept in mind with patients who have potentially low potassium
s, receiving cytotoxic therapy or diuretics. Electrolyte and cardiac status should also be monitored during
.ed-treatment in patients with impaired cardiac function.
or totfeatm ent, patients with gonorrhea should also be evaluated for syphilis. Specimens for darkfield
ation should be obtained from patients with any suspected primary lesions, and serologic tests should be
bed. In all cases where concomitant syphilis is suspected, monthly serological tests should be made for a
m o f * months.
e use of some penicillins (ampicillin, amoxicillin) has been associated with morbilliform rashes in some
f r > rtious mononucleosis. PIPRACIL* should be used with caution in the treatment of patients with infecononucleosis.
iractions:The mixing of PIPRACIL* with an aminoglycoside in vitro can result in substantial inactivation of the
iy cosides.
iring Pregancy or Lactation: Safety of PIPRACIL* use in pregnant women has not been determined. Because
eproduction studies are not always predictive of human response, this drug should be used during pregnancy
learlyyneeded. It has been found to cross the placenta in rats. Caution should be exercised when PIPRACIL*
listered to nursing mothers. It is excreted in low concentrations in milk.
Use: Dosages for children under the age of 12 have not been established.
REASONS: PIPRACIL* is generally well tolerated. The most common adverse reactions have been local in
ollowing intravenous or intramuscular injection. The following adverse reactions may occur:
al Reactions - In clinical trials thrombophlebitis was noted in 3.8% of patients. Pain, erythema, and/or indurahe Injection site in 1.9% of patients. Less frequent reactions: ecchymosis, deep vein thrombosis and
nas.

lersensitivity Reactions-Rash was noted in 1.9% of patients. Drug fever 2.1%. Less frequent findings: pruitis,
r eruptions, positive Coombs tests.
trolntestinal- Diarrhea and loose stools were noted in 2.8% of patients. Less frequent reactions: vomiting,
bloody diarrhea.
itic-Increases in liver enzymes (LDH, SGOT, SGPT), hyperbilirubinemia. Rarely, cholestatic hepatitis.
•I-Elevations of creatinine or BUN.
tral Nervous System - Headache, dizziness, fatigue.
iic and Lymphatic - Reversible leukopenia, neutropenia, thrombocytopenia and/or eosinophilia, bleeding and
in nrothrombin time have been reported. Reversible leukopenia (neutropenia) is more apt to occur in
reviving prolonged therapy at high dosages or in association with drugs known to cause this reaction,
urn Electrolytes - Individuals with liver disease or individuals receiving cytotoxic therapy or diuretics, were
rarely to demonstrate a decrease in serum potassium concentrations with high doses of PIPRACIL*
iculo-Skeletal- Rarely, prolonged muscle relaxation.
2r-Superinfection, including candidiasis.
\ND ADMINISTRATION: PIPRACIL* may be administered by the intramuscular route or intravenously by injecifusiofh Dosage and route of administration should be determined by the severity of the infection and
1 of the patient. The usual dosage for serious infections is 3 to 4 grams given every 4 to 6 hours as a 20 to 30
lfusion administered intravenously.
maximum daily dose usually administered to adults is 24 g/day, although higher doses have been used.

DOSAGE
Type of Infection
Serious infections such as septicemia, nosocomial pneumonia, intra
abdominal infections, aerobic and anaerobic gynecologic infections,
and skin soft-tissue infections.
Complicated urinary tract infections.
Uncomplicated urinary tract infections and most community-acquired
pneumonia.
Uncomplicated gonococcal urethritis.

Usual Total
Daily Dosage
12-18 gl.V.
(200-300 mg/kg)

Frequency of
Administration

8-16 gl.V.
(125-200 mq/kq)
6-8 g I.M. or I.V.
(100-125 mg/kg)
2 g I.M*

Every 6 to
8 hours
Every 6 to
12 hours
Single dose

Every 4 to
6 hours

*One gram of probenecid given orally 1/2 hour prior to injection.
Dosage In Renal Impairment
Creatinine
Urinary Tract
Urinary Tract
Clearance
Infection
Infection
Serious Systemic
mL/min.
(uncomplicated)
(complicated)
Infection
>40
No dosage adjustment necessary
20-40
No dosage adjustment necessary 9 g/day 3 g every 8 hrs.
12 g/day 4 g every 8 hrs
<20
6 g/day 3 g every 12 hrs.
6 g/day 3 g every 12hrs.
8 g/day 4 g every 12 hrs.
Patients on
*Hemodialysis removes 30-50% of piperacillin in 4 hours;
6 g/day 2 g every 8 hrs
Hemodialysis* 1 g additional dose should be administered following each dialysis period.
For patients with renal failure and hepatic insufficiency, measurement of serum levels of PIPRACIL* will provide
additional guidance for adjusting dosage.
Infants and Children - Dosages in infants and children under 12 years of age have not been established.
The average duration of PIPRACIL* treatment is from 7 to 10 days, except for gynecologic infections, in which
it is from 3 to 10 days; the duration should be guided by the patient’s clinical and bacteriological progress. For most
acute infections, treatment should be continued for at least 48 to 72 hours after the patient becomes asympto
matic. Therapy for Group A beta-hemolytic streptococcal infections should be maintained for at least 10 days to
reduce the risk of rheumatic fever of glomerulonephritis.
ADMINISTRATION
Intramuscular: When indicated by clinical and bacteriological findings, intramuscular administration of 6 to 8 g. daily
of PIPRACIL* in divided doses, may be utilized for initiation of therapy and this route may be considered for m ainte
nance therapy after clinical and bacteriologic improvement has been obtained with intravenous piperacillin sodium
treatment. Administration should not exceed 2 g. per injection at any one site. This route has been used primarily in
the treatment of patients with uncomplicated gonorrhea and urinary tract infections.
Adults and Children More Than 12 Years of Age: The reconstituted solution is given by deep intramuscular injection. The
preferred site of injection is the upper outer quadrant of the buttock (i.e. gluteus maximus). Also may be given in the
mid-lateral muscles of the thigh. The deltoid area should be used only if well developed, and then only w ith caution
to avoid radial nerve injury. Intramuscular injection should not be made into the lower or mid-third of the upper arm
Intravenous: The intravenous route should be used in the treatment of serious infections.
Direct Intravenous (Bolus) Injection: The vials should be reconstituted with 5 mL of suitable diluent listed below
and the resulting solution should be injected slowly over a period of 3 to 5 minutes to help avoid vein irritation.
Intravenous Infusion: A dilution of at least 15 mL per gram is recommended to reduce potential for vein irritation.
The reconstituted and diluted solution may be administered by intermittent or continuous drip. Intermittent infusion
should be administered over a period of about 30 minutes. During intermittent infusion it is desirable to discontinue
the primary intravenous solution. Any unused portion must be discarded. For continuous infusion the solution may
be administered over a longer period of time
RECONSTITUTION
For Intramuscular Use: Solutions for Reconstitution: Sterile Water for Injection, or if required
‘ Bacteriostatic Water for Injection,
**Lidocaine HC1 0.5 or 1% (without epinephrine)- For Intramuscular Use Only.
For Intravenous Use: Solutions for Reconstitution: Sterile Water for Injection, or if required,
'Bacteriostatic Water for Injection
‘ Either parabens or benzyl alcohol.
**Lidocaine HC1 is contraindicated in patients with a known history of hypersensitivity to local anesthetics of
the amide type.
RECONSTITUTION TABLE
Product
VOLUME OF
Approximate
Approximate
Size
Diluent to be added
Available Volume
Average Concentration
Vials 2 g
4.0 mL
5.0 mL
1 g/2.5 mL
3g
6.0 mL
7.5 mL
1 g/2.5 mL
4g
7.8 mL
10.0 mL
1 g/2.5 mL
Infusion Bottles
15 mL
3g
17 mL
20 mL
4g
23 mL
The prepared solution may be further diluted to the desired volume with any of the solutions for intravenous
infusion listed below.
1he contents of the 3 and 4 g infusion bottles should be diluted to at least 15 mL per gram
The appropriate quantity of reconstituted solution may be added to an intravenous bottle or bag containing
any of the solutions for intravenous infusion listed below.
Solutions for Intravenous Infusion:
Intravenous Solutions:
Intravenous Admixtures:
5% Dextrose in Water [D5W]
Normal Saline (+KCL 40 mEq).
0.9% Sodium Chloride (Normal Saline) [NS],
5% Dextrose/Water [D5W] (+KCL 40 mEq).
Dextrose 5% and 0.9% Sodium Chloride [D5NS].
5% Dextrose/Normal Saline [D5NS] (+KCL 40 mEq)
Lactated Ringer's Injection, U.S.P.
Ringer’s Injection, U.S.P. (+KCL 40 mEq)
Dextran 6 % in 0.9% Sodium Chloride.
Lactated Ringer's Injection, U.S.P. (+KCL 40 mEq).
STABILITY OF SOLUTIONS: PIPRACIL* is stable in both glass and plastic containers when reconstituted with recom
mended diluents and further diluted with the indicated intravenous solution and intravenous admixtures.
Stability studies have demonstrated chemical stability (pH, potency and clarity) through 24 hours at room
temperature and up to 72 hours refrigerated. Appropriate consideration of aseptic technique, however, recom
mends discarding unused portions after storage for 24 hours at room temperature or 48 hours refrigerated. If used
as a multi-dose container, the vials must be reconstituted only with the bacteriostatic diluents noted above.
INCOMPATIBILITY: Because of chemical instability, PIPRACIL* should not be used for intravenous administration with
solutions containing sodium bicarbonate
PIPRACIL* should not be added to blood products, protein hydrolysates or amino acids.
When PIPRACIL* is given concurrently with aminoglycosides, it is recommended that both drugs be used in full
therapeutic doses, but administered separately. PIPRACIL* should not be mixed with an aminoglycoside in a
syringe or infusion bottle, since this can result in inactivation of the aminoglycoside.
DOSAGE FORMS: PIPRACIL*(sterile, lyophilized piperacillin sodium) is available in vials containing amounts of pipera
cillin sodium equivalent to 2,3 and 4 grams of piperacillin. Available in boxes of 12 vials
Product Numbers: 2 g /v ia l-3879-48 3 g /v ia l-3882-49 4 g/vial - 3880-50
Available in 100 mL size infusion (“ piggyback”) bottles, containing sterile, freeze-dried piperacillin sodium
powder equivalent to 3 and 4 grams of piperacillin. Boxes of 12 infusion bottles
Product Numbers: 3 g/bottles - 3882-41 4 g/bottles - 3880-42
Piperacillin Sensitivity Discs impregnated with 100 ug of piperacillin are also available
Storage:
PIPRACIL* vials and infusion bottles should be stored at controlled room temperatures of 15-30°C (59-86°F)
Piperacillin Sensitivity Discs should be refrigerated upon receipt. Product Monograph available on request.
'PIPRACIL is a trade mark of Lederle Piperacillin, Inc.
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‘heir serv,ce *° ,ts readers the Canadian Journal o f Surgery is pleased to accept suitable classified advertisements. T hd*’
hhrba!.0.re
Regular c,assified rates (for each insertion): $35.00 for the first 40 words or less, additiotion nnivt3f5C r i c (addlt,onal $ 1 3 ®? for frame). Special Display under 75 words, 2 1/4" x 1 " $85.00. $5.00 charge (first inser
tion only) tor CJS box numbers. Display rates available on request.
Copy should be mailed to the Canadian Journal o f Surgery, PO Box 8650, Ottawa, Ontario K1G 0G8.
*
UROLOGIST — 31, trained in Quebec seeks prac
tice opportunity in Manitoba or Saskatchewan.
Consider all areas. Available December 1984. Reply
to : Dr. IMasri Saliba, 195 Des Frenes W est,
Quebec, PQ G1L 1G4. Tel.: (418) 622-5391 or
832-6939.
-S 84-038
GYNECOLOGIST — with training and interest in
reproductive endocrinology-infertility to join solo
practitioner serving population of 1/2 million in
4-season recreational area of central New York. Ex
cellent salary w ith partnership after 1 year. Prompt
parity of income. Gradual retirement of principal. No
investment required. Possible clinical appointment
at nearby medical school. Dr. M u rray Nusbaum ,
S t. Luke's M e m orial H ospital Center, Cham plin
A v e ., Utica, NY 13502.
— S84-040
LOCUM OBSTETRICIAN/GYNECOLOGIST FRCS(C) required for female gynecologist's prac-
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tice, 2 hours from Toronto, for February 1985.
Possibility of regular locums or practice-sharing.
Reply: Box S106, CJS.
- S84-042
GENERAL SURGEON : ON — Required in August
1985 to replace retiring surgeon in southwestern On
tario town. Practice by referral only. Hospital 200
beds. Must have FRCS(C) or be completing the
FRCS(C) degree in the fall of 1985. Sports and
recreational facilities available. Please write with
curriculum vitae to : Box S105, CJS.
— S84-041
AC AD E M IC APPOINTMENT : BC - Applica
tions are invited for the position of HEAD, DIVI
SION OF GENERAL SURGERY, Vancouver General
Hospital, with a joint appointment to the University
of British Columbia, Faculty of Medicine. The
nature of the duties will include directing the ad
ministrative, teaching and research activities of the
136-bed division at the Vancouver General Hospital;
a hospital with the rated capacity of 1040 acute care
beds, accommodation for 65 long-term care beds
and 198 extended care beds. This is a fully affiliated
teaching hospital of the University of British Colum
bia. The Division of General Surgery is actively in
volved in a wide range of surgery with expertise in
gastrointestinal surgery, trauma surgery, surgical
nutrition and surgical intensive care, hepatobiliary
surgery, esophageal surgery, colorectal surgery,
surgical oncology, head and neck surgery and
peripheral vascular surgery. The Head of the Divi
sion of General Surgery at the Vancouver General
Hospital must be appropriately qualified for a signifi
cant appointment to the Department of Surgery,
Faculty of Medicine, University of British Columbia.
In addition, the incumbent must be recognized as a
skilled surgeon and as a teacher of high repute. He
or she must have some background in research with
strong interest and capability of furthering an active
research program. Candidates are required to be
Fellows of the Royal College of Physicians and
Surgeons of Canada and be eligible to practise
medicine in British Columbia. Preference will be
given to applicants with demonstrated ad
ministrative skills and leadership qualities. Effective
date of appointment is July 1, 1985. Closing date for
receipt of applications is December 31, 1984. Ap
plications should be sent in confidence, accom
panied by a complete resume to : Dr. A .D . For
w ard, Head, D epartm ent of Surgery, 910 W est
10th A ve., 3rd Floor, Vancouver, BC V5Z 4E3. In
accordance w ith Canadian Immigration require
ments, this advertisement is directed to Canadian
citizens and permanent residents.
— S84-037
THE C A N A D IA N CONSENSUS G R O U P - for
the Surgical Treatment of Morbid Obesity, a group
of physicians interested in the surgical treatment of
morbid obesity, met in May 1983 with the intention
of exchanging knowledge and forming a National
Canadian Obesity Surgical Registry. The pro
ceedings of this meeting were published in the
Canadian Journal o f Surgery (Vol. 27, No. 2, March
1984, pages 119-136 and Vol. 27, No. 3, May 1984,
pages 227-238). A second consensus meeting was
held in May 1984. If you or any of your colleagues
would like to be placed on the mailing list for future
participation in this organization, please send your
name, address and hospital affiliation to: Dr. J.B.
Freeman, U niversity o f O ttaw a. Division of
General S urgery, O ttaw a General Hospital. 501
S m yth Rd.. O tta w a. ON K1H 8L6.
— S84-025

PROFESSOR AN D HEAD — Applications are in
vited for the position of Professor and Head of th e ^
Department of Surgery at the Faculty of Medicine,
University of Manitoba. Candidates should have a
substantial record and academic achievement in
1
surgery and extensive experience in teaching and
J
research, as well as proven administrative ex-,*
perience and clinical expertise. The department is
I
responsible for programs of education at the^
undergraduate and postgraduate levels. Both men
and women are encouraged to apply. In accordance^
with Canadian Immigration requirements, this ad is '
directed to Canadian citizens and permanent
residents of Canada. Applications and nominations T l
should be accompanied by a curriculum vitae and
l
submitted not later than November 30, 1984 to : D r . , ^
Joh n G. Wade, Dean, Faculty o f M edicine,
U niversity o f M anitoba, 753 M cD e rm o t A ve.,^
W innipeg, M B, Canada R3E0T6.
-S 84-033*

CLINICAL FELLOWSHIPS
Ewart Angus Intensive Care Unit *-*■
Wellesley Hospital
Toronto
Two positions available July 1, .1985 for a
period of 1 year in a Medical-Surgical Unit with
on-site computer support facilities. Duties com
prise clinical research in a strong academic and ^
teaching unit. Present research includes nutri
tional studies in critical illness, sepsis and noninvasive respiratory monitoring and respiratory
muscle function.
Reply to: Dr. D.P. Jones, D irecto r ^
EAICU, Suite 219, E.K. Jones Bldg., 160
W ellesley St. E., Toronto, ON M4Y 1J3,
(416)966-6656.
-S 84-024 *

A C A D E M IC APPOINTMENT : ON - Depart
ment of Surgery, University of Toronto requires a
staff surgeon, January 1985. Clinical/Annual ap-^
pointment at assistant professor level. Qualifica
tions : MD, FRCS. A fully trained gastrointestinal^
surgeon with extensive research experience in
gastrointestinal physiology and gut p e p tid e ^
chemistry. The successful applicant will be required
to spend at least fifty percent of his/her working
time in the laboratory. Clinical duties will include
regular on-call duties; resident and undergraduate
teaching both clinical and basic science. Contact :t
Dr. J .P . W add ell, S u rg e o n -in -C h ie f, St.
M ichael's Hospital Annex, 38 S huter St., Suite
507, T o ronto, ON M5B 1A6. Closing date for^
receipt of applications is November 31, 1984. In ac-^
cordance with Canadian Immigration requirements,
this advertisement is directed to Canadian citizens
and permanent residents.
— S84-039

GENERAL SURGEON: ON — required in a group
practice in northwestern Ontario. Duties would in- V
elude general practice in a modern clinic that ac- K.
commodates four practitioners who alternate call at v
the area's 44-bed hospital. Community has a stable
economic base and is located on a large lake —
recreational facilities are excellent. Underserviced
Area Grant available. Contact: Dr. V.W . A n io l, PO^
Box 311, Red Lake, ON P0V 2M0, (807) 727-2751.
— S84-020
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PIPRACIL

piperacillin
sodium

An Extended Spectrum of Activity

Pipracil is an effective advanced agent for
gram negative, gram positive and
anaerobic infections.
Pipracil (piperacillin sodium) is a major
advance in presumptive antibiotic therapy.
The bactericidal spectrum of Pipracil is
broader than other antibiotics, such as the
aminoglycosides, cephalosporins, penicillins
and clindamycin. Yet Pipracil has an excel
lent clinical safety profile, with a low sodium
content and with no reported nephrotoxicity,
ototoxicity or pseudomembranous colitis.
In addition, Pipracil achieves excellent
concentrations in body tissues and fluids.
By providing a high degree of efficacy

in a wide range o f mixed infections, Pipracil
is a logical therapeutic alternative for pre
sumptive therapy in surgery, urology and
gynecology, including patients with
impaired host defences.
D fD D
r l r l V W

The Spectrum o f a
^ l L Combination in
One Advanced Agent

Cyanamid Canada Inc.
‘ Pipracil is a trade mark o f Lederle Piperacillin, Inc.

For p re scrib in g in fo rm a tio n see page 6 2 3

BLUE MONOFILAMENT
POLYBUTESTER SUTURE

DAVIS+GECK
Cyanamid Canada Inc.

A TRADITION OF INNOVATION

Atria North, 2255 Sheppard Avenue East, Willowdale, (Ontario) M2J 4Y5
'Registered Trademark of American Cyanamid Company
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